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 Many chemotherapeutics induce cell death by attacking deoxyribonucleic acid (DNA). 
Unfortunately, many cancer drugs suffer from poor selectivity and high toxicity. In addition to 
poor selectivity, the cytotoxic effects of DNA damaging agents are often reduced by DNA repair 
mechanisms. To combat this, DNA repair inhibition is an attractive route for enhancing the 
efficacy of cancer treatment, either by monotherapy or combination therapy. An established target 
for DNA repair inhibition is DNA polymerase beta (Pol ), the primary polymerase in base 
excision repair (BER). Pol  is an attractive target because it is overexpressed and often mutated 
in certain cancers. However, current Pol  inhibitors lack the potency and selectivity necessary for 
therapeutic relevance. 
Small molecule libraries were synthesized and screened against WT Pol  and some select 
cancer-associated mutants. These compounds covalently and irreversibly inhibit Pol . The 
relationship between domain binding and activity inactivation was explored using first-generation 
inhibitors that selectively bind to different Pol  domains. In addition, a potent (IC50 = 409-458 
nM, KI = 1.8 M, kinact = 7.0 s
-1) and selective second-generation inhibitor was identified against 
WT Pol . This inhibitor selectively inactivated the polymerase activity via the disruption of DNA 
binding. A pro-inhibitor based on this molecule enhanced the cell killing effect of DNA damaging 
agents (i.e. methyl methanesulfonate (MMS) and bleomycin (BLM)) synergistically in HeLa and 
MCF-7 cells. 
The screen against mutant forms of Pol  did not yield any potent or selective inhibitors. 
The mutant library ultimately failed due to a fault in the screening method and a path forward to 
overcome this shortcoming has been outlined. The lack of a mutant inhibitor was disappointing 
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because while the WT Pol  inhibitor enhanced the cytotoxic effects of DNA damaging agents, it 
did not address the concern of producing selectivity for cancer cells versus healthy cells.  
DNA repair inhibition is also clinically useful for exploiting a cancer cell's inherent 
weakness by inducing synthetic lethality. Synthetic lethality is also attractive because it negates 
the need for DNA damaging agents. To establish selectivity for cancer cells, a synthetic lethal 
interaction between the Pol  inhibitor and an HR-deficiency was evaluated. The pro-inhibitor was 
synthetic lethal in BRCA1-deficient cells (MDA-MB-436). This effect was confirmed by knocking 
down Pol  by siRNA. This is the first report, to our knowledge, that confirms Pol  and BRCA1 

















Advisor: Prof. Marc Greenberg 
Readers: Prof. Rebekka Klausen 





 I am incredibly grateful to all the people who have helped me during my PhD work. Thank 
you to all my friends in Baltimore, at Johns Hopkins and at the Village church. Thanks to the 
former and current members of the Greenberg lab for their help, advice, and support over the past 
five years. Thank you to Dr. Daniel Laverty, Prof. Kun Yang, and Dr. Liwei Zheng for their 
encouragement, and willingness to help troubleshoot an experiment or reaction. Thank you to 
Marco Jacinto, Huijin Lee, Tingyu Wen, Alexandra Gittens, Haozhe Yang, and all other members, 
past and present, for their continued support and for creating a truly enjoyable environment in the 
lab. A special thanks to my friend and colleague, Jamie Alley, for her friendship, advice on 
experiments, and willingness to join me for a coffee break! 
I am extremely thankful to my advisor, Prof. Greenberg, for his mentorship during my time 
in his lab. His guidance, questions, and advice has helped me grow into a better scientist. His 
dedication to his research and his students’ success has and will continue to motivate me in my 
future endeavors. 
Thank you to the readers of my thesis, Prof. Klausen and Prof. Rokita, for their support 
during my candidacy. I would like to thank the University staff, Ananya Majumdar for his 
assistance in collecting 800 Mz NMR data, Katie Tripp for her training and help with biophysical 
instruments, and Phil Mortimer for his support in the mass spectrometry facility.  
Lastly, I am especially grateful for my family. Thank you to my parents and my brother, 
who have supported and visited me throughout this journey and have listened to me talk about my 
research for many hours. My husband, who moved to Baltimore and was incredibly understanding 
when I worked long days and weekends, continues to be an amazing support system and foundation 
for me. I am so thankful for his love and superior cooking skills.  
v 
 
Table of Contents 
Abstract ............................................................................................................................................ii 
Acknowledgements ......................................................................................................................... iv 
Table of Contents ............................................................................................................................. v 
List of Tables ................................................................................................................................ viii 
List of Figures .................................................................................................................................. x 
List of Schemes .............................................................................................................................. xv 
List of Abbreviations .................................................................................................................. xviii 
1. Introduction ............................................................................................................................. 1 
2.1 Cancer Therapeutics........................................................................................................ 6 
2.1.1 Alkylating agents ........................................................................................................ 6 
2.1.2 Antimetabolites ........................................................................................................... 8 
2.1.3 Anti-tumor antibiotics ............................................................................................... 10 
2.1.4 Other classes of chemotherapeutics .......................................................................... 11 
2.2 DNA Damage................................................................................................................ 12 
2.2.1 Abasic Sites ............................................................................................................... 13 
2.2.2 Oxidative DNA Damage ........................................................................................... 14 
2.2.2.1 Sugar Oxidation ................................................................................................ 15 
2.2.3 Single strand breaks .................................................................................................. 17 
2.3 DNA Repair .................................................................................................................. 18 
2.3.1 Base Excision Repair ................................................................................................ 19 
2.3.1.1 DNA Polymerase  ........................................................................................... 23 
vi 
 
2.3.1.1.1 Pol  8 kDa Lyase domain .......................................................................... 25 
2.3.1.1.2 Pol  31 kDa Polymerase domain ............................................................... 27 
2.3.1.1.3 The effects of Pol  levels in cells .............................................................. 30 
2.3.1.2 BER inhibition by oxidized AP lesions ............................................................ 34 
2.4  DNA Repair Inhibition ................................................................................................. 36 
2.5 Pol  is an anti-cancer target ......................................................................................... 37 
2.5.1 Pol  variants ............................................................................................................ 38 
2.6  Pol  inhibitors .............................................................................................................. 39 
2.6.1  Small molecule inhibitors ..................................................................................... 39 
Statement of the project ................................................................................................................ 42 
3.  Results & Discussion ............................................................................................................ 43 
3.1  First-generation library scaffold design ........................................................................ 43 
3.1.1  Diversification by Reductive Amination .............................................................. 50 
3.1.2  Amide Coupling Functionalization ....................................................................... 52 
3.2 In vitro biochemical assays ........................................................................................... 59 
3.2.1  Fluorescence-based strand displacement assay .................................................... 60 
3.2.2  Gel-based lyase assay ........................................................................................... 62 
3.2.3 Fluorescence-based lyase assay ................................................................................ 65 
3.2.4 Assays and DNA substrates used for different polymerases .................................... 69 
3.3  First-generation Pol  inhibitor(s) and their domain selectivity ................................... 70 
3.3.1 Lyase domain selectivity........................................................................................... 72 
3.3.2 Polymerase domain selectivity ................................................................................. 85 
vii 
 
3.3.3 The Significance of the 3’-oxime and the 3’-amide ................................................. 93 
3.4 WT Pol  inhibitor(s) starting from AZT ..................................................................... 96 
3.4.1 First-generation WT Pol  inhibitor: Functionalization at the 3’-position ............... 97 
3.4.2 Second generation inhibitor: Functionalization of 59 at the thymine 5-methyl 
position .................................................................................................................................. 99 
3.4.2.1  In Vitro biochemical and biophysical characterization of inhibitor 72 ............. 107 
3.4.2.2  Non-covalent analog of inhibitor 72 .................................................................. 112 
3.4.2.3  The effect of pro-72 in cells ............................................................................... 115 
3.5 Identification of Pol  mutant inhibitor(s) .................................................................. 120 
3.5.1  Mutants Screened ................................................................................................ 121 
3.5.2 First-generation mutant inhibitor: Functionalization at the 3’-position .................. 122 
3.5.3 Second-generation mutant inhibitor(s): Functionalization at the thymine 5-methyl 
position ................................................................................................................................ 127 
3.6 Synthetic lethality induced by Pol  inhibition ........................................................... 132 
4. Future Considerations ......................................................................................................... 140 
5.  Experimental Methods ........................................................................................................ 145 
References ................................................................................................................................... 257 
Appendices .................................................................................................................................. 284 





List of Tables 
Table 1. DNA substrates for assays. ............................................................................................. 70 
Table 2. Summary of inhibitor binding locations and activity inhibition. .................................... 92 
Table 3. Summary of Pol  lyase inactivation by 63 and 64. ....................................................... 99 
Table 4. Summary of kinetic parameters of 72 inhibition of Pol . ........................................... 104 
Table 5. Cell death induced by pro-72 in MCF-7 and MDA-MB-436 cells. ............................. 134 
Table 6. Percentage of cell death induced by Olaparib and pro-72 in MCF-7 and MDA-MB-436 
cells. .................................................................................................................................... 139 
Table 7. 10X Preincubation mixture for strand displacement assay(s). ..................................... 161 
Table 8. Reaction mixture for strand displacement assay(s). ..................................................... 161 
Table 9. 10X preincubation mixture for smaller wells. .............................................................. 162 
Table 10. Reaction mixtures for smaller wells. .......................................................................... 162 
Table 11. Preincubation mixture preparation. ............................................................................. 163 
Table 12. Reaction mixture preparation. ..................................................................................... 163 
Table 13. 10X Preincubation mixture for gel-based lyase assay(s). ........................................... 164 
Table 14. Reaction mixtures for gel-based lyase assay(s). ......................................................... 165 
Table 15.  10X Preincubation mixture for gel-based lyase assay(s). .......................................... 166 
Table 16. Reaction mixture for gel-based lyase assay(s). ........................................................... 166 
Table 17. 5X preincubation of enzyme/inhibitor for UBER assay. ............................................ 167 
Table 18. Reaction mixture for UBER assay. ............................................................................. 168 
Table 19. 10X preincubation mixture for primer extension assays. ........................................... 169 
Table 20. Reaction mixture for primer extension assays. ........................................................... 170 
ix 
 
Table 21. Lyase reaction kinetics before dialysis. ...................................................................... 171 
Table 22. Preincubation for trypsin digest(s). ............................................................................. 172 
Table 23. Trypsin digestion sample. ........................................................................................... 172 
Table 24. Chemical Shift Analysis of pro-72 NMR spectra. ..................................................... 378 
Table 25. Chemical shift analysis of 84 NMR spectra. .............................................................. 380 
Table 26. Chemical shift analysis of 89 NMR spectra. .............................................................. 384 





List of Figures 
Figure 1. MGMT inhibitor, disulfiram, blocks repair of O6Me dG. ............................................... 4 
Figure 2. Oxidized abasic lesions that inhibit Pol  ...................................................................... 5 
Figure 3. Structures of alkylating agents. ....................................................................................... 7 
Figure 4. DNA damage by TMZ and DTIC. .................................................................................. 7 
Figure 5. Cisplatin DNA adduct. .................................................................................................... 8 
Figure 6. Methotrexate mechanism of action. ................................................................................ 9 
Figure 7. 5FU mimics uracil and thymine. ..................................................................................... 9 
Figure 8. Structures of anti-tumor antibiotics. .............................................................................. 10 
Figure 9. Representative types of DNA damage. ......................................................................... 13 
Figure 10. Oxidized abasic lesions. .............................................................................................. 15 
Figure 11. Overview of DNA damage and repair pathways. ........................................................ 18 
Figure 12. Representative lesions that are repaired by BER. ....................................................... 19 
Figure 13. Mechanisms of (a) SP-BER and (b) LP-BER. ............................................................ 20 
Figure 14. Structure of Pol  (PDB: 1BPD). ................................................................................ 25 
Figure 15. Overlay of DNA-unbound (PDB: 1BPD, teal/pink/yellow/orange) and DNA-bound 
(PDB: 1BPX, blue/gray) crystal structures of Pol . ............................................................ 28 
Figure 16. Orientation of DNA binding residues (sticks). ............................................................ 30 
Figure 17. Telomere fusion can arise from Pol  overexpression. ............................................... 31 
Figure 18. Simplified mechanism of translesion synthesis. .......................................................... 32 
Figure 19. Structures of PARPi. ................................................................................................... 37 
Figure 20. Structures of natural product Pol  inhibitors. ............................................................ 40 
xi 
 
Figure 21. Irreversible inhibitor library (1) led to identification of inhibitor (2). ........................ 41 
Figure 22. Second generation of irreversible Pol  inhibitor. ....................................................... 42 
Figure 23. Retrosynthetic design of second-generation inhibitor library. .................................... 44 
Figure 24. Fluorescence-based strand displacement assay. .......................................................... 61 
Figure 25. Gel-based lyase assay. ................................................................................................. 63 
Figure 26. Transforming hypothetical raw data (left) into a preincubation plot (right). .............. 64 
Figure 27. Fluorescence-based UBER lyase assay. ...................................................................... 66 
Figure 28. Conditions to detect dRP using UBER assay.. ............................................................ 68 
Figure 29. First-generation inhibitor hit compounds 47 and 48. .................................................. 74 
Figure 30. Strand displacement assay of Pol  with 47. ............................................................... 75 
Figure 31. Strand displacement assay of Pol  with 48. ............................................................... 76 
Figure 32. Lyase activity in the presence of inhibitor hits 47 and 48. .......................................... 77 
Figure 33. Irreversible lyase inhibition of WT Pol  lyase activity by 47. ................................... 78 
Figure 34. Irreversible lyase inhibition of WT Pol  8 kDa domain lyase activity by 47. ........... 78 
Figure 35. Irreversible lyase inhibition of WT Pol  lyase activity by 48.. .................................. 79 
Figure 36. Inhibitor 47 has an IC50 value of 18.7 M in WT Pol . ............................................. 80 
Figure 37. Lyase activity of WT Pol  with 47 before and after dialysis. .................................... 81 
Figure 38. MS analysis of trypsin digestion of Pol  with 47. ..................................................... 82 
Figure 39. Inhibitor 47 did not inactivate strand displacement synthesis in the 31 kDa domain. 83 
Figure 40. The effect of inhibitor 47 on DNA binding in WT Pol  (a), 8 kDa Pol  (b), and 31 
kDa Pol  (c). ........................................................................................................................ 84 
xii 
 
Figure 41. First-generation inhibitor (2) targeted the polymerase domain. (a) gel-based lyase 
assay with WT enzyme and 8 kDa domain, (b) strand displacement assay with WT enzyme, 
(c) strand displacement assay with 31 kDa domain. ............................................................. 86 
Figure 42. The effect of inhibitor 2 on DNA binding in WT Pol  (a) 31 kDa Pol  (b) and 8 kDa 
Pol  (c). ................................................................................................................................ 88 
Figure 43. MS analysis of trypsin digestion of Pol  incubated with 2. ....................................... 90 
Figure 44.  Conformational changes when Pol  binds to DNA. ................................................. 91 
Figure 45. Compound 62 does not inhibit strand displacement activity of the intact enzyme. .... 96 
Figure 46. Strand displacement screen identified Hit compounds 63 and 64 against Pol . ........ 97 
Figure 47. Pol  strand displacement inhibition is dependent on the concentration of 63 and 64.
............................................................................................................................................... 98 
Figure 48. Inactivation of the Pol  31 kDa domain strand displacement activity. ...................... 99 
Figure 49. Hit compound and pro-inhibitor (72). ....................................................................... 101 
Figure 50. Compound 72 did not inhibit lyase activity. ............................................................. 102 
Figure 51. Pol  strand displacement inhibition is dependent on concentration and preincubation 
time with 72. ....................................................................................................................... 102 
Figure 52. IC50 plots for 72 at two preincubation times. ............................................................ 103 
Figure 53. Kitz-Wilson plot of 72. .............................................................................................. 104 
Figure 54. Strand displacement activity in response to dialysis of Pol  with 72. ..................... 106 
Figure 55. Selectivity of 72 against polymerase activity in model and mammalian polymerases.
............................................................................................................................................. 107 
Figure 56. pH dependence of Pol  inactivation by 72. .............................................................. 108 
xiii 
 
Figure 57. Thiols decrease the efficacy of 72. ............................................................................ 109 
Figure 58. MS analysis of trypsin digestion of Pol  incubated with 72. ................................... 110 
Figure 59. Crystal structure of WT Pol : Covalently modified Lys residues after incubation with 
72 (in pink) are in the DNA binding pocket. ...................................................................... 111 
Figure 60. Fluorescence anisotropy experiments with 72........................................................... 112 
Figure 61. Inactivation of strand displacement activity by 74 in WT Pol . .............................. 114 
Figure 62. Competition fluorescence anisotropy with 74 in WT Pol . ..................................... 114 
Figure 63. Cell viability of HeLa cells in response to pro-72. ................................................... 116 
Figure 64. Clonogenic assays show low toxicity of pro-72 in HeLa cells. ................................ 116 
Figure 65. Synergistic effect of pro-72 with DNA damaging agents on cell death in HeLa cells.
............................................................................................................................................. 118 
Figure 66. Toxicity of pro-72 in MCF-7 cells as determined via clonogenic assay. ................. 119 
Figure 67. Synergistic effect of pro-72 with DNA damaging agents on cell death in MCF-7 cells.
............................................................................................................................................. 120 
Figure 68. Crystal structure of the mutants (in pink) in the 8 kDa Pol  lyase domain (blue) 
bound to DNA (PDB: 1PBX). ............................................................................................ 121 
Figure 69. Identification of hit compounds 80 and 81 against for Pol  N24K and Pol  T79I, 
respectively, using the UBER lyase assay. ......................................................................... 124 
Figure 70. Gel-based and UBER lyase assay comparison in Pol  inactivation by hit compounds..
............................................................................................................................................. 126 
Figure 71. Hit compounds identified from UBER screen. .......................................................... 128 
Figure 72. Gel-based lyase assay analysis of mutant hits. .......................................................... 129 
xiv 
 
Figure 73. Mutant hits do not inactivate 8 kDa domain.............................................................. 130 
Figure 74. Inhibition of strand displacement activity in the intact enzyme (a) and the 31 kDa 
domain (b). .......................................................................................................................... 131 
Figure 75. Clonogenic assay of pro-72 toxicity in MDA-MB-436. ........................................... 134 
Figure 76. Synergistic effect of pro-72 with DNA damaging agents on cell death in MDA-MB-
436....................................................................................................................................... 135 
Figure 77. Pol  KD in MDA-MB-436 cells. ............................................................................. 136 
Figure 78. Effect of knocking down Pol  in MDA-MB-436 cells. ........................................... 137 
Figure 79. Effect of Olaparib in MCF-7 and MDA-MB-436 cells. ............................................ 138 
Figure 80. Toxicity of pro-72 in MCF-7 Pol  KD cells. .......................................................... 142 
Figure 81. Amino acid (pink) positions of colon cancer-associated Pol  mutants and their 





List of Schemes 
Scheme 1. DNA repair thwarts the effects of DNA damaging agents. ........................................... 2 
Scheme 2. Mechanism of BLM products. .................................................................................... 11 
Scheme 3. Formation of AP sites. ................................................................................................. 13 
Scheme 4. Activation of NCS. ...................................................................................................... 16 
Scheme 5. Proposed mechanism of C1’- and C5’- hydrogen atom abstraction product formation.
............................................................................................................................................... 16 
Scheme 6. General mechanism of (a) monofunctional glycosylase, (b) bifunctional glycosylase 
that catalyzes -elimination, (c) bifunctional glycosylase that catalyzes -elimination. .. 22 
Scheme 7. Proposed mechanism of 5’-dRP lyase activity. ........................................................... 26 
Scheme 8. Mechanism of polymerase activity. ............................................................................ 29 
Scheme 9. Inactivation of Pol  by DOB. .................................................................................... 35 
Scheme 10. Consecutive Mitsunobu reactions for alkoxyamine scaffold. ................................... 45 
Scheme 11. Retrosynthetic pathway of first-generation inhibitors(s). ......................................... 47 
Scheme 12. Synthesis of DOB-portion of first-generation inhibitor. ........................................... 48 
Scheme 13. Phosphoramidite coupling in either polarity. (a) 3’-OH (9) and 5’-phosphoramidite 
or (b) 3’-phosphoramidite (10) and 5’-OH. .......................................................................... 49 
Scheme 14. Synthesis of the acetate-protected DOB phosphoramidite (12). ............................... 50 
Scheme 15. Retrosynthetic (a) and forward (b) synthesis of aldehyde-containing nucleoside (16).
............................................................................................................................................... 50 
Scheme 16. Retrosynthetic (a) and forward (b) synthesis of aldehyde-containing scaffold 20. .. 52 
xvi 
 
Scheme 17. Retrosynthetic (a) and forward (b) synthesis of methyl ester-containing nucleobase 
22........................................................................................................................................... 53 
Scheme 18. Retrosynthetic (a) and forward (b) synthesis of carboxylic acid-containing scaffold 
26........................................................................................................................................... 54 
Scheme 19. Retrosynthetic (a) and forward (b and c) synthesis of azide-containing nucleobase 
via 2’-deoxyuridine (b) and thymidine (c). ........................................................................... 56 
Scheme 20. Retrosynthetic (a) and forward (b) synthesis of a phthalimide containing nucleobase.
............................................................................................................................................... 57 
Scheme 21. Retrosynthetic (a) and forward (b) synthesis of a trifluoroacetamide containing 
nucleobase. ............................................................................................................................ 58 
Scheme 22. Retrosynthetic (a) and forward (b) synthesis of amine-containing scaffold (45). .... 59 
Scheme 23. Cleavage of Nv to obtain 5’-dRP. ............................................................................. 62 
Scheme 24. Reaction between AP and UBER Probe. .................................................................. 65 
Scheme 25. Improved synthesis of the hit compounds. ................................................................ 74 
Scheme 26. Retrosynthetic (a) and forward (b) synthesis of 3’-N-trifluoroacetamide containing 
monomer 55. ......................................................................................................................... 93 
Scheme 27. Retrosynthetic (a) and forward (b) synthesis of 3’-amine scaffold (57). .................. 94 
Scheme 28. Synthesis of amide version of 2 (62). ........................................................................ 95 
Scheme 29. Synthesis of a second-generation library containing the 3’-hit compound moiety. 100 
Scheme 30. Thiols react with electrophilic species. ................................................................... 109 
Scheme 31. Synthesis of noncovalent inhibitor 74. .................................................................... 113 
Scheme 32. Synthesis of pro-inhibitor (pro-72). ........................................................................ 115 
xvii 
 
Scheme 33. Synthesis of Nv-protected DOB moiety. ................................................................. 122 
Scheme 34. Synthesis of Nv-protected scaffold 79 and library 58. ............................................ 123 
Scheme 35. Synthesis of first-generation mutant hits. ................................................................ 125 
Scheme 36. Synthesis of second-generation library (94). ........................................................... 127 




List of Abbreviations 
 
5IdU       5-iodo-deoxyuridine 
5FU       5-fluorouracil 
5FdUTP      5-fluoro-deoxyuridine triphosphate 
8-oxodG      8-oxo-7,8-dihydro-2’-deoxyguanosine 
A       fluorescence anisotropy 
Ac       acetate 
AP       apurinic/apyrimidinic 
Ape1       AP endonuclease 1 
ARP       aldehyde reaction probe 
AZT       3’-azidothymidine 
B-al       5’-nucleoside-5’-aldehydes 
BER       base excision repair 
BHQ       Black Hole Quencher 
BLM       bleomycin 
BRCT       BRCA1 C Terminus 
BSA       bovine serum albumin 
C       palm subdomain 
C2-AP       C2’-oxidized abasic lesion 
C4-AP       C4’-oxidized abasic lesion 
CHO       Chinese hamster ovary 
CP450       cytochrome P450 
D       thumb subdomain 
xix 
 
DOB       5’-(2-phosphoryl-1,4-dioxobutane) 
DDR       DNA damage response 
DMEM      Dulbecco’s Modified Eagle Medium 
DMT       dimethoxytrityl 
DNA       deoxyribonucleic acid 
dNTP       deoxynucleotide triphosphate 
DPC       DNA-protein crosslinks 
dRP       deoxyribose phosphate 
DSB       double strand break 
dsDNA      double stranded DNA 
DTIC       dacarbazine 
dU       2’-deoxyuridine 
EMS       ethyl methanesulfonate 
FBS       fetal bovine serum 
Fe       iron 
FEN1       flap endonuclease I 
H-bond      hydrogen bond 
HKL       honokiol 
hNEIL       human Nei-like DNa glycosylase 
hNTH1      human endonuclease III protein 1 
hOGG1      human 8-oxoguanine DNA glycosylase 1 
HO•       hydroxyl radical 
HR       homologous recombination 
xx 
 
ICL       interstrand crosslinks 
IC50       half maximal inhibitory concentration 
IR       ionizing radiation 
K72       Lys72 
KA       koetjapic acid 
KD       dissociation constant 
KI concentration of the inactivator at half-
maximal inactivation 
kinact maximal rate constant for inactivation 
kSS       steady state rate constant 
kST       single turnover rate constant 
L       2-deoxyribonolactone 
LA       linoleic acid 
LB       Luria broth 
LP-BER      long-patch base excision repair 
LPS       lipopolysaccharide 
Lys       lysine 
Me3 dA      N3-methyl deoxyadenosine 
MOA       mechanism of action 
MEF       mouse embryonic fibroblast 
Mg2+       magnesium ion 
MGMT      O6-methylguanine-DNA-methyltransferase  
MMR       mismatch repair 
xxi 
 
MMS       methyl methanesulfonate 
MNNG      N-methyl-N-nitrosoguanidine 
MNU       N-methyl-N-nitrosourea 
MS       mass spectrometry 
MutYH      human MutY DNA glycosylase 
N       finger subdomain 
NA       nervonic acid 
NBS       N-bromosuccinimide 
NCP       nucleosome core particle 
NCS       neocarzinostatin 
NER       nucleotide excision repair 
NHEJ       non-homologous end joining 
NSD1    nuclear receptor-bidning SET domain 
protein 1 
nt       nucleotide 
Nv       nitroveratryl 
O6Me dG      O6-methyl deoxyguanosine 
PA       pamoic acid 
PAR       poly-ADP ribose 
PARP       poly (ADP ribose) polymerase  
PARPi       PARP inhibitors 
PNK       polynucleotide kinase 
Pol         DNA polymerase  
xxii 
 
Pol        DNA polymerase  
Pol        DNA polymerase  
Pol        DNA polymerase  
Pol        DNA polymerase  
Pol        DNA polymerase  
Pol        DNA polymerase  
ROS       reactive oxygen species 
RNAi       RNA interference 
RSH       thiol 
SMUG1 single-strand selective monofuncation uracil 
DNA glycosylase  
SP-BER      short-patch base excision repair 
SSB       single strand break 
ssDNA      single strand DNA 
TAMRA      carboxytetramethylrhodamine 
TBS       tris-buffered saline 
TBST       tris-buffered saline with tween 20 
TCA       trichloroacetic acid 
TDG       thymine DNA glycosylase 
TdT       terminal deoxynucleotidyl transferase 
TFA       trifluoroacetic acid 
Tg       thymine glycol 
THF       tetrahydrofuran 
xxiii 
 
TI       therapeutic index 
TMZ       temozolomide 
TNR       trinucleotide repeat 
TRF2       telomeric repeat-binding factor 2 
UBER       universal base excision repair 
UDG        uracil DNA glycosylase 
V(D)J       Variable Diversity Joining 





A major approach to kill cells is by attacking nucleic acids using ionizing radiation (IR) or 
chemotherapeutics, such as bleomycin (BLM), temozolomide (TMZ), or cisplatin. While these 
cancer drugs have different mechanism of actions (MOAs) to induce cell death, they target 
deoxyribonucleic acid (DNA). Cancer cells are characterized by unregulated cell proliferation. 
They no longer possess the normal checks and balances that control and limit cell division. As a 
result, cancerous cells divide and reproduce much faster than normal cells. Many 
chemotherapeutic drugs are most effective at killing cells that are rapidly dividing.  
Unfortunately, a major challenge of chemotherapeutics is a lack of selectivity. Specifically, 
many drugs cannot distinguish between cancerous cells and healthy cells. This leads to undesirable 
non-specific toxicity and as a result, there is a need for the development of selective 
chemotherapeutics. A drug’s therapeutic index (TI) is a quantitative measurement of its relative 
safety. TI is a comparison of the amount of the drug that causes a therapeutic effect to the amount 
of drug that induces toxicity. DNA polymerase  (Pol ) is a DNA repair enzyme involved in the 
repair of small, non-bulky DNA lesions and imparts resistance to drugs that induce DNA lesions. 
Selective inhibitors of this enzyme that are effective in cells do not exist.  The goal of this research 
is to identify a small molecule inhibitor(s) of Pol  to improve the selectivity of cancer treatment 
either by enhancing an agent’s TI by increasing the cytotoxicity of DNA damaging agents or by 
inducing synthetic lethality in repair-deficient cancer cells. 
Many chemotherapeutics can be classified into two very broad classes: targeted therapies 
and standard chemotherapy. Targeted cancer therapies block the growth and spread of cancer by 
interfering with specific molecules or enzymes. These are often chosen deliberately based on 
extensive knowledge of protein expression levels in individual tumors and validation of the 
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molecular target. On the other hand, standard chemotherapy takes a broader approach. While this 
depends on the individual drug, a major target for many standard chemotherapeutics is DNA. 
Standard chemotherapeutics, such as IR or BLM, induce DNA damage. DNA repair thwarts the 
effects of DNA damaging agents and reduces the cytotoxicity of drugs, often requiring higher and 
more frequent doses (Scheme 1). While some cancers exhibit deficiencies in specific repair 
pathways, others overexpress DNA repair enzymes. An understanding of these changes in cancer 
cells can guide or hinder approaches involving DNA damage. DNA repair is a crucial mechanism 
of drug resistance, especially in cells that have higher expression levels of repair proteins than in 
noncancerous cells.1 To combat this resistance, DNA repair inhibition is an attractive route to 
enhance the cytotoxicity of DNA damaging drugs.1–4 
Scheme 1. DNA repair thwarts the effects of DNA damaging agents. 
 
Maintenance of the genome is vital and regulated by balanced expression levels of DNA 
repair enzymes. Genomic instability is a characteristic of most cancer cells. Cancer frequently 
results from damage and mutations in multiple genes controlling cellular division and tumor 
suppressors.5 In a sense, higher mutation rates in cancer cells are advantageous in terms of survival 
and proliferation because genomic instability can give rise to mutations that upregulate genes 
associated with cancer progression and downregulate genes associated with cancer suppression.5 
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Healthy cells maintain a balanced DNA damage response (DDR) with back-up enzymes and 
pathways, whereas cancerous cells often exhibit increased or decreased levels of certain repair 
pathways. Therefore, normal cells can accommodate for a deficiency of one pathway better than 
cancer cells. Cancerous cells must maintain genomic integrity to avoid apoptosis. Some cancers, 
especially those that upregulate mutagenic repair pathways or are deficient in a specific repair 
pathway, rely more heavily on a subset of repair pathways in comparison to normal cells.6,7 By 
this logic, DNA repair inhibition is more detrimental in cancer cells than in healthy cells by 
utilizing synthetic lethality (Section 2.4). Synthetic lethality occurs between two genes when the 
disruption of both yields cell death, while the loss of one does not. Synthetic lethality is induced 
by inhibiting an enzyme that is toxic only in cancer cells that are deficient in a different pathway. 
DNA repair inhibitors are used clinically in cases in which tumors have higher resistance 
to DNA damaging agents. For instance, the common alkylating agent, TMZ induces several DNA 
adducts including, O6-methyl deoxyguanosine (O6Me dG) (Figure 1).8 O6-alkylguanines are 
mutagenic because they pair with thymine and result in a GC to AT transition.9 This lesion is 
directly removed from DNA by O6-methylguanine-DNA-methyltransferase (MGMT).8 MGMT is 
overexpressed in 80% of brain tumors and is a therapeutic target especially for tumors resistant to 
alkylating agents.9 Furthermore, treatment of MGMT inhibitor, disulfiram, confers resistance to 
alkylating agents in brain tumors.9 
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Figure 1. MGMT inhibitor, disulfiram, blocks repair of O6Me dG.  
Pol  has been considered an attractive target for DNA repair inhibition. Pol  is the 
primary polymerase of an important DNA repair pathway, base excision repair (BER).10 Pol  is 
overexpressed in several types of cancer cells, suggesting that the lack of Pol  may be more 
detrimental to cancer.11 Pol  is postulated to be synthetic lethal in homologous recombination 
deficient cells.12 If confirmed, this would make Pol  a better target for monotherapy in BRCA1/2-
deficient cancers (Section 3.6). Multiple mutant forms of Pol  have been identified in a large 
percentage of tumors, which introduces the potential for identifying inhibitors selective for mutants 
associated with cancer over WT enzyme (Section 2.5).13 Enhancing selectivity to cancer cells over 
healthy cells improves the ratio of therapeutic effects compared to the induced toxicity, in turn 
augmenting a drug’s TI. Significantly, a lack of Pol  activity has been shown to enhance the 
cytotoxicity of DNA damaging agents.14–19 
Several inhibitors of Pol  have been identified but lack crucial properties required for 
clinical use (Section 2.6).20–28 The current limitations of known Pol  inhibitors include a lack of 
selectivity for Pol  over other polymerases, lack of potency, and undefined binding region. As a 
result, there is a need for the development of Pol  inhibitors that have been characterized 
completely (i.e. kinetics and binding) and are both selective and potent (Section 3.3-3.4). 
Previously, it was observed that oxidized abasic lesions, products of oxidative damage, 
irreversibly inactivate Pol  (Figure 2).29,30 Based on this finding, small molecules that mimic this 
form of damage were identified that irreversibly inhibit Pol .26,27 In the research presented, the 
selective binding to the unique domains of Pol  was evaluated (Section 3.3). Pol  was selectively 
and irreversibly inhibited by a small molecule(s) that mimics oxidized abasic lesions (Section 3.4). 
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The Pol  inhibitor was synthetic lethal in BRCA1-deficient cells (Section 3.6). An inhibitor 
library was screened against mutant forms of Pol  but did not yield any selective hit compounds 
due to a fault in the screening method (Section 3.5). A plan to overcome this flaw was outlined 
(Section 4).  If completed successfully, this would represent the first report of an inhibitor selective 
for a cancer-specific Pol  variant. This research contributes to the identification of chemical 
agents that distinguish between cancerous and healthy cells in order to reduce toxicity to healthy 
cells. 
 





2.1 Cancer Therapeutics 
Cancer is the second leading cause of death worldwide. It is a collection of diseases that 
can affect essentially any part of the body. Cancer is not caused by any single factor but often 
arises from multiple contributions, including genetic and environmental factors. Due to the 
complexity of the disease, there are various treatments for cancer, such as surgery, ionizing 
radiation (IR), and chemotherapeutics. Treatment must balance efficacy and toxicity. A major 
hurdle for cancer drugs is a lack of selectivity resulting in non-specific toxicity. Therefore, the 
dosage of cancer drugs is often limited by toxicity and drug resistance conferred by the 
overexpression of repair enzymes in some cancerous cells.3,4  
Many chemotherapeutics induce cell death by damaging deoxyribonucleic acid (DNA) 
(Scheme 1). Several clinically relevant standard chemotherapeutics that generate DNA damage 
can be characterized into three types: alkylating agents (Section 2.1.1), antimetabolites (Section 
2.1.2), and antitumor agents (Section 2.1.3). These agents are often agnostic towards cell type. 
Specifically, these drugs do not distinguish between tissues or healthy vs. cancer cells and, 
therefore, are generally associated with high toxicity. It is important to note that this list is not 
exhaustive, and many selective drugs exist that do not fit into these three categories. 
2.1.1 Alkylating agents 
Temozolomide (TMZ), dacarbazine (DTIC), and cisplatin (Figure 3) are examples of 
clinically relevant alkylating agents.4 Alkylating agents modify DNA in a way that blocks or 
changes replication and/or transcription.31 For example, N3-methyl deoxyadenosine (Me3 dA) 
blocks replication while O6-methyl deoxyguanosine (O6Me dG) does not block replication but 
rather preferentially base pairs with thymidine, leading to a mutation (Figure 4).9,31 The site and 
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identity of alkylation depends on the alkylating agent. For instance, the products of TMZ and DTIC 
do not resemble the cross-link formed from cisplatin. 
 
Figure 3. Structures of alkylating agents. 
DTIC is oxidized by cytochrome P450 (CP450) in the liver. TMZ and DTIC undergo 
hydrolysis and decarboxylation to a common intermediate (I) (Figure 4). A diazonium ion is 
released that reacts with a nucleophile in DNA.8 This results in the methylation of bases, which in 
some cases lead to the accumulation of apurinic/apyrimidinic (AP) sites in the DNA. TMZ is used 
to treat brain tumors and gliobastoma and DTIC is often used to treat skin cancer and Hodgkin’s 
lymphoma. 























































































Cisplatin is an alkylating-like platinum agent that reacts with deoxyguanosine in DNA. 
Depending on the local DNA sequence, this forms a cross-link between two adjacent guanines in 
the same strand (Figure 5). This forms a severe kink in the DNA, preventing normal cellular 
processes, like replication. Cisplatin therapy is effective in the treatment of testicular, ovarian, 
bladder, and cervical cancers.3,32  
 
Figure 5. Cisplatin DNA adduct. 
 
2.1.2 Antimetabolites 
Antimetabolites mimic the cell’s normal building blocks and substrates to disrupt cellular 
processes.3 Some examples of antimetabolites include methotrexate and 5-fluorouracil. 
Methotrexate inhibits dihydrofolate reductase, an enzyme that converts dihydrofolic acid 
to tetrahydrofolate (Figure 6). Tetrahydrofolate is a cofactor of many enzymes, including those 
involved in the biosynthesis of amino acids and nucleotides. Therefore, methotrexate blocks the 
synthesis of DNA by reducing the production of nucleotides. It is the primary antifolate used in 
chemotherapy to treat breast, ovarian, bladder, and head and neck cancers.33  
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Figure 6. Methotrexate mechanism of action. 
 
The antimetabolite, 5-fluorouracil (5FU), is used to treat breast, bowel, skin, and pancreatic 
cancer. This agent mimics the structure and size of natural nucleobases, uracil and thymine (Figure 
7). Enzymes involved in the biosynthesis of nucleotide triphosphates accept 5FU. Specifically, 
thymidylate synthase, the enzyme responsible for the synthesis of thymidine is inhibited by 5FU. 
This interaction blocks the synthesis of thymidine, one of the nucleosides required for DNA 
replication.34  


















































































2.1.3 Anti-tumor antibiotics 
Another popular class of chemotherapeutics is anti-tumor antibiotics. Within this class are 
two major subclasses: anthracyclines and non-anthracyclines. Anthracyclines interfere with 
enzymes involved in DNA replication by binding to the DNA. One of the most well-known 
anthracyclines is doxorubicin (Figure 8). Doxorubicin is a highly potent cancer drug and is used 
to treat a wide range of cancers, including liver, kidney, leukemia, gastric, and several others. 
Doxorubicin intercalates DNA and inhibits the progression of topoisomerase II, an enzyme 
responsible for relaxing supercoils in DNA that is required for DNA replication.3 
Figure 8. Structures of anti-tumor antibiotics. 
 
Non-anthracyclines damage DNA and induce cell death by some other mechanism. An 
example of this subclass is bleomycin (BLM) (Figure 8).35,36 There are a few 
derivatives in the BLM family (e.g. pingyangmycin, Blenoxane) that 
oxidatively damage DNA. It is typically used for squamous cell carcinomas, 
germ cell tumors, Hodgkin’s lymphomas, and testes tumors. BLM can be 
more effective when applied in combination treatment with other 
chemotherapeutics.3,37 For example, the cure rate for disseminated testicular 
cancer increased from 5% to 90% when cells were treated with a combination of BLM, etoposide 
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(a topoisomerase inhibitor, Section 2.1.4), and cisplatin.3 BLM forms a reactive radical in a metal-
dependent manner.35,36 The resultant radical abstracts the C4’-hydrogen from the sugar moiety and 
results in oxidized AP lesion, C4’-oxidized AP lesion (C4-AP), or a single strand break (SSB) 
(Scheme 2).36,38  
Scheme 2. Mechanism of BLM products. 
 
2.1.4 Other classes of chemotherapeutics 
Many other classes of chemotherapeutics exist, such as topoisomerase inhibitors, mitotic 
inhibitors, and several others.3 Topoisomerases are enzymes that participate in DNA unwinding 
that is  necessary for the initiation of replication.39 Topoisomerase inhibitors, such as etoposide, 
are used to treat certain leukemias, as well as lung, ovarian, colorectal, and pancreatic cancers.3,39 
Mitotic inhibitors typically inhibit enzymes that are required for cell division.40 Examples of 
mitotic inhibitors include Cabazitaxel (a derivative of taxol) and Vinblastine that are usually used 
in the treatment of breast, lung, myelomas, lymphomas, and leukemias.3,40 While there are many 
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other examples of clinically relevant chemotherapeutics, these drugs typically interrupt normal 
cellular division and replication, resulting in cell death and reducing proliferation in tumor cells. 
 
2.2 DNA Damage 
 DNA damage is an inescapable aspect of life. Every cell’s DNA experiences some form of 
damage at least 10,000 times per day.41 Multiple forms of DNA damage exist, each with different 
consequences, toxicity, and mechanisms for repair. Genomic integrity is threatened by endogenous 
sources and exogenous sources. Endogenous sources include spontaneous hydrolysis of the 
glycosidic bond and reactive oxygen species (ROS) that our own metabolism generates during 
cellular respiration. Exogenous physical and chemical sources include IR due to sun exposure and 
industrial pollutants. The damage can result in modification or loss of the nucleobase, oxidation 
of the deoxyribose sugar, and/or a break in the phosphodiester backbone (Figure 9).  
 It is crucial to understand how each lesion is formed, how frequently it occurs, and how it 
affects cellular processes. While some lesions are repaired efficiently, others lead to more 




Figure 9. Representative types of DNA damage. 
 
 2.2.1 Abasic Sites 
 AP sites are formed from hydrolysis of the nucleobase moiety of DNA (Scheme 3). The 
rate of depurination is very slow (k = 4 x 10-9 s-1 at 70o C and pH 7.4, t1/2 = 730 yrs).
44 Despite the 
slow rate, 10,000-20,000 AP lesions are formed in a cell every day due to the large size of the 
human genome, making it the most commonly produced DNA lesion.44,45 The rate of hydrolysis 
increases in response to treatment with alkylating agents because alkylated bases are better leaving 
groups.4 An AP lesion is the product of N-glycosylases that are involved in the repair of damaged 
nucleotides (Section 2.3). 
Scheme 3. Formation of AP sites. 
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 AP sites are efficiently repaired by a process known as base excision repair (BER) under 
normal cellular conditions (See Section 2.3.1). However, if left unrepaired, AP sites can lead to 
more deleterious forms of damage, such as interstrand crosslinks (ICLs) with the exocyclic amine 
of dG and dA.46,47 Unrepaired AP sites can lead to increased levels of DNA strand cleavage. The 
AP site is a cyclic hemiacetal that exists in equilibrium with the ring-opened aldehyde (Scheme 
3), which can undergo -elimination to yield a single strand break (SSB).48,49 In addition, AP sites 
block replicative polymerases during DNA synthesis, resulting in fork collapse if not bypassed by 
a translesion synthesis polymerase (Section 2.3.1.1.3).50 An AP lesion does not have a Watson-
Crick base-pair and, therefore, does not translate information to polymerases during replication. 
When a polymerase encounters an AP site, an adenosine is most often incorporated opposite the 
AP site. Therefore, AP is usually a pro-mutagenic lesion. 
 2.2.2 Oxidative DNA Damage 
 DNA is frequently damaged by oxidation. Intracellular oxidizing agents are produced by 
cellular respiration. ROS are produced endogenously (and exogenously) and their formation is 
initiated by the formation of superoxide anion from the reduction of molecular oxygen.51 
Superoxide dismutase processes the superoxide 
anion into hydrogen peroxide and oxygen.52 
Hydrogen peroxide is detoxified by catalase. 
However, in the presence of iron (Fe) hydrogen 
peroxide generates the highly reactive hydroxyl radical (HO•) via Fenton chemistry.53  
 Radiation therapy also relies on the formation of HO• in tumors from the direct ionization 
of water by -radiolysis.54 HO• is highly reactive and unselective. It abstracts hydrogens from the 
sugar moiety and directly damages the nucleobases in DNA by adding to -bonds. Nucleobase 
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Fe2+ + H2O2 Fe
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modification accounts for as much as 90% of HO• reactivity, while sugar oxidation accounts for 
less than 10%.55  
 2.2.2.1 Sugar Oxidation 
 Sugar oxidation occurs from the hydrogen abstraction from the sugar ring. Different 
oxidized abasic lesions are formed depending on the carbon position (Figure 10). Due to the high 
reactivity of HO•, hydrogen abstraction is typically governed by accessibility.56 C5’-hydrogen 
abstraction accounts for more than 50% of the HO• sugar oxidation reactivity while C4’-hydrogen 
abstraction accounts for about 20%.56  
 
Figure 10. Oxidized abasic lesions. 
 
 Sugar oxidation is also caused by exogenous radiomimetics, like BLM and 
neocarzinostatin (NCS). NCS is a bacterial natural product and is part of the enediyne family. 
Enediynes feature a macrocyclic ring with a conjugated system 
containing at least one double and two triple bonds. These minor 
groove binders are activated by reaction with a thiol (RSH) (Scheme 
4). The subsequent cycloaromatization forms a benzenoid diradical 
(NCS•). This highly reactive intermediate abstracts hydrogen atoms 




Scheme 4. Activation of NCS. 
 
NCS abstracts the C5’-, C4’-, and/or C1’-hydrogen from the 2’-deoxyribose. C1’-hydrogen 
abstraction yields the oxidized abasic lesion, 2-deoxyribonolactone (L) (Scheme 5, left). The 
mechanism of the C5’-hydrogen atom abstraction product formation is unclear but was proposed 
to go through a peroxyl radical intermediate (P) (Scheme 5, right).58 Intermediate P primarily leads 
to the 5’-aldehydes (B-al) (Scheme 5).58 A minor reaction pathway of P involves Criegée 
rearrangement (R) to release the upstream DNA with a 3’-formyl phosphate termini and an 
oxidized abasic lesion, 5’-(2-phosphoryl-1,4-dioxobutane) (DOB). 
 




 The other oxidized abasic lesion, C4-AP, is formed from C4’-hydrogen atom abstraction, 
(Scheme 2). These lesions (i.e. DOB, C4-AP, and L) are produced from NCS 
treatment. C4-AP produced is more frequently by BLM, where the C4’-position 
of the sugar is the primary target of BLM.  
 Oxidized AP lesions can lead to secondary forms of damage that occur due to their 
spontaneous reactivity. Oxidized AP lesions lead to the formation of more detrimental forms of 
damage, including ICLs, DNA-protein crosslinks (DPCs), and SSBs.42,59,60 The acyclic 1,4-
dialdehyde of DOB yields ICLs selectively with the exocyclic amine of dA opposite a 3’-adjacent 
dT.61 DOB also undergoes spontaneous -elimination to produce but-2-ene-1,4-dial, which forms 
pro-mutagenic exocyclic adducts with dA, dC, and dG.62–64 DOB and pC4-AP form DPCs with 
and inactivate the DNA repair enzyme, DNA polymerase  (Pol ) (Section 2.3.1.2).59 In a similar 
fashion, DOB and C4-AP also covalently modify lysine residues of histone proteins in the context 
of the nucleosome core particle (NCP).65,66 In addition, C4-AP forms ICLs with dC in DNA in 
response to BLM or IR, which was converted to a double strand break (DSB) when incorrectly 
repaired in vitro.67,68 The biological relevance of these reactions is unclear because the rate of ICL 
formation with oxidized AP sites is slow in vitro. Despite the low probability of ICL formation, a 
low frequency of ICL events can still present a negative biological effect. The detection of ICL 
formation between C4-AP and dC in cells support it’s biological relevance.67  
 2.2.3 Single strand breaks 
 The formation of SSBs in DNA is critically important in understanding DNA damage. 
SSBs are often formed from the processing and inherent reactivity of less deleterious damage (e.g. 
modified bases, sugar oxidation).43 For example, the major product of C4’ sugar oxidation is a 
single strand break with an unnatural terminus (i.e. 3’-phosphoglycolate). If left unrepaired, SSBs 
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can lead to a more dangerous DSB upon DNA replication. Therefore, proper repair of SSB is 
essential for maintaining genomic integrity.  
2.3 DNA Repair 
 To combat the toxicity of multiple forms of DNA damage, several DNA repair processes 
exist that focus on the removal and repair of limited sets of modifications (Figure 11). BER repairs 
non-bulky modifications to the nucleobase that may arise from oxidation, alkylation, or 
deamination, as well as AP and, albeit less efficiently, oxidized AP lesions.30,69 Nucleotide 
excision repair (NER) repairs bulky DNA adducts, ICLs, and nuclebase photodimers via the 
excision of several nucleotides in the damaged strand of DNA, followed by gap-filling and 
ligation. Mismatch repair (MMR) recognizes errors of DNA replication that result in a mismatch 
and excises the mis-incorporated nucleotide and inserts the correct base to restore the DNA. 
Homologous recombination (HR) and non-homologous end joining (NHEJ) repair DSBs and some 
types of ICLs.69,70  
Figure 11. Overview of DNA damage and repair pathways. 
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 2.3.1 Base Excision Repair  
There is a misconception that commonly formed lesions, such as small non-bulky adducts, 
AP sites, and SSBs, exhibit less severe biological consequences in the hierarchy of DNA damage.43 
However, the frequency and abundancy of these lesions present complications for the cell. BER 
acts on these lesions, is active in all aspects of life, and its contributing enzymes are constituitively 
expressed in mammalian cells.71 BER primarily acts on lesions that arise from alkylation and 
oxidation (Figure 12).71–75 This includes small methylation adducts, like Me3 dA, a cytotoxic 
replication-blocking lesion (Figure 4).71,74 This also includes damage formed from oxidizing 
agents, like 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) or thymine glycol (Tg).76,77 Another 
BER substrate is deoxyuridine (dU), which results from spontaneous deamination of cytosine or 
misincorporation during DNA replication.71,72,74 
Figure 12. Representative lesions that are repaired by BER. 
 
 BER is complex but can be divided into two major mechanisms: short-patch BER (SP-
BER) and long-patch BER (LP-BER) (Figure 13). The major difference between the two routes is 
the number of nucleotides incorporated during the polymerase step. LP-BER incorporates patches 
greater than one nucleotide (nt) and SP-BER incorporates a single nt.20,70 
 The general mechanism of SP-BER utilizes four major enzymes to carry out five steps 
(Figure 13a).70,78 Briefly, an N-glycosylase removes a damaged base by cleaving the glycosidic 
bond to reveal an AP site. In the case of spontaneous depurination of DNA or oxidized AP site 
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repair, this first step is unnecessary. The AP site is recognized by AP endonuclease 1 (Ape1). Ape1 
cleaves the phosphodiester bond 5’ to AP, generating a strand break with 3’-OH and 5’-
deoxyribose phosphate (5’-dRP) termini.79 The following two steps are carried out by Pol . The 
Pol  lyase domain removes the 5’-dRP group via -elimination to yield a 1-nt gap in DNA, which 
is filled in by Pol ’s polymerase domain.80–82 The resulting nick in the DNA is sealed by DNA 
ligase. 
 
Figure 13. Mechanisms of (a) SP-BER and (b) LP-BER. 
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In LP-BER, after the removal of the 5’-dRP termini, nucleotides are incorporated by Pol 
 (Scheme 13b). It has also been proposed that a higher fidelity polymerase, like Pol  or  may 
displace Pol  and incorporate multiple nucleotides to create a ~50-nt flap.20,69 This flap is removed 
by flap endonuclease 1 (FEN1).20 
There are at least 11 glycosylase enzymes in mammanlian cells that remove damaged or 
incorrect nucleobases.72,83 Glycosylases utilize a base flipping mechanism to excise the damaged 
nucleobase.75,83 Most glycosylases utilize base-flipping to search for and replace a damaged base 
in the genome.75,84 For example, uracil DNA glycosylase (UDG) inserts the hydrophobic side chain 
of a leucine residue into the DNA to disrupt the duplex and flip uracil into the active site of the 
glycosylase.75 In contrast, thymine DNA glycosylase (TDG) introduces an arginine residue into 
the minor groove of the DNA to search for a T-G mismatch and upon recognition, flips thymidine 
out of the duplex for cleavage.84 
SP-BER can proceed through a different mechanism depending on the identity of the 
glycosylase. Glycosylases are further classified as monofunctional or bifunctional enzymes. A 
monofunctional DNA glycosylase (e.g. UDG, SMUG1, TDG, MutYH) catalyzes the hydrolysis of 
the glycosidic bond (Scheme 6a). Bifunctional glycosylases (e.g. hNTH1, hOGG1, hNEIL) 
possess AP lyase activity, which would negate the need for some enzymes in the BER pathway 
(i.e. Ape1 in some instances, Pol ).82 However, the AP lyase activity of some bifunctional 
glycosylases (i.e. hNTH1, hOGG1, hNEIL3) is relatively weak and can be overridden by Ape1, 
reverting to a mechanism of a monofunctional glycosylase (Scheme 6a).85–88 In the case of a 
bifunctional glycosylase containing AP lyase activity, other enzymes are required for processing 
the ends of the strand break to create a suitable substrate for Pol ’s polymerase activity. For 
example, human oxoguanine glycosylase (hOGG1) recognizes 8-oxodG and cleaves the N-
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glycosidic bond. The lyase activity of hOGG1 catalyzes a -elimination, yielding an 3’-dRP and 
the 5’-phosphate (Scheme 6b). Ape1 hydrolyzes the phosphate backbone to reveal a 1 nt gap with 
3’-OH and 5’-phosphate groups. On the other hand, glycosylase activity of human Nei-like DNA 
glycosylase (hNEIL) proceeds through -elimination, followed by -elimination to leave a 3’-
phosphate and 5’-phosphate (Scheme 6c). The 3’-phosphate is processed by the phosphatase 
activity of polynucleotide kinase (PNK).82 
Scheme 6. General mechanism of (a) monofunctional glycosylase, (b) bifunctional glycosylase 
that catalyzes -elimination, (c) bifunctional glycosylase that catalyzes -elimination. 
 
In the case of a monofunctional glycosylase, Ape1 hydrolyzes the DNA on the 5’ side of 
an AP site. Ape1 is very efficient at this reaction (single turnover rate constant (kST) = 850 s
-1, 
steady state rate constant (kSS) = 2 s
-1).89 Ape1 also recognizes oxidized AP sites, albeit at a much 
lower efficiency (i.e. 5- to 10-fold less relative to AP).90,91 Ape1 is important for cell viability. 
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Knockout of Ape1 is embryonically lethal in mice.92 Furthermore, Ape1 is overexpressed in many 
cancer cell lines and its inhibition enhances the cytotoxicity of DNA damaging agents.2,93 
The major BER polymerases in humans are Pol  and DNA polymerase  (Pol ).69 These 
polymerases belong to the X-family. Other polymerases that possess dRP lyase activity, such as 
polymerase  (Pol ) and polymerase  (Pol ), have been implicated in BER.94 Pol  knockdown 
cells have been linked to a deficiency in BER.95 Separately, Pol  knockout cells exhibited 
increased sensitivity to oxidative stress caused by H2O2.
96 
 BER polymerases must catalyze two of the five steps in BER, with the exception of 
bifunctional glycosylases that catalyze -lyase activity. Pol  and Pol  each possess an 8 kDa 
lyase domain separate from their polymerase domain. Pol  is a 39 kDa enzyme. Pol  is larger 
(68 kDa) and possesses a BRCA1 C Terminus (BRCT) domain, which is utilized for protein-
protein interactions in the enzyme’s role in NHEJ.97 Despite these differences, the polymerases 
share substantial sequence homology (~32%) and the polymerase domains of each enzyme share 
more than 50% sequence identity.98–100 In contrast to many other polymerases, Pol  and  lack a 
3’-5’ exonuclease domain and have high error rates (10-4 compared to 10-6-10-8 for replicative 
polymerases) in mammalian cells.101 The primary role of these polymerases is not in replication 
but rather in maintaining genomic integrity.82  
 2.3.1.1 DNA Polymerase  
 There are 17 eukaryotic polymerases and 13 of these have roles in DNA repair. Pol  is 
one of four polymerases in the X-family: Pol , Pol , DNA polymerase  (Pol ), and terminal 
deoxynucleotidyl transferase (TdT).69 Pol  and TdT are primarily used in DSB repair, including 
NHEJ and Variable Diversity Joining (V(D)J) recombination. Pol  is the main polymerase in 
BER, while Pol  is considered a back-up polymerase to Pol  and has its own role in other repair 
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pathways, including NHEJ and V(D)J recombination.97,102 Pol  consists of two major domains: 
an 8 kDa amino terminal lyase domain (residues 1-87) and a 31 kDa carboxy terminal polymerase 
domain (residues 88-334) that are linked together through a protease sensitive region between 
residues 82-86.80,82,103 
 Binding studies of the two domains of Pol  show that the 8 kDa N-terminal domain has a 
higher affinity for single strand DNA (ssDNA), while the 31 kDa C-terminal domain binds double 
stranded DNA (dsDNA), deoxynucleotide triphosphates (dNTPs), and possesses polymerase 
catalytic activity but no ssDNA binding capacity (Figure 14).104 The crystal structure of Pol  
shows that the 31 kDa domain has three subdomains resembling a right hand: thumb (D), palm 
(C), and finger (N) subdomains, which has been observed in other polymerases (Figure 14).105 Pol 
 has a higher affinity for duplex DNA with nicks bearing 3’-OH/5’-PO4 termini.
81 On nicked 
DNA bearing a 5’-dRP group, Pol  performs both the dRP lyase and gap-filling polymerase 
activity (Figure 13).10  
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Figure 14. Structure of Pol  (PDB: 1BPD). Key: Lyase = 8 kDa Lyase domain; D = thumb, 
dsDNA binding subdomain; C = palm, catalytic subdomain; N = finger, dNTP binding subdomain 
of the 31 kDa polymerase domain. 
 
2.3.1.1.1 Pol  8 kDa Lyase domain 
The 8 kDa domain of Pol  is responsible for releasing the 5’-dRP group via a -elimination 
mechanism (Scheme 7). Based on the detection of the elimination product (X), researchers 
proposed that a Schiff base intermediate would form between the C1’ position of the AP and the 
active site lysine (Lys) in the 8 kDa lyase domain.105 Treatment with NaBH4 trapped the Schiff 







Scheme 7. Proposed mechanism of 5’-dRP lyase activity. 
 
The AP site is a cyclic hemiacetal that exists in equilibrium with the ring-opened aldehyde. 
However, the equilibrium lies more heavily on the ring-closed conformation, with only about 1% 
of the aldehyde present.48 Schiff base formation requires opening of the dRP ring to the C1’ 
aldehyde. The ring opened form occurs intrinsically during the interconversion between the - and 
-sugar configurations. It is possible that the active site Lys activates the hemiacetal mixture by 
protonation of the O4’ to promote ring opening and formation of the more nucleophilic, neutral 
Lys.105 When the iminium ion forms, the pKa of a C2’ hydrogen is reduced and deprotonation 
triggers -elimination, resulting in the 3’-C-O bond cleavage. Two models were proposed to 
explain Pol  recognition of the AP site. The first model involves a base-checking mechanism 
where a nucleophilic Lys residue in the lyase domain scans the DNA by forming hydrogen bonds 
(H-bonds) with the nucleobases and recognizes the AP site by the lack of H-bonding.106 The second 
model proposed that a histidine residue swings into the void created from the missing base in the 











































B = damaged nucleobase
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Schiff base formation by a Lys residue occurs in other enzymes that possess lyase activity. 
For example, Lys120 of the bifunctional glycosylase E.coli Nth catalyzes -elimination via schiff 
base formation. Site-directed mutagenesis experiments suggest that Pol  Lys72 (K72) is the 
primary amine that forms the Schiff base with the AP site in DNA.105 The K72R mutant still 
performs DNA synthesis but is unable to repair dRP sites. Mutants of the 8 kDa domain (K72R 
and K72Q) completely lost the ability to excise 5’-dRP, even though they were still able to form 
imine intermediates, albeit to a lesser extent than the wild type (WT) 8 kDa domain.105,107 In a 
separate experiment, the K72A mutant only reduced AP repair to 30% that of the WT Pol . The 
partially retained lyase activity of K72A mutant indicates that a different Lys residue in the active 
site may be able to substitute for K72 in its absence to carry out -elimination.103 The 8 kDa domain 
mutant containing K84A did not impair dRP lyase activity but the crystal structure of the enzyme 
suggests that K84 is the only Lys residue in the active site pocket close enough to the C1’ position 
capable of substituting for K72 in its absence.108 
Other lyase enzymes also typically use carboxylate or histidine side chains to deprotonate 
the C2’-H during -elimination but it is unclear whether Pol  has an appropriate residue that is 
suitably positioned.109 Analysis of a model with Pol  in complex with DNA containing a 
tetrahydrofuran (THF) analog of an AP site suggests Glu26 or Glu71 may be in close proximity to 
activate a water molecule for C2’-H deprotonation.107,108 
 2.3.1.1.2 Pol  31 kDa Polymerase domain 
 
The 31 kDa domain is responsible for polymerase activity and depends on the presence of 
two magnesium ions (Mg2+) that stabilize the transition state and orient the incoming dNTP in the 
correct position.110,111 The magnesium ions are observed in the crystal structure bound to all three 
phosphates of the incoming dNTP, as well as the side chain oxygens of the catalytic triad (Asp190, 
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Asp192, and Asp256), which are are required for catalysis. Catalysis occurs when the lyase domain 
closes in relation to the thumb domain, which may happen via favorable hydrophobic and van der 
Waal contacts between the thumb domain and the sugar moiety of the incoming nucleotide when 
the correct dNTP is present in the active site of the enzyme (Figure 15).112  
Figure 15. Overlay of DNA-unbound (PDB: 1BPD, teal/pink/yellow/orange) and DNA-bound 
(PDB: 1BPX, blue/gray) crystal structures of Pol . Key: Lyase = 8 kDa Lyase domain; D = thumb, 
dsDNA binding subdomain; C = palm, catalytic subdomain; N = finger, dNTP binding subdomain 
of the 31 kDa polymerase domain. 
 
When the correct dNTP is inserted into the active site, the 3’-OH is activated and attacks 
the -phosphate of the dNTP, elongating the primer strand and a pyrophosphate is released 
(Scheme 8). Pol  exhibits lower fideltiy compared to replicative polymerases and, therefore, is 







may be due to the higher acceptance of metal ion cofactors other than Mg2+.112,113 This was 
observed in Pol  crystals when non-templated nucleotidyl transfer occurred in the presence of 
Mn2+.114 The acceptance of Mn2+ by Pol  resulted in greater mutagenicity by promoting greater 
reactivity. Inclusion of other metal ion cofactors potentially alters the position of the nucleotide in 
the active site and lead to lower selectivity in distinguishing between nucleotides.112 
Scheme 8. Mechanism of polymerase activity. 
 
 Based on the crystal structure of Pol  complexed with DNA, several residues were 
identified that are important for binding interactions and catalytic function.115,116 Lys234, Arg254, 
Lys280, Arg283, Asn294, Glu295, and Tyr296 interact with the template DNA (Figure 16). Site-
directed mutagenesis experiments indicate Asn294 and Glu295 contribute significantly to the 
polymerase activity of Pol .117,118 Of the DNA binding residues, Lys234, and Arg254 are invariant 
across X-family polymerases.117 Residues Arg149, Ser180, Arg183, Ser188 interact with the 
incoming dNTP. Arg183 and Ser180 make direct contacts with the - and -phosphates of the 
dNTP and, indeed, alanine mutants of each position display a decrease in the catalytic function, 
suggesting they may play a role in stabilizing the transition state of the reaction.118 As expected, 
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mutation of any of the aspartate residues in the catalytic triad (Asp190, Asp192, and Asp256) result 
in a loss of catalytic activity.118 
Figure 16. Orientation of DNA binding residues (sticks). 
 
2.3.1.1.3 The effects of Pol  levels in cells 
Pol  is crucial for cell viability and its regulation is important for normal cellular functions. 
In cells that overexpress Pol , sequestration of telomeric repeat-binding factor 2 (TRF2) leads to 
premature telomere end fusion.101 Briefly, telomere end fusion occurs when two chromosome ends 
are linked together after telomeres lose their protective proteins (i.e. TRF2) and leads to problems 
with proper segregation during mitosis and meiosis (Figure 17).119 An overabundance of Pol  










Figure 17. Telomere fusion can arise from Pol  overexpression.  
 
In addition, two-fold overexpression of Pol  was found to promote genomic instability 
due to Pol  substitution for replicative and recombination pathways, processes that typically rely 
on high fidelity polymerases.11 For instance, Pol  overexpression in Chinese hamster ovary 
(CHO) cells resulted in a 4-12 fold increase in mutational events in cells. These cells also exhibited 
reduced sensitivity to bifunctional DNA-alkylating agents (e.g. cisplatin) because Pol  bypassed 
the lesions during translesion synthesis.11 Briefly, translesion synthesis (TLS) is a DNA damage 
tolerance process that allows DNA replication machinery to replicate past a lesion via TLS 
polymerase switching (Figure 18).120 Together, the reduced sensitivity and increased genomic 
instability phenotype in cancer cells may promote cancer progression.  
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Figure 18. Simplified mechanism of translesion synthesis. 
 
Pol  is constituitively expressed but is adaptive to cellular conditions. Expression of Pol 
, and in turn BER, is up-regulated in response to oxidative stress.121 For instance, oxidative stress 
induced by treatment with lipopolysaccharide (LPS) in mouse monocytes increases the expression 
of Pol . This led to increased BER activity in cells. LPS treatment in Pol  null cells exhibited 
more DNA damage, consistent with the idea that oxidative stress decreased the accumulation of 
DNA lesions on account of elevated levels of Pol -dependent BER.121 
Many cancer cells exhibit higher levels of DNA damage and generation of ROS. Pol  is 
overexpressed in many cancer cell lines.11 Overexpression is accompanied by decreased sensitivity 
to anticancer drugs, including cisplatin.11 In fact, the Pol  overexpression was associated with 
tumor metastasis and poor prognosis in esophageal cancer patients.122 This is likely to be disease-
dependent considering that low Pol  levels were also associated with aggressive phenotype and 
poor prognosis in breast cancer.123 Regardless, a decrease in BER due to Pol  inhibition precludes 
the reduced sensitivity to anticancer drugs. The reverse also holds true in that low levels of Pol  
expression result in deficient BER and hypersensitivity to DNA-damaging agents.4,14,19,78,124 
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A decrease in Pol  activity was first analyzed by using its own subdomains that lack 
polymerase activity. A 14 kDa truncation of the enzyme consisting of the lyase domain and the 
DNA binding domain (Figure 15, Lyase and D subdomains) that is capable of binding ssDNA and 
dsDNA but incapable of catalyzing polymerization is a competitive inhibitor of the intact enzyme. 
This truncated enzyme competed with Pol  for the primer-template substrate, reduced Pol  
activity, and decreased BER efficacy in vitro.124 The 14 kDa domain inhibited Pol  activity to a 
greater extent than the Klenow Fragment and Pol , two non-homologous polymerases, likely due 
to differences in substrate binding.124 Pol , as well as the 14 kDa truncation, acts on gapped DNA 
containing 3’-OH/5’-phosphate termini and this binding mode is unique to Pol .81 
Furthermore, Pol  knockout mice embryonic fibroblasts (MEFs) exhibited higher levels 
of cell death when exposed to monofunctional alkylating agents: methyl 
methanesulfonate (MMS), ethyl methanesulfonate (EMS), N-methyl-
N-nitrosourea (MNU), and N-methyl-N-nitrosoguanidine (MNNG).14 
Furthermore, Pol  knockdown by RNA interference (RNAi) induced 
hypersensitivity to MMS in MEFs.19 Pol -deficient cells were not hypersensitive to bifunctional 
alkylating agents, such as cisplatin and nitrogen mustard, as these tend to form bulkier lesions that 
require NER instead of BER. In addition, a lack of Pol  also does not enhance IR cytotoxicity.14,19 
Cell sensitivity to BLM in response to Pol  deficiency is inconsistent across several 
existing studies.17,18,125 Knockdown of Pol  in MEFs exhibited BLM hypersensitivity and 
increased oxidative damage and gene mutations.125 Pol  deficiency induced by triterpenoid 
inhibition resulted in the potentiation of BLM cytotoxicity.18 Similarly, suppression of the lyase 
activity via plant sterol inhibitors produced the same result.17 However, other studies report no 
significant BLM sensitivity in Pol  knockout MEFs and knockdown by RNAi.14,19,126 Altogether, 
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there are more reports that Pol  inhibition enhances BLM sensitivity; however, the reason for 
conflicting results is still unclear. 
 Balanced levels of Pol  are important for genomic stability. Knockouts of Pol , similar 
to other DNA repair enzymes, are embryonic lethal in mice.127,128 Embryonic lethality arises when 
gene expression is required during embryogenesis. Lack of Pol  during embryonic development 
results in embryo death. However, knock down of Pol  in mature cells does not lead to cell death. 
Several active Pol  variants have been identified in patient tumors (Section 2.5.1).13,129–131 The 
presence of cancer-specific mutants is significant because it presents a space for developing 
inhibitors that will preferrentially target mutants associated with a certain cancer over WT Pol  
in healthy cells. If successful, this strategy could reduce non-specific toxicity associated with 
chemotherapeutics. 
 2.3.1.2 BER inhibition by oxidized AP lesions 
 Oxidized AP lesions are processed with varied success by BER enzymes.30,91,132 Ape1 acts 
on DNA containing L and C4-AP lesions at a slower rate than incision of DNA containing AP.90,91 
In addition, Pol  is irreversibly inhibited by DOB and pC4-AP lesions by forming a covalent 
adduct with the active site Lys residue.29,30  
 As mentioned before, antitumor antibiotics, BLM and NCS, induce DNA damage via sugar 
oxidation and are very cytotoxic (Section 2.2.2.1). In an attempt to understand how these agents 
were so effective at killing cells, oligonucleotides containing oxidized AP lesions, DOB and pC4-
AP, were synthesized and used as homogenous substrates for Pol .29 The more potent inactivator 
of Pol , DOB covalently modified Lys72 and Lys84, consistent with inactivation by Schiff base 
formation between a active site Lys and the dialdehyde of DOB. With radiolabeled substrates, it 
was determined that 90% of the inhibition occurs from direct trapping by DOB and 10% occurs 
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from the release of butenedial that reacts with the enzyme (Scheme 9).29 Product analysis of Pol  
with DOB-containing DNA with and without FEN1 exhibits limited polymerase activity, 
suggesting DOB inhibits both SP-BER and LP-BER.30 The inhibition of Pol  by oxidized AP 
lesions can lead to more severe biological consequences than decreased BER. For example, DOB 
inactivation of Pol  led to strand breaks in a trinucleotide repeat (TNR) tract, which has 
implications in neurodegenerative diseases.133 
 
Scheme 9. Inactivation of Pol  by DOB. 
 
Inhibition of Pol  by DNA containing these lesions are not selective. For instance, pC4-
AP also inactivates Pol  and Pol  at the active site Lys residue in the respective lyase 
domains.134,135 Oxidized AP lesion, DOB, also inactivates Pol  and DNA Ligase I.133,134 This is 
significant because Pol , whose primary role is in NHEJ to repair DSBs, acts as a back-up 
polymerase in BER. Inactivation of both Pol  and Pol  may assist in toxicity to cells. In a similar 
way, the inhibition of both enzymes may increase the ability of DOB to decrease BER activity. In 
contrast, inhibition of multiple enzymes is generally undesired as it decreases selectivity and may 
induce adverse effects. 
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2.4  DNA Repair Inhibition 
DNA repair is a crucial mechanism for drug resistance pertaining to drugs that damage 
DNA.1 BER plays a role in resistance to alkylating agents by removing drug-induced DNA lesions. 
In addition, NER confers resistance against crosslinking agents, such as cisplatin. Importantly, 
tumor cells often have higher levels of certain DNA repair pathways to combat increased levels of 
DNA damage and maintain enough genomic integrity to avoid apoptosis. Reducing the 
effectiveness of repair pathways may capitalize on the difference between cancerous and healthy 
cells.101 Therefore, repair inhibition is an attractive route to enhance cell sensitivity to DNA 
damaging agents.14–19 
DNA repair inhibition is a growing field and therapeutic targets have been identified as 
possible routes to induce apoptosis in cancer cells as a monotherapy or to enhance the cytotoxicity 
of cancer therapeutics through combination therapy.2,20,70 Noteworthy targets of BER inhibition 
include Ape1 and poly (ADP-ribose) polymerase (PARP).2 Ape1 inhibition is unique to other 
targets because Ape1 also regulates reduction-oxidation activities in cells.92 Small molecule 
inhibition of Ape1 enhances the cytotoxicity of DNA damaging agents, like MMS, H2O2, BLM, 
TMZ, cisplatin, and IR.2 While some Ape1 inhibitors are nonspecific BER inhibitors, others are 
specific to Ape1 and are in various phases of clinical trials.2 
One of the most successful examples of DNA repair inhibitors are PARP inhibitors 
(PARPi), such as olaparib or rucaparib, in the treatment of breast and ovarian cancer (Figure 
19).136,137 PARP is involved in repair through the recognition of SSBs, synthesis of poly-ADP 
ribose (PAR), and recruitment of other enzymes to initiate DNA repair.138 PARPi trap PARP on 
the DNA and form PARP-DNA complexes. PARP-DNA complexes block the progression of the 
replication fork during DNA synthesis and lead to the formation of DSBs.139  
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Figure 19. Structures of PARPi. 
 
PARPi take advantage of an interaction called synthetic lethality. Two genes are considered 
synthetic lethal when a deficiency in both leads to cell death, whereas a deficiency in one of those 
genes does not. Treatment with a PARPi is most effective in patients with the BRCA1-mutant, a 
gene that encodes a tumor suppressor protein that functions in HR.139,140 The BRCA1 mutation in 
cells results in a deficiency in HR DSB repair and the cell resorts to error-prone NHEJ.2 More 
clearly, PARP inhibition is not toxic to healthy cells that are proficient in HR. However, the loss 
of both HR and PARP activity in cancer cells results in cell death. The PARP-DNA complex 
formed as a result of PARPi is more cytotoxic than unrepaired SSBs because the repair of the 
PARP-DNA complexes requires multiple enzymatic pathways, including Pol .139 Pol  knockouts 
are associated with PARPi hypersensitivity, suggesting that Pol  inhibitors and PARPi may work 
together to promote cell death.15 Furthermore, Pol  has been postulated to be synthetic lethal in 
homologous recombination deficient cells (e.g. BRCA1/2).12 
2.5 Pol  is an anti-cancer target 
Pol  has been identified as an attractive therapeutic target as a means to enhance the 
cytotoxicity of DNA damaging agents.2,20,21,70,141 Pol  is a good candidate for multiple reasons: it 
is overexpressed in cancer cells, its inhibition has improved the efficacy of chemotherapeutics, 
several variants have been identified in tumors, and it is the primary polymerase in BER. Through 
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the specific and efficient inhibition of Pol  in cancer cells exposed to DNA damaging agents, the 
accumulation of DNA damage induces apoptosis in cells (Scheme 1). 
As mentioned before, the balanced regulation of Pol  is necessary for proper genomic 
maintenance (Section 2.3.1.1.3). However, Pol  is overexpressed in many cancer cell lines, 
including ovarian, colon, and leukemia.11 Overexpression is accompanied with decreased 
sensitivity to anticancer drugs.11 The cancer-specific (in contrast to healthy cells) overexpression 
suggests Pol  activity is more important for cancer cell viability and its inhibition may be more 
toxic to cancer cells than in healthy cells. In contrast, low levels of Pol  expression result in 
deficient BER and hypersensitivity to DNA damaging agents.14,19,124 In support of this, inhibition 
of Pol  enhance the efficacy of chemotherapeutics, such as monofunctional alkylating agents. 
2.5.1 Pol  variants 
There is an abundance and variety of Pol  variants in patient tumors.13,129–131 In fact, Pol 
 mutants were identified in 30% of tumors in different tissues (e.g. colon).13 Variants associated 
with other cancers have also been identified (e.g. gastric and ovarian).130,131 For instance, a T889C 
point mutation in the coding region of the gene encoding Pol , POLB, in gastric tumors resulted 
in mutant L259S and correlates with gene overexpression.130 In colorectal cancer, 40% of patient 
tumors harbor mutations in the POLB gene.13 Of these, 31% of mutations result in an amino acid 
substitution that can alter protein structure and function. Mutations were found in both domains of 
the enzyme and the effect on enzymatic function varied depending on the identity and location of 
the mutant.13,129 
The impact on function was difficult to predict via computational algorithms. For example, 
lyase domain mutant T79I was predicted to have decreased function but in vitro enzyme activity 
was normal relative to WT.13 Alternatively, G231D mutant in the polymerase domain was 
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predicted to be tolerated but the enzyme activity was significantly reduced and resulted in 
chromosomal aberration phenotype, specifically a missing, extra, or irregular portion of 
chromosomal DNA.13,129 Functional Pol  mutants that are expressed in tumor cells represent a 
space to develop selectivity for cancerous cells over healthy cells. This has the potential to reduce 
non-specific toxicity. 
2.6  Pol  inhibitors 
 Reported small molecule Pol  inhibitors include bile acids, sulfolipids, naphthoic acids, 
and others.20,21 Currently, there are no Pol  inhibitors in the clinic because inhibitors identified 
often lack defined selectivity and binding region. In addition, several identified inhibitors exhibit 
poor potency (low M). The potencies of these compounds are typically reported as half maximal 
inhibitor concentration (IC50) values, which is a measurement of the effectiveness of a substance 
and equates the amount required to inhibit half of a specific enzyme (in this case, Pol ).  In some 
cases, the efficiency of an inhibitor is reported as dissociation constant (KD), which is the 
concentration of a ligand needed to occupy 50% of receptors.  
2.6.1  Small molecule inhibitors 
The first small molecule inhibitor(s) of Pol  identified were fatty acids, linoleic acid (LA) 
and nervonic acid (NA) (Figure 20).22,142,143 LA and NA were shown to bind the 8 kDa lyase 
domain and have IC50 values of 38 and 5.8 M, respectively. However, these inhibitors are not 
selective because they also reduce the activity of Pol , a non-homologous polymerase involved 
in the initiation of DNA replication.  
 Other Pol  inhibitors are natural products: koetjapic acid (KA) and pamoic acid (PA) 
(Figure 20).20,144,145 These also bind to the 8 kDa domain of Pol  with varying inhibitory 
efficiencies. KA has a reported IC50 value of 20 M and PA has a KD of 9 M.
144–146 While PA 
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binds the lyase domain, it inhibits both the lyase and polymerase activity of Pol  and was shown 
to enhance the efficacy of alkylating agent, MMS.144,145 
 In addition, lithocholic acid is a bile acid produced in liver cells that is active against Pol 
 (Figure 20).147 This compound binds the 8 kDa domain and exhibits an IC50 = 11 M and KD = 
1.56 mM. Lithocholic acid suppresses both lyase and polymerase activity and inhibits Pol  and 
.147 In addition to the nonselective inhibition of Pol , lithocholic acid interacts with several other 
cellular processes, including p53 degradation, inflammatory reactions, generation of ROS and 
reactive nitrogen species, which promotes colon carcinogenesis.148 
 More recently, honokiol (HKL), a biphenol compound, was identified as a Pol  inhibitor 
(Figure 20). HKL inhibits both Pol  (IC50 = 4.0 M) and Pol  (IC50 = 8.3 M).
25 The inhibition 
of both Pol  and Pol  is significant because this inhibitor can inactivate the primary and back-
up polymerase of BER. HKL inhibits polymerase activity and enhances BLM cytotoxicity in three 
different cancer cell lines.25 
Figure 20. Structures of natural product Pol   inhibitors. 
 As mentioned before, oxidized AP lesions in DNA inactivate Pol  (Section 2.3.1.2).29 This 
discovery inspired the design of a small molecule inhibitor library (1) of dinucleotide analogs that 
mimic the DOB lesion (Figure 21).26 The dinucleotide analog contained a methylene between the 
DOB moiety and the phosphate to improve chemical stability and discourage elimination. 
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Structural diversity was introduced at the 3’ end of the molecule through the introduction of an 
oxime that was diversified using a library of aldehydes. Candidate 2 (IC50 = 21 M) irreversibly 
inhibits Pol  in vitro (Figure 21). A bis-acetate pro-inhibitor (pro-2) was more effective in cell 
lysates and more cytotoxic.26 Pro-2 (20 M) potentiates the cytotoxicity of MMS between 2- and 
5- fold in prostate cancer cells, depending on the alkylating agent concentration. The pro-inhibitor 
is specific for Pol  over Pol  and the Klenow fragment.26 Inhibitor pro-2 is the first known 
irreversible inhibitor of Pol  and its synergistic effect with MMS supports the proposal of using 
a DNA damaging agent simultaneously with a DNA repair inhibitor as a viable cancer therapy. 
Figure 21. Irreversible inhibitor library (1) led to identification of inhibitor (2). 
A second generation inhibitor stemming from the previous study was designed to further 
functionalize pro-2 at the 5-methyl position of the thymidine nucleobase to probe other regions of 
the enzyme.27 Analysis of this new library (3) led to identification of 4 as a 50-fold more potent 
Pol  inhibitor (IC50 = 0.4 M) than previously studied 2 (Figure 22). Compound 4 also inhibits 
Pol  (IC50 = 0.25 M), which may enhance toxicity by inactivating both BER polymerases. The 
overall potentiation of MMS cytotoxicity was greater than that of BLM when pro-4 was used in 
cervical cancer HeLa cells.27 Levels of unrepaired dRP groups in the DNA were examined using 
an aldehyde reactive probe (ARP) in response to MMS (0.3-
0.4 mM) and pro-4 (5 M). A 3-fold increase of ARP 
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reactive sites in cells was observed after the removal of the damaging agent, suggesting that pro-
4 prolongs the lifetime of BER intermediates in cells (i.e. SSB with a 5’-dRP).27 When cells were 
treated with MMS and pro-4 for 2 h, followed by media replacement containing only pro-4, cell 
death continued to increase.27 DNA repair inhibition persists even after removal of the DNA 
damaging agent. This is consistent with the ability of pro-4 to prevent repair and extend the 
lifetime of DNA lesions that induce cell death.  
Figure 22. Second generation of irreversible Pol  inhibitor. 
Statement of the project 
 The goal of this project was to identify potent inhibitors selective for Pol  that are useful 
in cells and improve the selectivity of cancer treatment either by the efficacy of DNA damaging 
agents, such as MMS and/or BLM, or a synthetic lethal interaction between Pol  and repair-




3.  Results & Discussion 
3.1  First-generation library scaffold design 
Our goal was to improve the potency and selectivity of Pol  inhibitors by combining an 
electrophile and a molecule that resembles DNA with structural diversity. These molecules were 
designed based on how DOB inactivates Pol  (Section 2.3.1.2). While inhibitors have been 
synthesized previously using this approach (2, Figure 21 and 4, Figure 22), we were not convinced 
that earlier strategies were the only way to generate inhibitors.26,27 We, purposefully, tried to avoid 
previous approaches due to the low yielded synthesis of the C5-aminomethyl group, necessary for 
functionalization at that position.27 Prior to jumping into various synthetic routes, several issues 
were considered. 
A necessary aspect of an inhibitor library is generating structural diversity, which is crucial 
for identifying a potent and selective molecule. Introducing a variety of groups at a specific 
location on the scaffold allows for unique interactions between Pol  and the library molecule. 
First-generation inhibitors can be enhanced by introducing additional structural diversity at a 
different location on the molecule, resulting in a second-generation compound (Figure 23). 
However, we were unsure of the best method to introduce diversity, as well as the order of 
introducing structurally unique groups (X and Y in Figure 23).  
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Figure 23. Retrosynthetic design of second-generation inhibitor library. 
 
For our scaffold, the two most rational locations to introduce structural diversity are the 5-
methyl position of the thymidine base (X, Figure 23) and the 3’-position of the sugar (Y, Figure 
23). These sites require the least modification of the general structure (i.e. dinucleotide containing 
DOB). Reactions at these positions have already been established, negating any need for the 
development of extensive “new” chemistry. In a previous library, structural diversity was 
introduced by a 3’-alkoxyamine that was coupled to a variety of aldehydes.26 The synthesis of the 
precursor for preparing the oxime library required consecutive Mitsunobu reactions to orient the 
alkyoxyamine with the correct stereochemistry at the 3’-position (Scheme 10). Therefore, we 
wanted to explore other options for diversification to improve the library synthesis. The inhibitor 
identified in the oxime library (2, Figure 21) was further functionalized at the 5-methyl position 
of thymidine through an amide bond (4, Figure 22).27 In the second-generation library (3, Figure 
22), an azide was incorporated at the C5-methyl group of thymidine and following reduction, the 
amine scaffold was reacted with a library of carboxylic acids (3). 
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Scheme 10. Consecutive Mitsunobu reactions for alkoxyamine scaffold. 
 
Structural diversity is introduced at these positions by incorporating a suitably reactive 
functional group in the scaffold at either of these positions. Functionalization via reductive 
amination or amide coupling are attractive routes for making libraries. These transformations are 
well established for preparing libraries.26,27,149,150 Depending on the polarity of the reaction with 
the scaffold, a library of small molecules containing either an aldehyde, a carboxylic acid, or an 
amine would be useful. For example, a scaffold bearing an amine would react with a library of 
carboxylic acids to form amides. Fortunately, small molecules bearing these groups are vast, 
commercially available, and structurally diverse. These qualities are attractive for generating a 
library. 
An additional question we had was regarding the best way to disguise the electrophile that 
reacts with the enzyme. The DOB portion is an electrophilic moiety and, therefore, reactive with 
nucleophiles. The 1,4-dialdehyde has been used to trap lysine residues before.151 The electrophile 
(acyclic 1,4-dialdehyde) exists in equilibrium with its cyclic DOB form, a disguised version of the 
electrophile.30 The aldehydes must be protected for the entirety of the synthesis to prevent 
undesired reactions until the very last step when they are removed to reveal the DOB. Originally, 
pentenoyl groups were chosen because we needed a mild, quick method for cleaving acetals. 
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Pentenoyl groups have a long-standing history as aldehyde protecting groups, particularly in 
carbohydrate chemistry.152–155 Pentenoyl protecting groups are stable in basic conditions and are 
compatible with common protecting groups, such as silyl and acetamide groups required in the 
synthesis of the scaffold molecule. They are most often cleaved under mild oxidative conditions 
with N-bromosuccinimide (NBS). However, pentenoyl groups are not the only groups that can be 
used to mask the DOB. For instance, aldehydes can also be protected with acetate (Ac) or 
nitroveratryl (Nv) groups. 
Additional synthetic considerations involved the nucleobase and phosphate linkage used 
to mimic the DNA structure. Pol  does not exhibit a preference for any of the natural nucleobases. 
Therefore, thymidine was included in the scaffold because it is the easiest to work with (i.e. no 
protecting groups required on the nucleobase during synthesis) (Figure 23). An additional 
methylene between the phosphate and the 5’-DOB was included in the design to improve stability 
by discouraging elimination. 
As mentioned before, structural diversity is a necessary aspect of generating a library. At 
the 3’-terminus of the molecule, we chose to mask an amine via a trifluoroacetamide protecting 
group. However, we were uncertain about the functional group at the 5-methyl position, as well as 
the method for diversification (e.g. reductive amination or amide coupling). Therefore, several 
approaches for synthesizing a first-generation library were explored (Scheme 11). 
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Scheme 11. Retrosynthetic pathway of first-generation inhibitors(s). 
 
In an attempt to prepare a library via reductive amination, we tried to synthesize a scaffold 
containing a C5-aldehyde. However, generating a library via reductive amination between this 
scaffold and several amines proved to be difficult due to the instability of the products (Section 
3.1.1). Alternatively, we tried to synthesize a library via amide coupling. First, we tried to make a 
scaffold containing a C5-carboxylic acid and reacting it with a library of amines (Section 3.1.2). 
Ultimately, this was unsuccessful, so we chose to reverse the polarity of the amide bond formation 
by coupling a library of carboxylic acids with a scaffold containing a C5-amine (Section 3.1.2). 
After multiple iterations of synthetic routes (Schemes 19-22), we determined that preparing a C5-
aminomethyl group protected as its N-trifluoroacetamide proved to be most useful for generating 
a first-generation library (Section 3.3.1).  
This strategy of using a scaffold amine and carboxylic acid library was the same as previous 
second-generation inhibitor 4 (Figure 22), despite our hesitations regarding the approach (i.e. low 
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yield of C5-aminomethyl group).27 Ultimately, we functionalized both diversification points (X 
and Y, Figure 23) through amide coupling. In retrospect, this was economically favorable because 
it allowed us to use the same set of carboxylic acids in all synthesized libraries. 
Regardless of the nucleoside modification, the synthesis of the protected DOB moiety was 
constant (Scheme 12). The NaBH4 reduction of 3-furanaldehyde, followed by acetal introduction 
by lead tetraacetate yielded intermediate 5. This intermediate was acetylated (6) and hydrogenated 
(7). Reaction of 7 with pent-4-en-1-ol in the presence of a Lewis acid led to the introduction of the 
pentenoyl protecting groups (8). Subsequent deacetylation (9) and phosphitylation provided 
phosphoramidite 10.  
Scheme 12. Synthesis of DOB-portion of first-generation inhibitor. 
 
The phosphoramidite was coupled to an alcohol to form the dinucleotide scaffold of the 
first-generation library. The polarity of this reaction can be carried out in either direction (Scheme 
13). In some syntheses the phosphoramidite was prepared on the nucleoside (Scheme 13a) and in 
others it was part of the DOB portion (e.g. 10, Scheme 13b). The direction of the polarity used 
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higher yield. It was difficult to predict which route would offer better results as it depended upon 
the thymidine derivative used. 
 
Scheme 13. Phosphoramidite coupling in either polarity. (a) 3’-OH (9) and 5’-phosphoramidite 




 In some instances, the pentenoyl group was replaced by an acetate protecting group 
(Scheme 14). In this case, intermediate 5 was reduced (11) and phosphitylated to the acetate-
containing phosphoramidite (12). 
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Scheme 14. Synthesis of the acetate-protected DOB phosphoramidite (12). 
3.1.1  Diversification by Reductive Amination 
 
 Introduction of a carbonyl group on the nucleobase via an aldehyde started with 5-
iododeoxyuridine (5IdU, Scheme 15). Following orthogonal protection of the 5’- and 3’-alcohols 
(13), the aldehyde was incorporated at the 5-position of 13 to yield 15. Direct carbonylation was 
unsuccessful but vinylation (14) followed by oxidative cleavage led to the isolation of 15. The 5’-
dimethoxytrityl (DMT) group was selectively removed using trichloroacetic acid (0.1 M) to reveal 
16. 
Scheme 15. Retrosynthetic (a) and forward (b) synthesis of aldehyde-containing nucleoside (16). 
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Compounds 10 and 16 were coupled to form the phosphate triester (17), which was 
deprotected to provide the scaffold (18, Scheme 16). Different amines (i.e. n-butyl amine, benzyl 
amine, and aniline) were coupled to the aldehyde via reductive amination. The reductive amination 
was completed on a small scale (< 500 nmol) and was confirmed by MS. However, NBS 
deprotection of the pentenoyl protecting groups on the DOB moiety led to oxidation of the 
secondary amine. 
This scaffold was redesigned and resynthesized to bear acetate protecting groups instead 
of pentenoyl groups at the DOB moiety (Scheme 14). Phosphoramidite coupling of 12 and 16 
provided phosphate triester 19 (Scheme 16b). Deprotection of the phosphate and the 3’-silyl group 
provided the acetate protected scaffold (20). Similar to the previous synthesis, reductive amination 
with model compounds (i.e. n-butyl amine, benzyl amine, and aniline) led to formation of a 
secondary amine. However, the acetate deprotection of the DOB did not yield the desired product. 
We speculate this was due to reactivity between the amine and the electrophilic DOB moiety. 





Scheme 16. Retrosynthetic (a) and forward (b) synthesis of aldehyde-containing scaffold 20. 
 
 
3.1.2  Amide Coupling Functionalization 
 
To avoid the generation of a secondary amine, a carboxylate at the 5-methyl position was 
introduced (Scheme 17). We hypothesized that the carboxylate could be functionalized by a library 
of amines to make amides that would be stable to the oxidation conditions used to reveal DOB and 
not react with this functional group after it is deprotected. Furthermore, in terms of synthesizing a 
nucleoside bearing a carboxylic acid, a portion of the synthesis was already completed. Previously 
synthesized 13 (Scheme 15) was carbonylated in the presence of methanol to form the methyl ester 
(21, Scheme 17b). Deprotection of the 5’-hydroxyl group yielded 22. 
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 The 5’-hydroxyl group of 22 was phosphitylated (23) and coupled to previously 
synthesized 9 (Scheme 12) to yield phosphate triester 24 (Scheme 18). Following phosphate and 
3’-hydroxyl deprotection (25), the methyl ester was cleaved under basic conditions to yield 
scaffold molecule 26. Amide coupling of this scaffold was unsuccessful because the activating 
agents (i.e. HBTU and HOBt) reacted with the phosphate diester group. The activation of the 
phosphate resulted in coupling with the amine at both the phosphate and the carboxylate. Double 
coupling of the amine was observed by mass spectrometry and 1H NMR. In addition, the chemical 
shift of the phosphate resembled that of a phosphoramidate triester ( ~ 2 ppm) in the 31P NMR, 
which was further confirmation that the amine coupled to the phosphate. We hypothesized that the 
reverse polarity of the amide coupling (i.e. amine scaffold and carboxylic acid library) would be 
more successful and pre-activation of the carboxylic acid would prevent undesired activation of 
the phosphate group. This polarity is the same used in the synthesis of the previous second-
generation inhibitor (4, Figure 22, Section 3.1).27 
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 While planning the most efficient synthesis of the new scaffold (Scheme 19), we were 
aware of the challenges we were likely to face by starting from thymidine because of the 
difficulties in the synthesis of the previous inhibitor (4, Scheme 22).27 Therefore, we tried a more 
direct approach that introduced the azide via the oxidation of dU (27), followed by alcohol 
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activation and substitution (28, Scheme 19b).156 However, these first two steps required several 
days and were low yielding, so this pathway was not pursued further. 
Therefore, we reverted to thymidine as a starting point and introduced the azide at the 5-
methyl position (Scheme 19c). There are multiple ways in which this can be done. One method for 
introducing an azide at the 5-methyl position of thymine is via the bromide produced by the Wohl-
Ziegler reaction.157 Thymidine silylation (30) was high yielding and scalable to several grams. 
However, the following three steps involving one pot bromination and nucleophilic substitution 
by sodium azide (31) and subsequent selective 5’-desilylation to 29 were low yielding, less than 
20% overall (Scheme 19c, top). When dT was protected with acetate groups (32), the yields of the 
bromination and azide substitution reactions that yield azide-containing 33 were slightly improved 
(Scheme 19c, bottom). This route required several more alcohol deprotection and protection steps 
(34-36) before yielding the final target (29). However, despite the increase in reaction steps, the 
overall yield improved significantly and was more scalable than the previous route. 
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Scheme 19. Retrosynthetic (a) and forward (b and c) synthesis of azide-containing nucleobase via 
2’-deoxyuridine (b) and thymidine (c). 
 
Unfortunately, reduction of the C5-azide, necessary for functionalization, using triphenyl 
phosphine (PPh3) was unsuccessful. No reaction was observed when the azide (i.e. 29, 33, or 36) 
was reacted with PPh3 under multiple conditions (i.e. solid PPh3 or PPh3 on a polymer support). 
While hydrogenation did reduce the azide in the monomers (i.e. 29, 33, 36), this reaction was 
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incompatible with the pentenoyl-protected DOB structure, because the pentenyl group(s) is 
susceptible to reduction by H2. Furthermore, presumably due to the same Staudinger reaction, 
phosphoramidite coupling in the presence of an azide resulted in a very low yield (i.e. 20%) 
because P(III) was easily oxidized by N3. To avoid the azide, we tried different ways to introduce 
a protected amine, including as a phthalimide or trifluoroacetamide. The phthalimide was 
introduced in a similar manner as the azide; utilizing sodium phthalimide to displace the bromide 
to yield 37 (Scheme 20). The acetate protecting groups were efficiently deprotected to yield 38. 
As a model deprotection, the phthalimide group in either 37 or 38 to reveal the primary amine was 
attempted under multiple conditions (e.g. H2NNH2, MeNH2), but did not yield the desired product 
based on mass spectrometry and NMR. The identity of the reaction product(s) was never 
determined, and the synthesis of 39 was abandoned. 
Scheme 20. Retrosynthetic (a) and forward (b) synthesis of a phthalimide containing nucleobase. 
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After introducing the protected amine as the phthalimide was unsuccessful, we turned to a 
trifluoroacetamide group to mask the amine. The trifluoroacetamide protecting group was 
introduced by reduction (40), protection (41), and detritylation (42) of previously synthesized 36 
(Scheme 21).  
Scheme 21. Retrosynthetic (a) and forward (b) synthesis of a trifluoroacetamide containing 
nucleobase. 
 
The first-generation library was synthesized using this monomer (Scheme 22). Compound 
42 was phosphitylated (43) and coupled to previously synthesized 9 (Scheme 12) to yield 44. 
Following deprotections, the scaffold molecule (45) was coupled to a variety of carboxylic acids 
(140 compounds) and the pentenoyl groups were removed with NBS to generate the library of 
inhibitor candidates (46). 
Overall, the synthesis of the first-generation library bearing structural diversity at the 5-
methyl position of the nucleobase is twelve steps with an overall yield of 10%. The limiting step 
in this synthesis remains the bromination reaction required for incorporating a functional group at 
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the 5-methyl position. The bromination was low yielding and was not scalable above 1 g. To 
overcome this hurdle, multiple bromination reactions were carried out in parallel and combined so 
the final yield did not suffer due to one step. Altogether, approximately 150 mg of the final scaffold 
(45) was synthesized and a portion (i.e. 40 mg) was used to make a library. 
 
Scheme 22. Retrosynthetic (a) and forward (b) synthesis of amine-containing scaffold (45).  
 
 
3.2 In vitro biochemical assays 
 
 Upon library generation, biochemical assays were used to evaluate the inhibitory activity 
of the individual compounds. There were multiple ways to do so including qualitative high 
throughput assays and more laborious quantitative assays. In addition, Pol  is a bifunctional 
enzyme and its polymerase and lyase activities were analyzed separately. This is important because 
the inactivation of one activity does not necessarily translate to inactivation of the other. In other 
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words, the inactivation of the enzyme’s lyase and polymerase activity are not mutually inclusive. 
Furthermore, we could not predict which activity or activities the candidate inhibitor(s) would 
inhibit. 
 3.2.1  Fluorescence-based strand displacement assay 
 
 This high-throughput screening assay indirectly analyzed Pol ’s polymerase activity via 
a strand displacement assay (Figure 24).158 This assay utilized a ternary oligonucleotide complex 
containing a 3’-fluorophore (i.e. carboxytetramethylrhodamine (TAMRA)) and a 5’-quencher (i.e. 
Black Hole Quencher (BHQ), Figure 24). This assay was indirect because rather than detecting 
the incorporation of a nucleotide triphosphate, it measured the increase in fluorescence signal when 
the strand containing a fluorophore was displaced from the strand containing a quencher because 
of polymerization. As Pol  incorporated dNTPs in the 1 nt gapped DNA substrate (B, Table 1, 
Section 3.2.4), the strand containing the fluorophore was displaced, leading to an increase in 




Figure 24. Fluorescence-based strand displacement assay. 
 
  
This assay was originally used as a qualitative method to identify potential hits that must 
be analyzed further using more quantitative biochemical assays. Later, the assay was adapted to 
extract kinetic information from polymerase inhibitors. The data were fit to a single exponential 
growth equation (1) that follows a plateau. The plateau was important because the strand 
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displacement assay exhibited an induction period in which several nucleotides of the fluorescently 
labelled DNA were displaced before the fluorescently labeled oligonucleotide was released into 
solution. This induction time was determined by inspection and typically varied between 10 and 
15 min. The data were fit beginning at the time when a growth in fluorescence was observed. 
Y = F0 + (F1 – F0) × (1-e
-kt)     (1) 
Y is the fluorescence intensity, F0 is the fluorescence value at time 0, F1 is the fluorescence value 
at time , k is the rate constant, and t is time. Rate constants are extracted for each experiment and 
relative rates are determined using equation (2). 
krel = kinhibitor/kpol     (2) 
Where kinhibitor is the rate constant for experiments containing inhibitor and kpol is the rate constant 
for control experiments lacking inhibitor. 
3.2.2  Gel-based lyase assay 
 The gel-based lyase assay directly monitored Pol  excision of the 5’-dRP group in a 
ternary DNA complex (Figure 25). This assay utilized 3’-32P labeled DNA containing a 5’-dRP 
that was generated from an oligonucleotide containing a photolabile precursor to this unstable 
molecule (Scheme 23).29 An oligonucleotide with the precursor was radiolabeled and hybridized 
with template and flanking strands to form a ternary complex (A, Table 1, Section 3.2.4). The Nv 
protecting group was cleaved photolytically to reveal the 5’-dRP (Scheme 23).  
Scheme 23. Cleavage of Nv to obtain 5’-dRP. 
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This assay relied on 32P-radiolabeling and was more sensitive than the previously described 
fluorescence-based assay. Compared to the strand displacement assay, a smaller amount of DNA 
was needed to monitor the reaction. In the presence of active Pol , the 5’-dRP group was 
efficiently removed and the loss was visualized by gel electrophoresis in the form of a faster 
moving product (Scheme 7). The linear relationship between the amount of product versus time 
was used to determine the reaction rate. The relative enzyme activity was determined using 
equation 2 (Section 3.2.1). In the case of inactive Pol , the amount of product does not increase 
as a function of time (gray data, Figure 25).  
Figure 25. Gel-based lyase assay. 
 Relative rates are essential for extracting kinetic information and quantitative analysis. 
There are three major kinetic parameters used to describe and quantify the efficiency of an 
inhibitor. The first being an IC50, which represents the concentration of inhibitor that results in 
50% enzyme activity and is more often utilized to characterize reversible inhibitors. For an 
irreversible inhibitor, an IC50 plot used relative enzyme activity across multiple inhibitor 
concentrations at a single preincubation time (Section 3.3.2). Because inhibition by an irreversible 
inhibitor is dependent on preincubation time, an IC50 of a covalent inhibitor varies as this variable 
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is changed. The concentration of inactivator at half-maximal inactivation (KI) and the maximal 
rate constant for inactivation (kinact) are two other quantitative parameters that better describe an 
irreversible inhibitor. To obtain these values, the effect of inhibitor concentration and 
preincubation time on reaction velocity must be explored. This analysis required several kinetic 
experiments (Figure 26).  
 
Figure 26. Transforming hypothetical raw data (left) into a preincubation plot (right).  
 
Each data point in a preincubation plot comes from one set of experimental conditions in 
which product formation was measured over several time points, completed in triplicate. In the 
case of an irreversible inhibitor, the relationship between relative enzyme activity and 
preincubation time was linear at a single inhibitor concentration (equation 3). 
A= mt + b       (3) 
A Kitz-Wilson plot was valuable for evaluating covalent inhibition.159 A Kitz-Wilson plot 
showed the linear relationship between the half-life (t1/2 from multiple concentrations) and the 
inverse of the inhibitor concentration. The half-life of the enzyme (t1/2) was determined by using 
the y-intercept (b) and the slope of the linear relationship (m) to solve for the preincubation time 
(t) at which 50 % enzyme activity (A) remained (equation 3), based on the preincubation plot 
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(Figure 26). The x- and y-intercepts of a Kitz-Wilson plot were used to calculate the KI and kinact 
using equations 4 and 5, respectively.   
x-int = -1/KI      (4) 
y-int = ln(2)/kinact     (5) 
 
3.2.3 Fluorescence-based lyase assay 
 
 Initially, the previous two assays were our primary biochemical assays for analyzing Pol  
activity. In 2019, a novel fluorescence-based probe was reported for detecting BER glycosylase 
activity.160 The universal BER (UBER) probe contains a fluorophore connected to a reactive 
alkoxyamine. The alkoxyamine reacts with aldehydes. This assay was originally designed to detect 
an abasic site (AP) that forms after an N-glycosylase removes a damaged base, such as dU (Figure 
13). The probe is rigidified upon reaction with the aldehyde in the context of duplex DNA (Scheme 
24) and the loss of free movement (bond rotation) yields an increase in fluorescence signal (Figure 
27). 
 





Considering that the chemistry of the UBER probe relied on reaction between the 
alkoxyamine and a reactive aldehyde, we hypothesized that this assay could be adapted to detect 
5'-dRP lyase activity in a high-throughput manner (Figure 27). However, we first had to determine 
if the UBER assay would work for detecting 5’-dRP. We were unsure whether the greater 
flexibility of an incised DNA containing 5’-dRP would give rise to too small of an increase in 
fluorescence upon reaction with the UBER probe, reducing the sensitivity of the assay. 




To adapt this assay for our inhibitor screen, the UBER probe was reacted with a ternary 
complex containing 5’-dRP (Figure 27). To make this assay viable for high-throughput screening, 
we considered the following: 
1. The lowest DNA concentration needed to detect a signal is determined by the sensitivity 
of the fluorescence measurement. 
2. The ratio of DNA to Pol  must be optimized. A small ratio contributes to efficient 
processing of DNA by active Pol . However, a large ratio requires less enzyme. It is 
desirable to use a low concentration of enzyme during the screen because a high 
concentration of enzyme requires a higher concentration of inhibitor for inactivation 
(Section 3.3). Higher inhibitor concentrations are less desirable when trying to identify a 
good hit compound. 
3. The ratio of DNA to probe must be optimized. The DNA must be limiting relative to the 
probe to ensure the probe reaction goes to completion. However, we were unsure if a large 
excess of probe may produce a high background signal. Therefore, the background 
fluorescence signal of the probe must be minimal. 
 
Altogether, after considering the sensitivity of the probe with 5’-dRP and the concentration 
ratios of the different components (i.e. Pol  < DNA < UBER probe), the UBER probe was reacted 
with a ternary complex containing 5’-dRP (A, Table 1, Section 3.2.4). The background signal of 
the UBER probe at 5 M was minimal (left black bar, Figure 28). The fluorescence response of 
the probe was evaluated with a range of DNA concentrations with or without reaction with Pol . 
Several enzyme quenching methods, such as pH, EDTA, and SDS, were examined (Figure 28). 
We determined that the background signal of the UBER probe alone was low. A 5:1 concentration 
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ratio between the UBER probe (5 M) and 5’-dRP DNA (1 M) was enough to elicit a detectable 
fluorescence change. Furthermore, in the presence of Pol  (100 nM), the fluorescence signal 
decreased 2.5-fold.  
The lyase activity of Pol  decreased the amount of dRP, reducing the fluorescence signal. 
In contrast, an inhibitor was identified by a high fluorescence signal. This method was qualitative 
and identified potential inhibitors but required quantitative analysis after the initial screen (Section 
3.2.2). Lastly, we found that any quenching method we tried effectively quenched the enzyme, so 
we chose pH 6.5 for our screen because it simultaneously quenched the enzyme and slightly 
improved the efficiency of the UBER reaction (Figure 28). 
Figure 28. Conditions to detect dRP using UBER assay. DNA A containing dRP (5 M) was 
incubated with or without Pol  (100 nM) in 1X reaction buffer (50 mM HEPES, 50 mM KCl, 5 
mM MgCl2, 200 mM EDTA, 0.01% Tween 20, pH 7.5) for 20 min. After preincubation time, the 
solution was diluted 5-fold, quenched with various conditions (pH 6.5, 1% SDS or 10 mM EDTA) 
and mixed with the UBER probe (5 M) for 4-5 h. After incubation, fluorescence was measured 




3.2.4 Assays and DNA substrates used for different polymerases 
 
The previous assays described were most commonly used when screening and quantifying 
library molecules against Pol . However, different assays were used for in vitro selectivity assays 
because different polymerases have different substrate preferences and activities. The other 
polymerases used for determining selectivity were Klenow exo-, Pol , Pol , and Pol .  
These polymerases were chosen because their structures and activities were diverse 
compared to Pol . Klenow exo- is a model replicative polymerase, while the remaining have roles 
in mammalian DNA repair. The selectivity for Pol  and Pol  was especially of interest because 
Pol  is the back-up polymerase in BER and the two have a high sequence homology (Section 
2.3.1).98–100 
The DNA substrate for each assay depended on the activity and preferences of each enzyme 
(Table 1). Pol  preferred nicked ternary complexes (A and B, Table 1). In order to monitor lyase 
activity, the nick bore a 5’-dRP (A). Substrate B was also used for Klenow exo- because the assay 
was quick and convenient. Primer extension assays were used to test Pol  and Pol . However, 
the primer (C) for Pol  was a single strand of DNA and SYBR Gold was used to measure an 
increase in fluorescence that corresponds to newly synthesized DNA.161 The primer (D) for Pol  
was part of a duplex and was 5'-32P-labeled to detect nucleotide incorporation.162,163 Like Pol , 
Pol  preferred nicked and gapped ternary complexes. Pol  did not have sufficient lyase activity 
to quantify using substrate A so we used a 2-nt gapped complex (E) and measured the 
incorporation of two nucleotides.25 
An additional substrate (F) was used for fluorescence anisotropy experiments.135 This 





Table 1. DNA substrates for assays. 
X = dRP, F = TAMRA, Q = BHQ, Fl = dichloro-diphenyl-fluorescein (SIMA-HEX), pF = 
1 = lyase assay (Section 3.2.2 and Section 3.2.3), 2 = fluorescence assay (Section 
3.2.1) 
 
3.3  First-generation Pol  inhibitor(s) and their domain selectivity 
  
 The first goal of this research was to identify a potent and selective inhibitor for WT Pol 
. As mentioned before, previous inhibitors exhibit several shortcomings (Section 2.6). Therefore, 
we aimed to identify and fully characterize inhibitors using kinetics, mass spectrometry and 
binding assays. First-generation inhibitors represent a starting point but we anticipated that they 
would not be potent enough to warrant extremely detailed characterization. However, they are a 
necessary step in identifying a second-generation inhibitor (Figure 23).  
An important aspect of screening and evaluating inhibitors lies in the preincubation mixture. 
Several components can affect the inhibitory activity of a compound, including: 
• The concentration of enzyme in the preincubation and reaction mixture 
71 
 
• The ratio of inhibitor to enzyme 
• The amount of dilution from preincubation mixture to reaction mixture 
• Preincubation time 
As mentioned before, a low concentration of enzyme during preincubation was desirable 
because it required less inactivator to show an inhibitory effect (Section 3.2.3). The concentration 
of enzyme during preincubation was also determined by the reaction assay. The lower limit of 
enzyme concentration during the reaction mixture was determined by the need for there to be 
enough enzyme to measure activity. This limit was defined by the sensitivity of the assay. We 
determined that 5 nM Pol  was sufficient in our assays to monitor lyase and strand displacement 
activity. 
The ratio of inhibitor to enzyme was important because a larger ratio yields a greater inhibitory 
effect. However, it was impractical to use an extremely large ratio for the purposes of identifying 
potent inhibitors. An inhibitor that inactivated an enzyme at 5 mM was not very impressive. We 
were interested in compounds that inactivate Pol  at low M or, even better, nM concentrations. 
Therefore, the ratio of inhibitor to enzyme was optimized during a screen to yield a small, 
manageable number (i.e. < 10) of potent hit compounds. 
The preincubation dilution was also important when measuring enzyme activity. A large 
preincubation dilution was desirable because the rate at which the inhibitor inactivated the enzyme 
should be as low as possible while monitoring the enzyme catalyzed reaction. Furthermore, if the 
inhibitor concentration was high enough to continuously inactivate the enzyme during kinetic 
measurements, the concentration of active enzyme would continue to decrease during the assay. 
The limitations of the preincubation dilution were determined by the amounts of enzyme and 
inhibitor during the preincubation and reaction mixtures (described previously). Enzyme kinetics 
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were carried out at 5 nM Pol  We determined that a 50 nM Pol  preincubation mixture and a 
10-fold dilution generally satisfied all considerations. It should be noted that in some cases, the 
amount of dilution and concentration of enzyme was adjusted to fit the specifications of a certain 
assay. 
As mentioned previously, irreversible inhibition depends on the amount of time spent 
preincubating with the enzyme (Section 3.2.2). Therefore, preincubation time must be long enough 
to yield inhibition but short enough to still be convenient and easy to work with. Generally, we 
used a 30 min preincubation time during the screening process because handling so many library 
compounds (~80 at a time) required roughly 4-5 min to properly mix reagents (e.g. Pol , inhibitor, 
buffers, etc.) so a longer preincubation prevented experimental error. Once a hit was identified, we 
found that 20-30 min preincubations were sufficient for our experiments. At shorter preincubation 
times (e.g 5-10 min), we observed less inhibition at optimal inhibitor concentrations. 
3.3.1 Lyase domain selectivity 
 
Amine scaffold 45 (total 40 mg, 200 nmol per carboxylic acid coupled, Scheme 22) was 
functionalized with 280 different carboxylic acids, deprotected, and analyzed via the strand 
displacement assay (Figure 24). The amide bond reaction was optimized using standard activating 
agents (1.4 equiv. HBTU, 1.4 equiv. HOBt), base (20% v:v DIPEA), and a slight excess of the 
carboxylic acid (1.4 equiv.). These reactions were most effective when the amine (45) and the 
carboxylic acid were azeotropically dried together prior to adding the other reagents. Following 
amide coupling, the DOB component was unmasked using NBS (2.5 equiv.) in 30% H2O in 
acetonitrile. These library molecules were screened against Pol  using the fluorescence-based 
strand displacement assay (Section 3.2.1). Each compound (25 M) was preincubated with Pol 
 (100 nM) for 30 min, mixed with a 5X cocktail solution containing dTTP and fluorescently 
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labeled ternary complex (Figure 24; B, Table 1), and diluted further (10X for preincubation 
mixture, 5X for DNA) in 1X buffer in the assay reaction. The initial screen often identified several 
inhibitors, so all hit compounds were resynthesized and rescreened multiple times. False positives 
were ruled out by comparing inhibition induced by the hit compounds with inhibition induced by 
the free carboxylic acid(s) in the presence of all activating agents but no scaffold (45). 
This library (46) led to the identification of two hits (47 and 48, Figure 29). Two other 
compounds (094 and 097, Appendix 1) were identified in this screen, however, after additional 
assays, these were determined to be 
false positives. Compounds 47 and 
48 were by far the most potent hits 
identified in the library (Appendix 
1). Compounds 47 and 48 are 
regioisomers of each other. The structure of the hits identified was intriguing because the 
hydroxylated naphthoic acid moiety is present in other Pol  inhibitors (i.e. 4, Figure 22 and PA, 
Figure 20).27,145 We compared these two isomers with a library compound (100, Appendix 1) that 
was not identified in the screen, despite their similar structures (hydroxylated naphthoic acid). 
However, it was clear that the library compound that arose from coupling with 6-hydroxyl-2-
naphthoic acid (100, Appendix 1) was not a hit. This suggested that the 3-hydroxyl group of the 
naphthoic acid may be critical for binding, considering this group is present in the inhibitors 
identified, as well as 4 and PA. 
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Figure 29. First-generation inhibitor hit compounds 47 and 48. 
 
The library screen was completed with crude material. In order to analyze hit compounds 
quantitatively, 47 and 48 were synthesized on a larger scale and the pentenoyl protected analogues 
were purified. The amide coupling was improved by silylating the carboxylic acids (49 and 51) 
and coupling them as their NHS esters (50 and 52) (Scheme 25). Coupling scaffold 45 and the 
NHS ester (50 or 52) and subsequent desilylation yielded the pentenoyl protected precursors (53 
and 54) of the active inhibitor hits (47 and 48). 
 




Following a 30 min preincubation, compounds 47 and 48 completely inactivated Pol ’s 
strand displacement activity at around ~ 5 and 10 M respectively (Figures 30 and 31). The curves 
associated with concentrations ≥ 8 M are hidden behind the control associated with no enzyme 
(blue, Figures 30-31). Strand displacement assays were used as a qualitative tool to measure 
polymerase activity. We turned to the gel-based lyase assay to monitor the enzyme’s lyase activity 
(Figure 25, Section 3.2.2).  
 
Figure 30. Strand displacement assay of Pol  with 47. Pol  (100 nM) was preincubated with hit 
47 at various concentrations (listed) for 30 min. The preincubation mixture was diluted 10-fold 





Figure 31. Strand displacement assay of Pol  with 48. Pol  (100 nM) was preincubated with 
hit 48 at various concentrations (listed) for 30 min. The preincubation mixture was diluted 10-
fold and mixed with DNA cocktail solution, to yield 5 nM Pol , 50 nM DNA substrate B, and 
100 M dTTP. 
 
Inhibitors 47 and 48 inactivate the 8 kDa lyase domain at 25 and 50 M, respectively 
(Figure 32). A larger inhibitor concentration was used for these assays, in comparison to the strand 
displacement assays (Figures 30-31) because the 8 kDa domain was slightly less active than the 
WT Pol . To accommodate the decrease in activity, the lyase activity was measured at a higher 
concentration of 8 kDa Pol  and the inhibitor was scaled accordingly.  
Lyase inhibition was determined by using a single preincubation time (30 min) and time 
point (15 min) (Figure 32). These data are still qualitative and so to attain quantitative data, we 
measured the lyase activity as a function of time with multiple inhibitor concentrations and 
preincubation times (Figures 33-35). As expected, the relative activity decreased in response to 
longer preincubation times across all inhibitor concentrations of 47 and 48. As mentioned before, 
this behavior was indicative of irreversible inhibition (Section 3.2.2). Furthermore, this result was 
evident in both the intact enzyme (47, Figure 33; 48, Figure 35) and the 8 kDa domain (47, Figure 
34). Both the strand displacement and lyase assays indicated that 47 was the more potent inhibitor. 
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Each preincubation plot (Figures 33-35) required at least one week of experiments (Section 3.2.2). 
Considering inhibitor 48 was not as potent as 47 in the holo-enzyme, we chose not to evaluate the 
lyase activity of the 8 kDa domain as a function of time with multiple preincubation times and 
concentrations of 48. 
 
Figure 32. Lyase activity in the presence of inhibitor hits 47 and 48. 8 kDa Pol  (100 nM) was 
preincubated with BSA (0.01 mg/mL) and either 47 or 48 at various concentrations (listed) for 30 
min. Preincubation mixture was diluted 10-fold and mixed with 25 nM DNA substrate A. Reaction 
was completed in triplicate, stopped after 15 min of reaction time, quenched with 150 mM NaBH4, 





Figure 33. Irreversible lyase inhibition of WT Pol  lyase activity by 47. Pol  (50 nM) was 
preincubated with 47 at various concentrations (5, 10, 15, 20, 30 M) for a range of time. Each 
point represents a reaction of certain inhibitor concentration and preincubation time. The 
preincubation mixture was diluted 10-fold and mixed with 50 nM DNA substrate A, stopped at 
various time points, quenched with 150 mM NaBH4, and analyzed by gel electrophoresis to 
quantify product formation of the lyase reaction. Relative rates of 50 nM Pol  in the presence of 
47 at various concentrations (listed) compared to the rate of 50 nM Pol  in the absence of 
inhibitor. 
 
Figure 34. Irreversible lyase inhibition of WT Pol  8 kDa domain lyase activity by 47. 8 kDa Pol 
 (100 nM) was preincubated with 47 at various concentrations (5, 10, 20, 30 M) for a range of 
time. Each point represents a reaction of certain inhibitor concentration and preincubation time. 
The preincubation mixture was diluted 10-fold and mixed with 25 nM DNA substrate A, stopped 
at various time points, quenched with 150 mM NaBH4, and analyzed by gel electrophoresis to 
quantify product formation of the lyase reaction Relative rates of 100 nM Pol  8 kDa domain in 
the presence of 47 at various concentrations (listed) compared to the rate of 100 nM Pol  8 kDa 
domain in the absence of inhibitor. 
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Figure 35. Irreversible lyase inhibition of WT Pol  lyase activity by 48. Pol  (50 nM) was 
preincubated with 48 at various concentrations (5, 10, 15, 20, 30 M) for a range of time. The 
preincubation mixture was diluted 10-fold and mixed with 50 nM DNA substrate A, stopped at 
various time points, quenched with 150 mM NaBH4, and analyzed by gel electrophoresis to 
quantify product formation of the lyase reaction. Relative rates of 50 nM Pol  in the presence of 




While the preincubation plots (Figures 33-35) suggested that the inhibitors act in an 
irreversible manner, the data cannot be used to extract quantitative information, like IC50, KI, or 
kinact. The problem lied in the relative enzyme activity across multiple inhibitor concentrations. As 
the concentration of the inhibitor increased, the linear relationship between relative enzyme 
activity and preincubation time was more pronounced (i.e. steeper slope). However, when looking 
at a single preincubation time, the relative activity associated with each inhibitor concentration 
was not what was expected. For example, a lower concentration of inhibitor was expected to have 
the highest relative enzyme activity across all preincubation times when compared to experiments 
in which a higher inhibitor concentration was used. However, this is clearly not the case with 47 
and 48. As a result, any IC50 or Kitz-Wilson plot extrapolated from these data was nonsensical. 
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Therefore, we re-evaluated lyase inactivation by 47 using a 30 min preincubation time 
across multiple inhibitor concentrations. The elimination of multiple preincubation times 
significantly reduced the time required to complete this experiment. By measuring relative activity 
at a single time point (15 min), we determined 47 inhibited WT Pol  with and IC50 value of 18.7 
M (Figure 36). This is a slight improvement from previous first-generation inhibitor 2, which had 
an IC50 value of 21 M against WT Pol  (Figure 21).
26 Unsurprisingly, neither first-generation 
inhibitor (i.e. 2, 47) exhibited similar potency to second-generation Pol  inhibitor 4 (IC50 = 400 
nM, Figure 22).27 However, it is worth noting that the IC50 value of inhibitor 4 was determined 
using different conditions (i.e. smaller preincubation dilution).27 
Figure 36. Inhibitor 47 has an IC50 value of 18.7 M in WT Pol . 
 
The irreversible inactivation by 47 was confirmed by dialysis experiments with Pol  
(Figure 37). Untreated Pol  retained 70% activity after dialysis but, in the presence of 47 (80 M), 
Pol  was completely inactivated and did not regain any activity after dialysis. 
 






















Figure 37. Lyase activity of WT Pol  with 47 before and after dialysis. Pol  (100 nM) was 
preincubated with or without 47 (80 M) for 30 min. An aliquot of preincubation mixture (2.5 L) 
was diluted 10-fold and mixed with 150 nM DNA substrate A. Reaction was completed in 
triplicate, quenched with 150 mM NaBH4, and analyzed by gel electrophoresis to quantify product 
formation of the lyase reaction. Another aliquot of preincubation mixture (200 L) was injected 
into a 3 K, 100-500 L dialysis cassette and dialyzed against 1X reaction buffer (2 x 1 L, 50 mM 
HEPES, 50 mM KCl, 5 mM MgCl2, 200 mM EDTA, 0.01% Tween 20, pH 7.5) for 24 h at 4 
oC. 
After dialysis, the lyase kinetics were analyzed following previously stated conditions. 
 
 
Based on the evidence for irreversible inhibition and the nature of the DOB moiety to form 
crosslinks with Pol , the interaction between 47 and Pol  was analyzed by mass spectrometry 
(MS) (Figure 37). A single modified peptide containing active site lysines K72 and K81 (Fragment 
1) was detected upon trypsin digestion of intact Pol  incubated with 47 (10, 25 M). MS/MS 
fragmentation was required to determine the modified residue(s). The relative intensity of the 
parent peptide was low and the only fragmentation observed contained unmodified K81 (y3). By 
process of elimination, this suggested that K72 was modified. 
Furthermore, in the 8 kDa domain incubated with 47 (10, 25 M), two fragments 
containing K72 and K84 (Fragments 2 and 3) were detected with fragmentation data that supported 
K72 modification. The only internal lysine residue in Fragment 2 was K72. In addition, direct 
modification of K72 was observed in the MS/MS fragmentation (b7*). A single modification was 
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also detected on Fragment 3. While there is no fragmentation data for peptide 3, we were confident 
modification occurred on K84 because it was the only internal nucleophilic residue. 
Figure 38. MS analysis of trypsin digestion of Pol  with 47. Pol  (1 M) and 47 (10 M) were 
incubated in 1X reaction buffer (50 mM HEPES, pH 7.2, 5 mM MgCl2, 2 mM DTT) at 25 
oC for 
30 min. The mixture was concentrated with a 3K Amicon filter and washed 3-4 times with 1X 
reaction buffer. Digestion buffer (25 L), 500 mM Tris HCl, pH 7.0), 10X trypsin (25 L, 400 
M), and H2O (175 L) were added. The digestion sample (2 M Pol  and 40 M trypsin) was 
incubated at 37 oC for 5 h. A portion (10 L) of the digestion mixture was spun down and analyzed 
by UPLC-MS/MS using an ACQUITY UPLC HSS T3 Column (100 A, 1.8 m, 2.1 mm x 100 
mm). The flow rate was 0.3 mL/min running a gradient of 85:5:10 water: acetonitrile: 1% formic 
acid to 50:40:10 water: acetonitrile: 1% formic acid over 35 min. Analysis was conducted using 
BioPharmaLynx with tolerance set to 30 ppm and allowing for 4 missed cleavages. 
 
 We wanted to understand how inhibitor 47 selectively binds the 8 kDa domain but 
inactivated both the lyase and strand displacement activities in the holo-enzyme (Figures 30-36). 
By analyzing enzyme activity in the separate domains, we determined compound 47 had no effect 
on strand displacement synthesis by the 31 kDa domain (Figure 39), consistent with its binding in 
the 8 kDa domain. 
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Figure 39. Inhibitor 47 did not inactivate strand displacement synthesis in the 31 kDa domain. 31 
kDa Pol  (500 nM) was mixed with 47 (30 M) for 30 min. Preincubation mixture was diluted 
10-fold and mixed with 50 nM DNA substrate B and 100 M dTTP. 
 
 To evaluate the relationship between domains and activities, we used fluorescence 
anisotropy to measure Pol ’s DNA binding ability in response to inhibitor 47. Fluorescence 
anisotropy monitors the tumbling speed of fluorescently labelled DNA (F, Table 1), which 
decreases in response to binding a large enzyme. We were unsure if the separate domains (i.e. 8 
kDa, 31 kDa) would be large enough to distinguish a change in DNA tumbling rate. Despite the 
uncertainty, we found that compound 47 interfered with DNA binding in the holo-enzyme (Figure 
40a) and the 8 kDa domain (Figure 40b) but had no effect on DNA binding in the 31 kDa domain 
(Figure 40c).  



































Figure 40. The effect of inhibitor 47 on DNA binding in WT Pol  (a), 8 kDa Pol  (b), and 31 
kDa Pol  (c). 
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 3.3.2 Polymerase domain selectivity 
 
Intrigued by our previous results regarding 8 kDa domain specific binding, we were curious 
about previous Pol  inhibitors 2 and 4.26,27 Inhibitor 2 inhibited WT Pol  lyase activity with an 
IC50 of 21 M and also inactivated polymerase activity.
26 At that time, the group assumed that 
these compounds targeted the lyase domain because DOB in DNA modified K72 (Section 
2.3.1.2).29 However, definitive proof to support this (i.e. the separate domains or MS) was 
unavailable. In addition, the structure of 4 resembled inhibitors 2 and 47.  
 
 
To accomplish this, we used our gel-based lyase assay with WT Pol  and the 8 kDa domain 
and our strand displacement activity with WT Pol  and the 31 kDa domain (Figure 41). We 
confirmed that inhibitor 2 inactivated the lyase activity only in the holo-enzyme and had little 
effect on the 8 kDa domain (Figure 41a). Conversely, inhibitor 2 interfered with strand 
displacement activity in both the intact enzyme and the 31 kDa domain (Figure 41b and c). These 
data indicated that inhibitor 2 binds in the polymerase domain but inhibits both activities. 
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Figure 41. First-generation inhibitor (2) targeted the polymerase domain. (a) gel-based lyase assay 
with WT enzyme and 8 kDa domain, (b) strand displacement assay with WT enzyme, (c) strand 
displacement assay with 31 kDa domain. 
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While this result was not unwelcome, it was unexpected. As mentioned earlier, when in 
DNA, the DOB molecule modified Lys72 in the 8 kDa domain (Section 2.3.1.2).29 Based upon 
this, the group was looking for lyase inhibitors and assumed that lyase inactivation also affected 
polymerase activity. The primary screening method detected compounds that inactivate strand 
displacement activity. Consequently, any lyase inhibitors that only inactivated lyase activity would 
not be identified in this screen. 
We turned to fluorescence anisotropy to determine whether the original DOB-inspired 
inhibitor (2) also interfered with DNA binding in the holo-enzyme (Figure 42a) and the 31 kDa 
domain (Figure 42b). We analyzed fluorescence anisotropy in the intact enzyme with two 
concentrations of inhibitor 2 because we wanted to compare the effect on DNA binding with the 
same concentration used during kinetics (30 M) and a higher concentration (60 M) to ensure 
we could observe a significant difference in DNA binding. Sure enough, in the polymerase domain 
and the intact enzyme, DNA binding was disrupted in the presence of inhibitor 2. The decrease in 
DNA binding in the holo-enzyme in response to inhibitor 2 was concentration dependent.  
Fluorescence anisotropy with the 8 kDa domain did not show any change in DNA binding in the 






Figure 42. The effect of inhibitor 2 on DNA binding in WT Pol  (a) 31 kDa Pol  (b) and 8 




While separate domain kinetic assays are valuable for general binding information, they 
cannot determine which residue(s) was modified by the inhibitor. Therefore, we incubated Pol  
with inhibitor 2 (5 M), digested the protein with trypsin, and analyzed the peptide fragmentation 
by MS/MS (Figure 43). We detected several fragments but ultimately observed modifications on 
K127, K148, and K248. Fragments 4 and 5 overlap and cover amino acids 113-131. Fragment 6 
contained two internal lysine residues (K113, K120, and K127). Fragmentation of this peptide (y5* 
and y7*) suggested that modification occurred between residues 125-131. By process of 
elimination, the only internal lysine between 125 and 131 was K127. Furthermore, the only internal 
lysine in Fragment 5 was K127. Together, these indicated covalent modification occurred on 
K127. 
 Fragments 6 and 7 span amino acids 138-152. In this region, K142 and K148 were present 
but fragmentation in Fragment 6 suggested K148 is the site of modification. In Fragment 6, K142 
was detected unmodified (b6) and K148 was detected modified (y6* and y9*). Additional evidence 
for modification on K148 appeared in the detection of Fragment 7, where K148 was the only 
internal lysine available for covalent modification. 
 Fragments 8-10 overlap and consist of amino acids 235-258. Internal lysines included 
K244 and K248. In Fragment 8, K244 was unmodified (b10) but the longer fragmentation 
consisting of both K244 and K248 (b17*) appeared modified. Fragments 9 and 10 directly pointed 
to modification on K248 as it was the only internal lysine. Furthermore, these fragments start at 
amino acid 245, which means trypsin would have cleaved the protein at K244, suggesting it was 
unmodified. Fragmentation data of these peptides also supported modification on K248 (b6*, y11*, 
Fragment 9; b6*, y7*, y8*, y9*, Fragment 10). It is interesting that both the hydrated and dehydrated 
versions of the modification were observed across detected fragments. 
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Figure 43. MS analysis of trypsin digestion of Pol  incubated with 2. Pol  (1 mM) and 2 (5 M) 
were incubated in 1X reaction buffer (50 mM HEPES, pH 7.2, 5 mM MgCl2, 2 mM DTT) at 25 
oC for 30 min. The mixture was concentrated with a 3 K Amicon filter and washed 3-4 times with 
1X reaction buffer. Digestion buffer (25 L), 500 mM Tris HCl, pH 7.0), 10X trypsin (25 L, 400 
M), and H2O (175 L) was added. The digestion sample (2 M Pol  and 40 M trypsin) was 
incubated at 37 oC for 24 h. A portion (10 L) of the digestion mixture was spun down and 
analyzed by UPLC-MS/MS using an ACQUITY UPLC HSS T3 Column (100 A, 1.8 m, 2.1 mm 
x 100 mm). The flow rate was 0.3 mL/min running a gradient of 85:5:10 water: acetonitrile: 1% 
formic acid to 50:40:10 water: acetonitrile: 1% formic acid over 35 min. Analysis was conducted 
using BioPharmaLynx with tolerance set to 30 ppm and allowing for 4 missed cleavages. 
 
After MS analysis, we located these residues in the crystal structure of Pol  (Figure 44). 
We were surprised to find that none of the detected modified residues appear near the DNA, and 
yet we know that inhibitor 2 interferes with DNA binding (Figure 42). Furthermore, the structure 
of the polymerase domain does not change significantly upon binding the DNA.114,116 The position 
of lysines slightly shift position upon DNA binding (Figure 44). 
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 It is possible that modification at these lysines impact folding or initiate a conformational 
change that disrupts DNA binding and activity. However, it is likely that the discrepancy observed 
is just a matter of concentration of the inhibitor. The concentration of 2 (5 M) needed for MS 
analysis is significantly lower than the concentration used (30-60 M) in fluorescence anisotropy 
experiments. It was possible that inhibitor 2 was not very selective and that at higher 
concentrations, it would modify several lysines that, cumulatively, inhibit DNA binding. In 
support of this, we digested Pol  incubated with 2 (25 M) and observed modifications on several 
other lysines (i.e. K84, K113, K127, K167, K148, K234, K248), one of which has been implicated 
in DNA binding interactions (i.e. K234).117 
Figure 44.  Conformational changes when Pol  binds to DNA. Key: pink = 31 kDa Pol  without 







It is worth noting that just because inhibitor 2 binds in the polymerase domain, it is unclear 
whether second-generation inhibitor 4 does. This is unclear because 4 contains components of 
inhibitor 2 and 47, but these individual inhibitors bind the 31 kDa polymerase and 8 kDa lyase 
domains respectively (Table 2).  
 
Table 2. Summary of inhibitor binding locations and activity inhibition. 
 2 4 47 
Targets 31 kDa ND 8 kDa 
Lyase Activity Inhibits Inhibits Inhibits 
Polymerase Activity Inhibits Inhibits Inhibits 
MS K127, K148, K248 ND K72, K84 
Disrupts DNA binding Y – WT, 31 kDa 
N – 8 kDa 
ND Y – WT, 8 kDa 
N – 31 kDa 
Y = Yes, N = No 
 
The relationship between location of inhibitor binding and the activity(ies) inhibited is still 
unclear. How do inhibitors 2 and 47 bind different domains but inactivate both activities? We 
hypothesize that, in addition to the disruption of DNA binding, in certain cases, an allosteric 
conformational change occurs that interferes with the other domain DNA binding and activity. 
However, the current experiments are inadequate for correlating where and how an inhibitor binds 
with an allosteric effect. We imagine that solution NMR would be capable of identifying protein 
93 
 
dynamics and conformational changes that occur in response to inhibitor binding. In addition, X-
ray crystallography could be used to observe an allosteric Pol  conformational change. Regarding 
this second approach, inhibitor 47 has been sent to a collaborator for X-ray analysis. 
3.3.3 The Significance of the 3’-oxime and the 3’-amide 
 
 After identifying inhibitor 47, we altered the synthesis of the 3’-functionalized library. This 
synthesis started with commercially available 3’-azidothymidine (AZT) and after reduction and 
N-trifluoroacetamidation yielded 55 (Scheme 26). Starting with AZT significantly simplified the 
synthesis by avoiding consecutive Mitsunobu reactions. The Mitsunobu reaction was necessary 
when starting from thymidine to ensure stereochemistry retention at the C3’-position (Scheme 10).  
 
Scheme 26. Retrosynthetic (a) and forward (b) synthesis of 3’-N-trifluoroacetamide containing 
monomer 55. 
 
The first-generation scaffold was prepared by coupling compound 55 and 10 (Scheme 12) 
to generate the phosphate triester (56) (Scheme 27). Scaffold (57) was isolated following 
deprotection with concentrated aqueous ammonia and was used to generate library 58 (Section 
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3.4). However, we wanted to explore the impact of changing this functional group in the context 
of our inhibitors. In library 1, the 3’-alkoxyamine was functionalized by a library of aldehydes to 
form oximes (Figure 21). In contrast, library 58 consisted of a 3’-amine that was functionalized by 
a library of carboxylic acids to yield amides. The oxime and the amide are different in flexibility 
and length. These differences position the aryl group in different orientations and the resulting 
molecules can, therefore, experience unique binding interactions. 
 




 To evaluate whether this difference affect enzyme inhibition, we resynthesized inhibitor 2 
but in the context of the amide bond. In other words, we used the same commercially available 
aldehyde used in the synthesis of inhibitor 2 and transformed it into the corresponding carboxylic 
acid (Scheme 28). The 3’-alcohol was protected with a TBS group to yield 59. The carboxylic acid 
(60) was obtained in the subsequent oxidation, in which the TBS group fell off during the reaction 
and work up.164  Our optimized coupling conditions (i.e. HBTU and HOBt, Section 3.3) were used 
to couple scaffold 57 and 60 to yield 61. The pentenoyl groups were cleaved under oxidative 
conditions to yield the final compound (62) bearing the same aryl group in inhibitor 2, confirmed 
by MS. 
 





Compound 62 was analyzed using the strand displacement assay at multiple concentrations 
(Figure 45). It was clear that at concentrations as high as 50 M, 62 did not inhibit WT Pol . This 
contrasted with inhibitor 2, which has an IC50 of 21 M. Based on this 
experiment, we concluded that the differences between the oxime and the 
amide group were significant enough to yield different inhibitor hits. It is 
likely that the additional flexibility and length of the oxime positioned the 
substituted benzyl group uniquely. This result was reassuring because it 
indicated that the libraries are producing molecules that make specific interactions with the 
enzyme. 
Figure 45. Compound 62 does not inhibit strand displacement activity of the intact enzyme. Pol  
(50 nM) was preincubated with 62 at various concentrations (listed) for 30 min. The preincubation 
mixture was diluted 10-fold and mixed with DNA cocktail solution, to yield 5 nM Pol , 50 nM 
DNA substrate B, and 100 M dTTP. 
 
 
3.4 WT Pol  inhibitor(s) starting from AZT 
 
While inhibitor 47 provided a useful lead, the development of the 3’-library route through 
AZT (Schemes 26 and 27) was more convenient and efficient. Therefore, scaffold 57 was used to 
create a first-generation library (58). A modest polymerase inhibitor was identified in library 58 
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(Section 3.4.1). This hit compound led to the design of a second-generation library, where a potent 
and selective Pol  inhibitor was identified (Section 3.4.2). This compound was characterized 
extensively via in vitro (Section 3.4.2.1) and in vivo (Section 3.4.2.3) assays.  
3.4.1 First-generation WT Pol  inhibitor: Functionalization at the 3’-position 
 
In addition to modification at the 5-methyl position of thymine (Section 3.3.1), a first-
generation library involving 3’-functionalization was synthesized (Scheme 27, Section 3.3.3). 
Scaffold (57) (40 mg total, 200 nmol per carboxylic acid) was coupled to 280 carboxylic acids 
(Appendix 1) and deprotected with NBS to form the 3’-functionalized library (58). This first-
generation library was screened using the same conditions previously mentioned (Section 3.3.1). 
Library 58 led to the identification of hit compounds 63 and 64 (Figure 46). First round 
hits were screened multiple times to rule out false positives. Inhibition by hit compounds were 
compared to the inhibitory effects of the free acids. After three rounds, no other inhibitors were 
consistently identified in the library. Strand displacement inhibition was dependent on the 
concentration of 63 and 64 (red and green, Figure 47). By comparing the increase in fluorescence 
in response to inhibitor concentration, compound 63 (30 M) completely inactivated the strand 
displacement, while the same concentration of 64 (30 M) resulted in much less activation (Figure 
47). 




Figure 47. Pol  strand displacement inhibition is dependent on the concentration of 63 and 64. 
Pol  (100 nM) was preincubated with hit 63 or 64 at various concentrations (listed) for 20 min. 
The preincubation mixture was diluted 10-fold and mixed with DNA cocktail solution, to yield 5 
nM Pol , 50 nM DNA substrate B, and 100 M dTTP. 
 
The quantitative gel-based lyase assay indicated that hits 63 and 64 did not inactivate the 
lyase activity even at much higher concentrations (Table 3). This suggested that 63 and 64 did not 
inhibit the lyase activity. This result was unexpected. As mentioned earlier, while we identified 
Pol  inhibitors that selectively bind distinct domains (i.e. 2 and 47), they inactivated both activities 
(Section 3.3). Regardless, 63 was clearly a more potent polymerase inhibitor compared to 64 
(Figure 47). Therefore, 63 was analyzed further using the separate domains of Pol . Hit compound 
63 had no impact on the 8 kDa lyase domain activity but inhibited the strand displacement activity 
of the 31 kDa polymerase domain at 15-20 M (Figure 48). The observations were consistent with 
those described above with intact Pol , which suggested that 63 targets the polymerase domain. 
Hit 63 was distinct from previous inhibitors (2, 47) because it selectively targeted the 31 kDa 
domain and inactivated the polymerase activity, without affecting lyase activity. 
 





































Table 3. Summary of Pol  lyase inactivation by 63 and 64. 
 
 
Figure 48. Inactivation of the Pol  31 kDa domain strand displacement activity. 31 kDa Pol  
(500 nM) was mixed with 63 (15 or 20 M) for 30 min. Preincubation mixture was diluted 10-
fold and mixed with 50 nM DNA substrate B and 100 M dTTP. 
 
3.4.2 Second generation inhibitor: Functionalization of 59 at the thymine 5-methyl 
position 
 
The synthesis of the 3’-first-generation library (58) was efficient, effective, and identified 
an interesting hit candidate (63). Therefore, hit compound 63 guided the synthesis of a second-
generation library (Scheme 29). The second-generation library synthesis started with the silylation 
of AZT (65). Following a one pot reaction including bromination, ammonolysis and N-
trifluoroacetamidation (66), the 3’-azide was reduced and coupled to the carboxylic acid in the 
previous first generation hit compound (63) to yield intermediate 67. This intermediate underwent 
Hit Concentration (M) Relative lyase activity (%) 
63 
25 75  11 
30 87  9 
60 46  5 
120 46  7 
64 25 95  5 


































desilylation (68) and coupling with 10 (Scheme 12) to yield phosphate triester 69. The scaffold 
(70) was generated after the -cyano ethyl and N-trifluoroacetamide groups were removed under 
basic conditions. A library of carboxylic acids (~325 compounds) was coupled to the 5-
aminomethyl position (70, 25 mg total, 100 nmol per acid) and the reactive DOB moiety was 
deprotected with NBS to generate the second-generation library (71). 
Scheme 29. Synthesis of a second-generation library containing the 3’-hit compound moiety. 
 
 
In the second-generation screen, each compound (700 nM) was preincubated with Pol 
 (50 nM) for 25 min, mixed with a 5X cocktail solution containing dTTP and fluorescently 
labeled ternary complex (Figure 24, B, Table 1), and diluted together in 1X buffer (10X for 
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preincubation, 5X for DNA). The concentration of library compound(s) during the screen was 
much lower than the concentration in the first-generation screen. Higher concentrations (5 M) 
led to the identification of a large portion of the library (~50% of the compounds tested) as potential 
hits. This was encouraging because it suggested that we were going to identify a potent inhibitor. 
Even screening at a much lower concentration, the initial screen identified multiple compounds, 
so all hits were resynthesized and rescreened along with the free acids to rule out false positives 
(Section 3.3.1). After three rounds of screening, this library led to the identification of inhibitor hit 
(72, Figure 49). No other compounds with similar potency were identified using these screening 
conditions. This inhibitor hit bore a 3-hydroxylated naphthoic acid moiety, a structural element 
present in several other inhibitors libraries (i.e. 47 and 48) and inhibitors (i.e. 4 and PA).27,145  
Figure 49. Hit compound and pro-inhibitor (72). 
 
Compound 72 did not significantly inhibit the lyase activity of Pol  (Figure 50). At  M 
72, Pol  retained 75% of its lyase activity. This was not surprising considering that it was derived 
from the first generation hit 63, which did not inhibit the lyase activity. However, this meant that 
the gel-based lyase assay would not be applicable when trying to determine IC50 values and other 
quantitative data for inhibitor 72. 
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Figure 50. Compound 72 did not inhibit lyase activity. 
 
Consequently, the strand displacement assay (Figure 24) was used to extract kinetic 
information (Section 3.2.1). The irreversible inactivation of Pol  depends on the concentration of 
72 and preincubation time (Figure 51). Kinetic parameters of Pol  inactivation by 72 were gleaned 
from the data, including an IC50 and a KI and kinact (Figures 52 and 53, and Table 4).
159 
Figure 51. Pol  strand displacement inhibition is dependent on concentration and preincubation 
time with 72. Pol  (50 nM) was preincubated with 72 at various concentrations for multiple 
preincubated times. After preincubation time, the mixture was diluted 10-fold and mixed with 30 
nM DNA substrate B and 300 M dTTP. Relative rate of 50 nM Pol  in the presence of 72 at 
various concentrations (listed) compared to the rate of 50 nM Pol  in the absence of inhibitor. 
 
An IC50 value is not an appropriate method for evaluating an irreversible inhibitor because 
they are dependent on preincubation time (Section 3.2.2). An IC50 plot looks at a single 
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preincubation time and can, therefore, be misleading. This was evident in Figure 52 which displays 
two curves from different preincubation times that yield different IC50 values. With a 10 min 
preincubation time, the IC50 value of 72 is 458 nM. However, a 12 min preincubation time yields 
an IC50 value of 409 nM.  
Figure 52. IC50 plots for 72 at two preincubation times. Pol  (50 nM) was preincubated with 72 
at various concentrations for 10 min (blue) or 12 min (red). After preincubation time, the mixture 
was diluted 10-fold and mixed with 30 nM DNA substrate and 300 M dTTP. 
 
Although an IC50 value is not preferred to other kinetic measurements, it is the only method 
available to compare 72 to previous second-generation inhibitor 4.27 However, the conditions used 
thus far to evaluate the IC50 of 72 were different from those 
used for 4. The differences include shorter preincubation 
time and greater dilution for 72. Both factors are more 
stringent conditions for the inhibitor and therefore, led us to 
think that 72 may be more potent than 4 (Section 3.3). 
Therefore, the dilution and preincubation conditions used to 
evaluate 4 were repeated for 72 (Table 4, Appendix Figure 1). The IC50 value for 72 was 204 nM 
























against Pol , compared to 4, which had an IC50 value of 400 nM against Pol .
27 It should be 
noted that the IC50 value of 204 nM for 72 cannot be compared directly to the IC50 values obtained 
from 10 and 12 min preincubations (separated by a thick bar in Table 4) because the preincubation 
dilutions were also different (10 and 12 min, 10X; 30 min, 1.1X). 
Table 4. Summary of kinetic parameters of 72 inhibition of Pol . 
 kinact (s-1) KI (M) kinact/KI (M-1s-1) IC50 (nM) 
Preincubation time 
(min) (for IC50 only) 
72 
7.0 ± 1.0 x 10-3 1.8 ± 0.45 3.89 x 103 
458 10 
409 12 
   204 30 
4 - - - 400 30 
 
Based on the previous discussion, an IC50 value differed depending on whether it was 
derived from a shorter or longer preincubation time. As a result, inhibitor kinetic parameters, such 
as KI and kinact, are more meaningful. A Kitz- Wilson plot was used to determine these kinetic 
constants (Section 3.2.2).159 The KI of 72 is 1.8 ± 0.45 M and the kinact is 7.0 ± 1.0 x 10-3 s-1 
(Figure 53, Table 4). 















The KI represents inhibitor binding affinity and provides insight about the dosage needed 
to inhibit 50% of the enzyme target. Therefore, a smaller KI value indicates greater binding and a 
smaller concentration required to inhibit the target. A large kinact value is more desirable because 
it indicates a quick rate of enzyme inactivation. Furthermore, the kinact/KI is a measure of overall 
inhibitor efficiency.  Covalent inhibition is becoming increasingly more popular. Unfortunately, 
most potent, irreversible inhibitors of Pol  do not report these kinetic parameters so a direct 
comparison cannot be made.26,27 Recently, a low potency Pol  lyase inhibitor (KI = 1.44 mM) was 
identified whilst searching for compounds that directly engage with the lyase active site lysine (i.e. 
K72).165 Alternatively, while some irreversible inhibitors exist that target other polymerases, their 
kinetic parameters are limited to IC50 values.
166,167 Instead, we must compare 72 to irreversible 
inhibitors of other targets. For comparison, a novel covalent inhibitor of the histone 
methyltransferase nuclear receptor-binding SET domain protein 1 (NSD1) exhibited KI = 25.0 ± 
5.2 M, kinact = 4.8 ± 0.5 x 10-4 s-1, and kinact/KI = 19.6 M-1s-1.168 Despite the difference in target, 
inhibitor 72 exhibited a greater binding affinity for Pol , a faster rate of inactivation, and a higher 
inhibition efficiency than the NSD1 inhibitor exhibited for its target.  
Irreversible inactivation by 72 was also confirmed by dialysis (Figure 54). Pol  was 
inactivated following treatment with 72 (750 nM) and did not regain activity after dialysis. It is 
unclear why Pol  maintained 25% strand displacement activity before and after dialysis upon 
being exposed to 750 nM 72. In several other experiments (Figures 51, 55, 56, and 57), a lower 
concentration of 72 (500 nM) at the same preincubation time (20 min) resulted in greater 
inactivation (i.e. <10% enzyme activity retained) of Pol . 
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Figure 54. Strand displacement activity in response to dialysis of Pol  with 72. Pol  (50 nM) 
was preincubated with or without 72 (750 nM) for 20 min. An aliquot of preincubation mixture 
was diluted 10-fold and mixed with 30 nM DNA substrate B and 300 M dTTP. Another aliquot 
of the preincubation mixture (180 L) was injected into a 3.5 K, 100-500 L dialysis cassette and 
dialyzed against 1X reaction buffer (2 x 1 L, 50 mM HEPES, 50 mM KCl, 5 mM MgCl2, 200 mM 
EDTA, 0.01% Tween 20, pH 7.5) for 24 h at 4 oC. After dialysis, the strand displacement kinetics 
were analyzed following previously stated conditions. 
 
The selectivity of 72 was characterized by testing it against other polymerases, including 
model replicative polymerase, Klenow exo-, eukaryotic DNA repair polymerases, Pol  and , and 
the back-up BER polymerase, Pol .25,161–163,169 Different assays were used to quantify inhibition 
for each polymerase (See Section 3.2.4). 
Selectivity experiments showed that inhibitor 72 exhibited a strong preference for Pol  
over these four polymerases even at 20-fold higher concentration (10 M) of the inhibitor (Figure 
55). At 500 nM 72, all other polymerases tested retain full activity, while Pol  activity was 
completely reduced. Klenow exo- and Pol  were also unaffected at 10 M 72. At a higher 
concentration of 72 (10 M), the strongest inhibition occurs with Pol  and  and ranges from 26-
50% relative activity. The selectivity for Pol  over Pol  is especially significant because they 
exhibit 32% sequence homology and previous Pol  inhibitors have also been potent against Pol 
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 (i.e. 4 and HKL, Figure 20).25,27,98–100 This degree of preference for Pol  has never been observed 
before in a potent (nM) inhibitor, which makes this result very exciting! 
Figure 55. Selectivity of 72 against polymerase activity in model and mammalian polymerases. 
Polymerase (50 nM) was preincubated with or without 72 (500 nM, 10 μM) for 20 min. For 
fluorescence-based assays (Pol , Klenow exo-, and Pol ), an aliquot of preincubation mixture 
was diluted 10-fold and mixed with 30 nM DNA substrate and 300 μM dTTP (for Pol  and 
Klenow exo-) or 500 nM DNA and 400 μM dNTP (for Pol ). For gel-based assays (Pol  and , 
an aliquot of preincubation mixture was diluted 10-fold and mixed with 125 nM DNA (Pol , D; 
Pol , E) and 500 μM dNTPs at 37 oC (for Pol ) or 10 nM DNA and 500 μM dNTPs at 37 oC (for 
Pol ), stopped at various time points by quenching with an equal volume of 95% formamide 
buffer, and analyzed by gel electrophoresis. Data are the average ± SEM for three experiments. 
 
 
3.4.2.1  In Vitro biochemical and biophysical characterization of inhibitor 72 
 
After more characterization, it was determined that the inhibition by 72 was dependent on 
pH and the concentration of thiols (Figures 56 and 57). Interestingly, Pol  activity at pH 6.9 and 
8.0 was roughly half that at pH 7.4. While this was reproducible in our hands, it conflicted with 
other literature. Multiple reports suggest Pol  activity was enhanced at pH 8.0.170,171 Compound 
72 was most effective at physiological pH (7.4). Inactivation still occurred at slightly more acidic 
conditions (pH 6.9) but was completely disrupted at pH 8.0 (Figure 56). The pH effect was also 
observed after dialysis. When Pol  was preincubated at pH 7.4 with or without 72 (500 nM), Pol 
 activity was completely inactivated by 72 (denoted pH 7.4, checkered, Figure 56). When those 
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samples were dialyzed at pH 8.0 for 24 h and assayed for strand displacement activity at pH 7.4, 
there was no difference in activity between Pol  incubated with 72 (denoted pH 7.4*, checkered, 
Figure 56) and Pol  alone (denoted pH 7.4*, solid, Figure 56). The recovery of activity when 
comparing Pol  treated with 72 at pH 7.4 before (pH 7.4, checkered) and after (pH 7.4*, 
checkered) dialysis at pH 8.0 suggested that the inhibition was not only less effective at higher pH 
but was also reversible. 
 
Figure 56. pH dependence of Pol  inactivation by 72. Pol  (50 nM) was preincubated with (solid) 
or without (checkered) 72 (500 nM) for 20 min. An aliquot of preincubation mixture was diluted 




In addition, compound 72 was slightly less effective in the presence of thiol ([GSH] = 1, 5 
mM) (Figure 57). Thiols decreased the efficacy of 72 in a concentration-dependent manner. This 
effect is common with electrophilic covalent inhibitors.172,173 Thiols are strong nucleophiles that 
tend to decrease the effect of an electrophilic inhibitor by acting as a scavenger and decreasing the 
local concentration of active inhibitor available to inhibit the target enzyme (Scheme 30). 
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Figure 57. Thiols decrease the efficacy of 72. Pol  (50 nM) was preincubated with or without 72 
(500 nM) and GSH (0, 1, or 5 mM) for 20 min. An aliquot of preincubation mixture was diluted 
10-fold and mixed with 30 nM DNA substrate B and 300 M dTTP. 
 
Scheme 30. Thiols react with electrophilic species. 
 
We turned to mass spectrometry to determine the Pol  residue(s) modified by 72. Covalent 
modification was detected on K113 and K234 (Figure 58, Fragments 11 and 12). The modification 
observed was a result of reaction between a Lys residue and the DOB fragment followed by loss 
of a water molecule (Figure 58, right). Fragment 11 contained a single internal lysine residue 
(K113). The role of K113 is unknown but lies near the DNA binding region (Figure 59). Fragment 
12 contained 4 internal lysine residues (i.e. K230, K234, K244, and K248) and required MS/MS 
fragmentation to identify the lysine that was modified by compound 72. Further analysis of the 
MS data identified an unmodified fragment containing K230 (b13), an unmodified fragment 
containing K248 (y9), and an unmodified fragment containing K244 and K248 (y18). A fragment 
110 
 
with a single modification was observed that contained K230 and K234 (b21*) and another 
fragment containing a single modification included K234, K244, and K248 (y21*). Altogether, this 
suggested that of fragment 12, K234 was the modified lysine. K234 is known to be crucial for 
DNA binding interactions (Section 2.3.1.1.2).115–117 
 
Figure 58. MS analysis of trypsin digestion of Pol  incubated with 72. Pol  (1 M) and 72 (300 
nM) were incubated in 1X reaction buffer (50 mM HEPES, pH 7.2, 5 mM MgCl2, 2 mM DTT) at 
25 oC for 30 min. The mixture was concentrated with a 3 K Amicon filter and washed 3-4 times 
with 1X reaction buffer. Digestion buffer (25 L), 500 mM Tris HCl, pH 7.0), 10X trypsin (25 
L, 400 M), and H2O (175 L) was added. The digestion sample (2 M Pol  and 40 M trypsin) 
was incubated at 37 oC for 24 h. A portion (10 L) of the digestion mixture was spun down and 
analyzed by UPLC-MS/MS using an ACQUITY UPLC HSS T3 Column (100 A, 1.8 m, 2.1 mm 
x 100 mm). The flow rate was 0.3 mL/min running a gradient of 85:5:10 water: acetonitrile: 1% 
formic acid to 50:40:10 water: acetonitrile: 1% formic acid over 35 min. Analysis was conducted 
using BioPharmaLynx with tolerance set to 30 ppm and allowing for 4 missed cleavages. 
 
Modification near the DNA binding regions led us to investigate whether inhibitor 72 
impacted Pol ’s ability to bind DNA (Figure 59). We turned to fluorescence anisotropy to measure 
DNA binding in the presence or absence of 72 (Figure 60). It is evident, based on fluorescence 
anisotropy, that inhibitor 72 interfered with DNA binding, especially at lower concentrations of 
Pol . This effect was less prominent under high concentrations of enzyme because Pol  (200 
nM) was in such large excess over the DNA (250 pM) that even if 99% of the enzyme was 
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inactivated, the remaining 1% of active enzyme was still in excess over the DNA. Altogether, MS 
analysis and fluorescence anisotropy support the hypothesis that inhibitor 72 binds to the 
polymerase domain and hindered DNA binding. 
 
Figure 59. Crystal structure of WT Pol : Covalently modified Lys residues after incubation 





Figure 60. Fluorescence anisotropy experiments with 72. Dichloro-diphenyl-fluorescein-labeled 
DNA (250 pM) was incubated with Pol  (various concentrations) in reaction buffer (50 mM 
HEPES, pH 7.5, 20 mM KCl, 1 mM EDTA, and 1 mM -mercaptoethanol) in the presence of 
absence of inhibitor 72 (2 M). Samples containing various concentrations of polymerase were 
prepared by serial dilution with 1X reaction buffer containing 250 pM DNA F and 2 M 72 (to 
keep the concentration of DNA and 72 unchanged). The samples were incubated at 25 oC for 1 h 
and fluorescence anisotropy (A) was measured using a portion (125 L) of each sample with PMT 
voltage 800 mV, 8 nm slit width, and 535 nm excitation and 556 nm emission.  
 
 
3.4.2.2  Non-covalent analog of inhibitor 72 
 
To test the significance of the DOB moiety, a noncovalent inhibitor analogue that 
resembled inhibitor 72 but instead of the DOB moiety bore a methyl ester was synthesized 
(Scheme 31). The 5’-hydroxyl nucleoside (73) containing both aryl groups was phosphorylated 
with a commercially available dimethyl phosphoramidite, oxidized, and one of the methyl groups 
was cleaved to yield the noncovalent inhibitor analogue (74). 
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Scheme 31. Synthesis of noncovalent inhibitor 74. 
 
 
The inhibition of Pol ’s strand displacement activity by 74 was about 15-fold less potent 
than the inhibitor containing DOB (72) (Figure 61). We hypothesized that compound 74 would 
bind in the same area of the enzyme as 72 because of the similarity in structure despite compound 
74’s inability to covalently modify the enzyme. We used fluorescence anisotropy to determine if 
titration of 70 disrupted Pol ’s ability to bind DNA. Based on competition fluorescence anisotropy 
experiments, the noncovalent inhibitor (74) also interfered with DNA binding, albeit at a much 
higher concentration (> 15 M) than 72 (2 M) (Figure 54). While the data confirm that covalent 
modification by the DOB moiety enhanced Pol  inhibition, there was a discrepancy between the 
disruption of DNA binding interactions and the observed effect on enzyme activity for the 
noncovalent inhibitor (70). Based on fluorescence anisotropy data, < 5 M 74 did not affect DNA 




Figure 61. Inactivation of strand displacement activity by 74 in WT Pol . Polymerase  (50 nM) 
was preincubated with or without 74 (various concentrations) for 20 min. An aliquot of 




Figure 62. Competition fluorescence anisotropy with 74 in WT Pol . Dichloro-diphenyl-
fluorescein-labeled DNA F (250 pM) was incubated with Pol  (25 nM) in reaction buffer (50 mM 
HEPES, pH 7.5, 20 mM KCl, 1 mM EDTA, and 1 mM -mercaptoethanol) with various 
concentrations of 74 (0-50 M). After measuring anisotropy of initial sample containing 74 (1.6 
M), the next sample was prepared by titrating additional 74, allowing mixture to equilibrate for 





























3.4.2.3  The effect of pro-72 in cells 
 
The second-generation hit compound was also evaluated in cells using a pro-inhibitor (pro-
72). The pro-inhibitor was synthesized by coupling the 5’-OH nucleoside (73) bearing both aryl 
groups with previously synthesized phosphoramidite (12) (Scheme 32). 
Scheme 32. Synthesis of pro-inhibitor (pro-72). 
 
The toxicity of pro-72 was evaluated in HeLa cells using cell viability and clonogenic 
assays. HeLa cells were treated with pro-72 (0, 5, 25, 50, 100 M) for 1 or 2 h. Cell viability 
assays indicated that pro-72 killed less than 10% of the cells at these concentrations (Figure 63). 
A clonogenic assay of HeLa cells treated with pro-72 showed no significant cell death at low 
concentrations (5, 25 M) regardless of the treatment time (Figure 64). Significant toxicity 




Figure 63. Cell viability of HeLa cells in response to pro-72. 
 
 
Figure 64. Clonogenic assays show low toxicity of pro-72 in HeLa cells. HeLa cells were treated 
with pro-72 (various concentrations) for 1 or 2 h. After treatment, media containing pro-72 was 
removed, cells were harvested, counted, and seeded to allow for colony growth. Colonies were 
visualized by crystal violet. 
 
Nontoxic concentrations of pro-inhibitor were ideal for determining synergism with a DNA 
damaging agent. Synergism implies that the cell death resulting from combination treatment (AB) 
is greater than the additive cell death observed from individual treatments (A + B) (equation 6). 
Therefore, if an individual treatment was too toxic to the point where the additive effect was close 


















to or greater that 100% cell death, no synergism can be identified. Therefore, we used 5 or 25 M 
pro-72 in all clonogenic assays in the presence or absence of MMS or BLM. 
AB/(A+B) > 1      (6) 
A synergistic effect with MMS and BLM was tested for via a clonogenic assay at nontoxic 
concentrations of pro-72 (5, 25 M) (Figure 65). There was a synergistic effect between pro-72 
(5 M) and MMS. Combination treatment with MMS (0.2 mM) and pro-72 (5 M) for 1 h was 
2.5 times more effective at killing cells than the same treatment without pro-72. A longer treatment 
(2 h) of MMS killed 58% cells while the combination treatment resulted in 97% cells death, a 1.7-
fold enhancement. Curiously, for a 1 h treatment this synergistic effect was not enhanced by 25 
M pro-72 (light blue, Figure 65). Synergism using a longer treatment would likely be difficult to 
observe due to the extensive cell death already observed at 5 M pro-72. 
The synergistic effect between pro-72 and BLM was slightly greater than with MMS 
(Figure 65). A 1 h treatment of pro-72 (5 M) and BLM (2 M) enhanced the cell killing effect 
by 2.8-fold compared to the single treatment of BLM at the same concentration. The 2 h treatment 
of BLM was too toxic to observe a synergistic effect with pro-72. In the same way that nontoxic 
conditions of pro-72 were ideal, nontoxic (or little toxicity) conditions of DNA damaging agents 
were preferable for measuring synergism. Altogether, these data indicate our Pol  pro-inhibitor 





Figure 65. Synergistic effect of pro-72 with DNA damaging agents on cell death in HeLa cells. 
HeLa cells were treated with MMS (0.2 mM) or BLM (2 M) in the presence or absence of pro-
72 (various concentrations) for 1 or 2 h. After treatment, media containing pro-72 was removed, 
cells were harvested, counted, and seeded to allow for colony growth. Colonies were visualized 
by crystal violet. 
 
 
 The effectiveness of pro-72 was also tested in a breast cancer cell line, MCF-7 cells. We 
observed that HeLa cells were more robust than MCF-7 and we were unsure how the pro-inhibitor 
would fare in a more sensitive cell line. It was clear that pro-72 was generally more toxic in MCF-
7 (Figure 66) than in HeLa (Figure 64) cells. While a 1 h treatment of pro-72 (5 M) resulted in 
10% cell death in MCF-7 (Figure 66) or HeLa cells (Figure 64), a 2 h treatment of pro-72 (5 M) 
in MCF-7 cells increased cell death to 39% (Figure 66). Interestingly, we do not observe a 
significant change in cell death between 5 and 25 M pro-72 regardless of the treatment time. A 




Figure 66. Toxicity of pro-72 in MCF-7 cells as determined via clonogenic assay. MCF-7 cells 
were treated with pro-72 (various concentrations) for 1 or 2 h. After treatment, media containing 
pro-72 was removed, cells were harvested, counted, and seeded to allow for colony growth. 
Colonies were visualized by crystal violet. 
 
It is worth mentioning that biological replicates of cell experiments are more variable than 
in vitro experiments.174,175 For example, the same treatment of pro-72 (5 M; 2 h) in MCF-7 cells 
resulted in 45% cell death in one set of experiments (Figure 66) and 25% cell death in another set 
of experiments (Figure 67). This is important to keep in mind when analyzing data. 
To compare the activity of pro-72 in HeLa and MCF-7 cells, we used clonogenic assays 
to measure a synergistic effect between pro-72 and DNA damaging agents in MCF-7 cells. When 
MCF-7 cells were treated with MMS or BLM in the absence or presence of pro-72, a synergistic 
effect at killing cells was observed (Figure 67). The synergism between MMS and pro-72 was 
greater than that of BLM and pro-72. Treatment with MMS (0.2 mM) in the presence of pro-72 
(5 M) was 1.5 times more effective at killing cells that were treated with MMS (0.2 mM) for 1 h. 
However, a 2 h treatment of the DNA damaging agent was too harsh and resulted in too much cell 
death to accurately measure a synergistic effect. These experiments must be repeated under less 
toxic conditions to establish a synergistic effect upon longer treatments. Interestingly, a synergistic 
effect was not observed between BLM (2 M) and pro-72 (5 M). Considering that treating MCF-
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7 cells with BLM (2 M) for 1 h killed 60% of the cells and pro-72 killed 30%, this treatment was 
likely too harsh on the cells and it is possible a synergistic effect may be observed under less toxic 
conditions. 
Figure 67. Synergistic effect of pro-72 with DNA damaging agents on cell death in MCF-7 cells. 
MCF-7 cells were treated with MMS (0.2 mM) or BLM (2 M) in the presence or absence of pro-
72 (various concentrations) for 1 or 2 h. After treatment, media containing pro-72 was removed, 
cells were harvested, counted, and seeded to allow for colony growth. Colonies were visualized 
by crystal violet. 
 
 Altogether, pro-72 was more toxic in MCF-7 cells than in HeLa cells. In addition, 
synergism between pro-72 and DNA damaging agents in MCF-7 cells (Figure 67) was less 
impressive than synergism observed in HeLa cells (Figure 65) but still observed. 
 
3.5 Identification of Pol  mutant inhibitor(s) 
A potent inhibitor that is selective for a mutant form of Pol  associated with a specific 
cancer cell is highly desirable (Section 2.5.1). Improving the preference for a tumor over a healthy 
cell has the potential to enhance the agent’s therapeutic index (TI, Section 1). Therefore, another 






3.5.1  Mutants Screened 
 Mutant forms of Pol  have been identified in patient tumors.13 The degree to which each 
identified mutant has been characterized (i.e. relative activity) differs. Three plasmids containing 
active lyase mutants (i.e. N24K, P63L, and T79I) were acquired and expressed (Figure 68). At the 
time that we obtained the expression plamids for these mutants, we were focused on lyase mutants 
because our inhibitors were based on an oxidized abasic lesion (i.e. DOB), which covalently 
modified Lys72 of the lyase domain. We had requested the mutants prior to determining that 
inhibitor 2 or 72 targeted the polymerase domain (Section 3.3.2 and Section 3.4).29   
Figure 68. Crystal structure of the mutants (in pink) in the 8 kDa Pol  lyase domain (blue) 






3.5.2 First-generation mutant inhibitor: Functionalization at the 3’-position 
 
 The first-generation library for Pol  mutants was the same as the first-generation library 
for WT Pol . However, this library synthesis was altered to avoid the pentenoyl protecting groups 
on the DOB because the NBS deprotection of these groups was not trivial. More importantly, we 
determined that the deprotection conditions (i.e. NBS) were incompatible with several easily 
oxidized carboxylic acids (i.e. hydroxylated naphthoic acids). Instead, nitroveratryl (Nv) groups 
were used to protect the DOB (Scheme 33). Nv groups have been used previously in nucleic acid 
chemistry as photolabile precursors.26,27,29,135 Prior to synthesizing a DOB phosphoramidite with 
Nv protecting groups, I confirmed that photochemical cleavage would be compatible with the 
carboxylic acids that were incompatible with NBS deprotection. Nv groups are typically removed 
by exposure to 365 nm light. Naphthoic acids absorb light at this wavelength but are unreactive 
under the photolysis conditions used. Therefore, we were confident that this approach would be 
compatible across the library of carboxylic acids. Previously synthesized 7 (Scheme 12) was 
transformed into Nv-protected 75 in the presence of a Lewis acid (i.e. BF3 etherate) and the 
commercially available 6-nitroveratryl alcohol. Following deacetylation (76) and phosphitylation, 
the diastereomers of phosphoramidite 77 were separately isolated. 
Scheme 33. Synthesis of Nv-protected DOB moiety. 
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To generate the Nv-protected scaffold molecule for the same library (58) previously 
synthesized, 55 was coupled to 77 to yield phosphate triester 78 (Scheme 34). After phosphate and 
amine deprotection, the Nv-protected scaffold (79; 30 mg total, 100 nmol per carboxylic acid) was 
coupled to a library of carboxylic acids (~375 compounds) and deprotected in a mixture of 1:1 
MeCN/H2O by exposure to 365 nm light for 15 min. The deprotection of the Nv group was 
confirmed by MS and HPLC. Furthermore, the deprotection conditions were flexible. Successful 
deprotection was observed after as short at 10 min and as long as 30 min exposure to light with 
minimal decomposition. 
 
Scheme 34. Synthesis of Nv-protected scaffold 79 and library 58. 
 
This library was screened against the lyase mutants (N24K, P63L, and T79I), as well as 
WT Pol  using the fluorescence-based UBER lyase assay (Section 3.2.3, Figure 27) in order to 
identify any hit compounds selective for a mutant over the WT enzyme. This assay was important 
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because the use of the strand displacement assay for high-throughput screening may be ineffective 
for these purposes. All mutants tested contain the WT 31 kDa domain. Therefore, any selectivity 
identified in the strand displacement assay for the mutants would be based upon a distal 
modification and may be unreliable. 
Each compound (25 M) was preincubated with WT and mutant Pol  (100 nM) for 25 
min, incubated with substrate A for 25 min (Table 1), then diluted 5-fold, and mixed with the 
UBER probe (Figure 27). The first screen identified several inhibitors, so all hit compounds were 
resynthesized and rescreened to rule out false positives. 
 The fluorescence-based lyase assay identified two hit compounds: 80 and 81 for Pol  
N24K and T79I, respectively (Figure 69). Again, the presence of the naphthoic acid moiety has 
been commonly found in inhibitors of Pol . While the UBER assay was an excellent screening 
method, it was not sensitive enough to obtain quantitative kinetic information about lyase 
inactivation. Therefore, the gel-based lyase assay was used to evaluate these candidates further 
(Section 3.2.2). 
Figure 69. Identification of hit compounds 80 and 81 against for Pol  N24K and Pol  T79I, 
respectively, using the UBER lyase assay. 
 
Compounds 80 and 81 were resynthesized and purified on a larger scale (5-10 mg) because 
we determined the crude compounds were contaminated by activating agents (i.e. HBTU, HOBt). 
We found that completing the amide coupling with the corresponding carboxylic acid prior to 
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phosphoramidite coupling resulted in more pure final compounds (Scheme 35). In the synthesis of 
80, AZT was reduced and coupled to 6-hydroxy-2-methylquinoline-3-carboxylic acid to yield 82. 
Phosphoramidite coupling with 77 yielded phosphate triester 83. Following deprotection, the 
precursor (84) to inhibitor 80 was isolated. In the synthesis of 81, AZT was reduced and coupled 
to the NHS ester (86) of the Ac-protected hydroxylated naphthoic acid (85) to yield 87. This 
intermediate (87) was coupled to phosphoramidite 77 to yield 88. Compound 88 was deprotected 
to yield the precursor (89) to inhibitor 81. Each precursor (84 and 89) was converted to the active 
inhibitor (80 and 81) by cleaving the photolabile Nv group upon exposure to light. 
 




These hits were analyzed via the quantitative gel-based lyase assay (Section 3.2.2) and the 
qualitative UBER assay (Section 3.2.3). Regardless of the assay used, 80 was more potent against 
the N24K mutant than the WT enzyme (Figure 70). Inhibitor 80 reduced WT Pol  lyase activity 
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by about 30% in the gel-based lyase assay, while it had no effect on WT Pol  in the UBER assay. 
Meanwhile, inhibitor 80 reduced Pol  N24K lyase activity to about 35-40%, regardless of the 
assay used to quantify. By comparing the effect of inhibitor 80 in the separate assays, we observed 
a 35% difference in favor of Pol  N24K in the gel-base lyase assay versus a 60% difference in 
favor of Pol  N24K in the UBER assay. Therefore, we were wary that inhibitor 80 looked more 
selective for the N24K mutant against WT in the UBER assay, compared to the gel-based lyase 
assay. Across assays, 81 was less potent and less selective towards mutant T79I when comparing 
it to 80 with N24K.  
 
Figure 70. Gel-based and UBER lyase assay comparison in Pol  inactivation by hit compounds. 
Pol  or mutant (100 nM) was preincubated with hit compounds 80 or 81 (50 M) for 20 min. The 
preincubation mixture was diluted 10-fold or 5-fold and mixed with DNA substrate A for the gel-
based lyase assay or the UBER lyase assay, respectively. In the gel assay, aliquots were removed 
and frozen at various time points (0, 2, 4, 6, 8, 10 min), quenched with NaBH4, and analyzed by 
PAGE. In the UBER assay, the enzyme/DNA mixture incubated for 25 min and mixed with the 
UBER probe for 4 h prior to scanning with a Clariostar wellplate reader. 
 
It was evident that these compounds were not very potent (~50 M) but we pursued this 
further with the hope that potency and selectivity may improve in a second-generation inhibitor. 
Therefore, we synthesized a second-generation iteration of inhibitor 80 because it was more potent, 
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and slightly more selective for the N24K mutant. In addition to this, we thought the N24K may be 
a better candidate for targeting because the position of the mutant lies near the inside of the enzyme 
and towards the DNA (Figure 64). On the contrary, P63L and T79I are solvent-exposed and we 
expect it to be difficult to make specific contacts that would lead to inactivation. 
3.5.3 Second-generation mutant inhibitor(s): Functionalization at the thymine 5-
methyl position 
The synthesis of the second-generation scaffold was straight forward and similar to the 
synthesis of the previous second-generation scaffold for WT Pol  (Scheme 28). Previously 
synthesized 66 was reduced and coupled to the carboxylic acid used in the synthesis of 80 to yield 
compound 90 (Scheme 36). After silyl deprotection, the 5’-hydroxylated quinoline (91) was 
coupled to the Nv-protected DOB phosphoramidite (77) to form 92. Following deprotections, 
scaffold 93 was coupled to a library of 375 carboxylic acids (Appendix 1) and photochemically 
deprotected to make library 94. 
 
Scheme 36. Synthesis of second-generation library (94). 
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Library 94 (15 M) was screened against WT Pol  and Pol  N24K (100 nM) with a 25 
min preincubation period using the UBER assay (Section 3.2.3). We screened the library at 15 M 
because the scaffold partially inactivated Pol  at 20 M. Following the 25 min preincubation, 
substrate A was added to the enzyme/inhibitor solution and incubated for an additional 25 min 
(Table 1). The mixture was diluted 5-fold and mixed with the UBER probe (5 M) (Figure 27). 
Similar to the first-generation screen, several inhibitors were identified, so all hit compounds were 
resynthesized and rescreened, along with the free carboxylic acid control experiments, to rule out 
false positives.  
After three rounds of screening, 8 remaining compounds (95-102) showed partial 
inactivation of Pol  N24K in the UBER assay (Figure 67). However, the UBER assay was not 
used for quantitative analysis, so these compounds were analyzed via the gel-based lyase assay 
(Section 3.2.2). 
Figure 71. Hit compounds identified from UBER screen. 
 
It was evident none of the hit compounds 95-102 did not selectively inhibit Pol  N24K 
over the WT Pol  based on the gel-based lyase assay (Figure 72). Furthermore, the inhibitors were 
not very potent at 15 M (i.e. the greatest effect was roughly 50% enzyme activity). In summary, 




Figure 72. Gel-based lyase assay analysis of mutant hits. Pol  or mutant (100 nM) was 
preincubated with hit compounds (15 M) for 20 min. The preincubation mixture was diluted 10-
fold and mixed with DNA substrate A. Aliquots were removed and frozen at various time points 
(0, 2, 4, 6, 8, 10 min), quenched with NaBH4, and analyzed by PAGE.  
 
This led us to question why we did not observe an enhanced inhibitor in the second-
generation library. We hypothesized that if the inhibitor(s) were binding in the polymerase domain, 
we would not observe any selectivity because the mutant and the WT have the same 31 kDa 
domain. We chose the most effective hits (97, 100, and 102) and tested them in the 8 kDa domain 
(Figure 73). It was very clear that the second-generation hits and the first-generation compound 
(80) had no effect on the lyase activity of the 8 kDa domain. This supported our hypothesis that 




Figure 73. Mutant hits do not inactivate 8 kDa domain. 8 kDa Pol  (100 nM) was preincubated 
with hit compounds (15 or 50 M) for 20 min. The preincubation mixture was diluted 10-fold and 
mixed with DNA substrate A. Aliquots were removed and frozen at various time points (0, 2, 4, 6, 
8, 10 min), quenched with NaBH4, and analyzed by PAGE. 
 
To test this further, we analyzed our hits via the fluorescence-based strand displacement 
assay in the WT Pol  and the 31 kDa domain (Section 3.2.1). The second-generation hits (97, 
100, 102) at 15 M did not significantly inhibit the activity in the WT (Figure 74a) or the 
polymerase domain (Figure 74b), which was consistent with the gel-based lyase assay (Figure 72). 
A more significant decrease in strand displacement activity was observed for 80 (50 M) with WT 
enzyme and the 31 kDa domain (dark blue, Figure 74). This was consistent with WT Pol  





Figure 74. Inhibition of strand displacement activity in the intact enzyme (a) and the 31 kDa 
domain (b). Pol  (100 nM) or 31 kDa Pol  (250 nM) was preincubated with hit compounds (15 
or 50 M) for 20 min. The preincubation mixture was diluted 10-fold and mixed with DNA 
cocktail solution, to yield 5 nM Pol , 50 nM DNA substrate B, and 100 M dTTP. 
 
We suspect that we did not identify any potent, selective mutant inhibitor because our 
second-generation library was based off a compound that binds to the polymerase domain. We 
think that it is still possible to identify selective inhibitors for a mutant form of Pol  by generating 
the point mutations in the separate domains using site-directed mutagenesis (Section 4). We 
envision multiple approaches: 
1. Distinct domains containing the cancer-associated point mutations must be generated 
using site-directed mutagenesis. This will represent a definitive way to confirm mutant 
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selectivity using kinetic assays (Sections 3.2). 
2. Targeting lyase mutants: One could start with a first-generation compound that is a 
confirmed lyase domain binder (e.g. 47, Section 3.3.1) and generate a second-
generation library with the hydroxylated naphthoic acid already installed on the 
nucleobase. One could then screen the second-generation library for any molecules that 
preferentially inhibit a lyase mutant. 
3. Targeting polymerase mutants: Several mutants have been identified in the polymerase 
domain.13 Therefore, one could take the same approach and synthesize and screen a 
first-generation library against WT and polymerase mutants. From the hits identified, 
a second-generation library can be built from the most promising candidates.  
Regardless of the domain targeted, using the separate WT and mutant domains to confirm 
the location of binding before proceeding to a second-generation compound will be a more prudent 
approach. 
 
3.6 Synthetic lethality induced by Pol  inhibition 
 
As mentioned earlier, DNA repair inhibition is an attractive route at enhancing the 
cytotoxicity of DNA damaging agents (Section 2.4).14–19 We were hopeful that our work targeting 
a mutant form of Pol  would result in a compound that could selectively kill cancer cells, while 
leaving noncancerous cells alive (Section 3.5). The caveat of targeting WT Pol  is that it is 
constitutively expressed in all cells.176–178 By inducing synthetic lethality, one can produce 
selectivity for cancer cells, despite the target being expressed in all healthy cells. To review, 
synthetic lethality occurs when the loss or disruption of two genes results in cell death, whereas 
the loss of only gene in the pair does not (Section 2.4).  
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Inducing synthetic lethality in cancer cells that lack a particular pathway is a great way to 
exploit the cancer cell’s inherent weakness. An example of this is PARPi treatment in BRCA1-
deficient cancer cells.136,137 HR-deficient cells are more susceptible to PARP inhibitors due to a 
synthetic lethal interaction. Synthetic lethality is advantageous because it does not require the use 
of a DNA damaging agent. Rather, it can be induced by a monotherapy in repair-deficient cancer 
cells without affecting repair-competent noncancer cells. A synthetic lethal interaction between 
Pol  and BRCA-deficiency has been proposed for several years but has never been confirmed or 
used clinically due to the lack of therapeutically relevant Pol  inhibitors.12,69,101 
To evaluate synthetic lethality between Pol  and BRCA1, we treated breast cancer cell 
lines: MCF-7 (WT, Figures 66-67, Section 3.4.2.3) and MDA-MB-436 (BRCA1-deficient) with 
pro-72. The cytotoxicity of pro-72 to MDA-MB-436 cells was dependent on concentration and 
treatment time (Figure 75). In addition, it was evident that pro-72 was significantly more toxic to 
BRCA1-deficient cells (Figure 75) than WT MCF-7 cells (Figure 66) and WT HeLa cells (Figure 
64). For example, a 1 h treatment of MCF-7 cells with pro-72 (5 M) killed about 10% of the cells 
but the same treatment in MDA-MB-436 resulted in 42% cell death (Figure 75, Table 5). 
Furthermore, a 2 h treatment with pro-72 (5 M) killed 70% MDA-MB-436 cells, whereas the 
same treatment killed slightly more than half of that (i.e. 39%) in MCF-7 cells (Figures 66 and 75, 
Table 5). Altogether, this was a significant finding because it supported the proposed synthetic 




Figure 75. Clonogenic assay of pro-72 toxicity in MDA-MB-436. MDA-MB-436 cells were 
treated with pro-72 (various concentrations) for 1 or 2 h. After treatment, media containing pro-
72 was removed, cells were harvested, counted, and seeded to allow for colony growth. Colonies 
were visualized by crystal violet. 
 
Table 5. Cell death induced by pro-72 in MCF-7 and MDA-MB-436 cells. 
Pro-72 Treatment MCF-7 MDA-MB-436 
1 M, 2 h 9% 40% 
5 M, 1 h 10% 42% 
5 M, 2 h 39% 70% 
 
 
In addition to the higher toxicity of pro-72 in BRCA1-deficient cells, a slight synergistic 
effect between our pro-inhibitor and MMS was observed. As these cells are generally less healthy 
than WT cells, we used gentler conditions (i.e. 0.1 mM MMS). We observed a 1.4-fold 
enhancement of cell death for combination treatment of MMS (0.1 mM) and pro-72 (5 M) for 1 
h (Figure 76). Under harsher conditions (i.e. longer treatments with 0.1 mM MMS, 0.2 mM MMS), 
cell death was too extensive to observe a synergistic effect. Unsurprisingly, treatment with BLM 
was extremely toxic to BRCA-deficient cells (Figure 76). BLM induces DSBs and MDA-MB-436 




Figure 76. Synergistic effect of pro-72 with DNA damaging agents on cell death in MDA-MB-
436. MDA-MB-436 cells were treated with MMS (0.1, 0.2 mM) or BLM (2 M) in the presence 
or absence of pro-72 (various concentrations) for 1 or 2 h. After treatment, media containing pro-
72 was removed, cells were harvested, counted, and seeded to allow for colony growth. Colonies 
were visualized by crystal violet. 
 
To confirm the synthetic lethal interaction we observed between pro-72 and BRCA1-
deficiency, we determined: 
1. The effect of knocking down Pol  in BRCA1-deficient cells (MDA-MB-436). 
2. How pro-72 compares to a PARPi (Olaparib) in BRCA1-deficient cells (MDA-MB-436).  
To address the first issue, we turned to RNA interference to knock down Pol  in MDA-MB-
436 cells. We attempted to do this using Pol  shRNA because shRNA is packaged in a DNA 
plasmid which has several advantages, including being easy to handle and amplifiable in bacterial 
cells. However, transfection into cells using the suggested transfection reagent (FuGene 6) resulted 
in extensive (> 95%) cell death, attributed to poor transfection efficiency.179 The shRNA plasmid 
possessed resistance to puromycin as a selectable marker. After shRNA transfection, puromycin 
was added to media to yield only cells that were transfected by the plasmid. When puromycin was 
not used as a selectable marker, the cells harvested after shRNA transfection retained WT levels 
of Pol , determined by western blot analysis. 
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Therefore, we turned to siRNA to knock down Pol . Our first transfection with Pol  
siRNA using Lipofectamine RNAiMAX was partially successful, resulting in about 50% knock 
down in Pol . After increasing the ratio of siRNA:cells to 100 pmol:106 cells, we achieved a 70-
75% KD in Pol  expression (Figure 77), which was comparable to what is observed in the 
literature.179 The use of an internal standard (i.e. H3) allowed us to quantify the efficiency of Pol 
 knock down in cells. 
Figure 77. Pol  KD in MDA-MB-436 cells. siNT = RISC-free non-targeting control siRNA, 
siPol = siRNA targeting PolB gene. MDA-MB-436 cells were treated with either control siRNA 
(siNT) or Pol  siRNA (siPol) using two consecutive transfections of Lipofectamine RNAiMAX 
and siRNA (100 pmol/106 cells). Cells were transfected for 72 h, harvested, and reseeded for a 
clonogenic assay. A portion of transfected cells (1-2 x 106) were separate for Western Blot 
analysis. 
 
Cell viability assays using BRCA1-deficient control (solid) and Pol  KD (dashed) cells 
confirm several things (Figure 78). First, similar toxicity (~50%) was observed in the cells treated 
with a non-targeting siRNA control (siNT) in the presence of pro-72 (5 M) as previous biological 
replicates (Figures 75-76), confirming these experiments were consistent and reproducible. In 
addition, the treatment of pro-72 at higher concentration (25 M) in control cells resulted in more 
cell death. Secondly, knocking down Pol  in MDA-MB-436 cells was toxic and killed roughly 
50% of cells. Knocking down Pol  in MDA-MB-436 cells yielded similar cell death to MDA-
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MB-436 cells treated with pro-72 (i.e. 50% cell death). This supported our hypothesis that the loss 
of Pol  (either by inhibition or KD) was synthetic lethal in BRCA1-deficient cells. In contrast to 
the control cells, Pol  KD cells exhibited no additional cell death in response to treatment with 
pro-72. This suggested that pro-72 was not toxic in cells lacking Pol .  
Figure 78. Effect of knocking down Pol  in MDA-MB-436 cells. MDA-MB-436 control and Pol 
 knock down cells were treated with pro-72 (various concentrations) for 1 or 2 h. After treatment, 
media containing pro-72 was removed, cells were harvested, counted, and seeded to allow for 
colony growth. Colonies were visualized by crystal violet. 
 
Our second objective in this study was to compare the synthetic lethality of Pol  in 
BRCA1-deficient cells with the well-known synthetic lethality of PARPi in BRCA1-deficient cells 
(Section 2.4). Olaparib is a well characterized PARPi with FDA approval for the treatment of 
BRCA-mutated ovarian, breast, pancreatic, and prostate cancer (Figure 19).136,137 Olaparib is 
typically used in cells at 0.1-1 M.169 Therefore, MCF-7 and MDA-MB-436 cells were treated 
with Olaparib at 0.5 and 1 M for 1 and 2 h (Figure 79). We observed slight toxicity in MCF-7 
cells in response to Olaparib at either concentration or treatment time, resulting in less than 30% 
cell death. In MDA-MB-436 cells, greater cell death was observed (0.5 M, ~65% cell death; 1 
M, ~75-80% cell death). We did not observe a significant increase in toxicity in response to 




Figure 79. Effect of Olaparib in MCF-7 and MDA-MB-436 cells. MCF-7 and MDA-MB-436 cells 
were treated with pro-72 (various concentrations) for 1 or 2 h. After treatment, media containing 
pro-72 was removed, cells were harvested, counted, and seeded to allow for colony growth. 
Colonies were visualized by crystal violet. 
 
In comparison to pro-72, Olaparib was a more effective inhibitor at inducing synthetic 
lethality. For example, to achieve 65-70% cell death in MDA-MB-436, a 2 h treatment of pro-72 
(5 M) was necessary, a 10-fold decrease in potency compared to Olaparib (Figures 75 and 79, 
Table 6). On another note, a 2 h, 1 M treatment of Olaparib resulted in 80% cell death, whereas 
a 2 h, 1 M treatment of pro-72 yielded 40% cell death (Table 6). When comparing the treatments 
(2 h, 1 M inhibitor), the enhancement observed in BRCA1-deficient cells by pro-72 (4.4-fold) 
was greater than for Olaparib (3.3 fold)! In addition, across the treatments, pro-72 was less toxic 
than Olaparib in MCF-7 cells. It is worth mentioning that we did not expect pro-72 to be better at 
inducing synthetic lethality than Olaparib. However, this experiment is a nice comparison and 
shows that a small molecule inhibitor of Pol  has the potential to induce similar effects in a 




Table 6. Percentage of cell death induced by Olaparib and pro-72 in MCF-7 and MDA-MB-436 
cells. 
Treatment (2 h) MCF-7 MDA-MB-436 
Olaparib (0.5 M) 29% 67% 
Olaparib (1 M) 25% 82% 
Pro-72 (1 M) 9% 40% 
Pro-72 (5 M) 39% 70% 
 
The Pol  pro-inhibitor successfully induced synthetic lethality in BRCA1-deficient cells. 
We confirmed that knocking down Pol  by siRNA produced similar results in MDA-MB-436 
cells (Figure 78). This result is very thrilling because synthetic lethality makes Pol  a better 
therapeutic target and more selective for cancerous cells. 
To complete this project, we will re-evaluate for a synergistic cell killing effect of pro-72 
with damaging agent(s) in MCF-7 and MDA-MB-436 cells using gentler conditions (e.g. lower 
concentrations of DNA damaging agent(s), shorter treatment time, etc.). We suspect that using too 
harsh conditions resulted in too much toxicity to determine an accurate enhancement of cell death.  
 In addition, it has been shown that the loss of Pol  function enhances cell sensitivity to 
PARPi (Section 2.4).15 Therefore, it would be interesting to determine the amount of cell death in 





4. Future Considerations 
 
We discovered small molecules that are selective for distinct domains of Pol  (Section 
3.3.3). In some cases, we have identified small molecules (i.e. 63, 72) that selectively bind and 
inactivate the polymerase domain. In other cases, we identified compounds (i.e. 2, 47) that 
selectively bind to either the 31 kDa or the 8 kDa domain but regardless of the binding location, 
inactivate lyase and polymerase activity. While we know that our inhibitors interfere with DNA 
binding, we have been unable to elucidate the underlying mechanisms of how these compounds 
inactivate a single or both activities. We hypothesize there is a conformational change specific to 
certain binders that destabilize the enzyme and prevent DNA binding in both domains, thereby 
inhibiting both lyase and polymerase activity, but that this conformational change is only present 
in the holo-enzyme. 
 
Inhibitor 47 has been sent to a collaborator for x-ray analysis. It will be interesting to 
potentially observe the lysine adduct(s) formed from covalent modification by 47 and any 
corresponding conformational change in the Pol  structure as a result of the inhibitor. We propose 
using solution NMR to study protein dynamics of Pol  in response to 72 (selective polymerase 
binder and inhibitor) and 2 (selective polymerase binder but inactivates both activities). We 
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anticipate a conformational change occurs upon binding to 2 that does not occur upon binding to 
72. This would explain the double inactivation of inhibitor 2 and not in 72. 
 The second-generation Pol  WT inhibitor (72) has been extensively studied biochemically 
and in cells. We established its in vitro selectivity for Pol  over other polymerases. We plan to 
use WT MEFs as a comparison to HeLa cells to understand if our inhibitor has any selectivity 
between healthy and cancerous cells. In addition, WT MEFs and Pol -null MEFs will be used to 
establish intracellular selectivity for Pol .  
In addition to Pol -null MEFs, knock down of Pol  by siRNA in MCF-7 cells can 
determine selectivity in vivo. Using the same method used to knock down Pol  in MDA-MB-436 
cells, we knocked down Pol  to 30% relative expression in MCF-7 cells. We expect that if pro-
72 is selective for Pol , the inhibitor will be less toxic and less effective at killing cells 
synergistically in cells lacking Pol . Treatment of MCF-7 Pol  KD cells for 1 h with pro-72 does 
not exhibit nonselective toxicity, even at high concentrations (50-100 M) (Figure 80). 
Furthermore, at lower concentrations that are typically used for cell viability assays (5 M), there 
is no difference in toxicity between control cells and Pol  KD cells. Therefore, MMS sensitivity 
must be characterized in Pol  KD cells before determining synergism (or the lack of synergism). 
We anticipate there will be no synergistic effect observed between our pro-inhibitor (pro-72) and 
MMS in the KD cells.  
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Figure 80. Toxicity of pro-72 in MCF-7 Pol  KD cells. MCF-7 control and Pol  knock down 
cells were treated with pro-72 (various concentrations) for 1 or 2 h. After treatment, media 
containing pro-72 was removed, cells were harvested, counted, and seeded to allow for colony 
growth. Colonies were visualized by crystal violet. 
 
There is great potential for selective inhibitors that target mutant forms of Pol . As 
mentioned earlier, we expect this can be successful via two approaches: lyase and polymerase 
mutants (Section 3.5.3). The most important aspect of identifying selective inhibitors for a mutant 
will be to generate the point mutation in the distinct domain using site-directed mutagenesis. For 
example, generating the N24K mutant of the 8 kDa domain can confirm any inhibitors determined 
when screening the intact N24K Pol  mutant. The same can be done for any polymerase domain 
mutants screened. 
Alternatively, to identify inhibitors for lyase mutants, we propose a new synthetic route for 
the diversification on the nucleoside in a second-generation molecule. Huijin Lee has designed an 
improved method for synthesizing libraries containing structural diversity at the C4-position of a 
pyrimidine ring (Scheme 37). By using a dC template and modifying the exocyclic amine (103), 
both the yield and number of steps in the trifluoroacetamide synthesis at this position could be 




Scheme 37. Proposed second-generation mutant analog of 47.  
 
 
After a first-generation inhibitor (R, Scheme 37) is identified from library 58, we expect 
that this synthesis would be more straightforward and result in higher yields than previously used 
routes that modify the 5-methyl position of dT. Of course, it is likely that the different orientation 
will affect interactions between the inhibitors and Pol . We already established that changing the 
oxime to the amide yields very different inhibitor hits (Section 3.3.3).  
Upon synthesis of the new scaffold, the library compounds can be coupled at the C4-
ethylene diamine (104) and screened against the lyase mutants (N24K, P63L, and T79I) and Pol  
WT using the UBER assay to detect any hit compounds that selectively inactivate a mutant. In the 
proposed second-generation library, we hope that the bottom portion (R) of the molecule could 
direct the library to the lyase domain, and the top portion (R’) could establish unique binding 
interactions with mutants to improve selectivity and potency.  
Most of the inhibitors we have identified (i.e. 2, 63, 72) target the polymerase domain. 
Therefore, we propose the same approach of synthesizing the first-generation library (58) and 
screening for polymerase domain mutants. Polymerase domain variants (40) were isolated from 
colon cancer tumors.13 Mutants in the DNA binding region that retain normal function are of 
particular interest. These include R112W, H134Y, H135Y, Q136X*, and T233A* (*Normal or 
reduced activity was not determined) (Figure 81).13 A second-generation scaffold can be built from 
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the first-generation hit using the same method to identify mutants in the polymerase domain 
(Scheme 37). 
Regardless of the approach, we suggest utilizing the separate WT and generated mutant 
domains to evaluate selectivity of any hit compounds identified. We are hopeful that this will 
confirm the inhibitor is binding the desired mutant domain prior to exhaustively characterizing the 
inhibitor in vitro. 
 
Figure 81. Amino acid (pink) positions of colon cancer-associated Pol  mutants and their 











5.  Experimental Methods 
 
General Methods  
Modified oligonucleotides were synthesized on an Applied Biosystems Incorporated 394 
oligonucleotide synthesizer. Oligonucleotide synthesis reagents including 5’-phosphorylation reagent 
(Solid CPR II), SIMA HEX (dichloro diphenyl fluorescein) phosphoramidite, THF abasic site analogue 
(dSpacer), TAMRA phosphoramidite, and BHQ phosphoramidite were purchased from Glen Research 
(Sterling, VA). Oligonucleotides containing only native nucleotides were purchased from Integrated 
DNA Technologies (Coralville, IA) and were purified by 20% denaturing polyacrylamide gel 
electrophoresis (PAGE) (See below). Oligonucleotides were characterized using a Bruker AutoFlex 
III Maldi-TOF/TOF system. 
All chemicals were purchased from Sigma Aldrich, Fisher, or Alfa and were used without 
further purification. Small quantities of all library compounds (Appendix 1) were purchased from 
Sigma Aldrich but were from a variety of vendors (e.g. Enamine, CombiBlocks, ChemApex, etc.). Pol 
 was purchased from EnzyMax. Sybr Gold was purchased from ThermoFisher. Trypsin, dNTPs, 
terminal deoxynucleotide transferase, Klenow exo-, and T4 polynucleotide kinase were obtained from 
New England Biolabs. Radionuclides were from Perkin Elmer. Poly-Prep columns were from BioRad. 
C18-Sep-Pak cartridges were obtained from Waters. Zip-Tips were purchased from Millipore. 
Photolyses were carried out in a Rayonet photoreactor fitted with 16 lamps having a maximum output 
at 350 nm. Quantification of radiolabeled oligonucleotides was carried out using a Molecular 
Dynamics Phosphorimager 840 equipped with ImageQuant. 
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Tryptone and yeast extract were from BD Biosciences. Protease inhibitor cocktail (EDTA-free) 
was from Roche. HisTrap column, Heparin column, HiTrap Q column, HiTrap SP column, and Q 
Sepharose fast flow were from GE Healthcare. Affi-gel blue gel resin was from BioRad. BL21 (DE3) 
pLysS and Rosetta 2 DE3 E.coli were from Millipore. BL21 (CodonPlus) DE3-RIL and DH5 E.coli 
were from ThermoFisher. Maxi Prep and Mini Prep Kits were from Qiagen. Sonication was conducted 
using a Brandson SFX-150 sonifier. Protein purification was conducted using an AKTA FPLC. All 
centrifugations during protein preparation were done using a Beckman Coulter Allegra25r. 
UPLC-MS/MS analyses were carried out on a Waters Acquity/Xevo-G2 UPLC-MS system 
equipped with an ACQUITY UPLC HSS T3 Column (100 Å  m, 2.1 mm x 100 mm). Masses 
were obtained via deconvolution using MassLynx 4.2 software or BioPharmaLynx 1.3.2 software. 
Well plates used for organic solvents and photolyses were obtained from VWR. Well plates 
used for fluorescence assays were obtained from Corning (CLS3825, 384 well plates, for homogenous 
luminescent and HTRF assays). Fluorescence data were collected on a Varian Cary Eclipse 
fluorescence spectrophotometer equipped with a well plate attachment or a CLARIOstar Plus 
microplate reader at the Center for Molecular Biophysics at Johns Hopkins University. Fluorescence 
anisotropy measurements were conducted using an AVIV Biomedical Model ATF 107 
spectrofluorometer at the Center for Molecular Biophysics at Johns Hopkins University.  
The following items were generous gifts from colleagues. Mutant plasmids (Pol  N24K, Pol 
 P63L, and Pol  T79I) were received from Professor Joann Sweasy, University of Arizona Cancer 
Center. Plasmids for the 8 kDa and 31 kDa domains were from Dr. Sam Wilson, NIH. Pol  plasmid 
was from Professor Zucai Suo, Florida State University. The UBER probe precursor (CCVJ) was a gift 
from Professor Eric Kool, Stanford University. MCF-7 and MDA-MB-436 cell lines were acquired 
from Professor Theodore DeWeese, Johns Hopkins University.160 
147 
 
Dulbecco’s Modified Eagle Medium (DMEM) with high glucose, RPMI 1640 Medium with 
GlutaMAX supplement, Opti-MEM reduced serum medium, and insulin were obtained from 
ThermoFisher. Antibiotic antimycotic solution (penicillin, streptomycin, and amphotericin B), and 
fetal bovine serum (FBS) were obtained from MilliporeSigma. PBS buffer was obtained from Quality 
Biological. Pre-cast 4-20% SDS-PAGE, Precision Plus Protein WesternC standard, Western blot kit, 
and StrepTactin-HRP conjugate were from BioRad. NP-40 was obtained from Sigma Aldrich. All 
siRNAs (siGENOME RISC-Free Control, D-001220-01; siGENOME Human POLB siRNA, D-
005164-04) were purchased from Horizon Discoveries. All antibodies (Recombinant Anti-DNA 
Polymerase beta antibody, ab175197) were purchased from Abcam. Cells were counted using a 
BioRad TC20 cell counter. Western blots were carried out using a BioRad Trans-Blot Turbo Transfer 
system. Ponceau red stain was prepared with ponceau S tetrasodium salt (0.1%, Sigma Aldrich) and 
acetic acid (5%) in distilled H2O. Developing reagents were acquired from Thermo. Western blots 
were visualized using a Typhoon 9410 equipped with chemiluminescence imaging at the Integrated 
Imaging Center at Johns Hopkins University. 
All small molecules synthesized were characterized using a Bruker Avance 400 MHz 
Spectrometer or a Varian Inova 800 MHz spectrometer at Johns Hopkins University. 
Synthesis, Purification, and Characterization of Modified Oligonucleotides 
An oligonucleotide containing a 5’-dRP photolabile precursor was synthesized using standard 
phosphoramidites and protocols from Glen Research.29 The coupling step involving the AP precursor 
lasted 5 min and the phosphorylating agent (Solid CPR II) was double-coupled for 5 min each cycle. 
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Oligonucleotides were deprotected using a solution (0.8 mL) of concentrated ammonium 
hydroxide (400 L) and 40% methylamine in H2O (400 L) at 65 
oC for 1 h. Following deprotection, 
oligonucleotides were dried in a Speed Vac concentrator, resuspended in loading buffer (95% 
formamide with 10 mM EDTA), purified by 20% denaturing polyacrylamide gel electrophoresis 
(PAGE), and visualized using a TLC plate and UV lamp. Oligonucleotides containing photochemical 
precursors were exposed to UV light for the shortest time possible and were always covered with foil, 
whether the DNA was on the gel or in a tube. The band was cut from the gel, crushed into small pieces, 
and eluted from the gel matrix with elution buffer (2-10 mL, 100 mM NaCl, 1 mM EDTA) for 12 h 
with shaking. The solution was filtered using a Poly-Prep column and desalted using C18-Sep-Pak 
cartridges. 
All modified oligonucleotides in this thesis were previously characterized by MALDI-TOF-
MS (Table 1, Section 3.2.4).26,27,135 For MALDI-TOF-MS, oligonucleotides (100 pmol) were desalted 
by Zip-Tip and resuspended in matrix (1 L) containing 3-hydroxypicolinic acid (10 mg/mL) and 
ammonium citrate (30 mg/mL). 
Radiolabeling and Preparation of Oligonucleotide Complexes 
Oligonucleotides were 3’-32P labeled by −P Cordycepin triphosphate and terminal 
deoxynucleotidyl transferase. In addition, 3’-32P labeling was also completed using Klenow exo- 
and -32P-ATP, within a duplex containing a single 5’-dT overhang. In this case, the 3’-terminus 
of the 5’-dRP strand was 32P-labeled, denatured from the duplex, and purified by 20% denaturing 
PAGE. Labeling with 5’-32P labeling was completed by T4 polynucleotide kinase and -32P-ATP. 
Ternary complexes were hybridized by mixing 32P-labeled oligonucleotides with the appropriate 
template and flanking strand in a 1:2.5:5 ratio in phosphate buffered saline (10 mM sodium 
phosphate, 100 mM NaCl, pH 7.3), heating to 95 oC, and slowly cooling to 25 oC. 
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Ternary complexes containing fluorophore labeled oligonucleotides were prepared by 
annealing the fluorophore-labeled strand with the appropriate quencher-labeled template and 
flanking strand in a 1:2:3 ratio. 
Bradford Assay  
Bradford assays were used to determine the concentration of purified proteins and proteins 
in cell lysates. A standard curve was generated by adding Bradford reagent (950 L, Sigma 
Aldrich) to solutions (50 L) containing 50, 100, 250, 500, 750, 1000 mg/mL bovine serum 
albumin (BSA). After incubating for 10 min at 25 oC, the absorbance (595 nm) of each standard 
was measured using a spectrophotometer. Absorbance was plotted against amount of BSA and fit 
to a straight line. An aliquot of purified protein (5 L) was diluted 10-fold (50 L) and mixed with 
Bradford reagent (950 L). After incubating for 10 min, the absorbance (595 nm) was used to 
determine the concentration of protein based on the standard curve equation. 
Amplification of plasmid containing the 8 kDa fragment of Pol   
Luria broth (LB) Media and LB Agar were prepared and autoclaved to make plates. LB 
Media was prepared by dissolving 5 g Bacto-tryptone, 2.5 g Bacto-yeast, and 5 g NaCl in 500 mL 
H2O. LB Agar was prepared by dissolving 5 g Bacto-tryptone, 2.5 g Bacto-yeast, 7.5 g Agar and 
5 g NaCl in 500 mL H2O. These solutions were autoclaved for 25 min. While the LB Agar was 
still warm, an aliquot of ampicillin stock solution (1000X, 100 mg/mL ampicillin, 50 L) was 
sterilized using a sterile filter and added to the 500 mL LB Agar. In a sterile environment, the 
mixture was poured into plates and allowed to cool.  
DH5 competent cells (40 L) were thawed at 0 oC. pRSET plasmid containing the coding 
region for the 8 kDa Domain of Pol  (80 ng/L, 1 L) was added to the tube containing DH5 
cells and incubated at 0 oC for 30 min. After 30 min, the cells were placed in a 42 oC water bath 
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for 45 s and immediately put back on ice for 2 min. SOC outgrowth medium (200 L, 5x) was 
added to the cells. The medium shook at 37 oC for 1 h to allow the cells to recover. After 1 h of 
recovery time, multiple diluted cells samples (1:10, 1:50, and 1:100) were plated onto Agar plates 
containing ampicillin. 
The plates incubated at 37 oC overnight. After colonies had grown (~14 h), the plates were 
stored at 4 oC. An overnight culture was prepared by mixing an aliquot of LB media (10 mL) and 
ampicillin stock solution (1000X, 100 mg/mL, 10 L). One colony was removed from the DH5 
(1:100 dilution) plate and placed in the medium. The cells were resuspended and shaken at 37 oC 
overnight. After 14 h, the cells were spun down at (4 oC, 10 min, 4500 rcf). 
The Qiagen mini prep was used to purify the plasmid DNA. The steps were as follows: 
The supernatant was removed and replaced with 500 L of Resuspension P1 buffer with RNase 
A. The cells were resuspended and divided into two 250 L aliquots. To each mini prep sample, 
P2 Lysis Buffer, pH 11 (250 L) was added to break down the cell walls and the tube was inverted 
several times. To prevent DNA damage, P3 Neutralization buffer containing NaOAc, pH 4 (300 
L) was added until the mixture was homogeneous. The tubes were spun down for 10 min at 4 oC. 
The supernatant was collected and passed through the blue mini prep column. The flow-through 
was thrown away. PE Buffer with EtOH (750 L) was added to the column, incubated for 2 min, 
and spun down for 1 min at 4 oC. The flow-through was removed and this was repeated once more 
with PE Buffer. After the second wash with PE Buffer, the column was spun down twice for 2 min 
each. Amplified plasmid was eluted with 10 mM Tris buffer EB (50 L) and was spun down for 
1.5 min at 4 oC. The flow-through was collected and stored. A small portion (2 L) was used to 




Transformation and Expression of 8 kDa Pol   domain180,181  
LB media and LB Agar were prepared and autoclaved to make plates. LB Media was 
prepared by dissolving 5 g Bacto-tryptone, 2.5 g Bacto-yeast, and 5 g NaCl in 500 mL H2O. LB 
Agar was prepared by dissolving 2.5 g Bacto-tryptone, 1.25 g Bacto-yeast, 3.75 g Agar and 2.5 g 
NaCl in 250 mL H2O. These solutions were autoclaved for 25 min. While the LB Agar was still 
warm, an aliquot of ampicillin stock solution (1000X, 100 mg/mL ampicillin, 25 L) and an 
aliquot of chloramphenicol (1000X, 34 mg/mL chloramphenicol in EtOH, 25 L) were sterilized 
with a sterile filter and added to the 250 mL LB Agar. In a sterile environment, the mixture was 
poured into plates and allowed to cool.  
BL21 DE3 pLysS competent cells (20 L) were thawed at 0 oC. pRSET plasmid containing 
the coding region for the 8 kDa domain of Pol  (80 ng/L, 1 L) was added to the tube containing 
E.Coli cells and incubated at 0 oC for 30 min. After 30 min, the cells were placed in a 42 oC water 
bath for 45 s, and immediately put back in ice for 2 min. SOC outgrowth medium (100 L, 5x) 
was added to the cells. The cells were incubated at 37 oC for 1 h with shaking (180 RPM) to allow 
the cells to recover. After 1 h of recovery time, multiple diluted cell samples were prepared by 
mixing cells with SOC medium: 
1. Not diluted (50 L cells) 
2. 1:10 (5 L cells + 45 L SOC medium) 
3. 1:50 (1 L + 50 L SOC medium) 
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Each solution was plated onto separate agar plates containing ampicillin and 
chloramphenicol. The plates incubated at 37 oC overnight. After colonies had grown, the plates 
were stored at 4 oC. One colony was removed from the BL21 DE3 pLysS (1:50 dilution) plate and 
placed in LB media (10 mL) with ampicillin (1000X, 100 mg/mL, 10 L) and chloramphenicol 
(1000X, 34 mg/mL, 10 L). The cells were resuspended and shaken at 37 oC overnight. 
After 11.5 h, the starter culture was retrieved from the shaker and inoculated by spinning 
cells down (15,000 RCF, 4 oC, 10 min), removing the supernatant, and resuspending the pellet in 
fresh LB media (10 mL). In a sterile environment, culture media was prepared by mixing LB media 
(2 L), Ampicillin (2 mL, 100 mg/mL), Chloramphenicol (2 mL, 34 mg/mL), and starter culture 
(10 mL). Cultures were shaken at 37 oC at 250 RPM until the cells reached an OD of 0.5 (about 
4.5 h) At that point, IPTG (1 mL, 1000X 1 M) was added to each batch of cells to make a final 
concentration of 1 mM IPTG. The cells were shaken for another 3 h at 37 oC. 
After 3 h, the cells were harvested by spinning them down (15,000 RCF, 4 oC, 10 min) and 
removing the media. The dry pelleted cells were stored at -80 oC until purification. 
Purification of the 8 kDa domain of Pol  
Buffer A: 50 mM Tris HCl, 1 mM EDTA, pH 7.5, 1 mM PMSF, 0.1 mM protease inhibitor. 
Buffer B: 50 mM Tris HCl, 1 mM EDTA, 1 M NaCl, pH 7.5, 1 mM PMSF, 0.1 mM protease  
inhibitor. 
All buffers were supplemented with PMSF (1 mM) and protease inhibitor cocktail (0.1 
mM). Cells were thawed and resuspended in lysis buffer (20 mL, 50 mM Tris•HCl, 1 mM EDTA, 
500 mM NaCl, 0.1 mM inhibitor cocktail, pH 7.5). The cells were sonicated at 0 oC for 10 min (10 
min total time, 20 s on, 40 s off, 50% power). The cell lysate was centrifuged for 20 min at 15,000 
RCF at 4 oC. Q-sepharose resin (15 mL, 20% EtOH) was spun down and washed with H2O (2 x 
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15 mL) and Buffer B (2 x 15 mL), each time discarding the supernatant. The supernatant from the 
lysis was filtered with a sterile syringe into equilibrated Q-sepharose resin, diluted with Buffer A 
until 100 mM NaCl, and was shaken at 4 oC for 2 h. The ssDNA-cellulose resin (500 mg) was 
washed with H2O (2 x 10 mL) and Buffer B (2 x 10 mL). 
After 2 h, the Q-sepharose resin solution was passed through a gravity Poly-Prep column 
(20 mL, disposable), at 4 oC. The flow-through was collected and mixed with ssDNA-cellulose 
resin at 4 oC for 1 h. The solution was then passed through a prep column and the protein was 
eluted by increasing salt concentration (NaCl, 100 mM to 1 M). This purification was completed 
manually. Buffers containing multiple salt concentrations (i.e. 100 mM, 200 mM, 400 mM, 600 
mM, 800 mM, and 1 M NaCl, 10 mL each) were added to the column consecutively. Fractions (3 
x 3.3 mL) from each salt concentration were collected and analyzed by SDS-PAGE to determine 
which fractions contained the 8 kDa domain. The protein eluted at 200-400 mM NaCl, based on 
SDS PAGE analysis. 
The fractions containing the 8 kDa domain of Pol  were dialyzed overnight in Buffer B 
(2 x 500 mL). The fractions were poured into a SuperLoop and injected onto GE HiTrap SP FF 
column (5 mL) and eluted by increasing salt concentrations (1 mL/min, NaCl, 100 mM to 1 M in 
50 min, 2 mL fractions collected). The protein eluted around 400 mM NaCl, based on UV 
absorbance and SDS PAGE analysis. These fractions were combined and concentrated using a 3 
kDa 500 L Amicon filter until reaching a concentration of 68 M in 200 L (determined by 
Bradford assay), at which point a solution of glycerol in water (50 L, 50% v:v) was added to the 
stock. The final solution consisted of 55 M 8 kDa Pol , 10% v:v glycerol, and 250 L. The 




Transformation and Expression of the 31 kDa domain of Pol   
LB Media and LB Agar were prepared and autoclaved to make plates. LB Media was 
prepared by dissolving 45 g Bacto-tryptone, 22.5 g Bacto-yeast, and 45 g NaCl in 4.5 L H2O. LB 
Agar was prepared by dissolving 2.5 g Bacto-tryptone, 1.25 g Bacto-yeast, 3.75 g Agar and 2.5 g 
NaCl in 250 mL H2O. These solutions were autoclaved for 25 min. While the LB Agar was still 
warm, an aliquot of ampicillin stock solution (1000X, 100 mg/mL ampicillin, 250 μL) and an 
aliquot of chloramphenicol (1000X, 34 mg/mL chloramphenicol in EtOH, 250 μL) were sterilized 
in a sterile filter and added to the 250 mL of LB Agar. In a sterile environment, the mixture was 
poured into plates and allowed to cool. 
BL21 DE3 pLysS competent cells (20 μL) were thawed at 0 oC. pRSET plasmid containing 
the coding region for the 31 kDa Domain of Pol  (80 ng/μL, 1 μL) was added to the tube 
containing E.coli cells and incubated at 0 oC for 30 min. After 30 min, the cells were placed in a 
42 oC water bath for 45 s, and immediately put back in ice for 2 min. SOC outgrowth medium (100 
μL, 5x) was added to the cells. The cells were incubated at 37 oC for 1 h with shaking (180 RPM) 
to allow the cells to recover. After 1 h of recovery time, multiple diluted cell samples were 
prepared: 
1. 1:10 (5 μL cells + 45 μL SOC medium) 
2. 1:50 (1 μL + 50 μL SOC medium) 
3. 1:100 (0.5 μL cells + 45 μL SOC medium) 
Each solution was plated onto separate agar plates containing ampicillin and 
chloramphenicol. The plates were incubated at 37 oC overnight. After colonies had grown, the 
plates were stored at 4 oC. One colony was removed from the BL21 DE3 pLysS (1:50 dilution) 
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and placed in LB media (10 mL) with ampicillin (1000X, 100 mg/mL, 10 μL) and chloramphenicol 
(1000X, 34 mg/mL, 10 μL). The starter culture was shaken at 37 oC overnight. 
After 11.5 h, the starter culture was retrieved from the shaker and inoculated by removing 
the supernatant and resuspending the pellet in fresh LB medium (10 mL). In a sterile environment, 
culture media was prepared by mixing LB media (2 x 1 L), Ampicillin (2 x 1 mL, 100 mg/mL), 
Chloramphenicol (2 x 1 mL, 34 mg/mL), and starter culture (2 x 5 mL). Cultures were shaken at 
37 oC at 250 RPM until the cells reached an OD of 0.5 (about 5 h) At that point, IPTG (1 mL, 
1000X 1 M) was added to each batch of cells to make a final concentration of 1 mM IPTG. The 
cells were shaken for another 3 h at 37 oC. After 3 h, the cells were harvested by spinning them 
down (15,000 RCF, 4 oC, 10 min) and removing the media. The dry pelleted cells were frozen and 
stored at -80 oC until purification. 
Purification of the 31 kDa domain of Pol  
Buffer A: 50 mM Tris HCl, 1 mM EDTA, 500 mM NaCl, pH 7.5, 10 mM Na2S2O5, 1 mM  
PMSF, 0.1 mM protease inhibitor 
Buffer B: 10 mM Tris HCl, 1 mM EDTA, 1 mM PMSF, pH 7.5, 0.1 mM protease inhibitor 
Buffer C: 10 mM Tris HCl, 1 mM EDTA, 1 mM PMSF, 500 mM NaCl, pH 7.5, 0.1 mM  
protease inhibitor 
All buffers were supplemented with PMSF (1 mM) and protease inhibitor cocktail (0.1 
mM). Cells (~3.5 g) were thawed and resuspended in Buffer A (20 mL, 50 mM Tris HCl, 1 mM 
EDTA, 10 mM Na2S2O5, 500 mM NaCl, 0.1 mM inhibitor cocktail, pH 7.5). The cells were 
sonicated at 0 oC for 10 min (10 min total time, 10 s on, 20 s off, 50% power). The cell lysate was 
centrifuged for 20 min at 15,000 RCF at 4 oC. Cell lysate was filtered through a sterile filter into 
dialysis (3.5 K cut-off) bag and dialyzed against Buffer B at 4 oC  (2 x 1 L) for 18 h. Q-sepharose 
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resin (15 mL, 20% EtOH) was spun down (10 min, 10,000 RCF, 4 oC) and washed with H2O (2 x 
15 mL) and Buffer B (2 x 15 mL), each time discarding the supernatant. Dialyzed protein was 
filtered with a sterile syringe into equilibrated Q-sepharose resin and was shaken at 4 oC for 1.5 h. 
After binding, the Q-sepharose resin solution was passed through a gravity Poly-Prep column (20 
mL, disposable), at 4 oC. The flow-through was collected (2 x 10 mL) and the protein was eluted 
manually by increasing the concentration of NaCl (combining Buffer B and C: 0, 100, 200, 300, 
400, 500 mM NaCl, 10 mL each). Fractions (3 x 3.3 mL) from each salt concentration were 
collected and analyzed to determine which fractions contained the 31 kDa domain. Analysis by 
12% SDS PAGE indicated the protein eluted from 200-400 mM NaCl. Those fractions were pooled 
and dialyzed against Buffer B at 4 oC (2 x 1 L) for 18 h. 
Affi-gel blue gel resin (10 mL) was spun down (10 min, 10,000 RCF, 4 °C) and washed 
with H2O (2 x 10 mL) and Buffer B (2 x 10 mL), each time discarding the supernatant. The dialyzed 
protein was added to the equilibrated Affi-gel blue gel resin and shaken at 4 oC for 2 h. The solution 
was passed through a gravity Poly-Prep column (20 mL, disposable) at 4 oC and the protein was 
eluted manually at increasing salt concentrations (combining Buffer B and C: 0, 100, 200, 300, 
400, 500 mM NaCl, 10 mL each). Fractions (3 x ~3.3 mL) from each salt concentration were 
collected and analyzed to determine which fractions contained the 31 kDa domain. Analysis by 
12% SDS PAGE confirmed the protein eluted at 100-200 mM NaCl. Those fractions were pooled 
and concentrated with a 3K Amicon filter (pre-equilibrated with H2O (2 x 2 mL) and Buffer B (2 
x 2 mL)). The concentration was measured by Bradford assay to be 16.5 M (400 L). A solution 
of glycerol in water (100 L, 50% v:v) was added to the stock. The final solution consisted of 13.2 
M 31 kDa domain of Pol , 10% v:v glycerol, and 500 L. The 31 kDa domain/fragment of Pol 
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 was aliquoted, flash frozen, and stored at -80 oC until use. Activity was confirmed using the 
strand displacement assay (Section 3.2.1). 
Expression of Pol  mutants (N24K, P63L, T79I)13  
Pol  mutant pET28a construct plasmids (N24K, P63L, and T79I) were transformed into 
Rosetta 2 (DE3) cells (same procedure as described above). LB cultures supplemented with 50 
g/mL kanamycin and 34 g/mL chloramphenicol were grown overnight at 37 oC, diluted 1:100 
in LB media, and grown until reaching an A600 of ~0.5. Cultures were cooled down in a cold room 
to 4 oC while the incubator cooled to 20 oC. Cultures were not induced until they were below room 
temperature (e.g. cold to the touch) and the incubator reached 20 oC. Protein expression was 
induced with 1 mM IPTG at 20 oC overnight. After 16 h, cells were harvested by centrifugation (4 
x 15,000 RCF, 4 oC, 10 min), frozen, and stored at -80 oC. 
Purification of Pol  mutants (N24K, P63L, T79I)13 
Buffer A: 40 mM Tris HCl, 0.5 M NaCl, 5 mM Imidazole, 1 mM PMSF, 0.1 mM protease  
inhibitor, pH 8.0 
Buffer B: 40 mM Tris HCl, 0.5 M NaCl, 0.5 M Imidazole, 1 mM PMSF, 0.1 mM protease  
inhibitor, pH 8.0 
Buffer C: 40 mM Tris HCl, 1 M NaCl, 5 mM Imidazole, 1 mM PMSF, 0.1 mM protease  
inhibitor, pH 8.0 
All buffers were supplemented with PMSF (1 mM) and protease inhibitor cocktail (0.1 
mM). Cells (~3 g) were thawed and resuspended in Buffer A (30 mL). The cells were sonicated at 
0 oC for 10 min (10 min total time, 10 s on, 10 s off, 50% power). The cell lysate was centrifuged 
(20 min, 15,000 RCF, 4 oC). The supernatant of the cell lyase was filtered at 4 oC through a 0.2 
m sterile filter and applied to a pre-equilibrated HisTrap HP column (5 mL) via a SuperLoop. 
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HisTrap HP column was used with a linear imidazole elution gradient (1 mL/min, 100% Buffer A 
-> 100% Buffer B in 50 min, 2 mL fractions collected). Fractions containing mutant (eluted at 
~125-250 mM imidazole, determined by UV and SDS PAGE analysis) were combined and 
concentrated to 1 mL with a pre-equilibrated 10K Amicon filter (Pre-equilibration: 2 x 10 mL 
H2O; 2 x 10 mL Buffer A; spun at 7,500 RCF, 4
 oC) at 4 oC and then diluted to 10 mL. The resulting 
solution was sterilized with a sterile filter and applied to a 5 mL SP-FF column with a SuperLoop. 
SP-FF column was used with a linear NaCl elution gradient (1 mL/min, 100% Buffer A -> 100% 
Buffer C in 50 min, 2 mL fractions collected). Fractions containing mutant (eluted at ~0.5 – 0.6 M 
NaCl) were combined and concentrated. FPLC-purified proteins were analyzed by SDS-PAGE 
and Coomassie Blue staining. Protein concentration(s) (listed below) were determined using the 
A280 Nanodrop and the extinction coefficient for Pol  ( = 21,200 M-1cm-1).13  
[Pol  N24K] = 4.0 M, 2.4 mL 
[Pol  P63L] = 41.2 M, 0.8 mL 
[Pol  T79I] = 43.8 M, 0.64 mL 
Glycerol (50% v:v in water ; 600 L Pol  N24K, 200 L, Pol  P63L, 160 L, Pol  T79I) was 
added to each stock and the mutants (concentrations and volumes listed below) were aliquoted, 
flash frozen, and stored at -80 oC. Mutant activities were confirmed using the strand displacement 
assay (Section 3.2.1). 
[Pol  N24K] = 3.2 M, 3 mL, 10% v:v glycerol 
[Pol  P63L] = 33 M, 1 mL, 10% v:v glycerol 





Expression of Pol   
Pol  pET28 construct plasmids were transformed into BL21 (CodonPlus) DE3-RIL cells. 
LB cultures supplemented with 50 g/mL kanamycin and 34 g/mL chloramphenicol were grown 
overnight at 37 oC. After 14 h, the starter cultures were spun down (15,000 RCF, 4 oC, 10 min), 
replaced with fresh media, diluted 1:100 with LB media, and grown until reaching an A600 of ~0.5. 
Cultures were cooled to 4 oC in a cold room and the incubator cooled to 22 oC. Cultures were not 
induced until the cultures were below room temperature (e.g. cold to the touch) and the incubator 
reached 22 oC. Protein expression was induced with 0.4 mM IPTG at 22 oC for 6 h. After 6 h, cells 
were harvested by centrifugation (4 x 15,000 RCF, 4 oC, 10 min), frozen, and stored at -80 oC. 
Purification of Pol   
Buffer A: 20 mM NaH2PO4, 0.5 M NaCl, 1 mM DTT, 10% v:v glycerol, 1 mM PMSF, 0.1 mM  
protease inhibitor, pH 7.8 
Buffer B: 20 mM NaH2PO4, 0.5 M NaCl, 1 M Imidazole, 1 mM DTT, 10% v:v glycerol, 1 mM  
PMSF, 0.1 mM protease inhibitor, pH 7.8 
Buffer C: 20 mM NaH2PO4, 1 M NaCl, 1 mM DTT, 10% v:v glycerol, 1 mM PMSF, 0.1 mM  
protease inhibitor, pH 7.8 
All buffers were supplemented with PMSF (1 mM) and protease inhibitor cocktail (0.1 
mM). Cells (~1 g) were thawed and resuspended in Buffer A (10 mL) supplemented with PMSF 
(1 mM) and protease inhibitor cocktail (0.1 mM). The cells were sonicated at 0 oC for 10 min (10 
min total time, 10 s on, 10 s off, 50% power). The cell lysate was centrifuged (20 min, 15,000 
RCF, 4 oC). The supernatant of the cell lyase was filtered at 4 oC through a 0.2 m sterile filter 
and applied to a pre-equilibrated 5 mL HisTrap HP column (Pre-equilibration: 2 mL/min; Buffer 
A, 20 mL; Buffer B, 10 mL; Buffer A, 20 mL) via a SuperLoop. 
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HisTrap HP column was used with a linear imidazole elution gradient (1 mL/min, 100% 
Buffer A -> 100% Buffer B in 50 min, 2 mL fractions collected). Fractions containing Pol  (eluted 
at ~250-500 mM Imidazole, determined by UV and SDS PAGE analysis) were combined and 
concentrated to 1 mL with a pre-equilibrated 10K Amicon filter (Pre-equilibration: 2 x 10 mL 
H2O, 2 x 10 mL Buffer A; spun at 7,500 RCF, 4
 oC) at 4 oC and then diluted to 10 mL. The resulting 
solution was applied to a 5 mL Heparin column with a SuperLoop. The Heparin column was used 
with a linear NaCl elution gradient (1 mL/min, 100% Buffer A -> 100% Buffer C in 50 min, 2 mL 
fractions collected). Fractions containing Pol  (eluted at ~750 mM NaCl) were combined and 
concentrated. FPLC-purified proteins were analyzed by SDS-PAGE and Coomassie Blue staining. 
Protein concentration (14.5 M) was determined using a Bradford assay. All buffers contained 
10% v:v glycerol so the final solution consisted of 14.5 M Pol , 10% v:v glycerol, and 400 L. 
The protein was aliquoted, flash frozen, and stored at -80 oC. 
Fluorescence-based strand displacement assay (used for Pol , 31 kDa Pol , and Klenow exo-)  
A 10X preincubation mixture was prepared by mixing a 40X working solution of Pol  (25 
L, 400 nM) with an aliquot of the inhibitor (5 L, 1 mM in 1:1 MeCN/H2O, 40X) in 1X reaction 
buffer (total volume: 100 L; 50 mM HEPES buffer pH = 7.5, 5 mM MgCl2, 0.2 mM EDTA, 50 
mM KCl, 0.01 % Tween 20, 0.01 mg/mL BSA, and 4% glycerol by volume) (Table 7). The final 
concentration of the preincubation mixture was 100 nM Pol  (10X) and 50 M inhibitor (10X). 
The volume of inhibitor added was unchanged across experiments that used various inhibitor 
concentrations. To achieve various inhibitor concentrations, the stock solution of inhibitor (1 mM) 
was diluted appropriately for the desired conditions (e.g. for a 10X preincubation containing 10 
M inhibitor, a 40X inhibitor solution of 400 M was used). It should be noted that an equivalent 
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volume of 1:1 MeCN/H2O (5 L) was added to the control experiments to keep the percentage of 
organic solvents consistent. 
 
Table 7. 10X Preincubation mixture for strand displacement assay(s). 
 Volume added (L) 
40X 400 nM Pol  (or other polymerase) 25 
40X 1 mM inhibitor (or 1:1 MeCN/H2O for control) 5 
20X reaction buffer 5 
H2O 65 
Total1 100 
1Preincubated at 25 oC for 20-30 min. 
 
  
After 20-30 min preincubation (depending on the conditions), an aliquot (20 L) was 
diluted with 1X reaction buffer (80 L) and a 2X solution (100 L) containing the ternary complex 
B (100 nM, 2X; Table 1) and dTTP (200 M, 2X) (Table 8). The solution in the wells was mixed 
and the fluorescence measurements were collected immediately. The final mixture in the reaction 
well contained 10 nM Pol , 25 M inhibitor, 50 nM DNA, 100 M dTTP, 1X reaction buffer, 
and 0.25% MeCN. 
 
Table 8. Reaction mixture for strand displacement assay(s). 
 Volume added (mL) 
10X preincubation mixture 20 
2X DNA and dTTP mixture 100 






This method was adapted to accommodate a smaller well volume (30 L, 384-well plates). 
Despite the change, enzyme and inhibitor concentrations and dilutions remained consistent (Tables 
9 and 10 for volume changes). 
 
Table 9. 10X preincubation mixture for smaller wells. 
 Volume added (L) 
400 nM Pol  12.5 
1 mM inhibitor (or 1:1 MeCN/H2O for control) 2.5 
20X reaction buffer 2.5 
H2O 32.5 
Total1 50 
1Preincubated at 25 oC for 20-30 min. 
 
 
Table 10. Reaction mixtures for smaller wells. 
 Volume added (mL) 
10X preincubation mixture 3 
2X DNA and dTTP mixture 15 




Fluorescence-based strand displacement assay for IC50 value at a smaller dilution 
The following procedure was used to determine the IC50 value of 72 under previously used 
conditions that consist of a longer preincubation time and smaller dilution.27 
Multiple 44X working solutions of 72 (2, 4, 10, 20, and 40 M) were prepared in 1:1 
MeCN/H2O. A 1.1X pre-incubation mixture was prepared by mixing an 84X working solution of 
Pol  (2.5 L, 200 nM) with an aliquot of 72 (5 L, 44X, various concentrations listed above) in 
1X reaction buffer (total volume: 200 L; 50 mM HEPES buffer pH = 7.5, 5 mM MgCl2, 0.2 mM 
EDTA, 50 mM KCl, 0.01 % Tween 20, 0.01 mg/mL BSA, and 4% glycerol by volume) (Table 
11). The final preincubation mixtures contained 2.5 nM Pol  (1.1X) and inhibitor (0.05, 0.1, 0.2, 
163 
 
0.25, 0.5, 1 M, 1.1X). It should be noted that an equivalent volume of 1:1 MeCN/H2O was added 
to the control experiments to keep the percentage of organic solvents consistent. 
 
Table 11. Preincubation mixture preparation. 
 Volume added (L) 
84X 200 nM Pol  2.5 
44X 72 (or 1:1 MeCN/H2O for control) 5 
20X reaction buffer 10 
H2O 182.5 
Total1 200 
1Preincubated at 25 oC for 30 min. 
 
 
After a 30 min preincubation, an aliquot (19 L) was slightly diluted with a 20X solution 
(1 L) containing the ternary complex B (600 nM, Table 1) and dTTP (2 mM) (Table 12). The 
solution was mixed and fluorescence measurements were collected immediately. The final mixture 
in the reaction well contained 2.38 nM Pol , 72 (0.045, 0.09, 0.18, 0.23, 0.45, and 0.9 M), 30 
nM DNA, 100 M dTTP, 1X reaction buffer, and 1.2% MeCN. 
 
Table 12. Reaction mixture preparation. 
 Volume added (L) 
1.1X preincubation mixture 19 
20X DNA (600 nM)/dTTP (2 mM) 1 
Total 20 
 
Gel-based lyase assay (WT Pol )  
A 10X preincubation mixture was prepared by mixing a 100X working solution of Pol  
(5 L, 200 nM) with an aliquot of the inhibitor (2.5 L, 1 mM solution in 1:1 MeCN/H2O, 200X) 
in 1:1 MeCN/H2O in 1X reaction buffer (total volume: 50 L; 50 mM HEPES buffer pH = 7.5, 5 
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mM MgCl2, 0.2 mM EDTA, 50 mM KCl, 0.01 % Tween 20, 0.01 mg/mL BSA, and 4% glycerol) 
(Table 13). The volume of inhibitor added was unchanged across experiments that used various 
inhibitor concentrations. To achieve various inhibitor concentrations, the stock solution of 
inhibitor (1 mM) was diluted appropriately for the desired conditions (e.g. for a 10X preincubation 
containing 10 M inhibitor, a 40X inhibitor solution of 400 M was used). The concentration of 
the preincubation mixtures was 20 nM Pol  (10X) and 50 M inhibitor (10X). It should be noted 
that an equivalent volume of 1:1 MeCN/H2O was added to the control experiments to keep the 
percentage of organic solvents consistent. 
 
Table 13. 10X Preincubation mixture for gel-based lyase assay(s). 
 Volume added (L) 
100X 200 nM Pol  5 
40X 1 mM inhibitor (or 1:1 MeCN/H2O for control) 2.5 
20X reaction buffer 2.5 
H2O 40 
Total1 50 
1Preincubated at 25 oC for 30 min. 
 
 
The oligonucleotide containing 5’-dRP was generated by photolysis (350 nm, 20 min) 
following synthesis and purification.29 After a 30 min preincubation, an aliquot (3 L) was diluted 
with a 2X solution containing the ternary complex A (300 nM, 15 L; Table 1) in 1X reaction 
buffer (12 L) (Table 14). The final mixture in the reaction well contained 2 nM Pol , 5 M 
inhibitor, 150 nM DNA, 1X reaction buffer (supplemented with 0.01 mg/mL BSA, 4% glycerol), 






Table 14. Reaction mixtures for gel-based lyase assay(s). 
 Volume added (mL) 
10X preincubation mixture 3 
2X DNA A 15 
1X reaction buffer 12 
Total 30 
 
Time points of the reaction (2, 5, 10, 15, 20, and 25 min) were aliquoted and removed from 
the reaction mixture (4 L). Reaction was halted by flash freezing the aliquot in dry ice. After the 
25 min reaction was complete and all aliquots were frozen, the thawed mixtures were then 
stabilized by NaBH4 (4 L, 300 mM) for 2 hours at 4 oC. The samples were loaded onto a 20% 
denaturing PAGE gel and run for 4 h at 55 watts. The gel was exposed in a radiography cassette, 
which was scanned using a Phosphorimager. 
 
Gel-based lyase assay (8 kDa domain of Pol )  
A 10X preincubation mixture was prepared by mixing a 40X working solution of 8 kDa 
Pol  (12.5 L, 400 nM) with an aliquot of the inhibitor (2.5 L, 1 mM in 1:1 MeCN/H2O, 200X) 
in 1:1 MeCN/H2O in 1X reaction buffer (total volume: 50 L; 50 mM HEPES buffer, pH = 7.5, 5 
mM MgCl2, 4 mM DTT, 0.01 mg/mL BSA, 4% glycerol) (Table 15). The volume of inhibitor 
added was unchanged across experiments that used various inhibitor concentrations. To achieve 
various inhibitor concentrations, the stock solution of inhibitor (1 mM) was diluted appropriately 
for the desired conditions (e.g. for a 10X preincubation containing 10 M inhibitor, a 40X inhibitor 
solution of 400 M was used).  The concentration of the preincubation mixture was 100 nM 8 kDa 




Table 15.  10X Preincubation mixture for gel-based lyase assay(s). 
 Volume added (L) 
40X 400 nM 8 kDa Pol  12.5 
200X 1 mM inhibitor (or 1:1 MeCN/H2O for control) 2.5 
20X reaction buffer 2.5 
H2O 40 
Total1 50 
1Preincubated at 25 oC for 30 min. 
 
 
The oligonucleotide containing 5’-dRP was generated by photolysis (350 nm, 20 min) 
following synthesis and purification.29 After a 30 min preincubation, an aliquot (3 L) was diluted 
with a 2X solution of the ternary complex A (40 nM, 15 L; Table 1) in 1X reaction buffer (12 
L) (Table 16). The final mixture in the reaction well contained 10 nM 8 kDa domain, 20 nM 
DNA, 1X reaction buffer. 
 
Table 16. Reaction mixture for gel-based lyase assay(s). 
 Volume added (mL) 
10X preincubation mixture 3 
2X DNA A 15 




Aliquots (0, 2, 5, 10, 15, 20, and 25 min) were removed from the reaction mixture (4 L). 
Reaction was halted by flash freezing the aliquot in dry ice. After 25 min, all aliquots were frozen, 
the time points were then stabilized by NaBH4 (4 L, 300 mM) for 2 hours at 4 oC. The samples 
were loaded onto a 20% denaturing PAGE gel and run for 4 h at 55 watts. The gel was exposed in 




UBER probe deprotection160 
 
Compound CCVJ was acquired from the Kool lab from Stanford University. CCVJ (100 nmol) 
was dissolved in 50 L of a 1:1 solution of dry DCM and trifluoroacetic acid (TFA). After 4 h, the 
volatiles were evaporated under a stream of Argon. Remaining TFA was co-evaporated by the addition 
of toluene (10 L) yielding a red-orange residue. The product was confirmed by ESI-MS. 
ESI-MS m/z calculated for C18H22N4O2 (M + H) – 327.2, 327.3 observed. 
Fluorescence-based UBER lyase assay160  
A 5X preincubation mixture was prepared by mixing a 50X working solution of Pol  (2 
L, 1 M) with solution of inhibitor after photolysis (2 L, 250 M, 50X) in 1X reaction buffer 
(total volume: 20 L; 50 mM HEPES buffer, pH 7.3, 5 mM MgCl2, 2 mM DTT, 0.1 mg/mL BSA) 
(Table 17). The concentration of the preincubation mixture was 100 nM Pol  and 25 M inhibitor 
(5X).  
 
Table 17. 5X preincubation of enzyme/inhibitor for UBER assay. 
 Volume added (L) 
50X 1 M Pol  2 
50X 250 M inhibitor (or 1:1 MeCN/H2O for control) 2 







The oligonucleotide containing 5’-dRP was generated by photolysis (350 nm, 20 min) 
following synthesis and purification.29 After a 20 min preincubation, DNA (1 L, 100 M, A, 
Table 1) was added. This resulted in a second incubation mixture containing 95 nM Pol  and 5 
M DNA. This mixture was incubated for 25 min at 25 oC. An aliquot (4 L) of the 5X 
preincubation mixture containing Pol , inhibitor, and DNA was diluted with quenching buffer 
(50 mM HEPES, pH 6.5, 5 mM MgCl2, 2 mM DTT, 0.1 mg/mL BSA, 2 L). 10X Tris buffer (500 
mM, pH 7.0, 1.5M NaCl) and UBER probe (10X, 50 M in DMSO, 2 L) were added to the 20 
L solution ([Pol ] = 20 nM, [DNA] = 1 M, [inhibitor] = 5 M, [UBER] = 5 M). The reaction 
mixture was incubated for 4 h (Table 18). Fluorescence was measured using a Clariostar 
microplate reader with 5 nm slit width, 480 nm excitation, 500-560 nm emission scan.  
 
Table 18. Reaction mixture for UBER assay. 
 Volume added (L) 
5X preincubation (including A) 4 
10X Quenching buffer 2 
10X Tris buffer 2 





Primer Extension Assay (Pol )161  
A solution of 10X 72 (5 M or 100 M, 2 L) was mixed with a 40X solution of Pol  (200 
nM, 5 L) in 1X reaction buffer (20 mM Tris•HCl pH 7.5, 100 mM NaCl, 5 mM MnCl2, 0.5 mM 
TCEP, 10% glycerol, 0.01% NP-40, 0.1 mg/mL BSA) in a 384 microtiter well plate. This 10X 
preincubation mixture (50 nM Pol , 0.5 or 10 M 72) was incubated at 25 oC for 20 min. An 
aliquot of the 10X preincubation mixture (2 L) containing Pol  and 72 was added to a new well 
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and mixed with 1X buffer (8 L) and 2X cocktail solution (10 L) containing DNA substrate C 
(1 M), dNTPs (0.8 mM each), and 2X SYBR Gold in 1X buffer (Table 1). The final reaction 
mixture (20 L) contained 5 nM Pol , 0.05 or 1 M 72, 500 nM C, 0.4 mM dNTPs, 1X Sybr 
Gold in 1X reaction buffer. Fluorescence data was collected for 80-120 min on a Varian Cary 
Eclipse fluorescence spectrophotometer. 
Primer Extension Assays (Pol  and Pol )25  
A 10X working solution of 72 (5 or 100 M) was prepared in 1:1 MeCN/H2O. A 10X 
preincubation mixture was prepared by mixing a 50X working solution of polymerase (250 nM) 
with an aliquot of the inhibitor (5 or 100 M, 10X) in 1X reaction buffer (50 mM Tris•HCl, 50 
mM NaCl, 5 mM MgCl2, 5 mM DTT, 0.1 mg/mL BSA, 10% glycerol, pH 7.5) (see Table 19 for 
volumes). The concentration of the preincubation mixture was 50 nM polymerase (10X) and 0, 0.5 
or 10 M 72 (1X). 
 
Table 19. 10X preincubation mixture for primer extension assays. 
 Pol  (volume added, L) Pol  (volume added, L) 
50X Polymerase (250 nM) 2 3 
10X 72 (5 or 100 M) (or 1:1 
MeCN/H2O for control) 
1 1.5 
20X reaction buffer 1 1.5 
H2O 6 9 
Total1 10 15 
1Preincubated at 25 oC for 20 min. 
 
 
The samples containing 50 nM polymerase and 72 (0, 0.5, or 10 M) were preincubated at 
25 oC for 20 min. After preincubation, an aliquot (2 L, pol  or 3 L, pol ) was diluted with 
10X ternary complex (pol : 2 L, 500 nM D or pol : 3 L, 100 nM E), 10X dNTPs (5 mM; 2 
L, pol  or 3 L, pol ), and 1X reaction buffer (14 L, pol  or 21 L, pol ) (see Table 20 for 
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volumes). While the samples were incubated at 37 oC, aliquots (pol : 0, 2, 5, 10, 15, 20 min, 3 
L or pol : 0, 5, 15, 20, 30 min, 5 L) were removed and quenched by the addition of 95% 
formamide, 20 mM EDTA loading buffer (10 L). Aliquots were heated at 95 oC for 5 min, spun 
down, and loaded onto a 20% denaturing PAGE and run for 4 h at 55 watts. The gel was exposed 
in a radiography cassette, which was scanned using a Phosphorimager. 
 
Table 20. Reaction mixture for primer extension assays. 
 Pol  (volume added, L) Pol  (volume added, L) 
10X preincubation 2 3 
10X DNA 2 (500 nM D) 3 (100 nM E) 
10X dNTPs (5 mM) 2 3 
1X reaction buffer 14 21 
Total1 20 30 
1Incubated at 37 oC, taking time points between 0-30 min. 
 
General Procedure for Dialysis  
Pol  (100 nM, total volume 200 L) was preincubated in the absence or presence of 
inhibitor (e.g. 80 M 47) for 30 min at 25 oC in 1X reaction buffer (50 mM HEPES buffer pH = 
7.5, 5 mM MgCl2, 0.2 mM EDTA, 50 mM KCl, 0.01 % Tween 20, 0.01 mg/mL BSA, and 4% 
glycerol). The lyase activity of each sample was immediately measured by diluting an aliquot of 
each sample (2.6 L, 100 nM Pol , ±   ) 10-fold by mixing with 2X ternary complex A 
(13 L, 150 nM) in 1X reaction buffer (total volume: 26 L) (Table 21). The final concentrations 







Table 21. Lyase reaction kinetics before dialysis. 
 Volume added (L) 
10X preincubation (100 nM Pol  ±   ) 2.6 
2X A (150 nM) 13 
1X reaction buffer 10.4 
Total 26 
 
The lyase kinetics were carried out as previously described. Briefly, aliquots (4 L) were 
removed (0, 2, 5, 10, 15, and 20 min) from the reaction mixture. The reaction was halted by flash 
freezing the aliquot in dry ice. After 25 min, all aliquots were stabilized by NaBH4 (4 L, 300 mM) 
for 1-2 h at 4 oC. The samples were loaded onto a 20% denaturing PAGE gel and run for 4 h at 55 
watts. The gel was exposed in a radiography cassette, which was scanned using a Phosphorimager. 
The remaining sample (197.4 L) was dialyzed in a 3.50K MW cassette in reaction buffer 
(1 L, buffer exchanged after 12 h) containing 50 mM HEPES buffer (pH = 7.5, 5 mM MgCl2, 4 
mM DTT) for 24 h. The volume of the solution in the cassette was marked and no considerable 
volume change was observed after dialysis. The remaining lyase activity of the enzyme was 
measured as previously described (Table 21). Aliquots (4 L) were removed (0, 2, 5, 10, 15, 20 
min) and stabilized with NaBH4 (4 L, 300 mM) for 1-2 h at 4 
oC. The time points were analyzed 
by 20% denaturing PAGE (described above).  
This method was also used to analyze the effect of dialysis on the 8 kDa domain of Pol  
with minor changes: (1) 1X reaction buffer contained 50 mM HEPES buffer (pH = 7.5, 5 mM 
MgCl2, 2 mM DTT, 0.1 mg/mL BSA) and (2) the 10X 8 kDa domain preincubation concentration 
was increased to 200 nM, which after dilution was 20 nM. The concentration of inhibitor (80 M) 




UPLC MS/MS Analysis of Pol  modification by covalent inhibitors  
A 20X working solution of Pol  (25 L, 20 M, 500 pmol) was mixed with inhibitor (5 
L, 1 mM, 100X), H2O (420 L) and 10X reaction buffer (50 L, 500 mM HEPES buffer, pH = 
7.5, 50 mM MgCl2, 20 mM DTT) to yield a mixture of 1 M Pol , 10 M inhibitor, and 1X 
reaction buffer (50 mM HEPES buffer, pH = 7.5, 5 mM MgCl2, 2 mM DTT) (Table 22). 
 
Table 22. Preincubation for trypsin digest(s). 
 Volume added (L) 
20X 20 M Pol  25 
100X 1 mM inhibitor (or 1:1 MeCN/H2O for control) 5 
10X reaction buffer 50 
H2O 420 
Total1 500 
1Preincubated at 25 oC for 30 min. 
 
 
After 30 min incubation, the mixture (500 L, 1 M Pol ) was concentrated to 50 L (10 
M Pol ) with a 3K Amicon filter. Digestion buffer (25 L, 500 mM Tris•HCl pH 8.0), 10X 
trypsin (25 L, 400 M), and H2O (150 L) were added to yield a final mixture of 2 M Pol  and 
40 M trypsin (1:20 ratio) in 1X digestion buffer (total volume, 250 L, 50 mM Tris•HCl pH 8.0) 
(Table 23).  
 
Table 23. Trypsin digestion sample. 
 Volume added (L) 
10 M Pol  (preincubated with inhibitor and 
concentrated on a 3K Amicon) 
50 
10X digestion buffer 25 





The digestion sample was incubated at 37 oC overnight. A portion (100 L) of the digestion 
mixture was spun down (16,000 RCF, 10 min, 4 oC). The sample (10 L) was injected onto and 
analyzed by UPLC-MS/MS using an ACQUITY UPLC HSS T3 Column (100 Å, 1.8 m, 2.1 mm 
x 100 mm). The flow rate was 0.3 mL/min running a gradient from 85:5:10 water: acetonitrile: 1% 
formic acid to 50:40:10 water: acetonitrile: 1% formic acid over 35 min. Analysis was conducted 
using BioPharmaLynx with tolerance set to 30 ppm and allowing for 4 missed cleavages.  
The method described above was also used to analyze the 8 kDa domain of Pol  with 
minor changes: (1) the 8 kDa domain of Pol  solution contained 1 nmol enzyme (2) the 10X 
reaction buffer contained 500 mM HEPES buffer (pH = 7.5, 50 mM MgCl2, 20 mM DTT, 1 mg/mL 
BSA).  
This method was also adapted to multiple inhibitors by varying the concentration of 
inhibitor during incubation. The following concentrations were used for each inhibitor analyzed: 
[47] = 10 M, [2] = 5 M, [72] = 300 nM. For analysis of 2 and 72, the trypsin digestion buffer 
was adjusted to pH 7.1 because the adduct was reversible at pH 8.0 (Section 3.4.2.1). 
Fluorescence Anisotropy135  
Anisotropy measurements were conducted using a solution of dichloro-diphenyl-
fluorescein-labeled ternary complex F (2.5 nM, Table 1) and Pol  (varying concentrations) in 
reaction buffer (50 mM HEPES, pH 7.5, 20 mM KCl, 1 mM EDTA, and 1 mM -
mercaptoethanol). Samples also contained 10% storage buffer (20 mM Tris•HCl, pH 7, 300 mM 
NaCl, 10% glycerol, 5 mM BME) by volume. 
In a typical experiment, a sample (300 L) was prepared by mixing Pol  (30 L, 1 M) 
in storage buffer with 10X reaction buffer (30 L), F (30 L), a solution 50% MeCN in H2O 
containing or lacking 72 (200 M, 3 L) and H2O (207 L). These samples, termed solutions A 
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and A’ (A did not contain 72 and A’ contained 2 M 68), contained 250 pM ternary complex F, 
100 nM Pol , ± 2 M 72. Samples containing various concentrations of Pol  were prepared by 
serial dilution with solution B and B’. Solution B (10 mL) was prepared by mixing H2O (7.85 mL), 
with 10X reaction buffer (1 mL), 10X storage buffer (1 mL), F (50 nM, 50 L), and a solution of 
50% MeCN in H2O containing or lacking 72 (200 M, 100 L). Similarly, solution B did not 
contain 72 and was used exclusively to dilute solution A, whereas solution B’ contained 2 M 68 
and was used to dilute solution A’. By mixing equal volumes of A or A’ (150 L) with B or B’ 
(150 L) respectively, the concentration of Pol  decreased to 50 nM, while the concentration of 
DNA and 72 remain unchanged. An aliquot (150 L) of this new solution was then mixed with 
solution B or B’ (150 L) to prepare a new solution containing 25 nM Pol . Serial dilutions were 
repeated such that samples contained Pol  concentrations of 100 nM, 50 nM, 25 nM, 12.5 nM, 
6.25 nM, 3.13 nM, 1.56 nM, 0.78 nM, 0.39 nM, and 0.2 nM.  
Samples were incubated at 25 oC for 1 h and fluorescence anisotropy (A) was measured 
using a portion (125 L) of each sample with a PMT voltage of 800 mV, 8 nm slit width, 535 nm 
excitation and 556 nm emission. Fluorescence anisotropy was measured for F in the absence of 
enzyme (A0), and the change in anisotropy (A-A0) was calculated for each sample and plotted 
against the concentration of Pol . Each fluorescence anisotropy measurement was collected in 
triplicate. 
This method was also used for the 31 kDa domain of Pol  and 8 kDa domain of Pol . 
This method was adapted to analyze other inhibitors at various concentrations. The following 





Growing conditions for different cell lines  
HeLa cells were grown in DMEM with high glucose supplemented with 9% FBS and 1% 
antibiotic antimycotic solution (penicillin, streptomycin, and amphotericin B). 
MCF-7 and MDA-MB-436 cells were grown in RPMI 1640 Medium with GlutaMAX 
supplement, supplemented with 0.05% insulin, 9% FBS, and 1% antibiotic antimycotic solution. 
Cell viability assays  
Approximately 2 x 105 HeLa cells were plated in each well of a 6-well culture plate (well 
size; 35 mm x 18 mm) in DMEM containing 10% FBS (1 mL) and kept in a humidified incubator 
at 37 oC with 5% CO2 for 20 h. A stock solution of treatments (100X pro-72, 10 L; in 50% MeCN 
in H2O and/or 100X MMS (20 mM), 10 L; in DMEM-FBS medium) was diluted in culture 
medium (1 mL) to the appropriate concentration (pro-72: 0, 5, 25, 50, 100 M; MMS: 0.2 mM) 
and then added to the plates keeping the quantity of the MeCN constant at 0.5% for all tests.  
Cells were incubated for 1 or 2 h in a humidified incubator at 37 oC with 5% CO2. The 
medium was removed and washed with 1X PBS (2 x 1 mL). The cells were trypsinized with 0.25 
w/v Trypsin-EDTA (1 mL in each well, 5 min incubation at 37 oC), washed with DMEM-FBS (10 
mL) to quench the trypsin cleavage, and spun down (3,000 RCF x 5 min). The medium was 
removed, and the cells were resuspended with fresh DMEM-FBS (10 mL). A portion (10 L) of 
the cell suspension was thoroughly mixed with 10 L of 0.4% solution of trypan blue in PBS (pH 
7.2), and placed on a counting slide (BIO-RAD) to count the % of live cells using TC20 automated 
cell counter (BIO-RAD). A control experiment without treatment was carried out in parallel. All 





Clonogenic assay for cell survival  
Approximately 2 x 105 HeLa cells were plated in each well of a 6-well culture plate (well 
size; 35 mm x 18 mm) in DMEM containing 10% FBS (1 mL) and kept in a humidified incubator 
at 37 oC with 5% CO2. After overnight incubation, cells were subjected to either the vector (50% 
MeCN in H2O) or treatment (100X pro-72, 10 L; in 50% MeCN in H2O and/or 100X DNA 
damaging agent (e.g. 20 mM MMS, 200 M BLM; 10 L; in DMEM-FBS medium). For 
alkylation experiments, cells were incubated with MMS (0 or 0.2 mM), with or without pro-72 (5, 
25 M) at 37 oC with 5% CO2 for 1 or 2 h. After treatment, the medium was removed, and the 
cells were washed with 1X PBS (2 x 1 mL). The cells were trypsinized with 0.25 w/v Trypsin-
EDTA (1 mL in each well, 5 min incubation at 37 oC), washed with DMEM-FBS (10 mL) to 
quench the trypsin cleavage, and spun down (3,000 RCF x 5 min). The medium was removed, and 
the cells were resuspended with fresh DMEM-FBS (10 mL). The single cell suspensions were 
collected and counted using a TC20 Automated Cell Counter (BIO-RAD). 
Stock solutions of single cell suspensions were prepared for all untreated and treated cells. 
For example, 100 cells/mL stock solution of untreated cells were prepared; 500 cells/mL stock 
solutions of treated cells were prepared. The concentration of stock solution for each sample was 
determined based on expected toxicity of the treatment (i.e. higher concentrations for more toxic 
conditions). The appropriate number of cells for each experiment were seeded in each well of a 6-
well plate (well size; 35 mm x 18 mm) in 3 mL of DMEM-FBS medium. The cells were grown in 
a humidified incubator at 37 oC with 5% CO2 for 14 days. No significant change in media volume 
was observed after two weeks due to evaporation. After 14 days, the growth medium was 
discarded, and the attached cells were treated with 0.2% w/v crystal violet solution. The excess 
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dye was washed with water. The plates were dried and scanned with an HP Scanjet 3970 and 
colonies were counted using ImageJ (FIJI). 
Plating efficiencies (PE) and survival fractions (SF) were calculated as follows: PE = number of 
colonies/number of cells seeded; SF = PE/PEcontrol. 
Pol  knock down by siRNA179  
MDA-MB-436 cells (8 x 106) were seeded with RPMI 1640 medium into a 100 mm plate 
one day prior to transfection so cells would be adherent and ~80% confluent on the first day of 
transfection, determined by manual inspection. Transfection was completed as follows: 
1. Lipofectamine RNAiMAX (80 L) was diluted in Opti-MEM reduced serum medium (1 mL).  
2. In a separate tube, siRNA (either siNT or siPol, 10 M, 80 L, 800 pmol) was diluted in Opti-
MEM (500 L).  
3. The Lipofectamine solution was split (2 x 500 L aliquots) and mixed with either siNT or 
siPol solution to form the lipid-RNA complex at 25 oC for 5 min.  
4. The RPMI 1640 medium was removed and replaced with Opti-MEM medium (9 mL). After 5 
min incubation, the lipid-RNA solution (1 mL) was added to the cells.  
The following day, steps 1-3 were repeated and the resulting 2 x 500 L solutions were 
added to the corresponding cells (already in OPTI-MEM) incubating at 37 oC, 5% CO2. Cells were 
transfected with siRNA at 37 oC, 5% CO2 for 48 h after the second addition of siRNA. Cells were 
harvested and reseeded into 6-well plates for a clonogenic assay (described previously). A portion 
of the transfected cells (2 x 106) were used to determine knock down efficiency by Western blot. 





Western Blot Analysis  
Cells were trypsinized with 0.25 w/v Trypsin-EDTA (1 mL in each well, 5 min incubation 
at 37 oC), washed with RPMI 1640-FBS (10 mL) to quench the trypsin cleavage, and spun down 
(3,000 RCF x 5 min). The medium was removed, and cells were washed twice with cold 1X PBS 
buffer (2 x 3000 RCF, 4 oC, 5 min). The cell pellet was resuspended in nuclear fractionation lysis 
buffer (1 mL/107 cells; 20 mM HEPES pH 7.5, 0.25 M sucrose, 1 mM PMSF, 3 mM MgCl2, 0.2% 
NP-40, with protease inhibitor). Cells were incubated in lysis buffer on ice for 15 min with 
occasional mixing by inverting the tube back and forth, after which they were spun down (3,000 
RCF, 4 oC, 15 min). The supernatant was discarded. The cell pellet was resuspended and incubated 
in RIPA lysis buffer (0.5 mL/107 cells; 10 mM Tris pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% 
sodium deoxycholate, 0.1% SDS, 140 mM NaCl) on ice for 20 min with occasional mixing by 
inverting the tube back and forth. The cells were spun down (16,000 RCF, 4 oC, 10 min). The 
supernatant (i.e. cell lysate) was transferred to a new tube. The concentration of proteins in cell 
lysate were determined using a Bradford assay (described previously). Precision Plus Protein 
WesternC standard (5 L) protein ladder and Cell lysates (20 g of protein) were separated using 
SDS-PAGE. Two of each sample was loaded onto the gel to visualize the amount of Pol  present 
and an internal standard (i.e. -H3). The H3 antibody was used to quantify the relative amounts of 
H3 in the control and knock down cells to account for any variation in protein(s) loaded onto the 
gel. The relative amounts of H3 were used to normalize the knock down of Pol  expression 
observed. 
Proteins were transferred from the gel to a nitrocellulose membrane (25 V, 1 A, 30 min) 
using a BioRad Trans-Blot Turbo Transfer system. The membrane was stained with ponceau red 
stain for 5 min then washed with H2O until the background is removed. The membrane was cut 
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and separated so one set of samples could be incubated with the Pol  antibody and the other set 
with H3 antibody. The membranes were blocked with 3% BSA in 1X Tris-buffered saline tween 
(TBST; 20 mM Tris, 150 mM NaCl, 0.1% Tween) buffer for 30 min at 25 oC while shaking. The 
membranes were incubated with the primary antibody solution (Recombinant Anti-DNA 
Polymerase beta antibody, 1:1000 Ab in 3% BSA in TBST; Recombinant Anti-Histone H3 
antibody, 1:1000 Ab in TBST) at 4 oC overnight. The membranes were washed (3 x 10 s TBST, 5 
mL; 3 x 5 min TBST, 5 mL). In some cases, the antibody solution (-H3) was recovered and 
reused. The recovered antibody solution did not contain 3% BSA, was supplemented with 5% 
azide after initial use, and was stored at 4 oC. The first three rapid washes were to remove any 
remaining antibody solution and the latter three washes were longer to remove non-selective 
antibody binding. The membranes were incubated with secondary antibody solution (Rabbit anti-
goat antibody, 5 mL, 1:5000 Ab in 3% BSA in TBST with StrepTactin-HRP conjugate, 0.5 L) at 
25 oC for 1 h. The membranes were washed (3 x 10 s TBST, 5 mL; 3 x 5 min TBST, 5 mL). 
Membranes were kept in Tris-buffered saline (TBS; 20 mM Tris, 150 mM NaCl) buffer until 
incubated with developing reagent for 5 min and scanned using a Typhoon 9410 equipped with 










All Rf values provided in TLC information correspond to the product unless otherwise explicitly 
stated. 
Preparation of 526,185             
Commercially available 3-furaldehyde (4.38 mL, 5 g, 52.4 mmol, 1 eq) was added to a 
mixture of 10:1 Et2O/H2O (59 mL). The mixture was cooled to 0 
oC and stirred. Small 
aliquots of NaBH4 (3.27 g, 86.4 mmol, 6.65 eq) were added to the mixture carefully over 
a period of 15 min. The reaction was stirred in air for 30 min. After 30 min, TLC (4:1 Hex/EtOAc, Rf 
= 0.3) showed the complete conversion of the starting material (Rf = 0.5, UV active, did not stain with 
PAA) to a slightly more polar spot that was not UV active and stained dark purple with PAA. The 
reaction was quenched with water until there was no more bubbling. The ether layer was washed with 
water (2 x 50 mL) and the combined aqueous layers were extracted with ether (6 x 40 mL). The final 
organic layer was washed with brine (1 x 50 mL), dried with MgSO4, and concentrated under vacuum 
at 0 oC to yield 4.714 g (91.7%) of a yellow liquid. The product was volatile, so the rotary evaporatory 
water bath was cooled to 0 oC during concentration. NMR data showed the crude product was pure. 1H 
NMR (400 MHz, CDCl3) δ 7.36 (s, 2H), 6.38 (s, 1H), 4.46 (d, J = 4.9 Hz, 2H), 2.92 (d, J = 4.9 Hz, 
1H). 
Without purification, the intermediate (474.6 mg, 4.84 mmol, 1 eq) was 
combined with Pb(OAc)4 (3.22 g, 7.22 mmol, 1.5 eq). Glacial acetic acid 
(12.5 mL) was added to the flask, which was then flushed with Argon. The 
reaction was stirred at 25 oC for 21 h. When the reaction was complete by TLC (3:7 EtOAc/DCM, Rf 
= 0.4, stained with PAA), AcOH was removed via vacuum. Ether (50 mL) was added to the resulting 
residue and the precipitate was triturated with ether and removed. The filtrate was concentrated under 
vacuum and purified by column chromatography (7:3 Hexanes/EtOAc) to give 518 mg (58%) of a 2:1 
mixture of diastereomers (5). 1H NMR (400 MHz, CDCl3) δ 6.90 (dd, J = 1.0, 4.7 Hz, 1H), 6.69 (dd, 
J = 1.0, 4.7 Hz, 1H), 6.15 – 6.05 (m, 1H), 4.30 (q, J = 1.0 Hz, 2H), 2.19 – 2.07 (m, 6H).  
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Preparation of 6 
Compound 5 (150 mg, 0.685 mmol, 1 eq, 500 mM) and DMAP (8.6 mg, 
0.07 mmol, 0.1 eq) were added to a flask. The contents were flushed with 
Argon and dissolved in DCM (1.25 mL). The mixture was cooled to 0 oC. 
Acetic anhydride (0.33 mL, 3.5 mmol, 5 eq) was added slowly to the flask via syringe. Pyridine (0.68 
mL, 8.56 mmol, 12.5 eq) was added dropwise to the solution via syringe. After 2 h, the reaction was 
confirmed complete by TLC (6:4 EtOAc/DCM, Rf = 0.6, stained with PAA) and was quenched with 
sat. NaHCO3 until the pH was neutral. The mixture was diluted with EtOAc (5 mL) and washed with 
water (2 x 5 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL), the combined organic 
layers were washed with brine (1 x 30 mL), dried over Na2SO4, and concentrated under vacuum. The 
crude residue was purified by column chromatography (5:1 DCM/EtOAc) to yield 167 mg (85%) of 
6. 1H NMR (400 MHz, CDCl3) δ 6.83 (s, 1H), 6.70 – 6.56 (m, 1H), 6.22 – 5.89 (m, 1H), 4.83 – 4.57 
(m, 2H), 2.11 – 1.96 (m, 9H). 
Preparation of 7 
Compound 6 (150 mg, 0.69 mmol, 1 eq) was dissolved in EtOAc (17 mL). 
Rhodium on alumina catalyst (75.5 mg) was added to the pressure bottle 
equipped with a regulator. The vial was pressurized with H2 to 70 psi, 
purged three times, and stirred at 25 oC for 2-4 h. After venting the pressure bottle, TLC (1:1 
Hex/EtOAc, Rf = 0.4, stained with PAA) showed the starting material was no longer present. When 
complete, the reaction mixture was passed through celite to remove the Rh catalyst. The filtrate was 
concentrated under vacuum to give 127.5 mg (85%) of pale, yellow compound 7. No purification was 
needed. 1H NMR (400 MHz, CDCl3) δ 6.25 – 6.15 (m, 2H), 4.06 (m, 1H), 4.03 – 3.91 (m, 1H), 2.71 – 
2.56 (m, 1H), 2.38 (m, 1H), 2.04 – 1.88 (m, 9H), 1.83 – 1.67 (m, 1H). 
13C NMR (CDCl3) 170.7, 169.9, 169.5, 98.5, 96.4, 62.1, 41.6, 32.7, 21.5, 20.9, 20.7. 
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Preparation of 8 
BF3•etherate was distilled from CaH2 under vacuum and kept under 
Argon. Compound 7 (750 mg, 2.88 mmol, 1 eq, 160 mM) was dissolved 
in DCM (18 mL) and cooled to 0 oC. 4-Pentenol (1.86 mL, 1.49 g, 17.3 
mmol, 6 eq) was added to the reaction. BF3•etherate (8.14 mL, 1.67 M) 
was slowly added to the solution over a period of 15-20 min (until 
diluted to 28 mL, 600 mM). After 30 min, the reaction was incomplete when analyzed by TLC (7:3 
Hex/Et2O, stained with PAA) but degradation products began to appear, so the reaction was quenched 
with sat. NaHCO3 (5 mL), diluted with DCM (20 mL), and washed with sat. NaHCO3 (1 x 15 mL). 
The aqueous layer was extracted with DCM (4 x 20 mL). The organic layer was washed with water (1 
x 30 mL), brine (1 x 30 mL), and dried over Na2SO4. The residue was concentrated under vacuum and 
purified by column chromatography (8:2 hex/EtOAc) to give 228.6 mg (25.4%) of 8a and 519 mg 
(57.7%) of 8b (totaling 83%). 8a 1H NMR (400 MHz, CDCl3) δ 5.82 – 5.65 (m, 2H), 5.21 – 4.84 (m, 
6H), 4.24 – 3.99 (m, 2H), 3.75 – 3.57 (m, 2H), 3.45 – 3.22 (m, 2H), 2.61 (m, 1H), 2.42 – 2.17 (m, 1H), 
2.08 – 2.01 (m, 4H), 1.99 (d, J = 9.5 Hz, 3H), 1.93 – 1.74 (m, 1H), 1.67 – 1.50 (m, 4H). 8b 1H NMR 
(400 MHz, CDCl3) δ 5.91 – 5.68 (m, 2H), 5.10 – 4.83 (m, 6H), 4.15 – 3.88 (m, 2H), 3.73 (m, 2H), 3.55 
– 3.32 (m, 2H), 2.65 (ddd, J = 5.5, 7.4, 13.5 Hz, 1H), 2.39 (s, 1H), 2.32 – 2.18 (m, 1H), 2.16 – 2.08 
(m, 4H), 2.05 (s, 3H), 1.81 (ddd, J = 5.5, 7.4, 13.5 Hz, 1H), 1.73 – 1.59 (m, 4H). 
8a and 8b 13C NMR (CDCl3) 170.9, 170.8, 138.20, 138.18, 138.15, 114.8, 106.9, 106.2, 104.7, 104.2, 
103.5, 103.2, 67.6, 67.5, 67.4, 67.3, 67.2, 67.0, 64.8, 64.5, 63.3, 43.8, 43.2, 40.7, 34.7, 34.2, 33.4, 30.4, 






Preparation of 926 
A diastereomer of 8 (82 mg, 0.26 mmol, 1 eq, 150 mM) was dissolved 
in MeOH (1.7 mL). Sodium methoxide stock solution (700 mM) was 
prepared by dissolving Na metal (122 mg, 5.3 mmol) in MeOH (7.5 
mL). An aliquot of NaOMe (700 mM, 0.3 mL) was added to the 
reaction slowly (effectively diluting NaOMe to 100 mM). After 2 h, 
TLC (6:4 Hex/EtOAc, Rf = 0.2, stained with PAA) confirmed the reaction was complete by the 
disappearance of 8. The reaction was quenched with a few drops of AcOH until neutral pH. The 
reaction was diluted with DCM (20 mL) and washed with H2O (2 x 15 mL). The aqueous layer was 
extracted with DCM (4 x 20 mL) and the combined organic layers were washed with brine (1 x 30 mL) 
and dried over Na2SO4. The reaction was concentrated under vacuum to give 49.3 mg (70%) of 9. No 
purification was needed. 1H NMR (400 MHz, CDCl3) δ 5.91 – 5.65 (m, 2H), 5.23 – 4.88 (m, 6H), 3.93 
– 3.71 (m, 2H), 3.72 – 3.61 (m, 2H), 3.49 – 3.31 (m, 2H), 2.63 – 2.46 (m, 1H), 2.38-2.23 (ddd, J = 5.0, 
9.5, 13.3 Hz, 1H), 2.26 – 2.13 (m, 1H), 2.13 – 2.03 (m, 4H), 1.82 (ddd, J = 1.5, 7.8, 13.3 Hz, 1H), 1.65 
(dddt, J = 1.5, 5.0, 7.8, 9.5 Hz, 4H). 
Preparation of 10 
Compound 9 (58.2 mg, 0.22 mmol) was azeotropically dried with 
pyridine (2 x 0.5 mL). The reagent was cooled to 0 oC. DIPEA (0.18 
mL, 133 mg, 0.88 mmol, 4 eq) was added to the cold starting 
material and the reactants were dissolved in DCM (2.1 mL, 100 
mM). 2-Cyanoethyl-N, N-diisopropylchlorophosphoramidite (0.06 
mL, 60.4 mg, 0.26 mmol. 1.2 eq) was added and the cold mixture 
stirred with periodic monitoring by TLC (7:1 Hex/EtOAc, Rf = 0.3, 
stained with PAA). After 2 h, TLC showed complete conversion to the phosphoramidite. The reaction 
was diluted with freshly distilled EtOAc (10 mL). The organic layer was washed with saturated 
184 
 
bicarbonate solution (2 x15 mL) and the aqueous layers were extracted with distilled EtOAc (2 x 20 
mL). The combined organic layers were washed with brine (1 x 25 mL) and dried over Na2SO4. The 
organic layer was concentrated under vacuum and purified by column chromatography (7:1 distilled 
hexanes/distilled EtOAc) yielding 55.9 mg (54%) of 10. 1H NMR (400 MHz, CDCl3) δ 5.80 (dddt, J 
= 4.1, 8.2, 13.5, 16.0 Hz, 2H), 5.18 – 4.93 (m, 6H), 3.86 – 3.72 (m, 2H), 3.64 (dtd, J = 2.1, 6.0, 8.2 Hz, 
2H), 3.59 – 3.51 (m, 2H), 3.34 (dddd, J = 2.1, 4.1, 9.4, 16.0 Hz, 2H), 2.71 – 2.52 (m, 2H), 2.30 (ddd, 
J = 6.0, 9.4, 13.5 Hz, 2H), 2.11 – 2.02 (m, 4H), 1.93 – 1.76 (m, 1H), 1.65 – 1.55 (m, 6H), 1.17 (m, 
12H).  
31P NMR (400 MHz, CDCl3) δ 147.87. 
Preparation of 1127 
Compound 5 (163 mg, 0.886 mmol, 1 eq) was dissolved in EtOAc (16 mL, 
50 mM). Rhodium on alumina catalyst (85.2 mg) was added to the pressure 
bottle equipped with a regulator. The vial was pressurized with H2 to 70 
psi, purged three times, and stirred at 25 oC for 2-4 h. After venting the pressure bottle, TLC (4:6 
Hex/EtOAc, Rf = 0.3, stained with PAA) showed the starting material was no longer present. When 
complete, the reaction mixture was passed through celite to remove the Rh catalyst. The filtrate was 
concentrated under vacuum to a pale, yellow residue, which was purified by column chromatography 
(1:1 DCM/EtOAc) resulting in 67 mg (41%) of a mixture of diastereomers (11). 1H NMR (400 MHz, 
CDCl3) δ 6.44 (s, 1H), 6.34 (d, J = 1.0 Hz, 1H), 3.86 – 3.75 (m, 1H), 3.69 (dt, J = 5.5, 10.9 Hz, 1H), 








Preparation of 1227 
Compound 11 (67 mg, 0.28 mmol) was azeotropically dried with 
pyridine (2 x 0.5 mL). The flask was cooled to 0 oC. DIPEA (0.2 mL, 
144 mg, 1.12 mmol, 4 eq) was added to the cold starting material and 
the reactants were dissolved in DCM (1.2 mL, 200 mM). 2-
Cyanoethyl-N, N-diisopropylchlorophosphoramidite (75 L, 80 mg, 
0.34 mmol. 1.2 eq) was added and the cold mixture stirred with periodic monitoring by TLC (7:1 
Hex/EtOAc, Rf = 0.2, stained with PAA). After 2 h, TLC showed complete conversion to the 
phosphoramidite. The reaction was diluted with EtOAc (10 mL). The organic layer was washed with 
saturated bicarbonate solution (2 x15 mL) and the aqueous layers were extracted with EtOAc (2 x 20 
mL). The combined organic layers were washed with brine (1 x 25 mL) and dried over Na2SO4. The 
organic layer was concentrated under vacuum and purified by column chromatography (3:1 hexanes/ 
EtOAc) yielding 85 mg (75%) of 12. 1H NMR (400 MHz, CDCl3) δ 6.31 (m, 1H), 4.28 (m, 1H), 3.78 
(m, 3H), 3.55 (m, 3H), 2.79 (m, 1H), 2.60 (m, 2H), 2.44 (m, 1H), 2.04 (m, 6H), 1.81 (m, 1H), 1.14 (m, 
12H). 
31P NMR (162 MHz, CDCl3) δ 149.7, 149.5, 148.3, 148.1, 13.2. 
Preparation of 13186–188 
5-Iodo-2’-deoxyuridine (953 mg, 2.69 mmol) was azeotropically dried 
with pyridine (2 x 3 mL). DMT-Cl (1.63 g, 4.8 mmol, 1.8 eq) was added 
and reactants were dissolved in pyridine (15 mL, 180 mM) at 0 oC. The 
mixture turned orange and was monitored by TLC (5% MeOH in DCM, 
Rf = 0.7, UV active and stained orange then blue with PAA). After 2 h, 
side products (presumably the bis-tritylated product) were observed by TLC. The reaction was 
concentrated under vacuum to remove pyridine. The residue was dissolved in EtOAc (30 mL) and 
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became yellow. The solution was washed with sat. sodium bicarbonate (1 x 30 mL) and H2O (1 x 30 
mL). The aqueous layer was extracted with EtOAc (2 x 30 mL) and the combined organic layers were 
washed with brine (1 x 50 mL), dried over Na2SO4, and concentrated under vacuum. The crude material 
was purified by column chromatography (2:1 EtOAc/hexanes) to yield 1.53g (87%) of the DMT 
intermediate. 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.41 (m, 2H), 7.32 (dd, J = 2.7, 9.0 Hz, 6H), 
7.24 (m, 4H) 6.84 (d, J = 9.0 Hz, 4H), 6.30 (dd, J = 5.7, 7.7 Hz, 1H), 4.53 (dt, J = 2.7, 5.7 Hz, 1H), 
4.07 (q, J = 3.3 Hz, 1H), 3.79 (s, 6H), 3.42 (dd, J = 3.3, 10.7 Hz, 1H), 3.36 (dd, J = 3.3, 10.7 Hz, 1H), 
2.47 (ddd, J = 2.7, 5.7, 13.6 Hz, 1H), 2.28 (ddd, J = 5.7, 7.7, 13.6 Hz, 1H). 
The DMT intermediate (415 mg, 0.633 mmol) was azeotropically dried 
with pyridine (2 x 3 mL), while DMF was freshly distilled from CaH2. 
Imidazole (123 mg, 1.8 mmol, 2.8 eq) was added to the flask with 
starting material and the flask was resealed and flushed with Argon. 
Reagents were dissolved in DMF (4.2 mL, 150 mM). TBDMSCl (114.1 
mg, 0.76 mmol, 1.2 eq) was added and the mixture was heated to 55 oC with a water condenser. After 
21 h, TLC (5% MeOH in DCM, Rf = 0.9, UV active and stained orange then blue with PAA) confirmed 
reaction completion. The reaction was cooled, diluted with EtOAc (10 mL), and washed with brine (2 
x 10 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL), and the combined organic layers 
were dried over Na2SO4 and concentrated under vacuum. The crude residue was purified by column 
chromatography (1:1 hexanes/EtOAc) to yield 386 mg (80%) of 13. 1H NMR (400 MHz, CDCl3) δ 
9.11 (s, 1H), 8.19 (s, 1H), 7.40 (m, 2H), 7.36 – 7.29 (m, 5H), 7.20 (m, 2H), 6.84 (m, 4H), 6.27 (dd, J 
= 5.8, 7.6 Hz, 1H), 4.48 – 4.33 (m, 1H), 3.99 (q, J = 2.9 Hz, 1H), 3.78 (d, J = 0.5 Hz, 6H), 3.40 (dd, J 
= 2.9, 10.8 Hz, 1H), 3.27 (d, J = 10.8 Hz, 1H), 2.37 (ddd, J = 2.7, 5.8, 13.3 Hz, 1H), 2.18 (ddd, J = 5.8, 




Preparation of 14188 
Compound 13 (346 mg, 0.5 mmol) and Pd(PPh3)Cl2 (32.2 mg, 0.05 
mmol, 0.1 eq) were flushed with Argon. Tributyl vinyl tin (0.17 mL, 
184.6 mg, 0.6 mmol, 1.3 eq) was added. DMF was freshly distilled from 
CaH2 and sparged with Ar for 45 minutes. DMF (0.87 mL, 150 mM) was 
added to the reaction mixture and the flask was heated at reflux for 2 h. 
When TLC (5:1 Hex/EtOAc, Rf = 0.5, product was UV active and stained orange then pink then blue 
with PAA) confirmed reaction was complete, the reaction was cooled and diluted with EtOAc (3 mL), 
washed with sat. bicarbonate solution (2 x 3 mL), H2O (1 x 3 mL), and brine (1 x 3 mL). The aqueous 
layer was extracted with EtOAc (1x 10 mL) and the combined organic layers were washed with brine, 
dried over Na2SO4, and concentrated under vacuum. The crude material was purified by column 
chromatography (5:1 Hex/EtOAc) to yield 208 mg 14 (70%). 1H NMR (400 MHz, CDCl3) δ 9.18 (s, 
1H), 7.71 (s, 1H), 7.35 (m, 2H), 7.29 (s, 4H), 7.20 (m, 3H), 6.86 – 6.69 (m, 4H), 6.30 (d, J = 6.7 Hz, 
1H), 5.78 (m, 2H), 4.90 (m, 1H), 4.45 (dt, J = 3.3, 6.7 Hz, 1H), 3.95 (d, J = 3.3 Hz, 1H), 3.75 (s, 6H), 
3.43 (dd, J = 3.2, 10.7 Hz, 1H), 3.25 (dd, J = 3.2, 10.7 Hz, 1H), 2.33 (ddd, J = 3.3, 6.6, 13.3 Hz, 1H), 
2.16 (dt, J = 6.6, 13.3 Hz, 1H), 0.80 (s, 9H), -0.04 (s, 3H), 0.00 (s, 3H). 
Preparation of 15 
Compound 14 (197 mg, 0.294 mmol) and N-methylmorpholine N-oxide 
(69.6 mg, 0.6 mmol, 2 eq) were dissolved in acetone/H2O/tBuOH (4:1:1) 
mixture (2 mL, 150 mM). When the reactants were dissolved, 4% OsO4 
in water (50 L) was added and the mixture was stirred open to air at 25 
oC for 2 h. When TLC (5% MeOH in DCM, Rf = 0.5, UV active and 
stained orange then blue with PAA) showed complete conversion, NaIO4 (86.8 mg, 0.353 mmol, 1.2 
eq) was added and the reaction stirred for one hour until complete. The reaction was diluted with 
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EtOAc (4 mL) and H2O (2 mL). The aqueous layer was extracted with EtOAc (3 x 5 mL). The 
combined organic layers were washed with brine (1 x 15 mL), dried over Na2SO4, and concentrated 
under vacuum. The crude material was purified by column chromatography (5:1 -> 3:1 Hex/EtOAc) 
to yield 134 mg of 15 (68%). 1H NMR (400 MHz, CDCl3) δ 9.71 (s, 1H), 8.49 (s, 1H), 7.34 (d, J = 7.1 
Hz, 2H), 7.31 – 7.06 (m, 6H), 7.16 (m, 1H), 6.80 (d, J = 7.1 Hz, 4H), 6.14 (m, 1H), 4.27 (m, 1H), 4.04 
(q, J = 3.8 Hz, 1H), 3.74 (s, 6H), 3.36 (dd, J = 3.8, 10.8 Hz, 1H), 3.29 (dd, J = 3.8, 10.8 Hz, 1H), 2.45 
(m, 1H), 2.26 – 2.06 (m, 1H), 0.80 (s, 9H), -0.05 (s, 3H), -0.02 (s, 3H). 
Preparation of 16 
Aqueous trichloroacetic acid (TCA) solution (0.6 M) was prepared by 
dissolving TCA crystals (96.7 mg, 0.59 mmol) in distilled H2O (1 mL). 
Compound 15 (207 mg, 0.31 mmol) was dissolved in DCM (0.91 mL). The 
TCA solution (0.6 M, 0.63 mL) was added to the reaction flask (TCA (242 
mM) and 15 (200 mM)). After 20 min, TLC (5% MeOH in DCM, Rf = 0.3, 
UV active and stained blue with PAA) showed complete conversion. MeOH was avoided in all steps 
containing the aldehyde to avoid forming the acetal. When complete, the reaction was quenched with 
sat. bicarbonate solution until neutral pH, diluted with DCM (2 mL), and washed with bicarbonate 
solution (1 x 3mL). The aqueous layer was extracted with DCM (4 x 4 mL) and the combined organic 
layers were washed with brine (1x 15 mL), dried over Na2SO4, and concentrated under vacuum. 
Column chromatography (2:1 -> 1:1 Hex/EtOAC) yielded 102 mg (91%) of 16. 1H NMR (400 MHz, 
CDCl3) δ 9.91 (s, 1H), 9.88 (s, 1H), 8.87 (s, 1H), 6.19 (t, J = 6.2 Hz, 1H), 4.48 (dt, J = 4.2, 6.2 Hz, 
1H), 4.00 – 3.90 (m, 2H), 3.78 (s, 1H), 2.37 (ddd, J = 4.2, 6.3, 13.5 Hz, 1H), 2.25 (dt, J = 6.3, 13.5 Hz, 
1H), 0.85 (s, 9H), 0.05 (s, 6H). 
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Preparation of 17  
Compounds 10 (92.1 mg, 0.2 mmol, 1 eq) and 16 (87 mg, 0.23 
mmol, 1.2 eq) were azeotropically dried together with toluene 
(2 x 2 mL). S-Ethyl tetrazole/ACN (250 mM, 0.96 mL, 0.23 
mmol, 1.2 eq) was added to the flask. After 3 h of stirring at 
25 oC, TLC (2.5:1 EtOAc/Hex, Rf = 0.46 UV active and 
stained with PAA) indicates that the majority of 16 was 
consumed. tBuOOH (500 mM, 1.17 mL, 0.6 mmol, 3 eq) was 
added to the flask for 15-20 min. The contents of the flask were concentrated under vacuum and 
purified by column chromatography (6:1 DCM/EtOAc) to yield 97.1 mg (66%) of 17. 1H NMR (400 
MHz, CDCl3) δ 9.90 (s, 1H), 8.35 (m, 1H), 6.16 (dt, J = 2.9, 6.6 Hz, 1H), 6.01 (m, 1H), 5.87 – 5.67 
(m, 3H), 5.16 – 4.80 (m, 6H), 4.76 (m, 1H), 4.40 (m, 1H), 4.28 (m, 4H), 3.64 (td, J = 2.9, 6.6 Hz, 2H), 
3.50 (m, 1H), 3.34 (m, 1H), 2.76 (m, 2H), 2.36 (m, 1H), 2.14 (m, 1H), 2.04 (m, 4H), 2.00 – 1.73 (m, 
1H), 1.60 (m, 5H), 0.84 (s, 9H), 0.04 (s, 6H).  
13C NMR (400 MHz, CDCl3) δ 186.1, 106.1, 104.1, 88.3, 86.7, 85.9, 67.9, 41.6, 30.24. 30.20, 30.15, 
28.94, 28.86, 28.8, 25.7, 25.64, 25.60. 25.58, -4.7, -4.9. 
31P NMR (400 MHz, CDCl3) δ -1.8.  
IR: 3184, 3076, 2931, 2858, 2254, 1701, 1601, 1471, 1375, 1275.  




Preparation of 18 
Compound 17 (88.8 mg, 0.12 mmol) was dissolved in THF (1.2 
mL, 100 mM). TEA•3HF (590 L, 0.6 mmol, 5eq) was added to 
the flask and the reaction was stirred overnight. After confirmed 
complete by TLC (5% MeOH in DCM, Rf = 0.3, UV active and 
stained with PAA), the reaction was diluted with DCM (1 mL) 
and washed with H2O (1 x 2 mL), bicarb (1 x 2 mL), and brine 
(1 x 2 mL). The combined organic layers were dried over Na2SO4 
and concentrated under vacuum. Column chromatography (3% MeOH in DCM) provided 60.5 mg 
(81%) of the intermediate. 1H NMR (400 MHz, CDCl3) δ 9.87 (s, 1H), 8.37 (m, 1H), 6.18 (dt, J = 3.5, 
6.3 Hz, 1H), 5.78 (m, 2H), 5.58 (m, 1H), 5.19 – 4.80 (m, 6H), 4.49 (s, 1H), 4.34 (m, 5H), 4.16 (dd, J 
= 3.5, 6.3 Hz, 2H), 4.00 (m, 1H), 3.76 – 3.60 (m, 2H), 3.55 (dd, J = 2.5, 6.3 Hz, 1H), 3.36 (m, 1H), 
2.80 (t, J = 3.6 Hz, 2H), 2.50 (m, 1H), 2.23 (m, 2H), 2.07 (dd, J = 2.5, 3.6 Hz, 4H), 1.82 – 1.49 (m, 
4H), 1.20 (m, 1H).  
13C NMR (400 MHz, CDCl3) δ 149.4, 138.12, 138.08, 138.07, 137.97, 137.9, 114.7, 114.6, 111.2, 
105.2, 67.3, 67.1, 30.2, 30.10, 30.08, 30.0, 28.8, 28.7, 19.7, 19.6.  
31P NMR (400 MHz, CDCl3) δ -1.60, -1.61, -1.62, -1.64, -1.70, -1.74, -1.78, -1.80, -1.82, -1.85, -1.90, 
-1.94.  
IR: 3410, 3075, 2939, 2255, 1693, 1601, 1471, 1274, 1027.  
ESI-TOF m/z calculated for C28H40N3O12P (M + Na) − 664.2247, 664.2228 observed). 
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The intermediate (141.1 mg, 0.22 mmol) was dissolved in freshly 
distilled DMF (550 L) and DIPEA (550 L, 50% final 
solution). The reaction flask was heated to 50 oC for 25 h until 
complete as seen by TLC (20% MeOH in DCM, Rf = 0.3, UV 
active and stained with PAA). The reaction was cooled and 
concentrated under vacuum. Column chromatography (15% 
MeOH in DCM) provided 64.6 mg (50%) of 18. 1H NMR (400 
MHz, CD3OD) δ 9.70 (m, 1H), 8.65 (m, 1H), 6.16 (dd, J = 4.6, 7.8 Hz, 1H), 5.74 (m, 2H), 5.53 (m, 
1H), 5.15 – 4.81 (m, 6H), 4.40 (m, 2H), 4.03 (m, 2H), 3.97 (m, 1H), 3.81 (m, 1H), 3.61 (m, 2H), 3.50 
(m, 2H), 3.28 (m, 2H), 3.23 (m, 1H), 2.35 (m, 1H), 2.19 (m, 1H), 2.02 (t, J = 7.8 Hz, 4H), 1.67 – 1.46 
(m, 4H).  
13C NMR (400 mHz, CD3OD) δ 143.5, 97.1, 91.1, 83.7, 72.0, 59.8, 59.7, 58.6, 58.5, 54.8, 41.4. 
31P NMR (400 MHz, CD3OD) δ -0.1. 
IR: 3266, 2940, 2361, 2340, 1701, 1472, 1228, 1094, 1057.  
ESI-TOF m/z calculated for C25H36N2O12P- (M + H + Na) − 611.1987, 611.1959 observed). 
Preparation of 19 
Compounds 12 (140 mg, 0.55 mmol, 1.2 eq) and 16 (242 mg, 
0.42 mmol, 1 eq) were azeotropically dried together with 
degassed toluene (2 x 2 mL). S-Ethyl tetrazole/MeCN (250 
mM, 2.2 mL, 0.55 mmol, 1.2 eq) was added to the flask. After 
3.5 h of stirring at 25 oC, TLC (2.5:1 EtOAc/Hex, Rf = 0.6, 
UV active and stained with PAA) indicated the consumption 
of 16. tBuOOH (500 mM, 0.3 mL, 1.26 mmol, 3 eq) was 
added for 15-20 min. The contents of the flask were concentrated under vacuum and column 
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chromatography (2:1 EtOAc/Hex -> 3:1 EtOAc/Hex) provided 151 mg (50%) of 19. 1H NMR (400 
MHz, CDCl3) δ 9.91 (s, 1H), 8.36 (s, 1H), 6.33 (s, 1H), 6.17 (s, 1H), 4.41 (s, 1H), 4.29 (m, 6H), 
4.07 (m, 4H), 2.77 (s, 3H), 2.40 (s, 1H), 2.14 (m, 1H), 2.02 (s, 3H), 1.99 (s, 3H), 1.83 (s, 1H), 1.20 
(s, 9H), 0.04 (s, 6H). 
13C NMR (400 MHz, CDCl3) δ 196.2, 171.2, 169.9, 150.9, 149.2, 136.5, 98.4, 96.0, 86.7, 85.8, 
77.4, 77.1, 76.9, 62.7, 60.4, 56.0, 41.5, 39.2, 34.6, 32.6, 31.5, 29.6, 29.0, 25.6, 25.2, 22.6, 21.1, 
20.1, 19.7, 17.8, 14.5, 14.1, 12.3, 11.4, -4.7, -4.9. 
31P NMR (400 MHz, CDCl3) δ 8.91, 8.6, -1.6, -1.7, -1.9, -2.0. 
Preparation of 20 
Compound 19 (130 mg, 0.185 mmol) was dissolved in THF 
(1.85 mL, 100 mM). TEA•3HF (150 μL, 0.925 mmol, 5 eq) 
was added and reaction stirred overnight. After confirmed 
complete by TLC (5% MeOH in DCM, Rf = 0.25, UV active 
and stained with PAA), the reaction was diluted with DCM (2 
mL) and washed with H2O (1 x 3 mL), sat. sodium bicarbonate 
(1 x 3 mL), and brine (1 x 3 mL). The combined organic layers 
were dried over Na2SO4 and concentrated under vacuum. Column chromatography (3% MeOH in 
DCM) yielded 109 mg (100%) of the desilylated intermediate. 1H NMR (400 MHz, CD3CN) δ 
9.80 (s, 1H), 8.48 (s, 1H), 6.33 (s, 1H), 6.29 (s, 2H), 4.56 (s, 1H), 4.39 (s, 4H), 4.30 (m, 3H), 4.11 
(d, J = 2.8, 2H), 4.02 (s, 2H), 2.77 (dd, J = 1.8, 2.8 Hz, 2H), 2.47 (d, J = 1.8 Hz, 1H), 2.31 (d, J = 
5.2 Hz, 1H), 2.17 (d, J = 5.2 Hz, 1H), 2.05 – 1.90 (m, 6H). 
13C NMR (400 MHz, CD3CN) δ 205.6, 186.1, 170.5, 170.1, 166.4, 161.5, 149.5, 146.2, 111.3, 
105.0, 98.4, 86.8, 59.7, 54.2, 46.2, 40.4, 29.6, 29.4, 29.2, 29.0, 28.8, 28.7, 28.5, 20.4, 20.3, 20.0, 
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19.2, 13.6, 8.0. 
31P NMR (400 MHz, CD3CN) δ -1.72, -1.74. 
The intermediate (109 mg, 0.185 mmol) was dissolved in 
DMF (460 μL) and DIPEA (460 μL, 50% final solution). The 
reaction was heated to 50 oC for 25 h until complete as seen 
by TLC (20% MeOH in DCM, Rf = 0.15, UV active and 
stained with PAA). The reaction was cooled and concentrated 
under vacuum. Column chromatography (15% MeOH in 
DCM) provided 92 mg of 20 (94%). 1H NMR (400 MHz, 
CD3CN) δ 9.76 (s, 1H), 8.55 (s, 1H), 6.22 (dd, J = 5.0, 6.2 Hz, 1H), 6.16 (d, J = 5.0, Hz, 1H), 6.08 
(t, J = 6.2 Hz, 1H), 4.37 (s, 2H), 4.01 (m, 2H), 3.95 – 3.85 (m, 2H), 3.57 (m, 2H), 2.71 (m, 1H), 
2.44 (m, 1H), 2.34 (m, 1H), 2.21 (m, 1H), 1.98 (s, 6H). 
13C NMR (400 MHz, CD3CN) δ 187.7, 171.7, 171.0, 170.9, 150.5, 118.3, 112.3, 99.4, 97.4, 87.5, 
71.2, 65.4, 60.9, 55.2, 54.3, 49.8, 47.4, 42.7, 30.8, 21.3, 21.0, 19.2, 18.0, 14.4, 12.8, 1.8, 1.6, 1.40, 
1.38, 1.36, 1.19, 1.17, 1.1, 1.0, 0.8, 0.7, 0.5. 
31P NMR (400 MHz, CD3CN) δ -2.3. 
Preparation of 21 
Compound 13 (1.23 g, 1.5 mmol) and Pd(CH3CN)Cl2 (45.4 mg, 0.002 
mmol, 0.1 eq) were added to a pressure flask, sealed with a septum, 
and dried under vacuum for 15 min. Under Argon, triethylamine (0.8 
mL, 5.4 mmol, 3.6 eq) and freshly distilled MeOH (9 mL, 150 mM) 
were added to the flask. The pressure vessel was purged with CO 
three times and held at 24 psi. The mixture turned black while purging with CO. The vessel was 
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heated at 50 oC for 3 h until the reaction was complete by TLC (10% MeOH in DCM, Rf = 0.5, 
UV active and stained by PAA). The crude mixture was passed through a Celite column and 
concentrated under vacuum. The crude mixture was purified by column chromatography (2:1 
Hex/EtOAc -> 1:1 Hex/EtOAc) to yield 811mg of 21 (77%). 1H NMR (400 MHz, CDCl3) δ 8.77 
(s, 1H), 8.01 (s, 1H), 7.42 (d, J = 7.2 Hz, 2H), 7.32 (dd, J = 6.4, 8.9 Hz, 5H), 7.22 (m, 2H), 6.82 
(dd, J = 3.3, 8.9 Hz, 4H), 6.23 (d, J = 6.0 Hz, 1H), 4.31 (td, J = 3.3, 6.4 Hz, 1H), 3.99 (d, J = 3.2 
Hz, 1H), 3.79 (d, J = 0.5 Hz, 6H), 3.55 (dd, J = 3.2, 10.9 Hz, 1H), 3.21 (s, 3H), 2.41 (ddd, J = 3.3, 
6.0, 10.9 Hz, 1H), 2.20 (m, 1H), 1.55 (s, 3H), 0.80 (s, 9H), -0.07 (s, 3H), 0.00 (s, 3H). 
Preparation of 22 
Compound 21 (811 mg, 1.15 mmol) dissolved in DCM (4.37 mL). A 1 
mM stock solution of TCA was prepared by dissolving TCA crystals (462 
mg, 2.83 mmol) in H2O (2.83 mL). The TCA solution (1 M, 1.38 mL) 
was slowly added, and the reaction turned bright orange. The reaction 
was monitored by TLC (5% MeOH in DCM, Rf = 0.4, UV active and 
stained blue with PAA) until the bis-deprotected product began to form after 1 h. The reaction was 
quenched with sodium bicarbonate solution, diluted with DCM (10 mL), washed with bicarbonate 
solution (1 x 8 mL), and H2O (1 x 8 mL). The aqueous layer was extracted with DCM (3 x 10 mL) 
and the combined organic layers were washed with brine (1 x 30 mL), dried over Na2SO4, and 
concentrated under vacuum. Column chromatography (1.5% MeOH in DCM) was used to purify 
the crude mixture and resulted in 352 mg (76 %) of 22. 1H NMR (400 MHz, CDCl3) δ 8.90 (s, 
1H), 7.97 (s, 1H), 6.19 (t, J = 6.4 Hz, 1H), 4.52 (td, J = 3.8, 7.7 Hz, 1H), 4.02 (d, J = 6.4 Hz, 1H), 
3.98 (d, J = 3.8 Hz, 1H), 3.88 (s, 3H), 3.82 (d, J = 7.7 Hz, 1H), 2.35 (m, 2H), 0.90 (s, 9H), 0.09 (d, 
J = 0.5 Hz, 6H). 
195 
 
Preparation of 23 
Compound 22 (352 mg, 0.875 mmol) was azeotropically dried 
with pyridine (2 x 2 mL). The flask was cooled to 0 oC. DIPEA 
(452 mg, 0.64 mL, 3.5 mmol, 4 eq) and DCM (4 mL, 200 mM) 
were added to dissolve reagent. 2-Cyanoethyl-N,N-
diisopropylchlorophosphoramidite (248 mg, 0.234 mL, 1.05 
mmol. 1.2 eq) was added and the cold mixture stirred with 
periodic monitoring by TLC (2:1 Hex/EtOAc, Rf = 0.3, stained with PAA). After 2 h, TLC showed 
complete conversion to the phosphoramidite. The reaction was diluted with freshly distilled EtOAc 
(10 mL). The organic layer was washed with saturated bicarbonate solution (2 x15 mL) and the 
aqueous layers were extracted with distilled EtOAc (2 x 20 mL). The combined organic layers 
were washed with brine (1 x 25 mL) and dried over Na2SO4. The organic layer was concentrated 
under vacuum and purified by column chromatography (1:1 distilled hexanes/distilled EtOAc), 
yielding 420 mg (82%) of 23. 1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 18.0 Hz, 1H), 6.15 (t, J 
= 6.6 Hz, 1H), 4.80 (s, 1H), 4.50 (m, 1H), 4.16 (d, J = 2.0 Hz, 1H), 3.88 (m, 3H), 3.82 (t, J = 5.9 
Hz, 3H), 3.64 (m, 2H), 2.73 (dt, J = 2.0, 5.9 Hz, 2H), 2.39 (m, 1H), 2.30 (dd, J = 6.6, 13.3 Hz, 1H), 
2.20 (dd, J = 6.6, 13.3 Hz, 1H), 1.30 – 1.21 (m, 12H), 0.93 (s, 9H), 0.13 (s, 6H). 








Preparation of 24 
Compounds 9 (234 mg, 0.86 mmol, 1.2 eq) and 23 
(420 mg, 0.72 mmol, 1 eq) were azeotropically dried 
together with toluene (2 x 2 mL). S-Ethyl 
tetrazole/MeCN (250 mM, 3.44 mL, 0.86 mmol, 1.2 
eq) was added to the flask. After 4 h of stirring at 25 
oC, TLC (2:1 EtOAc/Hex, Rf = 0.35, UV active and 
stained with PAA) indicated consumption of 9. 
tBuOOH (5 M, 0.4 mL, 2.16 mmol, 3 eq) was added for 15-20 min. The contents were concentrated 
under vacuum and column chromatography (2:1 EtOAc/Hex) yielded 460 mg of 24 (70%). 1H 
NMR (300 MHz, CD3OD) δ 8.54 (s, 1H), 6.19 (d, J = 6.6 Hz, 1H), 5.80 (m, 2H), 5.00 – 4.90 (m, 
6H), 4.62 (s, 2H), 4.56 (d, J = 13.4 Hz, 1H), 4.34 (m, 4H), 4.13 (m, 2H), 3.82 (s, 3H), 3.68 (m, 
2H), 3.40 (m, 2H), 2.90 (m, 2H), 2.37 (m, 2H), 2.19 – 2.05 (m, 4H), 1.91 (m, 1H), 1.64 (dd, J = 
6.6, 13.4 Hz, 4H), 0.93 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H). 
13C NMR (400 MHz, CD3OD) δ 172.1, 150.4, 138.9, 115.0, 105.1, 66.3, 60.9, 52.2, 49.3, 49.1, 
48.89, 48.88, 48.87, 48.68, 48.67, 48.66, 48.5, 48.4, 48.2, 48.0, 32.2, 31.0, 30.9, 29.6, 25.9, 23.2, 
20.6, 19.8, 18.3, 15.2, 14.20, 14.16, -4.8, -5.0. 








Preparation of 25 
Compound 24 (400.8 mg, 0.5 mmol) was dissolved in 
THF (5 mL, 100 mM). TEA•3HF (400 μL, 2.5 mmol, 
5 eq) was added. After confirmed complete by TLC 
(10% MeOH in DCM, Rf = 0.4, UV active and stained 
with PAA), the reaction was diluted with DCM (5 mL) 
and washed with H2O (1 x 5 mL), sat. sodium 
bicarbonate (1 x 5 mL), and brine (1 x 5 mL). The 
combined organic layers dried over Na2SO4 and concentrated under vacuum. Column 
chromatography (5% MeOH in DCM) yielded 297.4 mg of the desilylated intermediate (87%). 1H 
NMR (400 MHz, CD3OD) δ 8.52 (s, 1H), 6.16 (t, J = 6.1 Hz, 1H), 5.87 – 5.71 (m, 2H), 5.25 – 4.84 
(m, 6H), 4.68 (s, 3H), 4.40 (t, J = 2.8 Hz, 1H), 4.28 (dd, J = 2.8, 6.1 Hz, 4H), 4.12 (s, 2H), 3.78 (s, 
3H), 3.63 (m, 2H), 3.33 (m, 2H), 2.86 (m, 2H), 2.41 (m, 1H), 2.24 (m, 1H), 2.05 (m, 4H), 1.81 (m, 
1H), 1.60 (m, 4H). 
13C NMR (400 MHz, CD3OD) δ 140.0, 138.9, 117.3, 114.9, 114.8, 105.8, 105.1, 82.4, 68.2, 
57.9, 54.4, 54.0, 52.2, 50.3, 49.5, 49.4, 49.3, 49.2, 49.1, 48.9, 48.7, 48.4, 48.2, 48.1, 48.0, 42.9, 
30.9, 30.8, 30.7, 29.5, 28.5, 19.8. 




The desilylated intermediate (50 mg, 0.075 mmol) was 
dissolved in DMF (187.5 μL) and DIPEA (187.5 μL, 
50% final solution). The reaction flask was heated at 
50 oC for 25 h until complete as seen by TLC (15% 
MeOH in DCM, Rf = 0.1, UV active and stained with 
PAA). The reaction was cooled and concentrated under 
vacuum. Column chromatography (15% MeOH in 
DCM) provided 41.2 mg of 25 (89%). 1H NMR (400 MHz, CD3OD) δ 8.56 (s, 1H), 6.04 (s, 1H), 
5.80 (m, 2H), 5.10 – 4.85 (m, 6H), 4.39 (s, 1H), 4.01 (s, 3H), 3.74 (s, 3H), 3.55 (m, 4H), 3.34 (m, 
2H), 2.99 (s, 1H), 2.29 (m, 2H), 2.20 (s, 1H), 2.05 (s, 4H), 1.84 (s, 1H), 1.58 (s, 4H). 
Preparation of 26 
Compound 25 (27.6 mg, 44.7 mmol) and K2CO3 (9.6 mg, 
67.1 mmol, 1.5 eq) were dissolved in a 1:1 mixture of 
MeOH/H2O (300 μL, 150 mM). The reaction stirred for 
20 h until complete by TLC (15% MeOH in DCM, 1% 
TEA, Rf = 0.35, UV active and stained by PAA). The 
crude mixture passed through a DOWEX Na+ ion 
exchange column to yield 23 mg of 26 (86%). 1H NMR 
(400 MHz, DMSO-d6) δ 8.39 (s, 1H), 6.02 (t, J = 6.5 Hz, 1H), 5.79 (m, 2H), 5.49 (s, 1H), 5.01 – 
4.91 (m, 6H), 4.20 (s, 1H), 3.95 (s, 1H), 3.78 (m, 3H), 3.56 (m, 4H), 3.32 (m, 2H), 2.20 (m, 2H), 





Preparation of 27156 
Deoxyuridine (2.44g, 10.7 mmol) was dissolved in H2O (15.4 mL). 
Formaldehyde (5.8 mL, 0.18 mol, 16.7 eq) and KOH (1.15 g, 21.4 mmol, 
2 eq) were added to the reaction mixture. The reaction was heated at 65 
oC and stirred for six days. Over four days, aliquots of KOH solution (4 
x 1.15 g, 20 mmol, 2 eq) in H2O (4 x 5 mL) were added to the reaction to 
maintain pH 11. Within two days, the reaction turned from colorless to dark brown. After a final 
6 days, TLC (20% MeOH in DCM, Rf = 0.35, UV active and stained by PAA) confirmed the 
conversion of starting material. The reaction was neutralized with DOWEX (500 x 8) H+ resin. 
The resin was filtered, washed with H2O, and the filtrate was concentrated. The crude material was 
dry loaded onto a silica gel column. Chromatography (10% MeOH, 5% MeCN in DCM) yielded 
448 mg (16%) of 27. 1H NMR (400 MHz, CD3OD) δ 7.91 (s, 1H), 6.24 (t, J = 6.6 Hz, 1H), 4.36 
(td, J = 3.4, 6.6 Hz, 1H), 4.27 (s, 2H), 3.88 (dd, J = 3.4, 6.6 Hz, 1H), 3.74 (dd, J = 4.0, 12.0 Hz, 
1H), 3.68 (dd, J = 4.0, 12.0 Hz, 1H), 2.22 (m, 2H). 
Preparation of 28156 
Compound 27 (130 mg, 0.51 mmol) was azeotropically dried with 
pyridine (2 x 2 mL). The starting material liquified once taken off vacuum 
and stored under Argon. The starting material was dissolved in freshly 
distilled dioxane (3.4 mL, 150 mM) and TMSCl (0.325 mL, 2.55 mmol, 
5 eq) was added. The reaction was heated at 50 oC with a water condenser 
and stirred for 2 h. After 2.5 h, the starting material appeared consumed by TLC (15% MeOH, 5% 
MeCN in DCM, Rf = 0.45, UV active and stained with PAA) so the reaction mixture was 
concentrated. The resulting crude was redissolved in DMF (1.4 mL, 350 mM) and NaN3 (112 mg, 
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1.53 mmol, 3 eq) was added. After 1 h, TLC (5% MeOH in DCM, Rf = 0.35, UV active and stained 
with PAA) confirmed conversion. The reaction was concentrated and purified by column 
chromatography (5% MeOH in DCM) to yield 53 mg (37%) of 28. 1H NMR (400 MHz, CD3OD) 
δ 8.09 (s, 1H), 6.21 (t, J = 6.6 Hz, 1H), 4.36 (td, J = 3.4, 6.6 Hz, 1H), 4.08 (s, 2H), 3.89 (dd, J = 
3.4, 6.6 Hz, 1H), 3.76 (dd, J = 3.6, 12.1 Hz, 1H), 3.69 (dd, J = 3.6, 12.1 Hz, 1H), 2.30 (m, 1H), 
2.21 (m, 1H). 
Preparation of 29189 
Compound 31 (38.1 mg, 0.074 mmol, 1 eq, 100 mM) was dissolved in THF 
(0.8 mL) and cooled to 0 oC. Aqueous TCA (102 mg, 0.625 mmol, 8.5 eq) 
was prepared in distilled H2O (0.5 mL) and added to the reaction. After 2.5 
h, TLC (2:1 Hex/EtOAc, Rf = 0.3, UV active and stained with PAA) showed 
conversion to the mono-protected nucleoside and a small amount of the fully 
deprotected nucleoside. The reaction was quenched with NaHCO3 solid followed by sat. NaHCO3 
solution until the pH reached 8. The mixture was diluted with DCM (10 mL) and washed with brine 
(2 x 10 mL). The aqueous layer was extracted with DCM (2 x 15 mL), the combined organic layers 
were dried over Na2SO4 and concentrated under vacuum. The residue was purified by column 
chromatography (3% MeOH in DCM) resulting in 13.6 mg (46%) of a clear oil (29). 1H NMR (400 
MHz, CDCl3) δ 7.81 (s, 1H), 6.17 (m, 1H), 4.50 (m, 1H), 4.11 (m, 2H), 3.99 (m, 2H), 3.78 (dd, J = 








Preparation of 30190 
Thymidine (506 mg, 2.1 mmol, 1 eq) was azeotropically dried with 
pyridine (3 x 2 mL). Reagent was dissolved in distilled DMF (14 mL, 
150 mM). Imidazole (355 mg, 2.5 eq) and TBDMSCl (707 mg, 2.2 eq) 
were added to the mixture. The reaction was heated under Argon at 50 
oC overnight. When confirmed complete by TLC (5% MeOH in DCM, 
Rf = 0.6, UV active and stained with PAA), the reaction was cooled and diluted with EtOAc (20 mL). 
The organic layer was washed with sat. NH4Cl (3 x 20 mL) and brine (2 x 30 mL). The combined 
aqueous layers were extracted using EtOAc (2 x 50 mL). The combined organic layers were dried over 
Na2SO4 and concentrated under vacuum. The residue was purified by column chromatography (2:1 
hexanes/EtOAc) to yield 720 mg (80%) of 30. 1H NMR (400 MHz, CDCl3) δ 8.34 (s, 1H), 7.45 (d, J 
= 1.3 Hz, 1H), 6.31 (m, 1H), 4.38 (m, 1H), 3.91 (d, J = 1.3 Hz, 1H), 3.85 (dd, J = 2.6, 11.4 Hz, 1H), 
3.74 (dd, J = 2.6, 11.4 Hz, 1H), 2.23 (dd, J = 2.6, 14.0 Hz, 1H), 2.01 (m, 1H), 1.89 (s, 3H), 0.89 (d, J 
= 14.0 Hz, 18H), 0.11 (m, 12H). 
Preparation of 31189 
Compound 30 (155 mg, 0.33 mmol, 1 eq, 165 mM) was mixed with NBS 
(105.6 mg, 0.6 mmol, 1.8 eq) and AIBN (10.7 mg, 0.065 mmol, 0.18 eq). 
Distilled benzene (2 mL) was added to dissolve the reactants. The 
mixture was sparged with Ar for 20 minutes. The reaction was refluxed 
(80 oC) and stirred for 30-45 min, while the mixture turned orange-
yellow. When TLC (2:1 Hex/EtOAc, 2% MeOH, Rf = 0.4, UV active and stained with PAA), showed 
the starting material was mostly converted without the formation of side products, the mixture was 
immediately filtered through a glass frit and concentrated under vacuum to give a yellow crude residue. 
The residue was dissolved in DMF (1.5 mL, 200 mM) and stirred under Argon. NaN3 (44 mg, 0.677 
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mmol, 2 eq) was added to the solution, turning red in color. The reaction was heated to 60 oC and 
stirred for 1-2 h. When TLC (1:1 Hex/EtOAc, 2% MeOH, UV active and stained with PAA), showed 
the starting material was mostly converted without the formation of side products, the reaction was 
cooled and diluted with EtOAc (30 mL), washed with water (2 x 20 mL), and brine (2 x 20 mL). The 
aqueous layer was extracted with EtOAc (2 x 40 mL), and the combined organic layers were dried over 
Na2SO4 and concentrated under vacuum to give a red crude residue. The residue was purified by 
column chromatography (7:1 DCM/EtOAc) to give 65.9 mg (39.2%) of 31. 1H NMR (400 MHz, 
CDCl3) δ 7.71 (s, 1H), 7.46 (d, J = 2.3 Hz, 1H), 6.30 (dd, J = 5.8, 13.6 Hz, 1H), 4.39 (dd, J = 2.3, 3.5 
Hz, 1H), 4.21 – 4.01 (m, 1H), 3.95 (m, 2H), 3.86 (td, J = 3.5, 11.4 Hz, 1H), 3.76 (td, J = 2.3, 11.4 Hz, 
1H), 2.27 (ddd, J = 2.3, 5.8, 13.6 Hz, 1H), 2.03 – 1.95 (m, 1H), 0.96 – 0.84 (m, 18H), 0.24 – 0.02 (m, 
12H). 
Preparation of 32191 
Thymidine (3.08 g, 12.7 mmol, 1 eq) was azeotropically dried with 
pyridine (2 x 8 mL). DMAP (159 mg, 1.27 mmol, 0.2 eq) was added to 
a flask and flushed with Argon. The reagents were dissolved in distilled 
DCM (6.7 mL) and cooled to 0 oC. Pyridine (12.5 g, 12.8 mL, 158.8 
mmol, 12.5 eq) was added slowly to the solution. Next, acetic anhydride 
(3.82 g, 6 mL, 63.6 mmol, 5 eq) was added dropwise. After 3.5 h, TLC (3:2 EtOAc/Hex, Rf = 0.8, 
stained with PAA) confirmed the reaction complete, the reaction was quenched with sat. NaHCO3 
until neutral pH was reached. The mixture was diluted with EtOAc (15 mL) and washed with water 
(2 x 15 mL). The aqueous layer was extracted with EtOAc (2 x 30 mL) and the combined organic 
layers were washed with brine (1 x 50 mL) and dried over Na2SO4. The crude residue was purified 
by column chromatography (1:1 Hex/EtOAc) to yield 3.8 g (93%) of 32. 1H NMR (400 MHz, 
CDCl3) δ 10.10 (s, 1H), 7.21 (s, 1H), 6.24 (dd, J = 4.2, 8.4 Hz, 1H), 5.13 (d, J = 6.8 Hz, 1H), 4.28 
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(dd, J = 4.2, 12.1 Hz, 1H), 4.23 (dd, J = 3.3, 12.1 Hz, 1H), 4.15 (dd, J = 3.3, 6.8 Hz, 1H), 2.37 (dd, 
J = 6.0, 8.4 Hz, 1H), 2.13 (m, 1H), 2.03 (d, J = 6.0 Hz, 6H), 1.83 (s, 3H). 
Preparation of 33192 
Compound 32 (785.8 mg, 2.44 mmol, 1 eq) was mixed with NBS (693.9 
mg, 3.9 mmol, 1.8 eq) and AIBN (64 mg, 0.39 mmol, 0.18 eq). Distilled 
benzene (16 mL) dissolved the reactants. The mixture was sparged with 
Ar for 20 min. The reaction was heated to reflux (80 °C) and stirred for 
30-45 min while the mixture turned red. When TLC (2:1 EtOAc/Hex, 
Rf = 0.6, UV active and stained with PAA), showed the starting material was mostly consumed 
without the formation of side products, the mixture was immediately filtered through a glass frit 
and concentrated under vacuum to give a yellow crude residue. The residue was redissolved in 
DMF (12 mL, 200 mM). NaN3 (904 mg, 4.88 mmol, 2 eq) was added to the solution, which turned 
brown. The reaction was heated to 60 °C and stirred for 1-2 h. When TLC (2:1 EtOAc/Hex, Rf = 
0.2, UV active and stained with PAA), showed the disappearance of the intermediate, the reaction 
was cooled and diluted with EtOAc (30 mL), washed with water (2 x 40 mL), and brine (2 x 40 
mL). The aqueous layer was extracted with EtOAc (2 x 80 mL) and the combined organic layers 
were dried over Na2SO4 and concentrated under vacuum to give a red crude residue. The residue 
was purified by column chromatography in 1:1 Hex/EtOAc to give 628 mg (55%) of 33. 1H NMR 
(400 MHz, CDCl3) δ 7.57 (s, 1H), 6.29 (dd, J = 5.6, 8.5 Hz, 1H), 5.22 (dt, J = 1.9, 8.5 Hz, 1H), 
4.40 (dd, J = 4.2, 12.1 Hz, 1H), 4.31 (dd, J = 4.2, 12.1 Hz, 1H), 4.28 – 4.26 (m, 1H), 4.22 (dd, J = 
1.0, 14.4 Hz, 1H), 4.12 (dd, J = 1.0, 14.4 Hz, 1H), 2.52 (ddd, J = 1.9, 5.6, 14.4 Hz, 1H), 2.30 – 




Preparation of 34193 
Compound 33 (300 mg, 0.82 mmol) was dissolved in dioxane (12 mL, 
68 mM). Concentrated NH4OH (29% in water, 12 mL, 18 M) was added 
to the reaction ([33] = 34 mM, [NH4OH] = 9 M). The reaction was stirred 
for 18 h. Analysis by TLC (4:1 EtOAc/Hex, Rf = 0.05, UV active and 
stained with PAA) confirmed the absence of starting material. The 
reaction was concentrated and purified by column chromatography (4:1 EtOAc/Hex -> 100 % 
EtOAc, dry loaded) to yield 127 mg (50%) of 34. 1H NMR (400 MHz, CD3OD) δ 8.09 (s, 1H), 
6.21 (t, J = 6.6 Hz, 1H), 4.36 (td, J = 3.4, 6.6 Hz, 1H), 4.03 (s, 2H) 3.89 (dd, J = 3.4, 6.2 Hz, 1H), 
3.76 (dd, J = 3.4, 12.1 Hz, 1H), 3.69 (dd, J = 3.7, 12.1 Hz, 1H), 2.26 (dd, J = 3.7, 6.2 Hz, 1H), 2.19 
(m, 1H). 
Preparation of 35194 
Compound 34 (895.5 mg, 3.16 mmol) was azeotropically dried with 
pyridine (2 x 3 mL). DMT-Cl (1.32 g, 3.79 mmol, 1.2 eq) was added 
and reactants were dissolved in pyridine (6.4 mL, 500 mM) at 0 oC. 
The mixture turned orange and was monitored by TLC (5:1 
EtOAc/Hex, Rf = 0.3, UV active and stained orange then blue with 
PAA). After 2 h, a side product (presumably the bis-tritylated product) was observed via TLC. 
Therefore, the reaction was concentrated under vacuum. The residue was dissolved in EtOAc (30 
mL) and washed with sat. sodium bicarbonate (1 x 30 mL) and H2O (1 x 30 mL). The aqueous 
layer was extracted with EtOAc (2 x 30 mL) and the combined organic layers were washed with 
brine (1 x 50 mL), dried over Na2SO4, and concentrated under vacuum. The crude material was 
purified by column chromatography (5:1 EtOAc/hexanes) to yield 1.078 g (60%) of 35. 1H NMR 
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(400 MHz, CDCl3) δ 8.56 (s, 1H), 7.82 (s, 1H), 7.65 (m, 1H), 7.36 (m, 1H), 7.30 – 7.22 (m, 5H), 
6.80 (m, 4H), 6.37 (d, J = 5.8 Hz, 1H), 4.57 (t, J = 3.0 Hz, 1H), 4.06 (s, 2H), 3.76 (s, 6H), 3.52 (d, 
J = 13.7 Hz, 1H), 3.45 (d, J = 3.2 Hz, 1H), 3.40 – 3.34 (dd, J = 3.2, 13.7 Hz, 2H), 3.32 (d, J = 13.5 
Hz, 2H), 2.44 (ddd, J = 3.0, 5.8, 13.5 Hz, 1H), 2.34 – 2.24 (m, 1H). 
Preparation of 36194 
Compound 35 (452.2 mg, 0.77 mmol, 1 eq) was azeotropically dried 
with pyridine (3 x 1 mL). Distilled DMF (2.6 mL, 300 mM) dissolved 
35. Imidazole (330. mg, 4.64 mmol, 6 eq) and TBDMSCl (377 mg, 
2.32, 3 eq) were added to the mixture. The reaction was heated at 50° 
C and stirred overnight. When confirmed complete by TLC (2:1 
Hex/EtOAc, Rf = 0.25, UV active and stained with PAA), the reaction was cooled and diluted with 
EtOAc (20 mL). The organic layer was washed with sat. NH4Cl (3 x 20 mL) and brine (2 x 30 
mL). The combined aqueous layers were extracted using EtOAc (2 x 50 mL). The combined 
organic layers dried over Na2SO4 and concentrated under vacuum. The residue was purified by 
column chromatography (2:1 hexanes/EtOAc) yielding 289 mg (55%) of 36. 1H NMR (400 MHz, 
CDCl3) δ 7.92 (s, 1H), 7.35 (d, J = 8 Hz, 2H), 7.24 (dd, J = 3.7, 8 Hz, 7H), 6.78 (d, J = 8 Hz, 4H), 
6.27 (t, J = 6.2 Hz, 1H), 4.49 (td, J = 2.4, 3.7 Hz, 1H), 4.05 (d, J = 3.7 Hz, 1H), 3.75 (s, 6H), 3.56 
(d, J = 13.7 Hz, 1H), 3.52 (dd, J = 2.7, 10.7 Hz, 1H), 3.42 (d, J = 13.7 Hz, 1H), 3.33 (dd, J = 2.7, 
10.7 Hz, 1H), 2.39 (dd, J = 3.7, 6.2 Hz, 1H), 2.28 (dd, J = 6.2, 13.7 Hz, 1H), 0.85 (s, 9H), 0.07 (s, 






Preparation of 37 
Compound 32 (1.25 g, 3.8 mmol, 1 eq) was mixed with NBS (1.26 
g, 6.9 mmol, 1.8 eq) and AIBN (122 mg, 0.69 mmol, 0.18 eq). 
Distilled benzene (19 mL, 200 mM) dissolved the reactants. The 
mixture was sparged with Ar for 20 min. The reaction was heated 
to reflux (80 °C) and stirred for 30-45 min, during which the 
mixture turned red. At that time, TLC (4:1 EtOAc/Hex, Rf = 0.5, UV active and stained with PAA), 
showed the starting material was mostly converted without the formation of side products, the 
mixture was immediately filtered through a glass frit and concentrated under vacuum to give a 
yellow crude residue. The residue was redissolved in DMF (15 mL, 200 mM) and stirred under 
Argon. Potassium phthalimide (1.41 g, 7.6 mmol, 2 eq) was added to the solution, which turned 
brown in color. The reaction was heated at 60° C. After 2 h, TLC (4:1 EtOAc/Hex, Rf = 0.3, UV 
active and stained with PAA), showed the disappearance of the intermediate. The reaction was 
cooled, diluted with EtOAc (30 mL), and washed with water (2 x 40 mL) and brine (2 x 40 mL). 
The aqueous layer was extracted with EtOAc (2 x 70 mL), and the combined organic layers were 
dried over Na2SO4 and concentrated under vacuum to give a red crude residue. The residue was 
purified by column chromatography (4:1 EtOAc/Hex) to give 523 mg (30%) of 37. 1H NMR (400 
MHz, CDCl3) δ 7.98 (s, 1H), 7.85 – 7.61 (m, 5H), 6.24 (dd, J = 5.9, 8.6 Hz, 1H), 5.20 (d, J = 5.9 
Hz, 1H), 4.57 (m, 2H), 4.41 – 4.28 (m, 1H), 4.28 – 4.15 (m, 2H), 2.52 – 2.40 (m, 1H), 2.24 – 2.12 






Preparation of 38 
Compound 37 (430 mg, 0.91 mmol) was dissolved in MeOH (3.67 
mL) and triethylamine (648 mg, 0.89 mL, 6.4 mmol, 7 eq). The 
reaction was stirred at 25 oC for 26 h until complete by TLC (4:1 
EtOAc/Hex, Rf = 0.1, UV active and stained with PAA). The 
crude material was purified by column chromatography (4:1 
EtOAc/Hex -> 100% EtOAc) to give 152 mg (45%) of 38. 1H NMR (400 MHz, CD3OD) δ 8.00 
(s, 1H), 7.83 (dd, J = 3.0, 5.6 Hz, 2H), 7.72 (dd, J = 3.0, 5.6 Hz, 2H), 6.24 (t, J = 6.4 Hz, 1H), 4.55 
(m, 2H), 4.00 (s, 1H), 3.96 (s, 1H), 3.78 (s, 1H), 3.64 (1H), 2.38 (s, 1H), 2.31 (d, J = 6.4 Hz, 1H). 
Preparation of 40 
Compound 36 (153.9 mg, 0.261 mmol) dissolved in a solution of 60% 
MeOH, 20% tBuOH, 20% H2O (5.2 mL, 50 mM). Activated 
palladium on carbon (102.4 mg, 60 wt%) was added and the mixture 
was flushed with a Hydrogen balloon three times. The reaction was 
sparged with H2 for several hours, with multiple rounds of refilling 
the balloon. After 4 h, TLC (1:1 Hex/EtOAc, UV active and stained with PAA) confirmed the 
starting material (Rf= 0.6) converted to the product (Rf= 0.02). The crude mixture was filtered 
through Celite and concentrated to yield 139.7 mg (93%) of 23. 1H NMR (400 MHz, CD3OD) δ 
7.85 (s, 1H), 7.42 (d, J = 6.8 Hz, 2H), 7.36 – 7.21 (m, 7H), 6.97 – 6.71 (m, 4H), 6.24 (m, 1H), 4.52 
(t, J = 4.0 Hz, 1H), 3.94 (dd, J = 4.0, 6.8 Hz, 1H), 3.82 (dd, J = 3.2, 10.7 Hz, 1H), 3.76 (s, 6H), 
3.69 (d, J = 4.0 Hz, 1H), 3.49 (dd, J = 3.2, 10.7 Hz, 1H), 3.18 – 3.03 (m, 1H), 2.40 – 2.24 (m, 2H), 




Preparation of 41 
Crude 40 (83.8 mg, 0.12 mmol) was dissolved in freshly distilled 
THF (2.48 mL, 50 mM). Distilled triethylamine (0.26 mL, 1.86 
mmol, 15 eq) and ethyl trifluoroacetate (0.15 mL, 1.24 mmol, 10 
eq) was added to the flask. The reaction was stirred for 4 hours at 
25 oC. TLC (1:1 Hex/EtOAc, Rf = 0.5, UV active and stained orange 
then blue by PAA) confirmed conversion to product. The reaction concentrated to yield 65.4 mg 
(70%) of 41. 1H NMR (400 MHz, CDCl3) δ 7.82 (s, 1H), 7.40 (d, J = 7.5 Hz, 2H), 7.35 – 7.09 (m, 
7H), 6.81 (d, J = 7.5 Hz, 4H), 6.24 (t, J = 6.4 Hz, 1H), 4.40 (t, J = 2.8 Hz, 1H), 3.93 (d, J = 3.4 Hz, 
1H), 3.74 (s, 6H), 3.69 (t, J = 6.4 Hz, 3H), 3.37 (dd, J = 2.8, 10.6 Hz, 1H), 3.29 (dd, J = 3.4, 10.6 
Hz, 1H), 2.28 (m, 1H), 2.14 (m, 1H), 0.79 (s, 9H), 0.01 (s, 3H), -0.04 (s, 3H). 
Preparation of 42 
Crude 41 (116.9 mg, 0.15 mmol) was dissolved in 3% TCA in DCM 
(2.48 mL, 50 mM). The reaction stirred for 1.5 h until TLC (1:1 
hex/EtOAc, Rf = 0.2, UV active and stained blue with PAA) showed 
starting material conversion to product. The reaction was quenched 
with sat. sodium bicarbonate (3 mL) and diluted with DCM (5 mL). 
The organic layer was washed with bicarbonate solution (1 x 8 mL). The aqueous layer was 
extracted with DCM (3 x 10 mL) and the combined organic layers were washed with brine (1 x 40 
mL), dried with Na2SO4, and concentrated. The crude mixture was purified by column 
chromatography (2:1 Hex/EtOAc) to yield 59 mg (64%) of 42. 1H NMR (400 MHz, CDCl3) δ 8.44 
(s, 1H), 8.26 (s, 1H), 6.20 (t, J = 6.4 Hz, 1H), 4.47 (q, J = 3.2 Hz, 1H), 4.17 (d, J = 6.4 Hz, 2H), 
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3.97 (s, 1H), 3.96 (dd, J = 3.2, 9.8 Hz, 2H), 3.76 (d, J = 9.8 Hz, 1H), 2.42 – 2.29 (m, 1H), 2.25 – 
2.11 (m, 1H), 0.88 (m, 9H), 0.11 – 0.00 (m, 6H). 
13C NMR (400 MHz, CDCl3) δ 164.3, 158.5, 158.1, 150.4, 141.8, 117.2, 114.3, 109.1, 88.5, 86.7, 
77.4, 77.1, 76.8, 71.8, 61.8, 41.9, 36.6, 25.7, 21.1, 18.0, -4.78, -4.9. 
ESI-TOF m/z calculated for C18H28F3N3O6Si (M + H) – 468.1699, 468.1766 observed. 
Preparation of 43 
Compound 42 (59 mg, 0.126) was azeotropically dried with 
distilled pyridine (2 x 0.5 mL). The flask was cooled to 0 oC. 
DIPEA (65 mg, 90 μL, 0.504 mmol, 4 eq) was added to the cold 
starting material and the reactants dissolved in DCM (1.25 mL, 
100 mM). 2-Cyanoethyl-N, N-diisopropylchlorophosphor-
amidite (35.7 mg, 34 μL, 0.151 mmol. 1.2 eq) was added and 
the reaction was monitored periodically by TLC (1:1 Hex/EtOAc, Rf = 0.6, stained with PAA). 
After 2 h, TLC showed complete conversion to the phosphoramidite. The reaction was diluted 
with freshly distilled EtOAc (3 mL). The organic layer was washed with sat. bicarbonate solution 
(2 x 5 mL) and the combined aqueous layers were extracted with distilled EtOAc (2 x 10 mL). The 
combined organic layers were washed with brine (1 x 25 mL) and dried over Na2SO4. The organic 
layers were concentrated under vacuum and the crude material was purified by column 
chromatography (3:1 distilled hexanes/distilled EtOAc) yielding 44.3 mg (55%) of 43. 1H NMR 
(400 MHz, CDCl3) δ 8.02 (s, 1H), 6.31 (t, J = 6.5 Hz, 1H), 4.44 (dd, J = 3.4, 6.6 Hz, 1H), 4.19 (dd, 
J = 3.4, 13.3 Hz, 1H), 4.03 (d, J = 2.4 Hz, 2H), 3.93 (t, J = 2.4 Hz, 2H), 3.82 (m, 2H), 3.59 (m, 
2H), 2.67 (t, J = 6.6 Hz, 2H), 2.40 – 2.22 (m, 2H), 2.11 (dt, J = 6.5, 13.3 Hz, 1H), 1.26 – 1.14 (m, 
12H), 0.88 (s, 9H), 0.13 – 0.03 (m, 6H). 
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13C NMR (400 MHz, CDCl3) δ 171.1, 163.84, 163.81, 150.1, 150.0, 140.1, 117.1, 109.2, 109.1, 
85.2, 77.3, 77.0, 76.6, 72.4, 71.7, 60.3, 58.5, 43.1, 43.0, 41.1, 34.6, 31.5, 29.0, 25.6, 25.2, 24.65, 
24.57, 24.5, 22.6, 20.96, 20.4, 20.3, 18.7, 17.8, 14.1, 14.0, 11.3. 
31P NMR (400 MHz, CDCl3) δ 148.9, 148.7. 
ESI-TOF m/z calculated for C27H45F3N5O7PSi (M + Na) − 690.2778, 690.2438 observed. 
Preparation of 44 
Compounds 43 (44.3 mg, 0.068 mmol, 1 eq) 
and 9 (29.7 mg, 0.082 mmol, 1.2 eq) were 
azeotropically dried together with toluene (2 x 
2 mL). S-Ethyl tetrazole/MeCN (250 mM, 330 
μL, 0.082 mmol, 1.2 eq) was added to the 
flask. After 3.5 h, TLC (2.5:1 EtOAc/Hex, Rf 
= 0.6, UV active and stained with PAA) 
indicated that the majority of 9 was consumed. tBuOOH (500 mM, 40.8 μL, 0.204 mmol, 3 eq) 
was added for 15-20 min. The reaction was concentrated under vacuum and column 
chromatography (1:1 EtOAc/Hex -> 3:1 EtOAc/Hex) yielded 43 mg (75 %) of 44. 1H NMR (400 
MHz, CDCl3) δ 9.61 (m, 1H), 8.15 (s, 1H), 7.76 (s, 1H), 6.28 (q, J = 6.8 Hz, 1H), 5.80 (m, 2H), 
5.58 (m, 1H), 5.65 – 4.89 (m, 6H), 4.77 (d, J = 3.4 Hz, 1H), 4.40 (d, J = 3.4 Hz, 1H), 4.36 – 4.25 
(m, 5H), 4.02 (s, 1H), 3.68 (dd, J = 3.2, 6.0 Hz, 2H), 3.54 (m, 1H), 2.77 (t, J = 6.0 Hz, 2H), 2.32 
(m, 1H), 2.10 (d, J = 6.8 Hz, 5H), 1.84 (m, 1H), 1.73 – 1.61 (m, 6H), 0.87 (s, 9H), 0.08 (d, J = 1.9 
Hz, 6H). 
13C NMR (400 MHz, CDCl3) δ 163.4, 150.1, 138.1, 114.83, 114.8, 110.8, 108.0, 85.1, 68.7, 67.3, 
67.1, 67.0, 62.7, 31.6, 30.2, 29.0, 28.9, 25.6, 22.6, 21.1, 17.8, 14.2, 14.1, 11.4, -4.8, -5.0. 
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31P NMR (400 MHz, CDCl3) δ -1.8, -1.9. 
ESI-TOF m/z calculated for C36H56F3N4O12PSi (M - H) − 851.3354, 851.3229 observed. 
Preparation of 45 
Compound 44 (28.5 mg, 0.033 mmol) was 
dissolved in THF (330 μL, 100 mM). 
TEA•3HF (28 μL, 0.17 mmol, 5 eq) was added 
to the flask and the reaction was stirred at 25 
oC overnight. After confirmed complete by 
TLC (3:1 EtOAc/Hex, Rf = 0.1, UV active and 
stained with PAA), the reaction was diluted 
with DCM (2 mL) and washed with H2O (1 x 3 mL), sat. sodium bicarbonate (1 x 3 mL), and brine 
(1 x 3 mL). The combined organic layers were dried over Na2SO4 and concentrated under vacuum. 
Column chromatography (4:1 EtOAc/Hex -> 100% EtOAc) provided 22 mg (92 %) of the 
desilylated intermediate. 1H NMR (400 MHz, CDCl3) δ 9.75 (s, 1H), 8.09 (s, 1H), 7.76 (s, 1H), 
6.25 (s, 1H), 5.80 (dd, J = 6.2, 10.3 Hz, 2H), 5.60 (m. 1H), 5.10-4.90 (m, 6H), 4.77 (d, J = 10.3 
Hz, 1H), 4.49 (s, 1H), 4.32 (s, 4H), 4.21 (s, 2H), 4.09 (s, 2H), 3.68 (m, 2H), 3.60 – 3.46 (m, 1H), 
3.40 (s, 1H), 2.80 (d, J = 6.2 Hz, 2H), 2.41 (s, 1H), 2.16 (s, 2H), 2.09 (m, 4H), 1.75 – 1.56 (m, 
4H). 
13C NMR (400 MHz, CDCl3) δ 137.9, 131.1, 114.7, 107.7, 105.2, 77.3, 77.0, 76.7, 53.4, 50.3, 46.0, 
30.0, 28.8, 25.6, 8.4. 
31P NMR (400 MHz, CDCl3) δ -1.81, -1.84, -1.9, -2.1. 
ESI-TOF m/z calculated for C30H42F3N4O12P (M -H) − 737.2489, 737.2353 observed. 
212 
 
The desilylated intermediate (27.5 mg, 0.037 mmol) 
was dissolved in concentrated aqueous ammonia (560 
μL). The reaction was capped and stirred at 0 oC 
overnight. After 10 h, TLC (15% MeOH in DCM, Rf = 
0.2, UV active and stained with KMnO4) confirmed the 
disappearance of starting material. The reaction was 
concentrated to yield 22.1 mg (100%) of 45. The desired 
product confirmed by ESI-MS m/z calculated for C25H40N3O11P (M -H)− 588.16, 588.2 observed. 
ESI-TOF m/z calculated for C25H40N3O11P (M -H)− 588.2400, 588.2308 observed. 
General Procedure for the preparation of Library 45 
Amine scaffold 46 (100 nmol) was azeotropically dried with carboxylic acid (140 nmol, 
1.4 eq) in pyridine (1 x 15 L) using a Speed Vac concentrator in a 384-well microtiter plate 
(VWR). To each well, a 2X activating solution (5 L; 28 mM HBTU and 28 mM HOBt in DMF), 
DIPEA (2 L), and DMF (3 L) were added. The final concentrations during reaction were: [46] 
= 10 mM, [acid] = 14 mM, [HBTU] = 14 mM, [HOBt] = 14 mM, 20% DIPEA in DMF. The well 
plate was shaken at 25 oC overnight. Some wells were analyzed by ESI-MS to confirm coupling 
efficiency. The solutions were concentrated using a Speed Vac concentrator and the well plate was 
covered and stored at -80 oC. 
Immediately before an assay, the amide was thawed, dissolved in DMF (4 L, 25 mM). 
An aliquot (2 L, 50 nmol) was mixed with NBS (8 L, 15 mM, 2.4 eq, 40% H2O in MeCN) at 0 
oC for 9 min. The concentrations during reaction were: [SM] = 5 mM, [NBS] = 12 mM, 20% DMF, 
3% H2O in MeCN. After 4 min, sat. Na2S2O3 (5 L) was added and reaction quenched on ice for 
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10 min. Samples were concentrated with a Speed Vac concentrator. Some samples were analyzed 
ESI-MS to confirm product formation. 
Preparation of 47 
A stock solution of 54 (20 mM) in 6% 
H2O in MeCN was prepared and stored 
at -20 oC. An aliquot of the stock 
solution (5 μL, 100 nmol) was cooled to 
0 oC. A solution of recrystallized NBS 
(5 μL, 30 mM, 300 nmol, 3 eq) was added and the reaction was stirred for 4 min (final: [54] = 5 
mM, 3% H2O, [NBS] = 15 mM). After 4 min, saturated Na2S2O3 (10 μL) was added and the 
reaction was stirred for 10 min to quench it. The reaction was concentrated, dissolved in 1:1 
MeCN/H2O, and analyzed by ESI.  
ESI-MS m/z calculated for C26H30N3O14P (M-1) 638.14 calculated, 638.24 observed. 
364 = 1.72 × 10
3 M-1cm-1 
Preparation of 48 
A stock solution of 53 (20 mM) in 
6% H2O in MeCN was prepared 
and stored at -20 oC. An aliquot of 
the stock solution (5 μL, 100 
nmol) was cooled to 0 oC. A 
solution of recrystallized NBS (5 μL, 30 mM, 300 nmol, 3 eq) was added and the reaction stirred 
for 4 min (final: [53] = 5 mM, 3% H2O, [NBS] = 15 mM). After 4 min, saturated Na2S2O3 (10 μL) 
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was added and the reaction was stirred for 10 min to quench it. The reaction was concentrated, 
dissolved in 1:1 MeCN/H2O, and analyzed by ESI.  
ESI-MS m/z calculated for C26H28N3O13P (M - H2O - H)− 621.14 calculated, 621.16 observed. 
380 = 1.35 × 10
3 M-1cm-1 
Preparation of 49195 
3,5-Dihydroxy naphthoic-2-carboxylic acid (485 mg, 2.37 mmol) was 
azeotropically dried with pyridine (3 x 1 mL). TBDMSCl (1.09 g, 7.11 
mmol, 3 eq) and imidazole (967 mg, 14.2 mmol, 6 eq) were added to 
the flask. The contents were dissolved in DMF (9.5 mL, 250 mM) and 
reaction was heated at 60 oC and stirred overnight. The following morning, TLC (3% MeOH in 
DCM) suggested starting material was consumed so H2O (0.2 mL) was added, and the reaction 
was stirred for 2 h. Afterwards, the reaction was concentrated and purified by column 
chromatography (4:1 Hex/EtOAc -> 1:1 Hex/EtOAc) to yield 400 mg (53%) of 49. 1H NMR (400 
MHz, CDCl3) δ 8.46 (s, 1H), 7.44 (s, 1H), 7.26 (d, J = 7.6 Hz, 1H), 6.96 (d, J = 7.6 Hz, 1H), 6.72 
(d, J = 7.6 Hz, 1H), 1.00 (s, 9H), 0.19 (s, 6H). 
Preparation of 50195 
Compound 49 (238 mg, 0.75 mmol) was azeotropically dried 
with pyridine (2 x 1 mL). NHS (128.8 mg, 1.12 mmol, 1.5 eq), 
and EDC (219 mg, 1.12 mmol, 1.5 eq) were added to the flask 
and the reagents were dissolved in DMF and stirred overnight at 
25 oC. After 16 h, TLC (5% MeOH in DCM, Rf = 0.7) suggested the SM was completely converted 
so the reaction was concentrated. The product was purified by column chromatography (3:1 
Hex/EtOAc -> 1:1 Hex/EtOAc) to yield 62 mg (20%) of 50. 1H NMR (400 MHz, CDCl3) δ 8.66 
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(s, 1H), 7.68 (s, 1H), 7.44 (d, J = 8 Hz, 1H), 7.21 (t, J = 8 Hz, 1H), 6.94 (d, J = 8 Hz, 1H), 2.95 (s, 
4H), 0.88 (s, 9H), 0.29 (s, 6H). 
Preparation of 51195 
3,7-Dihydroxy naphthoic-2-carboxylic acid (121 mg, 0.41 
mmol) was azeotropically dried with pyridine (3 x 1 mL). 
TBDMSCl (155 mg, 1.02 mmol, 2.5 eq) was added to the flask. 
The contents were dissolved in DMF (4.1 mL, 100 mM). DBU 
(187 mg, 183 μL, 1.23 mmol, 3 eq) was added and the reaction was heated to 60 oC. After 2 h, 
TLC (5% MeOH in DCM, Rf = 0.8) suggested complete conversion. The reaction was diluted with 
H2O (5 mL) and the product was extracted with DCM (2 x 15 mL). The combined organic layers 
were washed with brine (1 x 30 mL), dried over Na2SO4, and concentrated. Column 
chromatography (DCM -> 1% MeOH in DCM) yielded 967 mg (81%) 51. 1H NMR (400 MHz, 
CDCl3) δ 7.64 (d, J = 8 Hz, 1H), 7.24 (m, 4H), 1.11 (s, 18H), 0.47 (d, J = 8 Hz, 6H), 0.33 (s, 6H). 
Preparation of 52195 
Compound 51 (86.5 mg, 0.2 mmol) was azeotropically 
dried with pyridine (1 x 0.8 mL). NHS (34.7 mg, 0.3 
mmol, 1.5 eq) and EDC (57.8 mg, 0.3 mmol, 1.5 eq) were 
added to the flask and the reagents were dissolved in 
DMF and stirred overnight at 25 oC. After 16 h, TLC (5% MeOH in DCM, Rf= 0.7) suggested the 
SM was completely converted so the reaction was concentrated. The product was purified by 
column chromatography (DCM -> 1% MeOH in DCM) to yield 62 mg (60%) of 52. 1H NMR (400 
MHz, CDCl3) δ 8.93 (s, 1H), 8.55 (s, 1H), 7.59 (d, J = 8.8 Hz, 1H), 7.32 (s, 1H), 7.18 (d, J = 8.8 
Hz, 1H), 2.94 (s, 4H), 1.01 (s, 9H), 0.24 (s, 6H). 
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Preparation of 53 
NHS ester 50 (10 mg, 16 μmol, 1.2 
eq), scaffold 45 (8 mg, 14 μmol), and 
DIPEA (3 μL, 16 μmol, 1.2 eq) were 
dissolved in DMF (270 μL, 50 mM). 
The reaction was heated at 60 oC 
overnight. After 16 h, TLC (20% 
MeOH in DCM, Rf = 0.3) suggested 
the scaffold was still present but a significant number of new spots had formed so the reaction was 
concentrated and purified by column chromatography (15% MeOH in DCM -> 20% MeOH in 
DCM) to yield 11 mg of the amide intermediate (77%). The TBS group is labile and the NMR 
indicates these protons integrate to less than expected. Therefore, the product(s) isolate is likely a 
mixture of silylated and desilylated. This is not an issue because this intermediate is immediately 
desilylated (below). 1H NMR (400 MHz, CD3OD) δ 8.40 (m, 1H), 8.08 (s, 1H), 7.53 (d, J = 14 
Hz, 1H), 7.13 (m, 1H), 6.84 (dd, J = 8, 14 Hz, 1H), 6.29 (m, 1H), 5.80 (m, 4H), 5.55 (m, 1H), 4.96 
(m, 6H), 4.56 (m, 1H), 4.48 (m, 2H), 4.35 (m, 1H), 4.11 (m, 2H), 4.03 (m, 2H), 3.92 (m, 1H), 3.56 




The amide intermediate (11 mg, 0.012 
mmol) was dissolved in THF (120 μL, 
100 mM). TEA•3HF (10 μL, 0.06 
mmol, 5 eq) was added to the flask and 
the reaction was stirred at 25 oC 
overnight. After confirmed complete by 
TLC (15% MeOH in DCM, Rf = 0.4, 
UV active and stained with PAA), the reaction was concentrated and purified by column 
chromatography (10% MeOH in DCM -> 20% MeOH in DCM) provided 10 mg (99 %) of 53. 1H 
NMR (400 MHz, CDCl3) δ 8.44 (s, 1H), 8.02 (d, J = 8 Hz, 1H), 7.55 (s, 1H), 7.36 (d, J = 8 Hz, 
1H), 7.10 (t, J = 8 Hz, 1H), 6.80 (d, J = 8 Hz, 1H), 6.29 (m, 1H), 5.79 (m, 4H), 4.94 (m, 6H), 4.49 
(m, 5H), 4.30 (m, 1H), 4.08 (m, 4H), 3.57 (m, 2H), 2.30 (m, 2H), 2.11 (m, 3H), 2.08 (m, 4H), 1.60 
(m, 4H). 
ESI-TOF m/z calculated for C36H45N3O14P (M + H) – 777.2717, 777.2330 observed. 
Preparation of 54 
NHS ester 52 (10 mg, 16 μmol, 
1.2 eq), scaffold 45 (8 mg, 14 
μmol), and DIPEA (3 μL, 16 
μmol, 1.2 eq) were dissolved 
in DMF (270 μL, 50 mM). The 
reaction was heated at 60 oC 
overnight. After 16 h, TLC 
(20% MeOH in DCM, Rf = 0.3) suggested the scaffold was still present but a significant number 
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of new spots had formed so the reaction was concentrated and purified by column chromatography 
(15% MeOH in DCM -> 20% MeOH in DCM) to yield 11 mg of the amide intermediate (77%). 
1H NMR (400 MHz, CDCl3) δ 9.67 (s, 2H), 7.96 (s, 1H), 7.86 (s, 1H), 7.55 (d, J = 9.6 Hz, 1H), 
7.37 (d, J = 9.6 Hz, 1H), 7.25 (dd, J = 2.4, 8.8 Hz, 2H), 7.06 (m, 1H), 6.16 (t, J = 6.6 Hz, 1H), 5.80 
(m, 2H), 4.94 (m, 4H), 4.45 (q, J = 2.4 Hz, 2H), 4.41 (s, 1H), 4.10 (d, J = 12 Hz, 2H), 4.05 (m, 
1H), 3.89 (m, 1H), 3.85 (q, J = 3.3 Hz, 1H), 3.71 (dd, J = 3.3, 12 Hz, 1H), 3.65 (dd, J = 3.3 Hz, 
4H), 2.23 (m, 4H), 2.18 (m, 3H), 1.56 (m, 4H), 0.99 (m, 5H), 0.88 (s, 7H), 0.08 (s, 4H). 
The amide intermediate (11 mg, 
0.012 mmol) was dissolved in 
THF (120 μL, 100 mM). 
TEA•3HF (10 μL, 0.06 mmol, 5 
eq) was added to the flask and the 
reaction was stirred at 25 oC 
overnight. After confirmed 
complete by TLC (15% MeOH in DCM, Rf = 0.4, UV active and stained with PAA), the reaction 
was concentrated and purified by column chromatography (10% MeOH in DCM -> 20% MeOH 
in DCM) provided 10 mg (99 %) of 54. 1H NMR (400 MHz, CD3OD) δ 10.00 (s, 1H), 8.60 (s, 
1H), 7.95 (s, 1H), 7.53 (d, J = 6 Hz, 1H), 7.34 (s, 1H), 7.16 (s, 1H), 7.09 (d, J = 6 Hz, 1H), 6.22 (t, 
J = 3.8 Hz, 1H), 5.84 (m, 4H), 4.99 (m, 5H), 4.46 (m, 4H), 4.07 (m, 4H), 3.92 (s, 1H), 3.77 (d, J = 






Preparation of 55196,197 
AZT (2.19, 8.2 mmol) was dissolved in 50% MeOH, 30% tBuOH, 20% 
H2O (82 mL, 100 mM). Activated palladium on carbon (1.3 g, 60 wt%) 
was added and flushed with a hydrogen balloon three times. The flask 
was sparged with H2 for several hours. After 3 h, TLC (3% MeOH in 
DCM, UV active and stained with PAA) confirmed the starting material 
(Rf = 0.8) converted to the product (Rf = 0.02). The crude mixture was filtered through Celite and 
concentrated to yield 1.7 g of (86%) of the 3’-amine. 1H NMR (400 MHz, CD3OD) δ 7.87 (s, 1H), 
6.18 (dd, J = 2, 6.8 Hz, 1H), 3.86 (dd, J = 2, 10 Hz, 1H), 3.77 (dd, J = 3.2, 10 Hz, 1H), 3.70 (quint, 
J = 3.2 Hz, 1H), 3.54 (q, J = 6.8 Hz, 1H), 2.26 (m, 1H), 2.20 (m, 1H), 1.88 (s, 3H).  
The crude mixture (1.72 g, 7.12 mmol) was dissolved in THF (25 mL, 
280 mM). Triethylamine (14 mL, 106.8 mmol, 15 eq) and ethyl 
trifluoroacetate (8.4 mL, 71.3 mmol, 10 eq) were added to the flask to 
make a final concentration of 100 mM. The reaction was stirred for 4 h 
at 25 oC. TLC (3% MeOH in DCM, Rf = 0.5, UV active and stained by 
PAA) confirmed conversion to product. The reaction was concentrated 
and purified by column chromatography (1% MeOH in DCM to yield 2.29 g (93%) of 55. 1H NMR 
(400 MHz, CD3OD) δ 7.85 (s, 1H), 6.27 (t, J = 6.4 Hz, 1H), 4.60 (q, J = 6.4 Hz, 1H), 3.97 (quint, 
J = 2.8 Hz, 1H), 3.85 (dd, J = 2.8, 12 Hz, 1H), 3.73 (dd, J = 2.8, 12 Hz, 1H), 2.40 (m, 2H), 1.89 
(s, 3H). 
13C NMR (400 MHz, CD3OD) δ 166.2, 159.4, 158.9, 158.6, 152.2, 138.0, 118.6, 115.8, 111.5, 
85.9, 85.6, 62.3, 50.7, 37.9, 12.3, 9.09. 
ESI-TOF m/z calculated for C12H14F3N3O5 (M + H) − 338.0886, 338.3413 observed. 
220 
 
Preparation of 56 
Compounds 10 (101 mg, 0.38 mmol, 1.2 eq) and 55 (172 mg, 
0.32 mmol, 1 eq) were azeotropically dried together with 
toluene (2 x 1 mL). S-Ethyl tetrazole/MeCN (250 mM, 1.5 mL, 
0.38 mmol, 1.2 eq) was added to the flask. After 4 h, TLC (1:1 
EtOAc/Hex, Rf = 0.6, UV active and stained with PAA) 
indicated that the majority of 55 was consumed. tBuOOH (500 
mM, 200 μL, 1 mmol, 3 eq) was added and the reaction was 
stirred for 15-20 min. The reaction was concentrated under 
vacuum and column chromatography (2:1 EtOAc/Hex) yielded 131 mg (56 %) of 56. 1H NMR 
(400 MHz, CDCl3) δ 10.36 (d, J = 10.1 Hz, 1H), 8.86 (d, J = 5 Hz, 1H), 7.46 ( d, J = 2 Hz, 1H), 
6.38 (q, J = 5 Hz, 1H), 5.74 (dsextet, J = 2, 4 Hz, 2H), 5.10-4.90 (m, 6H), 4.51 (s, 1H), 4.34 (s, 
2H), 4.25 (q, J = 6 Hz, 2H), 4.16 (s, 2H), 4.06 (m, 1H), 3.63 (sextet, J = 2 Hz, 2H), 3.33 (m, 2H), 
2.75 (q, J = 6 Hz, 3H), 2.44 (q, J = 8 Hz, 2H), 2.28 (m, 1H), 2.15 (m, 1H), 2.01 (d, J = 4 Hz, 4H), 
1.96 (s, 3H), 1.58 (q, J = 4 Hz, 4H).  
31P NMR (400 MHz, CDCl3) δ -1.97, -2.00. -2.04, -2.1, -2.4, -2.5, -2.6, -2.7, -2.9. 









Preparation of 57 
Compound 56 (115 mg, 0.15 mmol) was dissolved in 
concentrated aqueous ammonia (1.5 mL). The reaction was 
stirred at 0 oC for 4 h. After 4 h, TLC (20% MeOH in DCM, Rf 
= 0.2, UV active and stained with KMnO4) confirmed the 
disappearance of starting material. The reaction was 
concentrated to yield 85 mg (100%) of 57. 1H NMR (400 MHz, 
CD3OD) δ 6.34 (t, J = 5.8 Hz, 1H), 5.78 (m, 2H), 5.10-4.98 (m, 
6H), 4.13 (s, 3H), 3.88 (m, 2H), 3.66 (m, 2H), 3.40 (q, J = 5.8 Hz, 2H), 2.81 (s, 2H), 2.68 (t, J = 7 
Hz, 1H), 2.49 (m, 1H), 2.44 (m, 2H), 2.30 (m, 1H), 2.06 (t, J = 7 Hz, 4H), 1.93 (s, 3H), 1.60 (quint, 
J = 7 Hz, 4H). 
31P NMR (400 MHz, CD3OD) δ 0.07. 
General Procedure for the preparation of Libraries 58 and 71 
Amine scaffold 57 or 66 (100 nmol) was azeotropically dried with carboxylic acid (140 
nmol, 1.4 eq) in pyridine (1 x 15 L) using a Speed Vac concentrator in a 384-well microtiter plate 
(VWR). To each well, a 2X activating solution (5 L; 28 mM HBTU and 28 mM HOBt in DMF), 
DIPEA (2 L), and DMF (3 L) were added. The final concentrations during reaction were: 
[57/66] = 10 mM, [acid] = 14 mM, [HBTU] = 14 mM, [HOBt] = 14 mM, 20% DIPEA in DMF. 
The well plate was shaken at 25 oC overnight. Some wells were analyzed by ESI-MS to confirm 
coupling efficiency. The solutions were concentrated using a Speed Vac concentrator and the well 
plate was covered and stored at -80 oC. 
Immediately before an assay, the amide was thawed, dissolved in DMF (4 L, 25 mM). 
An aliquot (2 L, 50 nmol) was mixed with NBS (8 L, 15 mM, 2.4 eq, 40% H2O in MeCN) at 0 
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oC for 9 min. The concentrations during reaction were: [SM] = 5 mM, [NBS] = 12 mM, 20% DMF, 
30% H2O in MeCN. After 9 min, Na2S2O3 (5 L, 200 mM) was added and reaction quenched on 
ice for 10 min. Samples were concentrated with a Speed Vac concentrator. Some samples were 
analyzed ESI-MS to confirm product formation. 
Preparation of 5927 
Commercially available 2,6-dichloro-3-hydroxy-4-methoxy 
benzaldehyde (14 mg, 0.06 mmol) was azeotropically dried in pyridine 
(2 x 0.2 mL). TBSCl (12 mg, 0.08 mmol, 1.2 eq) and DMAP (5 mg, 0.02 
mmol, 0.4 eq) were added. The reagents were dissolved in TEA (40 mg, 
60 L, 0.4 mmol, 7 eq) and DCM (450 L, 150 mM). The reaction was stirred overnight at 25 oC. 
After 20 h, TLC (3% MeOH in DCM, Rf = 0.8, UV active) suggested reaction complete. The 
reaction was diluted with DCM (5 mL) and washed with bicarbonate solution (1 x 5 mL) and brine 
(1 x 5 mL). The combined aqueous layers were extracted with DCM (1 x 10 mL). The combined 
organic layers were dried over Na2SO4, concentrated, and purified by column chromatography 
(1:10 EtOAc/Hex -> 1:4 EtOAc/Hex) to yield 17 mg (85%) of 59. 1H NMR (400 MHz, CDCl3) δ 
10.38 (s, 1H), 6.82 (s, 1H), 3.86 (s, 3H), 1.01 (s, 9 H), 0.18 (s, 6H). 
Preparation of 60164 
Aldehyde 59 (17.1 mg, 0.05 mmol) was dissolved in THF (0.18 mL). 
NaH2PO4 (6.8 mg, 0.03 mmol, 0.6 eq) and H2O (71 μL) were added 
and the reaction stirred at 25 oC for 10 min. After 10 min, NaClO2 (20 
mg, 0.2 mmol, 4 eq) and 30% H2O2 (50 μL) were added and reaction was stirred at 25 oC. After 
2.5 h, TLC (4:1 Hex/EtOAc, Rf = 0.1, UV active) suggested the starting material was consumed 
so the mixture was diluted with EtOAc and washed with H2O (2 x 1 mL). The combined aqueous 
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layers were extracted with EtOAc (4 x 2 mL). The combined organic layers were dried over 
Na2SO4 and concentrated. The crude was purified by column chromatography (5% MeOH in DCM 
-> 10% MeOH in DCM) to yield 8.9 mg (50%) 60. 1H NMR (400 MHz, CD3OD) δ 6.82 (s, 1H), 
3.92 (s, 3H). 
Preparation of 61 
Scaffold 57 (10 mg, 0.02 mmol) and 60 (5.7 mg, 0.025 mmol, 
1.4 eq) were azeotropically dried together with pyridine (2 x 
0.5 mL). HBTU (9.3.0 mg, 0.025 mmol, 1.4 eq) and HOBt 
(9.3 mg, 0.025 mmol, 1.4 eq) were added to the starting 
materials. The contents were dissolved in DMF (350 mL) and 
DIPEA (70 μL). The reaction was stirred at 25 oC overnight. 
TLC (20% MeOH in DCM, Rf = 0.3, UV active and stained 
with PAA) suggested 60 was consumed. The reaction was 
concentrated and purified by column chromatography (5% 
MeOH in DCM) to yield 10.9 mg (79%) of 61. 1H NMR (400 
MHz, CD3OD) δ 8.05 (dd, J = 1.4, 8.5 Hz, 1H), 7.91 (t, J = 1.4 Hz, 1H), 7.51 (t, J = 8.5 Hz, 1H), 
6.98 (s, 1H), 6.37 (m, 1H), 6.27 (m, 1H), 5.80 (m, 2H), 5.16-4.95 (m, 6H), 4.67 (m, 1H), 4.62 (m, 
1H), 4.25 (m, 1H), 4.20 (m, 2H), 4.10 (m, 2H), 3.65 (m, 3H), 2.72 (m, 1H), 2.42 (m, 2H), 2.29 (m,  
2H), 2.08 (m, 4H), 1.97 (s, 3H), 1.62 (t, J = 3.4 Hz, 4H). 






Preparation of 62 
Compound 61 (2 L, 20 mM, 40 nmol) was mixed with H2O 
(3 L) and NBS (5 L, 25 mM, 2.5 eq, MeCN) at 0 oC for 9 
min. The concentrations during reaction were: [SM] = 5 mM, 
[NBS] = 12.5 mM, 20% DMF, 30% H2O in MeCN. After 9 
min, Na2S2O3 (10 L, 200 mM) was added and reaction 
quenched on ice for 10 min. The crude material was 
concentrated by Speed Vacuum concentrator and analyzed by 
ESI-MS. 
ESI-MS m/z calculated for C23H26Cl2N3O12P (M – H2O+ H) – 636.06, 636.21 observed. 
Preparation of 63 
Scaffold 57 (17 mg, 0.03 mmol) and 5-(4-chlorophenyl)-3-
(trifluoromethyl) furan-2-carboxylic acid (11 mg, 0.04 
mmol, 1.4 eq) were azeotropically dried together with 
pyridine (2 x 1 mL). HBTU (14.0 mg, 0.037 mmol, 1.4 eq) 
and HOBt (5 mg, 0.037 mmol, 1.4 eq) were added to the 
starting materials. The contents were dissolved in DMF (1.04 
mL) and DIPEA (260 μL). The reaction was stirred at 25 oC 
overnight. TLC (20% MeOH in DCM, Rf = 0.3, UV active 
and stained with PAA) suggested 57 was consumed. The 
reaction was concentrated and purified by column 
chromatography (5% MeOH in DCM) to yield 21.2 mg 
(96%) of the precursor to 63. 1H NMR (400 MHz, CD3OD) δ 7.76 (d, J = 6.8 Hz, 1H), 7.70 (d, J 
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= 7.6 Hz, 2H), 7.59 (d, J = 6.8 Hz, 2H), 7. 50 (d, J = 7.6 Hz, 1H), 7.35 (quint, J = 6.8 Hz, 4H), 
6.37 (t, J = 3.6 Hz, 1H), 5.78 (m, 2H), 5.00 (m, 6H), 4.68 (m, 1H), 4.15 (d, J = 1.6 Hz, 1H), 4.10 
(m, 2H), 3.90 (m, 2H), 3.66 (dd, J = 1.6, 5.2 Hz, 2H), 2.49 (m, 1H), 2.40 (d, J = 1.6 Hz, 2H), 2.30 
(m, 1H), 2.07 (d, J = 6.4 Hz, 4H), 1.97 (s, 3H), 1.90 (m, 1H), 1.60 (quint, J = 6.4 Hz, 4H). 
31P NMR (400 MHz, CD3OD) δ -2.4, -3.0. 
ESI-TOF m/z calculated for C37H44ClF3N3O12P (M - H) − 844.2303, 844.2221 observed. 
273 = 2.0 × 10
4 M-1cm-1 
The pentenoyl protected inhibitor was stored as a 25 
mM stock solution in DMF at -20 oC. An aliquot of the 
starting material (2 μL, 50 nmol) was placed in a 
microtiter well plate and cooled to 4 oC. Cold H2O (3 
μL) was added to the well. NBS in MeCN (25 mM, 5 
μL) was added and the well plate was shaken at 4 oC for 
9 min. After 9 min, the reaction was quenched by an 
equal volume of Na2S2O3 (200 mM in H2O, 10 L) and 
the plate was shaken for additional 5-10 min. The 
reaction was concentrated by speed vacuum, redissolved in 1:1 MeCN/H2O and used directly. 
Reaction Conditions: [SM] = 5 mM, [NBS] = 12.5 mM, 30% H2O, 20% DMF, 50% MeCN 
Quenching Conditions: [SM] = 2.5 mM, [NBS] = 6.25 mM, [Na2S2O3] = 100 mM, 65% H2O, 
10% DMF, 25% MeCN. 





Preparation of 64 
Scaffold 57 (15 mg, 0.03 mmol) and 3-(4-
hydroxyphenoxy) benzoic acid (8.5 mg, 
0.04 mmol, 1.4 eq) were azeotropically 
dried together with pyridine (2 x 1 mL). 
HBTU (14.0 mg, 0.04 mmol, 1.4 eq) and 
HOBt (5 mg, 0.04 mmol, 1.4 eq) were added 
to the starting materials. The contents were 
dissolved in DMF (1.04 mL) and DIPEA 
(260 μL). The reaction was stirred at 25 oC overnight. TLC (20% MeOH in DCM, Rf = 0.3, UV 
active and stained with PAA) suggested 57 was consumed. The reaction was concentrated and 
purified by column chromatography (5% MeOH in DCM) to yield 9.4 mg (46%) of the precursor 
to 64. 1H NMR (400 MHz, CD3OD) δ 7.89 (s, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.71 (s, 1H), 6.91 
(dd, J = 3.2, 8.8 Hz, 2H), 6.90 (s, 1H), 6.83 (s, 2H), 6.38 (t, J = 3.2, 1H), 5.80 (m, 2H), 5.08-4.95 
(m, 6H), 4.69 (m, 1H), 4.16 (s, 1H), 4. 23 (m, 2H), 4.10 (m, 2H), 3.97 (m, 1H), 3.88 (m, 2H), 3.63 
(m, 2H), 2.42 (m, 3H), 2.07 (q, J = 1.6 Hz, 4H), 1.97 (s, 3H), 1.89 (m, 1H), 1.60 (q, J = 1.6 Hz, 
4H). 
31P NMR (400 MHz, CD3OD) δ -2.01. 
ESI-TOF m/z calculated for C38H48N3O13P (M - H) − 784.2925 calculated, 784.4690 and 767.2130 
(-OH) observed. 




The pentenoyl protected inhibitor was stored 
as a 25 mM stock solution in DMF at -20 oC. 
An aliquot of the starting material (2 μL, 50 
nmol) was placed in a microtiter well plate 
and cooled to 4 oC. Cold H2O (3 μL) was 
added to the well. NBS in MeCN (25 mM, 5 
μL) was added and the well plate was shaken at 4 oC for 9 min. After 9 min, the reaction was 
quenched by an equal volume of Na2S2O3 (200 mM in H2O) and the plate was shaken for an 
additional 5-10 min. The reaction was concentrated by speed vacuum, redissolved in 1:1 
MeCN/H2O and used directly. 
Reaction Conditions: [SM] = 5 mM, [NBS] = 12.5 mM, 30% H2O, 20% DMF, 50% MeCN 
Quenching Conditions: [SM] = 2.5 mM, [NBS] = 6.25 mM, [Na2S2O3] = 100 mM, 65% H2O, 
10% DMF, 25% MeCN. 
ESI-MS m/z calculated for C28H31N3O13P (M - H) – 648.16, 648.65 observed. 
Preparation of 65198 
AZT (587 mg, 2.19 mmol, 1 eq) was azeotropically dried twice with 
pyridine (2 x 1 mL). Imidazole (604 mg, 8.76 mmol, 4 eq) and 
TBDMSCl (672 mg, 4.38 mmol, 2 eq) were added and dissolved in 
DMF (4.5 mL, 500 mM). The reaction was heated to 50° C overnight. 
When confirmed complete by TLC (5% MeOH in DCM, Rf = 0.5, UV 
active and stained with PAA), the reaction was cooled and diluted with EtOAc (10 mL). The 
organic layer was washed with sat. NH4Cl (3 x 15 mL) and brine (2 x 15 mL). The combined 
aqueous layers were extracted using EtOAc (2 x 50 mL). The combined organic layers were dried 
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over Na2SO4 and concentrated under vacuum. The residue was purified by column 
chromatography (2:1 Hex/EtOAc) yielding 825 mg (95%) of 65. 1H NMR (400 MHz, CDCl3) δ 
8.72 (s, 1H), 7.43 (s, 1H), 6.22 (t, J = 6.8 Hz, 1H), 4.24 (q, J = 3.2 Hz, 1H), 3.96 (d, J = 3.2 Hz, 
1H), 3.94 (dd, J = 2.8, 14 Hz, 1H), 3.79 (dd, J = 2.8, 14 Hz, 1H), 2.44 (m, 1H), 2.22 (m, 1H), 1.91 
(s, 3H), 0.93 (s, 9H), 0.13 (s, 6H). 
13C NMR (400 MHz, CDCl3) δ 134.9, 111.0, 84.5, 84.4, 62.9, 60.5, 37.9, 25.9, 25.7, 25.6, 18.3, 
12.5, -5.4, -5.5. 
Preparation of 66 
Compound 65 (982.8 mg, 2.58 mmol, 1 eq) was mixed with NBS (366 
mg, 2.06 mmol, 0.8 eq) and dissolved in distilled benzene (13 mL, 200 
mM). The mixture was sparged with Ar for 20 minutes. The reaction 
was activated by sun lamp. The reaction was stirred for 1 h while the 
mixture turned red. When TLC (1:1 Hex/EtOAc, UV active and 
stained with iodine) showed a mixture of starting material and one new spot, a second aliquot of 
0.8 eq NBS was added to the reaction. After a total of 2 h and 2 x 0.8 eq NBS added, the SM was 
consumed to yield one major spot. The mixture was immediately filtered through a glass frit and 
diluted with DCM (10 mL) and H2O (20 mL). The aqueous layer was extracted with DCM (2 x 20 
mL) and the combined organic layers were washed with sat. bicarbonate solution (1 x 40 mL), 
brine (1 x 40 mL), dried over Na2SO4, and concentrated under vacuum to give 853.6 mg (72%) a 
yellow crude residue. 1H NMR (400 MHz, CDCl3) δ 9.67 (s, 1H), 7.84 (s, 1H), 6.17 (t, J = 6.4 Hz, 
1H), 4.24 (m, 2H), 4.20 (m, 1H), 3.98 (m, 1H), 3.96 (dd, J = 2.8, 11.6 Hz, 1H), 3.80 (dd, J = 2.8, 
11.6 Hz, 1H), 2.50 (m, 1H), 2.25 (m, 1H), 0.94 (s, 9H), 0.14 (s, 6H). 
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The crude material (853.2 mg, 1.85 mmol) was dissolved in EtOH (13 
mL). Concentrated aqueous ammonia (23 mL, 15.7 M, 47.1 mmol, 25 
eq) was added to the flask. The reaction was stirred at 25 oC for 1.5 h. 
After 1.5 h, TLC (10% MeOH in DCM, Rf = 0.3) suggested the 
bromide intermediate was consumed. The reaction was concentrated 
and purified by column chromatography (DCM -> 3% MeOH in DCM) to yield 339 mg (43%) of 
the second intermediate. 1H NMR (400 MHz, CDCl3) δ 7.78 (s, 1H), 6.06 (t, J = 6.4 Hz, 1H), 4.22 
(m, 1H), 3.88 (q, J = 4.4 Hz, 1H), 3.82 (d, J = 4.4 Hz, 1H), 3.78 (d, J = 4.4 Hz, 1H), 3.73 (s, 2H), 
2.35 (t, J = 6.4 Hz, 2H), 0.85 (s, 9H), 0.05 (s, 6H). 
13C NMR (400 MHz, CDCl3) δ 164.3, 150.3, 140.2, 109.2, 85.1, 84.6, 62.9, 60.6, 50.1, 37.3, 
25.8, 22.4, 18.3, -5.4, -5.5. 
ESI-TOF m/z calculated for C16H28N6O4Si (M + H) – 397.1941 calculated, 397.2012 observed. 
The second intermediate (313.5 mg, 0.791 mmol) was dissolved in 
THF (5.2 mL, 280 mM). Triethylamine (1.6 mL, 11.8 mmol, 15 eq) 
and ethyl trifluoroacetate (0.95 mL, 7.91 mmol, 10 eq) were added to 
the flask to make the final concentration 100 mM. The reaction was 
stirred for 4 hours at 25 oC. TLC (3% MeOH in DCM, Rf = 0.5, UV 
active and stained by PAA) confirmed conversion to product. The 
reaction was concentrated and carried further to the next step without further purification, yielding 
500 mg of 66 (91%). 1H NMR (400 MHz, CDCl3) δ 10.17 (s, 1H), 7.91 (s, 1H), 7.80 (s, 1H), 6.13 
(t, J = 6.4 Hz, 1H), 4.23 (q, J = 4 Hz, 1H), 4.20 (s, 2H), 4.00 (q, J = 4 Hz, 1H), 3.91 (dd, J = 3.6, 




13C NMR (400 MHz, CDCl3) δ 162.9, 161.3, 160.9, 149.9, 138.7, 117.8, 114.9, 109.2, 84.8, 84.6, 
60.8, 59.9, 53.2, 49.2, 45.5, 37.4, 35.7, 7.9. 
ESI-TOF m/z calculated for C18H27F3N6O5Pi (M + H) – 493.1764, 493.1716 observed. 
Preparation of 67 
Compound 66 (22.5 mg, 0.05 mmol) was dissolved in 50% MeOH, 
20% H2O, 30% tBuOH (1 mL). Activated Pd/C (14.1 mg, 60 wt%) 
was added to the solution. The reaction was continuously sparged with 
H2 (1 atm). After 1 h, TLC (5% MeOH in DCM, UV active and stained 
with PAA, Rf = 0.35) suggested the reaction was complete. The 
mixture was passed through a Celite column and concentrated to 17 
mg (82%) of crude amine, which was carried forward without further purification. 1H NMR (400 
MHz, CD3OD) δ 7.83 (s, 1H), 6.18 (t, J = 6.4 Hz, 1H), 4.12 (s, 2H), 3.93 (dd, J = 4, 11.2 Hz, 1H), 
3.88 (dd, J = 4, 11.2 Hz, 1H), 3.77 (dt, J = 1.2, 4 Hz, 1H), 3.50 (q, J = 6.4 Hz, 1H), 2.25 (m, 2H), 
0.93 (s, 9H), 0.12 (d, J = 1.2 Hz, 6H). 
Crude amine (17 mg, 0.033 mmol) and 5-(4-chlorophenyl)-3-
(trifluoromethyl) furan-2-carboxylic acid (14.2 mg, 0.05 
mmol, 1.4 eq) were azeotropically dried together with 
pyridine (2 x 1 mL). HBTU (17.8 mg, 0.05 mmol, 1.4 eq) and 
HOBt (6.3 mg, 0.05 mmol, 1.4 eq) were added to the starting 
materials. The contents were dissolved in DMF (528 μL) and 
DIPEA (132 μL). The reaction was stirred at 25 oC overnight. 
TLC (10% MeOH in DCM, Rf = 0.4, UV active and stained 
with PAA) suggested the starting material was gone. The 
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reaction was concentrated and purified by column chromatography (1:1 Hex/EtOAc -> 5% MeOH, 
1:1 Hex/EtOAc) to yield 18.1 mg (75%) of 67. 1H NMR (400 MHz, CDCl3) δ 8.23 (s, 1H), 8.10 
(d, J = 6.4 Hz, 1H), 7.86 (s, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.63 (d, J = 8.2 Hz, 2H), 6.09 (t, J = 6.4 
Hz, 1H), 4.59 (t, J = 4 Hz, 1H), 4.12 (t, J = 4 Hz, 2H), 3.88 (m, 2H), 2.43 (m, 1H), 2.25 (m, 1H), 
0.82 (s, 9H), 0.04 (s, 6H). 
13C NMR (400 MHz, CDCl3) δ 162.7, 160.8, 150.1, 134.9, 129.0, 126.5, 125.8, 125.6, 120.1, 
117.3, 110.7, 108.9, 105.9, 85.6, 54.7, 38.4, 36.5, 31.4, 25.7, 18.2, 16.9, -5.6. -5.7. 
Preparation of 68 
Compound 67 (135 mg, 0.19 mmol) was dissolved in THF (3.6 
mL). TEA•3HF (74 mg, 0.46 mmol, 0.08 mL, 2.5 eq) was 
added to the flask. The reaction was stirred at 25 oC overnight. 
TLC (5% MeOH in DCM, Rf = 0.5, UV active and stained with 
PAA) confirmed conversion to product. The reaction was 
concentrated and purified by column chromatography (DCM -
> 2% MeOH) to yield 100 mg (86%) of 68. 1H NMR (400 MHz, 
CDCl3) δ 8.28 (t, J = 6.9, 1H), 7.79 (m, 3H), 7.74 (dd, J = 1.6, 
6.9 Hz, 1H), 7.57 (dd, J = 1.6, 8 Hz, 1H), 7.23 (d, J = 8 Hz, 
1H), 7.19 (m, 2H), 6.06 (q, J = 4.4 Hz, 1H), 4.54 (t, J = 7.6 Hz, 1H), 4.32 (d, J = 7.6 Hz, 1H), 4.21 
(dd, J = 5.6, 14.8 Hz, 1H), 4.15 (dd, J = 5.6, 14.8 Hz, 1H), 3.84 (d, J = 10.8 Hz, 1H), 3.74 (d, J = 
10.8 Hz, 1H), 2.30 (m, 2H). 
13C NMR (400 MHz, CDCl3) δ 163.2, 160.8, 157.2, 153.0, 149.9, 134.1, 128.6, 127.4, 126.1, 
124.4, 123.9, 120.2, 117.9, 110.9, 108.6, 107.4, 83.9, 50.1, 46.1, 8.31, 8.29, 8.26, 8.24, 8.23. 
ESI-TOF m/z calculated for C24H19ClF3N4O7 (M + H) − 625.0846, 625.0844 observed. 
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Preparation of 69 
Compounds 68 (61 mg, 0.08 mmol, 1.2 eq) and 
10 (32 mg, 0.07 mmol, 1 eq) were azeotropically 
dried with toluene (2 x 0.5 mL). S-Ethyl 
tetrazole/MeCN (250 mM, 1 mL, 0.24 mmol, 1.2 
eq) was added to the reaction flask. After 3 h, 
TLC (2:1 EtOAc/Hex, Rf = 0.5, UV active and 
stained with PAA) indicated that the majority of 
68 was consumed. tBuOOH (500 mM, 18 mg, 40 
μL, 0.20 mmol, 3 eq) was added for 15-20 min. 
The reaction was concentrated and column chromatography (2:1 EtOAc/Hex) yielded 61 mg (90 
%) of 69. 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 5.9, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.35 (d, J 
= 8.4 Hz, 2H), 7.07 (d, J = 3.6 Hz, 1H), 6.22 (t, J = 5.9, 1H), 5.78 (m, 2H), 4.99 (m, 6H), 4.75 (m, 
1H), 4.40 (m, 3H), 4.30 (m, 4H), 4.28 (m, 2H), 3.88 (m, 2H), 3.61 (m, 2H), 3.38 (m, 2H), 2.78 
(quint, J = 3.6 Hz, 2H), 2.63 (m, 1H), 2.52 (m, 2H), 2.45 (m, 1H), 2.08 (m, 4H), 1.88 (m, 1H), 
1.62 (m, 4H). 
13C NMR (400 MHz, CDCl3) δ 137.9, 135.1, 129.0, 126.5, 125.6, 114.6, 114.5, 66.6, 65.8, 30.1, 
30.0, 28.6, 269, 26.1, 14.6. 
31P NMR (400 MHz, CDCl3) δ 7.8, -0.9, -1.0, -2.57, -2.62, -2.63, -2.65, -2.67, -2.69, -2.71, -3.06, 
-3.1. 
19F NMR (300 MHz, CDCl3) δ -64.02, -64.03, -64.1, -78.12, -78.13 -78.2. 




Preparation of 70 
Compound 67 (8 mg, 0.008 mmol) was dissolved in 
concentrated aqueous ammonia (160 μL). The 
reaction was capped and stirred at 25 oC. After 5 h, 
TLC (15% MeOH in DCM, Rf = 0.1, UV active and 
stained with PAA) confirmed the disappearance of 
starting material and formation of a new spot. The 
reaction was concentrated and purified by column 
chromatography (5% MeOH in DCM -> 20% 
MeOH in DCM) to yield 9.3 mg (73%) of 70. 1H 
NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 7.76 (d, J = 11.6 Hz, 2H), 7.68 (q, J = 5.2 Hz, 1H), 7.50 
(d, J = 11.6 Hz, 2H), 7.24 (m, 3H), 6.28 (t, J = 5.2 Hz, 1H), 5.80 (m, 2H), 4.95 (m, 6H), 4.78 (q, J 
= 8.6 Hz, 1H), 4.26 (m, 2H), 4.08 (m, 2H), 3.83 (m, 4H), 3.63 (m, 2H), 2.53 (q, J = 8.6 Hz, 2H), 
2.47 (m, 2H), 2.09 (m, 4H), 1.60 (m, 4H). 
13C NMR (400 MHz, CD3OD) δ 166.3, 164.8, 139.4, 137.9, 136.3, 130.3, 128.4, 128.3, 127.0, 
115.0, 114.98, 111.3, 108.1, 106.0, 68.5, 68.2, 62.2, 55.7, 43.7, 36.8, 35.1, 31.5, 31.4, 31.39, 31.35, 
30.03, 30.00, 19.2, 18.6, 17.2, 13.0, 12.5. 
31P NMR (400 MHz, CD3CN) δ -2.3. 
ESI-TOF m/z calculated for C37H45ClF3N4O12P (M - H) − 859.2412, 859.2277 observed. 
Preparation of NHS-Ester for 72 
Commercially available 1,6-dibromo-3-hydroxy-2-
naphthoic acid (102 mg, 0.3 mmol) was azeotropically dried 
in pyridine (2 x 1 mL). NHS (54 mg, 0.45 mmol, 1.5 eq), 
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and EDC (86 mg, 0.45 mmol, 1.5 eq) were added to the flask and the reagents were dissolved in 
DMF and stirred overnight at 25 oC. After 16 h, TLC (2% MeOH in DCM, Rf = 0.8, UV active) 
suggested the SM was completely converted so the reaction was concentrated. The product was 
purified by column chromatography (DCM -> 1% MeOH in DCM) to yield 119 mg (90%) of NHS 
ester (X). 1H NMR (400 MHz, CDCl3) δ 9.79 (s, 1H), 8.60 (s, 1H), 8.09 (d, J = 8.8 Hz, 1H), 8.01 
(s, 1H), 7.75 (d, J = 8.8 Hz, 1H), 2.97 (s, 4H). 
13C NMR (400 MHz, CDCl3) δ 169.6, 162.5, 153.4, 134.6, 133.6, 131.2, 130.6, 128.2, 127.7, 
118.3, 115.0, 107.2, 53.4, 53.1, 36.4, 31.4, 29.6. 
ESI-TOF m/z calculated for C15H9NO5 (M + H) − 441.8847, 441.3207 observed. 
Preparation of 72 
Scaffold 70 (14 mg, 0.016 mmol) 
and X (11 mg, 0.024 mmol, 1.5 eq) 
were azeotropically dried together 
with pyridine (2 x 1 mL). The 
contents were dissolved in DMF 
(350 μL) and DIPEA (5 μL). The 
reaction was stirred at 25 oC 
overnight. TLC (20% MeOH in 
DCM, Rf = 0.3, UV active and 
stained with PAA) suggested the starting materials were converted to a new spot. The reaction was 
concentrated and purified by column chromatography (2:1 Hex/EtOAc -> 1:1 Hex/EtOAc -> 1:1 
Hex/EtOAc, 5% MeOH) to yield 12.2 mg (45%) of the precursor to 72. The product was passed 
through a DOWEX (Na+) column for clearer NMR analysis. 1H NMR (400 MHz, CD3OD) δ 8.38 
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(s, 2H), 8.02 (s, 3H), 7.98 (d, J = 7.2 Hz, 2H), 7.74 (d, J = 8.8 Hz, 1H), 7.61 (d, J = 7.2, 2H), 7.48 
(d, J = 8.8 Hz, 1H), 7.24 (m, 1H), 6.30 (s, 1H), 5.82 (m, 2H), 4.99 (m, 6H), 4.73 (s, 1H), 4.44 (s, 
1H), 4.22 (s, 1H), 4.1 (m, 1H), 3.73 (m, 3H), 3.66 (m, 2H), 3.41 (m, 2H), 2.53 (m, 1H), 2.48 (m, 
2H), 2.12 (q, J = 7.2 Hz, 4H), 2.05 (m, 2H), 1.63 (q, J = 7.2 Hz, 4H). 
13C NMR (400 MHz, CD3OD) δ 164.8, 132.6, 132.2, 131.1, 129.9, 128.1, 117.6, 36.9, 31.6. 
31P NMR (400 MHz, CD3OD) δ 4.8, 1.7, -0.1, -0.2. 
ESI-TOF m/z calculated for C48H49ClF3N4O14P (M - H) − 1185.0990, 1185. 0579 observed. 
275 = 1.96 × 10
4 M-1cm-1, 370 = 3.81 × 10
3 M-1cm-1 
The starting material was stored as 
a 25 mM stock solution in DMF at 
-20 oC. An aliquot of the starting 
material (2 μL, 50 nmol) was 
placed in a microtiter well plate 
and cooled to 4 oC. Cold H2O (3 
μL) and NBS in MeCN (25 mM, 5 
μL) was added and the well plate 
was shaken at 4 oC for 9 min. After 9 min, the reaction was quenched by an equal volume of 
Na2S2O3 (200 mM in H2O) and well plate was shaken for additional 5-10 min. The reaction was 
concentrated by speed vacuum, redissolved in 1:1 MeCN/H2O and used directly. 
Reaction Conditions: [SM] = 5 mM, [NBS] = 12.5 mM, 30% H2O, 20% DMF, 50% MeCN 
Quenching Conditions: [SM] = 2.5 mM, [NBS] = 6.25 mM, [Na2S2O3] = 100 mM, 65% H2O, 
10% DMF, 25% MeCN. 
ESI-TOF m/z calculated for C48H49ClF3N4O14P (M + H) – 1049.9738, 1049.9699 observed. 
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Preparation of 73 
Compound 68 (50 mg, 0.08 mmol) was dissolved in 
concentrated aqueous ammonia (0.8 mL). The reaction was 
capped and stirred at 25 oC. After 5 h, TLC (5% MeOH in 
DCM, Rf = 0.2, UV active) confirmed the disappearance of 
starting material and formation of a new, more polar spot. The 
reaction was concentrated to yield 45 mg of crude amide. 
 
 
The crude amide (45 mg, 0.08 mmol) and 
NHS ester X (36 mg, 0.09 mmol. 1.1 eq) were 
azeotropically dried together in pyridine (2 x 
0.5 mL). The contents were dissolved in 
DMF (1.6 mL). The reaction was stirred at 25 
oC overnight. TLC (1:1 EtOAc/Hex, 2% 
MeOH, UV active, Rf = 0.2) suggested the 
starting materials were converted to product. 
The reaction was concentrated and purified by column chromatography (2:1 Hex/EtOAc -> 1:1 
Hex/EtOAc -> 1:1 Hex/EtOAc -> 2% MeOH -> 1:1 Hex/EtOAc, 5% MeOH) to yield 53 mg (78%) 
of 73. 1H NMR (400 MHz, CD3OD) δ 8.56 (s, 3H), 8.34 (s, 1H), 8.26 (s, 1H), 8.04 (m, 3H), 7.94 
(d, J = 8 Hz, 1H), 7.86 (d, J = 8 Hz, 1H), 7.21 (s, 1H), 6.30 (t, J = 6.8 Hz, 1H), 4.69 (m, 1H), 4.34 
(d, J = 3.2 Hz, 2H), 4.03 (d, J = 2.8 Hz, 1H), 3.87 (dd, J = 3.2, 13.9 Hz, 1H), 3.77 (dd, J = 2.8, 
13.9 Hz, 1H), 2.45 (m, 2H). 
237 
 
13C NMR (400 MHz, CD3OD) δ 175.0, 127.9, 127.2, 118.28, 111.6, 55.7, 26.2, 19.2. 
ESI-TOF m/z calculated for C33H24Br2ClF3N4O8 (M + H) – 854.9602, 854.9636 observed. 
Preparation of 74 
Compound 73 (20 mg, 0.023 mmol) 
and dimethyl N, N-diisopropyl 
phosphoramidite (6 mg, 6 μL, 0.03 
mmol, 1.3 eq) were azeotropically 
dried together in pyridine (2 x 0.2 mL). 
S-ethyl tetrazole/MeCN (250 mM, 0.2 
mL, 0.05 mmol, 2.2 eq) was added to 
the reaction flask. After 3.5 h, TLC 
(2:1 EtOAc/Hex) suggested the majority of 73 was consumed. tBuOOH (0.5 M, 7 mg, 15 μL, 0.07 
mmol, 3 eq) was added for an additional 20 min. The reaction was concentrated and purified by 
column chromatography (1:1 Hex/EtOAc -> 1:1 Hex/EtOAc, 2% MeOH) to yield 8 mg (42%) of 
the intermediate phosphate triester. 1H NMR (400 MHz, CDCl3) δ 8.61 (s, 1H), 8.15 (d, J = 4.8 
Hz, 1H), 7.96 (s, 1H), 7.87 (m, 2H), 7.53 (m, 4H), 7.33 (t, J = 4.8 Hz, 4H), 7.04 (s, 1H), 6.28 (m, 
1H), 4.67 (m, 1H), 4.38 (m, 3H), 4.28 (m, 3H), 3.67 (s, 2H), 2.42 (m, 2H). 
31P NMR (400 MHz, CDCl3) δ 10.6, 2.1, 0.0. 




The intermediate phosphate triester (8 mg, 
0.008 mmol) and NaI (2 mg, 0.008 mmol, 
1 eq) were dissolved in acetone (0.1 mL). 
The reaction was stirred at 25 oC for 72 h. 
TLC (10% MeOH in DCM, Rf = 0.2) 
showed a new spot and loss of starting 
material. The reaction was concentrated 
and purified by column chromatography 
(EtOAc -> 25% Isopropanol in EtOAc -> 1:1 EtOAc/Isopropanol -> 2:2:1 EtOAc/ 
Isopropanol/H2O) and Na+ DOWEX column to yield 7.8 mg (100%) of 74. 1H NMR (400 MHz, 
CD3OD) δ 7.75 (d, J = 8.8 Hz, 1H), 7.67 (m, 2H), 7.63 (d, J = 1.2 Hz, 1H), 7.50 (d, J = 8.8 Hz, 
2H), 7.43 (dd, J = 1.2, 8.4 Hz, 2H), 7.26 (m, 2H), 6.90 (d, J = 8.4 Hz, 1H), 6.35 (t, J = 6 Hz, 1H), 
5.23 (m, 1H), 4.27 (m, 5H), 3.63 (m, 2H), 3.54 (m, 1H), 3.49 (m, 2H), 2.87 (m, 3H). 
13C NMR (400 MHz, CD3OD) δ 131.3, 124.9, 124.7, 118.6, 112.4, 52.6, 28.1, 28.0, 15.4. 




Preparation of pro-72 
Compounds 73 (30 mg, 0.035 
mmol) and 12 (35 mg, 0.042 
mmol, 1.2 eq) were azeotropically 
dried together in pyridine (2 x 1 
mL). Sethyl tetrazole/MeCN (250 
mM, 0.25 mL, 0.053 mmol, 1.5 
eq) was added to the reaction 
flask. After 4 h, TLC (1:1 
EtOAc/Hex) suggested the majority of 73 was consumed. tBuOOH (0.5 M, 10 mg, 25 μL, 0.11 
mmol, 3 eq) was added for 20 min. The reaction was concentrated and purified by column 
chromatography (1:1 Hex/EtOAc -> 1:1 Hex/EtOAc, 5% MeOH) to yield 25 mg (60%) of the 
intermediate phosphate triester. 1H NMR (400 MHz, CDCl3) δ 8.16 (m, 1H), 7.87 (s, 1H), 7.78 (d, 
J = 8.8 Hz, 1H), 7.50 (s, 1H), 7.29 (d, J = 8.8 Hz, 1H), 6.95 (s, 1H), 6.75 (m, 1H), 6.36 (quint, J = 
3.2 Hz, 1H), 6.20 (s, 1H), 6.15 (m, 1H), 4.74 (q, J = 5.6 Hz, 1H), 4.31 (m, 4H), 4.23 (m, 6H), 3.82 
(d, J = 5.6 Hz, 1H), 3.51 (m, 1H), 2.77 (m, 4H), 2.53 (m, 1H), 2.08 (s, 3H), 2.03 (s, 3H), 2.00 (m, 
1H), 1.87 (m, 1H). 
13C NMR (400 MHz, CDCl3) δ 169.8, 100.8, 98.2, 60.2, 50.5, 32.2, 25.2, 20.9, 20.83, 20.77, 19.8, 
19.7, 14.6, 14.0. 
31P NMR (400 MHz, CDCl3) δ 17.3, 14.3, 9.2, 9.1, 8.1, 7.9, 7.8, 7.75, 7.70, 7.6, 7.5, -0.5, -0.9, - 
1.4, -1.9, -2.0, -2.5, -2.6, -2.7, -2.8. 




The intermediate phosphate 
triester (25 mg, 0.023 mmol) was 
dissolved in DMF (0.5 mL) and 
DIPEA (0.5 mL). The reaction 
was stirred at 25 oC overnight. 
The following morning, TLC (5% 
MeOH in DCM, Rf = 0.2, UV 
active) suggested product 
formation. The reaction was concentrated and purified by column chromatography (2% MeOH in 
DCM -> 5% MeOH in DCM) and Na+ DOWEX to yield 12.4 mg (50%) of pro-72. 1H NMR (800 
MHz, CD3OD) δ 8.53 (s, 1H), 8.12 (s, 1H), 8.02 (s, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.78 (d, J = 8.5 
Hz, 2H), 7.56 (d, J = 8.8 Hz, 1H), 7.53 (d, J = 8.5 Hz, 2H), 7.24 (s, 1H), 6.30 (quint, J = 5.4 Hz, 
1H), 6.25 (m, 1H), 4.73 (t, J = 6 Hz, 1H), 4.61 (q, J = 6 Hz, 1H), 4.49 (d, J = 14 Hz, 1H), 4.42 (dd, 
J = 3.6, 14 Hz, 1H), 4.24 (m, 3H), 4.14 (m, 1H), 4.05 (t, J = 7 Hz, 1H), 2.62 (m, 2H), 2.48 (q, J = 
6 Hz, 2 H), 2.05 (m, 3H), 1.99 (s, 3H), 1.92 (s, 1H), 1.84 (m, 1H). 
13C NMR (800 MHz, CDCl3) δ 175.7, 170.4, 170.1, 168.6, 163.8, 161.7, 157.5, 154.3, 150.7, 
139.5, 138.6, 135.0, 133.9, 131.3, 130.8, 129.0, 128.4, 127.1, 126.5, 125.7, 125.3, 119.6, 118.3, 
115.0, 111.1, 106.2, 101.1, 100.0, 98.6, 96.7, 85.7, 83.3, 65.0, 63.4, 59.7, 50.2, 43.2, 37.1, 35.4, 
32.0, 26.7, 24.7, 22.6, 19.7, 19.6, 19.5, 14.2. 
31P NMR (400 MHz, CD3OD) δ 6.4, 4.4, 4.3, 4.0, 3.9, 1.6, 1.5, 1.2, -0.26, -0.29, -0.4, -0.5. 




Preparation of 75 
BF3•etherate was distilled from CaH2 at vacuum pressure. Compound 7 
(1.73 g, 6.6 mmol, 1 eq) was dissolved in dry DCM (10 mL) and cooled 
to 0 oC. 6-Nitro veratryl alcohol (NvOH) (8.5 g, 40 mmol, 8 eq) was 
added to the reaction. BF3•etherate (5.7 g, 5 mL, 40 mmol, 8 eq.) was 
added slowly over a period of 15-20 min. After 30 min, TLC (1:1 
Hex/EtOAc, Rf = 0.3) suggested reaction was complete. The reaction was 
quenched with sat. NaHCO3, diluted with DCM, and washed with sat. 
NaHCO3 (1x10 mL). The aqueous layer was extracted with DCM (4x 15 mL) and the organic layer 
was washed with water (1x 30 mL), brine (1x30 mL) and dried over Na2SO4. The residue was 
concentrated and purified by column chromatography (5% EtOAc in DCM) to give 1.8 g (48%) of 75. 
This product was difficult to purify away from the NvOH reagent so the impure product was carried 
forward to the next step. 1H NMR (400 MHz, CDCl3) δ 7.69 (s, 3H), 7.17 (s, 2H), 5.2 (m, 2H), 4.94 
(dd, J = 0.5, 6.6 Hz, 3H), 3.99 (s, 3H), 3.97 (m, 5H), 3.94 (s, 4H), 3.91 (s, 3H), 3.83 (d, J = 6.6 Hz, 
1H), 2.63 (t, J = 6.6 Hz, 1H), 2.04 (m, 3H). 
Preparation of 76 
Compound 75 (1.8 g, 3.2 mmol) was dissolved in MeOH (3 mL). Sodium 
methoxide stock solution (2.5 M) was prepared by dissolving Na metal 
(580 mg, 25.2 mmol) in MeOH (10 mL). An aliquot of 2.5 M NaOMe (6.5 
mL) was added to the reaction solution slowly (effectively diluting the NaOMe to 1.7 M). After 2 h, 
TLC (25% EtOAc in DCM, Rf = 0.3) confirmed reaction complete. The reaction was quenched with 
AcOH until neutral pH, diluted with DCM (20 mL), and washed with H2O (2 x15 mL). The aqueous 
layer was extracted with DCM (4 x 20 mL) and the organic layer was washed with brine (1 x 30 mL) 
and dried over Na2SO4. The reaction was concentrated and purified by column chromatography (DCM 
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-> 25% EtOAc in DCM) to yield 1.1 g (70%) of 76. 1H NMR (400 MHz, CDCl3) δ 7.63 (s, 2H), 7.12 
(m, 2H), 5.05 (m, 2H), 4.91 (m, 3H), 3.93 (s, 6H), 3.88 (s, 6H), 3.80 (m, 2H), 2.25 (m, 2H), 2.41 (m, 
1H), 2.24 (m, 1H). 
Preparation of 77 
Compound 76 (279 mg, 0.53 mmol) was azeotropically dried with 
pyridine (2 x 2 mL). The flask cooled to 0 oC. DIPEA (284 mg, 
0.4 mL, 2.2 mmol, 4 eq) was added to the cold starting material 
and the reactants dissolved in DCM (2 mL, 250 mM). 2-
Cyanoethyl-N, N-diisopropylchlorophosphoramidite (150 mg, 
0.15 mL, 0.6 mmol. 1.2 eq) was added. After 2 h, TLC (3:1 Hex/EtOAc, Rf = 0.3, stained with 
PAA) showed complete conversion to the phosphoramidite. The reaction was diluted with EtOAc 
(10 mL). The organic layer was washed with saturated bicarbonate solution (2 x15 mL) and the 
aqueous layers were extracted with EtOAc (2 x 20 mL). The combined organic layers were washed 
with brine (1 x 25 mL) and dried over Na2SO4. The organic layer was concentrated under vacuum 
and purified by column chromatography (3:1 hexanes/EtOAc) yielding 312 mg (81%) of 77. 1H 
NMR (400 MHz, CDCl3) δ 7.72 (s, 2H), 7.64 (s, 1H), 7.23 (t, J = 6.4 Hz, 1H), 7.13 (s, 1H), 5.43 
(m, 1H), 5.27 (m, 1H), 5.00 (m, 5H), 4.02 (m, 4H), 3.97 (s, 3H), 3.94 (s, 3H), 3.83 (d, J = 6.4 Hz, 
2H), 3.61 (m, 2H), 2.66 (m, 3H), 2.19 (s, 1H), 2.06 (s, 1H), 1.21 (m, 12H). 




Preparation of 78 
Compounds 77 (82 mg, 0.16 mmol) and 55 (182 mg, 0.34 
mmol, 2.2 eq) were azeotropically dried together in pyridine 
(2 x 1 mL). S-ethyl tetrazole/MeCN (250 mM, 0.75 mL, 0.19 
mmol, 1.2 eq) was added to the reaction flask. After 4 h, TLC 
(25% EtOAc in DCM, Rf = 0.5) suggested the majority of 55 
was consumed. tBuOOH (0.5 M, 21 mg, 50 μL, 0.23 mmol, 
1.5 eq) was added for 20 min. The reaction was evaporated to dryness under vacuum and purified 
by column chromatography (DCM -> 5% MeOH in DCM) to yield 77 mg (60%) of 78. 1H NMR 
(400 MHz, CDCl3) δ 10.2 (s, 1H), 8.8 (q, J = 6 Hz, 1H), 7.63 (s, 1H), 7.43 (s, 1H), 7.10 (m, 1H), 
6.33 (s, 1H), 5.37 (m, 1H), 5.17 (m, 1H), 4.94 (m, 2H), 4.85 (m, 1H), 4.57 (s, 1H), 4.35 (s, 2H), 
4.28 (m, 3H), 4.20 (s, 2H), 4.09 (m, 1H), 4.02 (m, 1H), 3.95 (s, 6H), 3.89 (s, 3H), 2.78 (q, J = 6 
Hz, 2H), 2.65 (m, 1H), 2.51 (m, 1H), 2.27 (m, 2H), 1.87 (s, 3H), 1.79 (m, 1H), 1.21 (m, 2H). 
13C NMR (400 MHz, CDCl3) δ 164.1, 155.2, 153.5, 153.4, 150.8, 149.0, 147.8, 124.1, 117.1, 
108.0, 56.4, 56.3, 56.2, 53.4, 27.1, 19.7, 14.8, 12.3. 
31P NMR (400 MHz, CDCl3) δ 14.0, 8.1, -2.0, -2.10, -2.11, -2.14, -2.2, -2.21, -2.3, -2.4, -2.5, -3.0, 
-3.6. 




Preparation of 79 
Compound 78 (77 mg, 0.08 mmol) was dissolved in MeCN 
(0.5 mL) and TEA (0.5 mL). The reaction was stirred at 25 oC 
for 16 h. TLC (5% MeOH in DCM, Rf = 0.3) suggested 
reaction was complete. The reaction was concentrated to yield 
70 mg of crude material. 1H NMR (400 MHz, CDCl3) δ 7.55 
(s, 2H), 7.45 (s, 1H), 7.05 (s, 2H), 6.91 (m, 1H), 6.18 (s, 1H), 
5.32 (s, 1H), 5.22 (s, 1H), 5.10 (s, 1H), 4.87 (m, 1H), 4.76 (m, 2H), 4.50 (m, 1H), 4.14 (s, 2H), 3.97 
(m, 3H), 3.87 (s, 4H), 3.82 (s, 4H), 3.79 (t, J = 4 Hz, 3H), 3.71 (s, 2H), 2.54 (m, 1H), 2.40 (m, 3H), 
1.76 (s, 3H). 
ESI-TOF m/z calculated for C35H40F3N5O19P (M - H) – 923.2013, 923.2099 observed. 
The crude material (32 mg, 0.035 mmol) was further 
deprotected by addition of NaOH (1.7 mL, 0.1 M, 5 eq.) in 
20% MeCN in H2O. After 2 h, the reaction was quenched by 
an equal molar equivalent of formic acid (17 L, 1 M). The 
reaction was evaporated to dryness to yield 29 mg (100%) of 
79. 1H NMR (400 MHz, CD3OD) δ 7.78 (m, 1H), 7.76 (m, 1H), 7.67 (m, 2H), 7.55 (m, 1H), 7.22 (m, 
2H), 6.20 (m, 1H), 5.40 (m, 1H), 5.29 (m, 1H), 5.17 (m, 1H), 5.00 (m, 1H), 4.82 (m, 2H), 4.07 (s, 
3H), 3.94 (m, 6H) 3.89 (s, 5H), 3.85 (s, 2H), 3.77 (m, 2H), 3.59 (m, 1H), 2.86 (s, 1H), 2.26 (m, 
2H), 2.17 (m, 2H), 1.84 (m, 3H).  
31P NMR (400 MHz, CD3OD) δ 4.7, 0.44, 0.41, 0.36, 0.32, 0.27, 0.22, 0.17, 0.12, 0.07. 




General Procedure for preparing Library 58 through Scaffold 79 
Amine scaffold 79 (50 nmol) was azeotropically dried with carboxylic acid (140 nmol, 1.4 
eq) in pyridine (1 x 15 L) using a Speed Vac concentrator in a 384-well microtiter plate (VWR). 
To each well, a 2X activating solution (5 L; 28 mM HBTU and 28 mM HOBt in DMF), DIPEA 
(2 L), and DMF (3 L) were added. The final concentrations during reaction were: [79] = 5 mM, 
[acid] = 7 mM, [HBTU] = 7 mM, [HOBt] = 7 mM, 20% DIPEA in DMF. The well plate was 
shaken at 25 oC overnight. Some wells were analyzed by ESI-MS to confirm coupling efficiency. 
The solutions were concentrated using a Speed Vac concentrator and the well plate was covered 
and stored at -80 oC. 
Immediately before an assay, the amide was thawed, dissolved in 1:1 MeCN/H2O (10 L, 
5 mM). Samples were photolyzed in a clear 384-well plate (VWR) using a transilluminator at 365 
nm for 15 min. During photolysis, the plate was covered with aluminum foil and a fan was turned 
on near the system to prevent heating the samples. Prior to carrying out the photolysis on the entire 
library, the photolysis reaction was carried out on model compound (79) for 10-30 min and 
analyzed by ESI and HPLC, to determine optimal time. The reaction was complete after 15 min. 
There was no significant difference in reaction products after longer photolysis times (i.e. 30 min). 
It should be noted that prior to use in an assay, the sample was diluted to a final volume of 10 L 
to account for solvent evaporation during photolysis. Some samples were analyzed ESI-MS to 




Preparation of 80 
Scaffold 79 (10 mg, 0.01 mmol) and 6-hydroxy-2-
methylquinoline-3-carboxylic acid (6 mg, 0.022 mmol, 2 
eq) were azeotropically dried together in pyridine (2 x 0.5 
mL). HBTU (6 mg, 0.02 mmol, 1.4 eq) and HOBT (2 mg, 
0.02 mmol, 1.4 eq) were added to the reaction flask. The 
contents were dissolved in DMF (0.2 mL) and DIPEA 
(40 L). The reaction was stirred at 25 oC overnight. TLC 
(5% MeOH in DCM, Rf = 0.3) suggested the starting materials were converted to product. The 
reaction was evaporated to dryness under vacuum and purified by column chromatography (DCM 
-> 5% MeOH in DCM) to yield 10 mg (90%) of 84.  
A small portion of 84 (50 nmol, 5 mM in 1:1 MeCN/H2O) was photolyzed at 365 nm for 15 min. 
The product was confirmed by analyzing an aliquot of the reaction (2 L) by ESI-MS. 
ESI-MS m/z calculated for C26H31N4O12P (M - H) – 621.17, 621.25 observed. 
Preparation of 81 
Scaffold 79 (10 mg, 0.01 mmol) and 52 (5.8 mg, 0.014 mmol, 
1.4 eq) were azeotropically dried together with pyridine (2 x 
0.5 mL). The contents were dissolved in DMF (0.2 mL) and 
DIPEA (40 L). The reaction was stirred at 25 oC overnight. 
TLC (5% MeOH in DCM, Rf = 0.3) suggested the starting 
materials were converted to product. The reaction was 
evaporated to dryness under vacuum and purified by column 
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chromatography (DCM -> 5% MeOH in DCM) to yield 6 mg (60%) of 89. 
A small portion of 89 (50 nmol, 5 mM in 1:1 MeCN/H2O) was photolyzed at 365 nm for 15 min. 
The product was confirmed by analyzing an aliquot of the reaction (2 L) by ESI-MS. 
ESI-MS m/z calculated for C26H30N3O13P (M - H) – 622.15, 622.10 observed. 
Preparation of 82 
The precursor to 55 (3’-amino deoxythymidine) (210 mg, 0.87 mmol, 
1.6 eq) and 6-hydroxy-2-methylquinoline-3-carboxylic acid (125 mg, 
0.52 mmol) were azeotropically dried together with pyridine (1 x 1 
mL). HBTU (280 mg, 0.73 mmol, 1.4 eq) and HOBt (100 mg, 0.73 
mmol, 1.4 eq) were added and reagents were dissolved in DMF (6 mL) 
and DIPEA (1.5 mL, 20%). Reaction was stirred at 25 oC overnight. 
The following day, TLC (3% MeOH, Rf = 0.7) suggested the 
carboxylic acid was consumed. The reaction was concentrated and 
purified by column chromatography (DCM -> 3% MeOH in DCM) to yield 156 mg (65%) 82. 1H 
NMR (400 MHz, DMSO-d6) δ 11.3 (s, 1H), 10.00 (s, 1H), 8.95 (d, J = 7.4 Hz, 1H), 8.15 (s, 1H), 7.83 
(s, 1H), 7.79 (d, J = 9 Hz, 1H), 7.33 (d, J = 9 Hz, 1H), 7.17 (s, 1H), 6.28 (t, J = 6.5 Hz, 1H), 5.17 (s, 




Preparation of 83 
Compounds 77 (63 mg, 0.09 mmol) and 82 (92 mg, 0.22 
mmol, 2.5 eq) were azeotropically dried together in pyridine 
(2 x 1 mL). S-ethyl tetrazole/MeCN (250 mM, 1 mL, 0.25 
mmol, 2.7 eq) and DCM (1 mL) were added to the reaction 
flask. After 4 h, TLC (3% MeOH in DCM, Rf = 0.5) 
suggested the majority of 82 was consumed. tBuOOH (0.5 
M, 24 mg, 50 μL, 0.26 mmol, 2.8 eq) was added for 20 min. 
The reaction was evaporated to dryness under vacuum and 
purified by column chromatography (DCM -> 3% MeOH 
in DCM) to yield 50 mg (53%) of 83. 1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H), 8.17 (s, 1H), 7.73 
(d, J = 7.5 Hz, 1H), 7.64 (d, J = 7.5 Hz, 1H), 7.54 (m, 1H), 7.29 (m, 2H), 6.99 (m, 2H), 6.31 (s, 1H), 
5.33 (s, 2H), 5.04 (m, 1H), 4.87 (m, 2H), 4.72 (m, 1H), 4.47 (s, 2H), 4.31 (s, 3H), 3.92 (s, 3H), 3.88 
(m, 5H), 3.69 (m, 3H), 3.17 (q, J = 6.6 Hz, 2H), 3.14 (q, J = 7.4 Hz, 2H), 2.79 (s, 2H), 2.70 (s, 3H), 
2.57 (s, 1H), 2.36 (s, 1H), 2.16 (s, 1H), 1.77 (s, 3H),1.32 (t, J = 6.6, 4H). 




Preparation of 84 
Compound 83 (20 mg, 0.02 mmol) was dissolved in 50% 
TEA in MeCN (0.5 mL). The reaction was stirred overnight 
at 25 oC. The following day, the reaction was concentrated 
and purified by a DOWEX Na+ exchange column to yield 
18 mg (94%) of 84.  1H NMR (800 MHz, CD3OD) δ 8.17 (m, 
1H), 7.80 (t, J = 8 Hz, 1H), 7.69 (dd, J = 7.2, 8 Hz, 2H), 7.52 
(m, 1H), 7.35 (m, 1H), 7.27 (quint, J = 3 Hz, 2H), 7.16 
(quint, J = 3 Hz, 1H), 7.07 (q, J = 7.2 Hz, 1H), 6.35 (m, 
1H), 6.25 (m, 1H), 5.42 (m, 3H), 5.10 (m, 2H), 4.88 (m, 
2H), 4.70 (m, 2H), 4,65 (quint, J = 5 Hz, 1H), 4.25 (t, J = 4 Hz, 1H), 4.22 (q, J = 4 Hz, 1H), 4.19 
(m, 2H), 4.14 (q, J = 5 Hz, 1H), 4.05 (m, 1H), 3.97 (d, J = 5 Hz, 3H), 3.87 (m, 4H), 3.77 (m, 2H), 
2.70 (m, 3H), 2.52 (m, 1H), 2.44 (m, 1H), 2.23 (m, 2H), 2.11 (m, 1H), 1.98 (s, 1H), 1.93 (m, 2H). 
13C NMR (800 MHz, CD3OD) δ 169.7, 165.0, 164.9, 157.5, 155.9, 152.5, 147.7, 143.1, 142.3, 
139.1, 134.2, 130.0, 127.5, 127.3, 123.7, 123.5, 122.9, 117.4, 110.6, 110.2, 110.0, 107.6, 107.4, 
106.8, 104.9, 104.8, 104.0, 84.6, 83.4, 66.8, 66.4, 65.9, 65.5, 65.2, 55.5, 55.3, 55.2, 50.7, 41.2, 
39.9, 39.0, 37.1, 33.9, 32.8, 26.7, 21.4, 14.1. 
31P NMR (400 MHz, CD3OD) δ -2.0, -2.1, -2.3. 
ESI-TOF m/z calculated for C44H49N6O20P (M + H) – 1013.2739, 1013.2813 observed. 





Preparation of 85199 
3, 5-Dihydroxy naphthoic-2-acid (122 mg, 0.6 mmol, 1 eq) and DMAP 
(7.17 mg, 0.06 mmol, 0.1 eq) were dissolved in DCM (1.5 mL) and 
cooled to 0 oC. Pyridine (559 mg, 0.57 mL, 7.03 mmol, 12.5 eq) was 
added slowly to the solution. Next, acetic anhydride (358 mg, 0.33 mL, 
3.5 mmol, 6 eq) was added dropwise. After 2.5 h, TLC (10% MeOH in DCM, Rf = 0.7) confirmed 
the reaction was complete. The reaction was quenched with sat. NaHCO3 until neutral pH. The 
mixture was diluted with EtOAc (5 mL) and washed with water (2 x 10 mL). The aqueous layer 
was extracted with EtOAc (2 x 20 mL), the combined organic layers were washed with brine (1 x 
30 mL) and dried over Na2SO4. The crude residue was purified by column chromatography (1:1 
Hex/EtOAc-> 1:2 Hex/EtOAc) to yield 40 mg (20%) of 85. 1H NMR (400 MHz, CD3CN) δ 8.68 
(s, 1H), 7.94 (d, J = 8 Hz, 1H), 7.65 (s, 1H), 6.58 (t, J = 8 Hz, 1H), 7.41 (d, J = 8 Hz, 1H), 2.43 (s, 
3H), 2.32 (s, 3H). 
Preparation of 86 
Compound 85 (630 mg, 2.2 mmol) was azeotropically dried with 
pyridine (2 x 1 mL). N-hydroxysuccinimide (360 mg, 3.3 mmol, 
1.5 eq) and EDC (640 mg, 3.3 mmol, 1.5 eq) were added and the 
reagents were dissolved in DMF (4 mL). The reaction stirred at 25 
oC overnight. The following day, TLC (3% MeOH in DCM, Rf = 0.8) suggested the starting 
material was consumed. The reaction was concentrated and purified by column chromatography 
(3:1 Hex/EtOAc -> 1:1 Hex/EtOAc) to yield 503 mg (60%) of 86. 1H NMR (400 MHz, CDCl3) δ 
876 (s, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.65 (s, 1H), 7.55 (dd, J = 7.7, 8.2 Hz, 1H), 7.46 (d, J = 7.7 




Preparation of 87 
 The precursor to 55 (3’-amino deoxythymidine) (260 mg, 1.1 mmol, 2.4 
eq) and 86 (176 mg, 0.46 mmol) were azeotropically dried together with 
pyridine (1 x 1 mL). The reagents were dissolved in DMF (2.2 mL) and 
DIPEA (0.6 mL, 20%). The reaction was stirred at 25 oC overnight. The 
following day, TLC (3% MeOH, Rf = 0.7) suggested the carboxylic acid 
was consumed. The reaction was concentrated and purified by column 
chromatography (DCM -> 3% MeOH in DCM) to yield 120 mg (45%) 
87. 1H NMR (400 MHz, DMSO-d6) δ 8.05 (d, J = 6.8 Hz, 1H), 8.00 (s, 
1H), 7.90 (d, J = 9 Hz, 1H), 7.38 (d, J = 2.2 Hz, 1H), 7.35 (dd, J = 2.2, 9 Hz, 1H), 7.22 (s, 1H), 
6.12 (t, J = 6.8 Hz, 1H), 4.56 (m, 1H), 4.35 (s, 2H), 4.14 (m, 1H), 3.37 (s, 1H), 2.67 (s, 2H), 2.27 
(s, 2H), 2.12 (m, 1H), 2.06 (s, 3H), 1.59 (s, 3H). 
Preparation of 88 
Compounds 77 (30 mg, 0.04 mmol) and 87 (35 mg, 0.07 
mmol, 1.75 eq) were azeotropically dried together in pyridine 
(2 x 0.5 mL). S-ethyl tetrazole/MeCN (250 mM, 0.4 mL, 0.1 
mmol, 2.5 eq) was added to the reaction flask. After 4 h, TLC 
(3% MeOH in DCM, Rf = 0.5) suggested the majority of 87 
was consumed. tBuOOH (0.5 M, 12 mg, 25 μL, 0.13 mmol, 
3.2 eq) was added for 20 min. The reaction was evaporated to 
dryness under vacuum and purified by column 
chromatography (DCM -> 3% MeOH in DCM) to yield 25 
mg (60%) of 88. 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 5 Hz, 2H), 7.60 (m, 2H), 7.46 (m, 1H), 
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7.20 (m, 2H), 7.05 (m, 1H), 6.27 (d, J = 5 Hz, 1H), 5.37 (m, 2H), 5.06 (m, 1H), 4.91 (m, 3H), 4.73 
(m, 2H), 4.46 (m, 3H), 4.29 (m, 4H), 3.95 (m, 4H), 3.88 (m, 5H), 3.82 (m, 2H), 2.80 (m, 2H), 2.65 
(s, 6H), 2.54 (m, 1H), 2.43 (s, 3H), 2.17 (s, 1H), 1.87 (m, 2H).  
31P NMR (400 MHz, CDCl3) δ -2.06, -2.11, -2.16, -2.19, -2.23, -2.26, -2.31. 
Preparation of 89 
Compound 88 (20 mg, 0.02 mmol) was dissolved in 50% 
TEA in MeCN (0.5 mL). The reaction was stirred overnight 
at 25 oC. The following day, the reaction was concentrated 
and purified by a DOWEX Na+ exchange column to yield 19 
mg (95%) of 89. 1H NMR (800 MHz, CD3OD) δ 8.31 (s, 1H), 
7.84 (s, 1H), 7.59 (m, 2H), 7.46 (m, 2H), 7.28 (s, 2H), 7.09 (m, 
2H), 7.01 (m, 1H), 6.78 (m, 1H), 6.38 (m, 1H), 5.40 (m, 2H), 
5.06 (m, 1H), 4.78 (m, 2H), 4.28 (m, 2H), 4.18 (m, 2H), 4.02 (m, 
1H), 3.93 (m, 4H), 3.83 (m, 8H), 3.75 (m, 2H), 2.63 (s, 1H), 2.51 
(m, 2H), 2.23 (m, 1H), 2.07 (m, 1H), 1.95 (m, 3H). 
13C NMR (800 MHz, CD3OD) δ 169.3, 165.0, 157.5, 154.4, 153.3, 151.5, 150.9, 147.6, 139.9, 
136.6, 129.75, 129.68, 129.1, 128.4, 128.3, 110.6, 110.0, 109.9, 109.2, 107.7, 107.4, 105.8, 104.8, 
84.6, 83.9, 66.3, 66.2, 65.2, 55.5, 55.4, 55.2, 39.0, 37.3, 33.9, 29.4, 26.8, 24.8, 14.2, 11.3. 
31P NMR (400 MHz, CD3OD) δ -2.0, -2.1, -2.16, -2.19, -2.23, -2.26, -2.30. 
ESI-TOF m/z calculated for C44H49N5O21P (M + H) – 1014.2579, 1014.2628 observed. 





Preparation of 90 
Compound 66 (340 mg, 0.73 mmol) was azeotropically dried with 
6-hydroxy-2-methylquinoline-3-carboxylic acid (240 mg, 1.0 
mmol, 1.4 eq) in pyridine (2 x 1 mL). HBTU (370 mg, 1.0 mmol, 
1.4 eq) and HOBt (150 mg, 1.0 mmol, 1.4 eq) were added. Reagents 
were dissolved in DMF (3.2 mL, 200 mM) with 20% DIPEA (0.8 
mL). The reaction was stirred at 25 oC overnight. The following day, 
the reaction was concentrated and purified by column 
chromatography to yield 328 mg (70%) of 90. 1H NMR (400 MHz, 
CDCl3) δ 8.07 (s, 1H), 7.79 (s, 2H), 7.57 (s, 1H), 7.43 (m, 2H), 6.17 
(t, J = 7.2 Hz, 1H), 4.53 (m, 1H), 4.07 (m, 2H), 4.00 (m, 1H), 3.93 (d, J = 2.4 Hz, 2H), 2.39 (s, 
3H), 2.31 (s, 3H), 2.25 (m, 2H), 0.89 (s, 9H), 0.11 (d, J = 1.8 Hz, 6H). 
Preparation of 91 
Compound 90 (160 mg, 0.25 mmol) was dissolved in THF (1.1 
mL). TEA•3HF (99 mg, 0.62 mmol, 0.1 mL, 2.5 eq) was added to 
the flask. The reaction was stirred at 25 oC overnight. TLC (3% 
MeOH in DCM, Rf = 0.2, UV active and stained with PAA) 
confirmed conversion to product. The reaction was concentrated 
and purified by column chromatography (1:1 Hex/EtOAc -> 2% 
MeOH in 1:1 Hex/EtOAc) to yield 191 mg (75%) of 91. 1H NMR 
(400 MHz, CD3OD) δ 8.2 (d, J = 10 Hz, 2H), 7.85 (d, J = 11.8 Hz, 
2H), 7.47 (m, 1H), 7.38 (dd, J = 3.6, 11.8 Hz, 1H), 7.18 (d, J = 3.6 Hz, 1H), 6.27 (t, J = 8.3 Hz, 
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1H), 4.75 (q, J = 10 Hz, 1H), 4.18 (s, 2H), 3.97 (dd, J = 3.6, 16.3 Hz, 1H), 3.88 (dd, J = 5, 16.3 
Hz, 1H), 3.72 (q, J = 10 Hz, 1H), 2.71 (s, 3H), 2.53 (t, J = 8.3 Hz, 2H). 
Preparation of 92 
Compounds 77 (132 mg, 0.18 mmol, 4 eq) and 
91 (25 mg, 0.04 mmol) were azeotropically dried 
together in pyridine (2 x 1 mL). S-ethyl 
tetrazole/MeCN (250 mM, 0.75 mL, 0.19 mmol, 
4.5 eq) was added to the reaction flask. After 4 h, 
TLC (3% MeOH in DCM, Rf = 0.5) suggested 
the majority of 91 was consumed. tBuOOH (0.5 
M, 21 mg, 50 μL, 0.2 mmol, 5 eq) was added for 20 min. The reaction was evaporated to dryness 
under vacuum and purified by column chromatography (DCM -> 5% MeOH in DCM) to yield 45 
mg (95%) of 92. 1H NMR (400 MHz, CDCl3) δ 8.2 (m, 2H), 7.85 (m, 1H), 7.75 (m, 1H), 7.56 (m, 
2H), 7.44 (m, 2H), 7.30 (m, 1H), 7.20 (m, 2H), 7.02 (m, 1H), 6.28 (s, 1H), 5.44 (m, 2H), 5.04 (m, 
2H), 4.86 (m, 4H), 4.28 (m, 7H), 3.92 (s, 6H), 3.85 (m, 9H), 3.73 (s, 4H), 2.92 (m, 1H), 2.79 (s, 
1H), 2.70 (s, 3H), 2.58 (m, 1H), 2.23 (m, 1H), 1.77 (m, 4H). 




Preparation of 93 
Compound 92 (45 mg, 0.04 mmol) was dissolved 
in MeCN (0.25 mL) and TEA (0.25 mL). The 
reaction stirred at 25 oC for 16 h. TLC (5% 
MeOH in DCM, Rf = 0.3) suggested reaction was 
complete. The reaction was concentrated to yield 
30 mg (66%) crude material. The crude material 
was purified by DOWEX Na+ ion exchange 
column and lyophilized three times to remove excess triethylamine. 1H NMR (800 MHz, CD3OD) 
δ 8.20 (m, 1H), 7.80 (m, 1H), 7.71 (m, 1H), 7.63 (d, J = 2.8 Hz, 1H), 7.54 (m, 2H), 7.34 (d, J = 2.8 
Hz, 1H), 7.20 (s, 2H), 7.06 (m, 1H), 6.30 (s, 1H), 5.41 (m, 2H), 5.04 (m, 1H), 4.81 (m, 2H), 4.28 
(m, 4H), 4.21 (m, 2H), 4.14 (m, 1H), 4.05 (q, J = 6 Hz, 1H), 3.97 (d, J = 14 Hz, 2H), 3.93 (d, J = 
14 Hz, 3H), 3.87 (m, 4H), 3.87 (m, 4H), 3.76 (m, 2H), 2.80 (t, J = 6 Hz, 1H), 2.70 (d, J = 6 Hz, 
2H), 2.67 (m, 1H), 2.52 (m, 2H), 2.11 (m, 1H), 1.88 (m, 1H), 1.31 (m, 3H). 
13C NMR (800 MHz, CD3OD) δ 169.7, 163.5, 157.5, 157.4, 157.2, 156.3, 155.9, 153.7, 153.3, 
152.5, 151.3, 150.7, 147.7, 142.3, 139.8, 139.7, 139.2, 139.1, 134.2, 130.0, 129.8, 128.2, 127.3, 
126.2, 123.0, 116.9, 115.4, 110.1, 110.0, 109.5, 109.1, 108.5, 107.6, 107.4, 104.8, 85.4, 83.7, 66.3, 
65.8, 64.8, 55.2, 37.6, 32.8, 29.4, 26.7, 23.4, 21.9, 21.8, 21.4, 19.0, 17.9, 14.2, 7.9. 
31P NMR (400 MHz, CD3OD) δ -2.1, -2.16 -2.19, -2.23, -2.26 -2.30. 
ESI-TOF m/z calculated for C46H49F3N7O21P (M + H) – 1124.2671, 1124.2737 observed. 
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The crude material (15 mg, 0.013 mmol) was 
dissolved in concentrated aqueous ammonium 
hydroxide (0.6 mL, 20 mM). After 2 h, the reaction 
was quenched by an equal molar equivalent of formic 
acid (12 L, 1 M). The reaction was evaporated to 
dryness to yield 14 mg (100%) of 93. The product was 
confirmed by UPLC-MS.  
ESI-TOF m/z calculated for C44H50N7O20P (M + H) – 1028.2848, 1028.2908 observed. 
General Procedure for Amide Coupling and Deprotection for Library 94 (Includes the 
preparation of 95-102) 
Amine scaffold 93 (50 nmol) was azeotropically dried with carboxylic acid (70 nmol, 1.4 
eq) in pyridine (1 x 15 L) using a Speed Vac concentrator in a 384-well microtiter plate (VWR). 
To each well, a 2X activating solution (5 L; 14 mM HBTU and 14 mM HOBt in DMF), DIPEA 
(2 L), and DMF (3 L) were added. The final concentrations during reaction were: [93] = 5 mM, 
[acid] = 7 mM, [HBTU] = 7 mM, [HOBt] = 7 mM, 20% DIPEA in DMF. The well plate was 
shaken at 25 oC overnight. Some wells were analyzed by ESI-MS to confirm coupling efficiency. 
The solutions were concentrated using a Speed Vac concentrator and the well plate was covered 
and stored at -80 oC. 
Immediately before an assay, the amide was thawed. The crude amide (50 nmol, 10 L, 5 
mM in 1:1 MeCN/H2O) was photolyzed at 365 nm for 15 min using a transilluminator. It should 
be noted that prior to use in an assay, the sample was diluted to a final volume of 10 L to account 
for solvent evaporation during photolysis. The product was confirmed by analyzing an aliquot of 
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Appendix 2. Supplementary Data including NMR Spectra and MALDI-TOF 
Appendix Figure 1. IC50 of 72 under other conditions. 
Appendix Figure 2. 1H NMR Spectrum of precursor to 5. 






















Appendix Figure 3. 1H NMR Spectrum of 5. 
Appendix Figure 4. 1H NMR Spectrum of 6. 
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Appendix Figure 6. 1H NMR Spectrum of 8a. 




Appendix Figure 8. 13C NMR Spectrum of 8a and 8b. 
Appendix Figure 9. 1H NMR Spectrum of 9. 
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Appendix Figure 11. 31P NMR Spectrum of 10. 





Appendix Figure 13. 1H and 31P NMR Spectrum of 12. 
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Appendix Figure 14. 1H NMR Spectrum of Precursor to 13. 
Appendix Figure 15. 1H NMR Spectrum of 13. 
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Appendix Figure 16. 1H NMR Spectrum of 14. 
Appendix Figure 17. 1H NMR Spectrum of 15. 
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Appendix Figure 18. 1H NMR Spectrum of 16. 
Appendix Figure 19. 1H NMR Spectrum of 17. 
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Appendix Figure 20. 13C and 31P NMR Spectrum of 17. 
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Appendix Figure 21. 1H and 13C NMR Spectrum of Precursor to 18. 
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Appendix Figure 22. 31P NMR Spectrum of Precursor to 18. 
Appendix Figure 23. 1H NMR Spectrum of 18. 
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Appendix Figure 24. 13C and 31P NMR Spectrum of 18. 
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Appendix Figure 25. 1H and 13C NMR Spectrum of 19. 
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Appendix Figure 26. 31P NMR Spectrum of 19. 
Appendix Figure 27. 1H NMR Spectrum of Precursor to 20. 
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Appendix Figure 28. 13C and 31P NMR Spectrum of Precursor to 20. 
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Appendix Figure 29. 1H and 13C NMR Spectrum of 20. 
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Appendix Figure 30. 31P NMR Spectrum of 20. 
Appendix Figure 31. 1H NMR Spectrum of 21. 
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Appendix Figure 32. 1H NMR Spectrum of 22. 
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Appendix Figure 33. 1H and 31P NMR Spectrum of 23. 
315 
 
Appendix Figure 34. 1H and 13C NMR Spectrum of 24. 
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Appendix Figure 35. 31P NMR Spectrum of 24. 
Appendix Figure 36. 1H NMR Spectrum of Precursor to 25. 
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Appendix Figure 37. 13C and 31P NMR Spectrum of Precursor to 25. 
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Appendix Figure 38. 1H NMR Spectrum of 25. 
Appendix Figure 39. 1H NMR Spectrum of 26. 
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Appendix Figure 40. 1H NMR Spectrum of 27. 
Appendix Figure 41. 1H NMR Spectrum of 28. 
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Appendix Figure 42. 1H NMR Spectrum of 29. 
Appendix Figure 43. 1H NMR Spectrum of 30. 
321 
 
Appendix Figure 44. 1H NMR Spectrum of 31. 
Appendix Figure 45. 1H NMR Spectrum of 32. 
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Appendix Figure 46. 1H NMR Spectrum of 33. 
Appendix Figure 47. 1H NMR Spectrum of 34. 
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Appendix Figure 48. 1H NMR Spectrum of 35. 
Appendix Figure 49. 1H NMR Spectrum of 36. 
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Appendix Figure 50. 1H NMR Spectrum of 37. 
Appendix Figure 51. 1H NMR Spectrum of 38. 
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Appendix Figure 52. 1H NMR Spectrum of 40. 
Appendix Figure 53. 1H NMR Spectrum of 41. 
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Appendix Figure 54. 1H NMR Spectrum of 42. 
Appendix Figure 55. 1H NMR Spectrum of 43. 
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Appendix Figure 57. 1H and 13C NMR Spectrum of 44. 
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Appendix Figure 58. 31P NMR Spectrum of 44. 
Appendix Figure 59. 1H NMR Spectrum of Precursor to 45. 
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Appendix Figure 61. 1H NMR Spectrum of 49. 
Appendix Figure 62. 1H NMR Spectrum of 50. 
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Appendix Figure 63. 1H NMR Spectrum of 51. 
Appendix Figure 64. 1H NMR Spectrum of 52. 
333 
 
Appendix Figure 65. 1H NMR Spectrum of Precursor to 53. 
Appendix Figure 66. 1H NMR Spectrum of 53. 
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Appendix Figure 67. 1H NMR Spectrum of Precursor to 54. 
Appendix Figure 68. 1H NMR Spectrum of 54. 
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Appendix Figure 69. 1H NMR Spectrum of Precursor to 55. 
Appendix Figure 70. 1H NMR Spectrum of 55. 
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Appendix Figure 71. 13C NMR Spectrum of 55. 
Appendix Figure 72. 1H NMR Spectrum of 56. 
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Appendix Figure 73. 31P NMR Spectrum of 56. 
Appendix Figure 74. 1H NMR Spectrum of 57. 
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Appendix Figure 75. 31P NMR Spectrum of 57. 
Appendix Figure 76. 1H NMR Spectrum of 59. 
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Appendix Figure 77. 1H NMR Spectrum of 60. 
Appendix Figure 78. 1H NMR Spectrum of 61. 
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Appendix Figure 79. 31P NMR Spectrum of 61. 
Appendix Figure 80. 1H NMR Spectrum of Precursor to 63. 
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Appendix Figure 81. 31P NMR Spectrum of Precursor to 63. 
 




Appendix Figure 83. 31P NMR Spectrum of Precursor to 64. 
Appendix Figure 84. 1H NMR Spectrum of 65. 
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Appendix Figure 85. 13C NMR Spectrum of 65. 
Appendix Figure 86. 1H NMR Spectrum of Precursor to 66. 
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Appendix Figure 87. 13C NMR Spectrum of Precursor to 66. 
Appendix Figure 88. 1H NMR Spectrum of 66. 
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Appendix Figure 89. 13C NMR Spectrum of 66. 
Appendix Figure 90. 1H NMR Spectrum of Precursor to 67. 
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Appendix Figure 91. 1H NMR Spectrum of 67. 
Appendix Figure 92. 13C NMR Spectrum of 67. 
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Appendix Figure 93. 1H NMR Spectrum of 68. 
Appendix Figure 94. 31P NMR Spectrum of 68. 
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Appendix Figure 95. 1H NMR Spectrum of 69. 
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Appendix Figure 96. 13C and 31P NMR Spectrum of 69. 
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Appendix Figure 97. 19F NMR Spectrum of 69. 








Appendix Figure 100. 1H and 13C NMR Spectrum of X in the preparation of 72. 
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Appendix Figure 101. 31H and 31P NMR Spectrum of Precursor to 72. 
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Appendix Figure 102. 1H and 13C NMR Spectrum of 73. 
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Appendix Figure 104. 1H and 13C NMR Spectrum of 74. 
357 
 
Appendix Figure 105. 31P NMR Spectrum of 74. 
Appendix Figure 106. 1H NMR Spectrum of Precursor to pro-72. 
358 
 
Appendix Figure 107. 13C and 31P NMR Spectrum of Precursor to pro-72. 
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Appendix Figure 108. 1H and 13C NMR Spectrum of pro-72. 
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Appendix Figure 109. 31P NMR Spectrum of pro-72. 
Appendix Figure 110. 1H NMR Spectrum of 75. 
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Appendix Figure 111. 1H NMR Spectrum of 75. 
Appendix Figure 112. 1H NMR Spectrum of 77. 
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Appendix Figure 113. 31P NMR Spectrum of 77. 
Appendix Figure 114. 1H NMR Spectrum of 78. 
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Appendix Figure 115. 13C and 31P NMR Spectrum of 78. 
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Appendix Figure 116. 1H NMR Spectrum of Precursor to 79. 
Appendix Figure 117. 1H NMR Spectrum of 79. 
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Appendix Figure 118. 31P NMR Spectrum of 79. 








Appendix Figure 121. 1H and 13C NMR Spectrum of 84. 
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Appendix Figure 122. 31P NMR Spectrum of 84. 
Appendix Figure 123. 1H NMR Spectrum of 85. 
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Appendix Figure 124. 1H NMR Spectrum of 86. 








Appendix Figure 127. 1H and 13C NMR Spectrum of 89. 
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Appendix Figure 128. 31P NMR Spectrum of 89. 
Appendix Figure 129. 1H NMR Spectrum of 90. 
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Appendix Figure 130. 1H NMR Spectrum of 91. 
Appendix Figure 131. 1H NMR Spectrum of 92. 
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Appendix Figure 132. 31P NMR Spectrum of 92. 
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Appendix Figure 133. 1H and 13C NMR Spectrum of Precursor to 93. 
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Appendix Figure 134. 31P NMR Spectrum of Precursor to 93. 
 
Appendix Figure 135. MALDI-TOF of 5’-dRP precursor oligonucleotide; m/z calculated for (M 
+ H)− 4738.745, 4738.821 observed. 
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Appendix 3. 1D and 2D NMR Analysis of final inhibitors. 





Table 24. Chemical Shift Analysis of pro-72 NMR spectra. 





Integration Chemical Shift Description 
8.53 s 1 128.4 1075 (1/4) 
8.12 S 1 139.5 dT aromatic (1/1) 
8.02 S 1 130.8 1075 (2/4) 
7.92 D (J = 8.8 Hz) 1 126.5 1075 (3/4 
7.78 D (J = 8.5 Hz) 2 125.7 006 aromatic 
(2/2) 
7.56 D (J = 8.8 Hz) 1 131.3 1075 (4/4) 
7.53 D (J = 8.5 Hz) 2 129.0 006 aromatic 
(2/2) 
7.24 S 1 106.2 006 furan (1/1) 
6.30 Quint (J = 5.4 Hz) 1 85.7 C1’ (1/1) (~85 
ppm) 
6.25 M 1 96.7 Acetal (1/2) (~95-
110 ppm) 
4.73 T (J = 6 Hz) 1 50.2 Acetal (2/2) 
4.61 Q (J = 7 Hz) 1 59.7 C3’ (1/1) 
4.49 D (J = 14 Hz) 1 35.4 C5’ (1/2) 
4.42 Dd (J = 14 Hz, 3.6 Hz) 1 35.4 C5’ (2/2) 
4.24 M 3 65.0 Amide methylene 
(1/2) (CNR ~45-
65 ppm) 
83.3 DOB linker (2/2) 
(COH ~50-90 
ppm) 
4.14 M 1 65.0 Amide methylene 
(2/2) 
4.05 T (J = 7 Hz) 1 63.4 C4’ (1/1) 
2.62 M 2 24.7 DOB methine 
37.1 C2’ (1/2) 
2.48 Q (J = 6 Hz) 2 37.1 C2’ (2/2) 
32.0 DOB C2’ (1/2) 
2.05 M 3 19.6 Ac (3/3) 
1.99 S 3 19.7 Ac (3/3) 
1.92 S 1   
1.84 M 1 32.0 DOB C2’ (2/2) 










































Analysis of 84: 
 
 
Table 25. Chemical shift analysis of 84 NMR spectra. 
Proton Carbon  








8.17 M 1 134.2 dT (1/1) 
7.80 T (J = 8 Hz) 1 127.5 8931 (1/4) 
7.69 Dd (J = 8, 7.2 
Hz) 
2 107.4 Nv (2/2) 
7.52 M 1 117.4 8931 (2/4) 
7.35 M 1 122.9 8931 (3/4) 
7.27 Quint/d (J = 6.6, 
0.2 Hz) 
2 123.7 Nv (2/2) 
7.16 Quint (J = 3 Hz) 1 110.0 8931 (4/4) 
7.07 Q (J = 7.2 Hz)  110.2  
6.35 M 1 84.6 C1’ 
6.25 M 1   
5.42 M 3 104.8 Acetal (2/2) 
    C3’ (1/1) 
5.10 M 2 66.4 DOB linker 
4.88 M 2 66.4 Nv methylene (2/4) 
4.70 M 2 50.7  
4.65 Quint (J = 5 Hz) 1 50.7  
4.25 T (J  = 4 Hz) 1 65.2 C4’ (1/1) 
4.22 Q (J = 4 Hz) 1 65.5 C5’ (1/2) 
4.19 M 2 83.4 Nv methylene (4/4) 
4.14 Q (J = 5 Hz) 1 65.5 C5’ (2/2) 
4.05 M 1   
3.97 Dt (J = 14, 5 Hz) 3 55.5 Nv OMe (3/12) 
3.87 M 4 55.3 Nv OMe (7/12) 
3.77 M 2 55.2 Nv OMe (9/12) 
2.70 M 3 21.4 8931 Me (3/3) – 
chemical shift in 
8931  acid Me is 3.1 
ppm 
2.52 M 1 37.1 C2’ (1/2) 
2.44 M 1 37.1 C2’ (2/2) 
2.23 M 2 33.9 DOB C2’ (2/2) 
2.11 M 1 33.9 C3’ methine 
1.98 S 1 14.1 dT Me (1/3) 
1.93 M 2 14.1 dT Me (3/3) 




















142.3 Quaternary Carbons 
8931 (5) 
dT (2 x 1) 
amide (1) 




















Table 26. Chemical shift analysis of 89 NMR spectra. 
Proton Carbon  






8.31 S 1 129.1 1085 (1/5) 
7.84 S 1 136.6 dT aromatic (1/1) 
7.59 m 1 107.7 1085 (2/5) 
7.46 M 2 105.8 Nv (2/2) 
7.28 S 2 110.6 Nv (2/2) 
7.09 m 1 128.3 1085 (3/5) 
7.01 M 1 109.9 1085 (4/5) 
6.78 M 1 109.2 1085 (5/5) 
6.38 M 1 84.6 C1’ (1/1) (~85 
ppm) 
5.40 m 2 104.8 Acetal (2/2) 
5.06 M 1 66.2 C3’ (1/1) 
4.78 M 2 65.8 C5’ (2/2) 
4.28 M 2 83.9 Nv linker (2/4) 
4.18 M 2 66.3 DOB linker (2/2) 
4.02 M 1 65.2 C4’ (1/1) 
3.93 M 4 55.2 Nv OMe (4/12) 
3.83 M 8 55.2 Nv OMe (8/12) 
3.75 M 2 55.2 Nv OMe (12/12) 
2.51 M 2 37.3 DOB C2’ (2/2) 
2.23 M 1 33.9 C2’ (1/2) 
2.07 M 1 33.9 C2’ (2/2) 
1.95 M 3 11.3 dT Me (3/3) 
Missing Nv linker (2/4) 

























dT (2 x 1) 

















Table 27. Chemical shift analysis of Precursor to 93 NMR spectra. 
Proton Carbon  






8.20 M 1 139.8 dT (1/1) 
7.80 M 1 134.2 8931 (1/1) 
7.71 M 1 128.2 8931 (1/2) 
7.63 D (J = 2.8 Hz) 1 107.6 8931 (3/4) 
7.54 M 2 107.4 Nv (2/2) 
7.34 D (J = 2.8 Hz) 1 123.0 8931 (4/4) 
7.20 S 2 108.5 Nv (2/2) 
7.06 M 1 110.0  
6.30 S 1 85.4 C1’ (1/1) (~85 ppm) 
5.41 M 2 104.8 Acetal (2/2) 
5.05 M 1   
4.81 M 2 66.3 DOB linker (2/2) 
4.28 M 4 83.7 Nv linker (4/4) 
4.21 M 2 64.8 Amide methylene 
(2/2) 
4.14 M 1 66.3 C4’ (1/1) 
4.05 Q (J = 6 Hz) 1 65.8 C3’ (1/1) 
3.97 D (J = 14 Hz) 2  C5’ (2/2) 
3.93 D (J = 14 Hz) 3 55.2 Nv OMe (3/12) 
3.87 M 4 55.2 Nv OMe (7/12) 
3.85 M 4 55.2 Nv OMe (11/12) 
3.76 M 2 55.2 Nv OMe (12/12) 
 (1/2) 
2.80 T (J = 6 Hz) 1 21.9 C2’ (1/2) 
2.70 D (J = 6 Hz) 1 21.9 C2’ (1/2) 
2.67 M 1 23.4 DOB methine 
2.52 M 2 37.6  
2.11 m 1 32.8 DOB C2’ (1/2) 
1.88 M 1 32.8 DOB C2’ (2/2) 
1.31 M 3 26.7 8931 Me (3/3)  

























dT (2 x 1) 
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